

01-12-2023

**09:30 - 10:30** **Type: Special session** **Hall 406**  
**Title: Opening session and Keynote lecture**  
 Chair: Andres Cervantes, ES; Brigette Ma, HK; Sanjay Popat, GB

09:30 - 09:40 **Welcome address by the ESMO President, Prof. Andrés Cervantes**  
A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES

09:40 - 09:45 **Scientific Co-Chairs: Programme and key highlights of the meeting**  
B. Ma<sup>1</sup>, S. Popat<sup>2</sup>, <sup>1</sup>The Chinese University of Hong Kong, Sha Tin, HK, <sup>2</sup>The Royal Marsden Hospital - NHS Foundation Trust, London, GB

09:45 - 10:05 **Token of Appreciation Endorsing society representatives**  
A. Speakers, Lugano, CH

10:05 - 10:25 **Keynote lecture: Transitioning liquid biopsies from research to practice**  
T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

**10:45 - 12:15** **Type: Educational session** **Hall 405**  
**Title: Treatment optimisation in early triple negative breast cancer (TNBC)**  
 Chair: Michail Ignatiadis, BE; Mastura Md Yusof, MY

10:45 - 11:10 **Optimal application of preoperative immunotherapy and management of residual disease post-neoadjuvant therapy in early TNBC**  
M. Ignatiadis, Institute Jules Bordet, Brussels, BE

11:10 - 11:35 **What is the optimal systemic treatment of stage 1 TNBC?**  
B. Pistilli, Institut Gustave Roussy, Villejuif, Cedex, FR

11:35 - 12:00 **New treatment strategies including immunotherapies and antibody drug conjugates (ADCs) in the neo-adjuvant and adjuvant setting**  
S. Loi, Peter MacCallum Cancer Centre, Melbourne, AU

12:00 - 12:15 **Q&A and discussion**  
A. Speakers, Lugano, CH

<b>10:45 - 12:15</b>	<b>Type: Educational session</b> <b>Title: An eye on the future: Promising agents from early drug development in gastrointestinal tumours</b> Chair: Elisa Fontana, GB; Stephen Chan, HK	<b>Hall 404</b>
10:45 - 11:05	<b>Novel therapies for gastroesophageal cancer</b> <u>K. Shitara</u> , National Cancer Center Hospital East, Kashiwa, JP	
11:05 - 11:25	<b>Bispecific antibodies: Early activity signals in gastrointestinal tumours</b> <u>E. Fontana</u> , Sarah Cannon Research Institute SCRI UK, London, GB	
11:25 - 11:45	<b>Targeted therapies in hepatobiliary cancers</b> <u>A. Lamarca</u> , Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES	
11:45 - 12:05	<b>Novel drug combinations in colorectal cancer</b> <u>T.W. Kim</u> , Asan Medical Center / Asan Cancer Institute, Seoul, KR	
12:05 - 12:15	<b>Q&amp;A and discussion</b> <u>A. Speakers</u> , Lugano, CH	
<b>10:45 - 12:15</b>	<b>Type: Proffered paper session</b> <b>Title: Mixed Proffered paper and Mini oral session: Gynaecological cancers</b> Chair: Sudeep Gupta, IN; Keiichi Fujiwara, JP; Smruti Koppikar, IN	<b>Hall 401</b>
10:45 - 10:55	<b>285O - Prevalence of homologous recombination deficiency in ovarian, primary peritoneal, and/or fallopian tube cancer: Results from the international HALO study</b> A. Tyulyandina <sup>1</sup> , S. Bujassoum <sup>2</sup> , M. Mokhtar <sup>3</sup> , <u>S. Khokhlova</u> <sup>4</sup> , C.-H. Wu <sup>5</sup> , <sup>1</sup> N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, <sup>2</sup> National Center for Cancer Care and Research, Doha, QA, <sup>3</sup> NEMROCK - Kasr Alainy Centre of Clinical Oncology & Nuclear Medicine, Cairo, EG, <sup>4</sup> National Medical Research Center of Oncology named after N.N. Blokhin, Moscow, RU, <sup>5</sup> Chang Gung Memorial Hospital-Kaohsiung, Kaohsiung, TW	
10:55 - 11:00	<b>286MO - Efficacy of low dose nivolumab in recurrent / metastatic cervical cancer</b> <u>S. Devabhaktuni</u> <sup>1</sup> , A. Singh <sup>2</sup> , J.T. Georgy <sup>2</sup> , J. Antonisamy <sup>1</sup> , D.B. Thumaty <sup>2</sup> , A. John <sup>2</sup> , <sup>1</sup> CMC - Christian Medical College Hospital Vellore, Vellore, IN, <sup>2</sup> CMC - Christian Medical College Hospital, Vellore, IN	
11:00 - 11:05	<b>287MO - Real-world experience with maintenance PARP inhibitor plus minus bevacizumab in newly diagnosed advanced ovarian cancer with germline BRCA mutations or homologous recombination deficiency (HRD) positive</b> <u>S. Roy</u> <sup>1</sup> , J. Ghosh <sup>1</sup> , A. Bhattacharjee <sup>1</sup> , S. Ganguly <sup>2</sup> , B. Biswas <sup>1</sup> , Y. Patel <sup>1</sup> , S. Pal <sup>1</sup> , J. Karmakar <sup>1</sup> , D. Mishra <sup>1</sup> , S. Vinarkar <sup>1</sup> , I. Dey <sup>1</sup> , R. Demde <sup>1</sup> , J. Bhaumik <sup>1</sup> , A. Ghosh <sup>1</sup> , B. Chakraborti <sup>1</sup> , <sup>1</sup> TMC - Tata Medical Center, Kolkata, IN, <sup>2</sup> Tata Medical Center, Kolkata, IN	

- 11:05 - 11:15 **Invited Discussant 285O, 286MO and 287MO**  
S. Koppikar, Bombay Hospital and Medical Research Center, Mumbai, IN
- 11:15 - 11:20 **Q&A and discussion**  
A. Speakers, Lugano, CH
- 11:20 - 11:25 **288MO - InnoVA TV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator's choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer**  
K. Fujiwara<sup>1</sup>, B. Slomovitz<sup>2</sup>, A. Gonzalez Martin<sup>3</sup>, E. Kalbacher<sup>4</sup>, A. Bagameri<sup>5</sup>, S. Ghamande<sup>6</sup>, J.-Y. Lee<sup>7</sup>, S. Banerjee<sup>8</sup>, F. Maluf<sup>9</sup>, D. Lorusso<sup>10</sup>, K. Yonemori<sup>11</sup>, E. Van Nieuwenhuysen<sup>12</sup>, L. Manso<sup>13</sup>, L. Woelber<sup>14</sup>, A. Westermann<sup>15</sup>, A. Covens<sup>16</sup>, E. Whalley<sup>17</sup>, M.S.L. Teng<sup>17</sup>, I. Soumaoro<sup>18</sup>, I. Vergote<sup>12</sup>, <sup>1</sup>Saitama Medical University International Medical Center, Saitama, JP, <sup>2</sup>Mount Sinai Medical Center, Miami Beach, US, <sup>3</sup>Cancer Center Clinica Universidad de Navarra, Madrid, Spain and GEICO, Madrid, ES, <sup>4</sup>Centre Hospitalier Universitaire de Besançon, Besançon, FR, <sup>5</sup>Országos Onkológiai Intézet, Budapest, HU, <sup>6</sup>Georgia Cancer Center, August University, Augusta, US, <sup>7</sup>Yonsei University College of Medicine, Seoul, KR, <sup>8</sup>The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, GB, <sup>9</sup>Hospital Beneficencia Portuguesa of Sao Paulo, Sao Paulo, BR, <sup>10</sup>Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome and Catholic University of Sacred Heart, Rome, IT, <sup>11</sup>National Cancer Center - Tsukiji Campus, Chuo-ku, JP, <sup>12</sup>Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, and Belgium and Luxembourg Gynaecological Oncology Group, Leuven, BE, <sup>13</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>14</sup>Arbeitsgemeinschaft Gynäkologische Onkologie Study Group and University Medical Center Hamburg-Eppendorf, Hamburg, DE, <sup>15</sup>Amsterdam University Medical Centres, Amsterdam, NL, <sup>16</sup>Sunnybrook Research Institute, Toronto, CA, <sup>17</sup>Seagen Inc., Bothell, US, <sup>18</sup>Genmab, Princeton, US
- 11:25 - 11:30 **289MO - Fruquintinib plus sintilimab in advanced cervical cancer (CC) patients (pts): Results from a multicenter, single-arm phase II study**  
X. Wu<sup>1</sup>, D. Wang<sup>2</sup>, J. Wang<sup>3</sup>, Y. Huang<sup>4</sup>, T. Yi<sup>5</sup>, G. Li<sup>6</sup>, J. Zhang<sup>7</sup>, K. Wang<sup>8</sup>, Y. Kang<sup>9</sup>, A. Liu<sup>10</sup>, X. Han<sup>1</sup>, P. Lu<sup>11</sup>, H. Shi<sup>11</sup>, P. Tan<sup>11</sup>, S. Fan<sup>11</sup>, M. Shi<sup>11</sup>, W. Su<sup>11</sup>, <sup>1</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>2</sup>Liaoning Cancer Hospital & Institute, Shenyang, CN, <sup>3</sup>Hunan Cancer Hospital, Changsha, CN, <sup>4</sup>Hubei Cancer Hospital, Wuhan, CN, <sup>5</sup>Xiangyang Central Hospital, Xiangyang, CN, <sup>6</sup>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, <sup>7</sup>Guangxi Medical University Affiliated Tumor Hospital, Nanning, CN, <sup>8</sup>The Second Affiliated Hospital of Nanjing Medical University, Nanjing, CN, <sup>9</sup>Obstetrics and Gynecology Hospital of Fudan University, Shanghai, CN, <sup>10</sup>The Second Affiliated hospital of Nanchang University, Nanchang, CN, <sup>11</sup>HUTCHMED (China) Limited - Research Center, Shanghai, CN
- 11:30 - 11:35 **290MO - Efficacy and safety of topical sintilimab administration in conjunction with CRT and Californium-252 neutron brachytherapy in first-line advanced gynecological squamous cell carcinoma patients**  
X. Li, J. Lu, S. Liu, H. Song, X. Huang, General Hospital of Heilongjiang Province Agricultural Land Reclamation Bureau, Harbin, CN

- 11:35 - 11:45 **Invited Discussant 288MO, 289MO and 290MO**  
A. Leary, Institut Gustave Roussy, Villejuif, FR
- 11:45 - 11:50 **Q&A and discussion**  
A. Speakers, Lugano, CH
- 11:50 - 11:55 **LBA8 - Preliminary efficacy of pembrolizumab plus lenvatinib (PL) in recurrent clear cell gynecological cancer (CCGC): Phase II LARA trial (GCGS-OV4/ APGOT-OV3)**  
N. Ngoi<sup>1</sup>, J.-Y. Lee<sup>2</sup>, Y.W. Lim<sup>1</sup>, D. Lim<sup>3</sup>, Y.L. Thian<sup>3</sup>, A. Gopinathan<sup>3</sup>, S.E. Lim<sup>1</sup>, J. Low<sup>4</sup>, J. Ng<sup>4</sup>, P. Tong<sup>4</sup>, J. Zhu<sup>5</sup>, B.C. Tai<sup>5</sup>, Y.J. Lee<sup>2</sup>, J. Park<sup>2</sup>, J.-W. Kim<sup>6</sup>, B.-G. Kim<sup>7</sup>, D.S. Tan<sup>1</sup>,  
<sup>1</sup>National University Cancer Institute, Singapore, Singapore, SG, <sup>2</sup>Yonsei University, Seoul, KR, <sup>3</sup>National University Hospital, Singapore, Singapore, SG, <sup>4</sup>National University Hospital, Singapore,, Singapore, SG, <sup>5</sup>National University of Singapore, Singapore, SG, <sup>6</sup>Seoul National University Hospital, Seoul, KR, <sup>7</sup>Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR
- 11:55 - 12:00 **291MO - Determining the maximum tolerated dose of paclitaxel combined with fixed dose of cisplatin for hyperthermic intraperitoneal chemotherapy in ovarian cancer: A multicenter phase I trial**  
J. Li<sup>1</sup>, M. Wu<sup>2</sup>, Z. Lin<sup>1</sup>, Y. Lai<sup>1</sup>, B. Zhang<sup>1</sup>, Y.-F. Ye<sup>3</sup>, Y. Lu<sup>1</sup>, Y. Peng<sup>4</sup>, <sup>1</sup>Sun Yat-sen Memorial Hospital, Guangzhou, CN, <sup>2</sup>Sun Yat-Sen University, Guangzhou, CN, <sup>3</sup>Sun Yat sen Memorial Hospital, Guangzhou, CN, <sup>4</sup>Shenshan medical center, Sun Yat-Sen University, Shanwei, CN
- 12:00 - 12:10 **Invited Discussant LBA8 and 291MO**  
K. Fujiwara, Saitama Medical University International Medical Center, Saitama, JP
- 12:10 - 12:15 **Q&A and discussion**  
A. Speakers, Lugano, CH
- 10:45 - 12:15 Type: Proffered paper session** **Hall**  
**Title: Mixed Proffered paper and Mini oral session: Developmental and** **402**  
**precision medicine**  
Chair: Jayesh Desai, AU; Matthew Krebs, GB
- 10:45 - 10:55 **402O - A randomized phase III trial of site-specific therapy guided by the 90-gene expression assay versus empiric chemotherapy in patients with cancer of unknown primary**  
Z. Luo<sup>1</sup>, X. Liu<sup>1</sup>, X. Zhang<sup>1</sup>, S. Jiang<sup>1</sup>, M. Mo<sup>1</sup>, Q. Wang<sup>1</sup>, Y. Wang<sup>1</sup>, L. Zhou<sup>1</sup>, S. Hu<sup>1</sup>, H. Yang<sup>1</sup>, Y. Hou<sup>1</sup>, Y. Chen<sup>1</sup>, X. Lu<sup>1</sup>, X. Zhou<sup>1</sup>, W. Li<sup>1</sup>, X. Yang<sup>1</sup>, K. Chen<sup>1</sup>, J. Cao<sup>1</sup>, Q. Xu<sup>2</sup>, X. Hu<sup>1</sup>, <sup>1</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>2</sup>Canhelp Genomics Co., Ltd., Hangzhou, CN
- 10:55 - 11:05 **Invited Discussant 402O**  
L. Mileshkin, Peter MacCallum Cancer Center, Melbourne, AU

- 11:05 - 11:10 **Q&A and discussion**  
A. Speakers, Lugano, CH
- 11:10 - 11:15 **404MO - Tertiary lymphoid structures localization and maturation heterogeneities correlate with divergent microenvironment features and immune responses of clear cell renal cell carcinoma**  
W. Xu<sup>1</sup>, H. Zhang<sup>1</sup>, D. Ye<sup>1</sup>, W. Liu<sup>2</sup>, <sup>1</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>2</sup>Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, CN
- 11:15 - 11:20 **405MO - Pan-cancer analysis of 4-1BB transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors**  
Y. Uehara<sup>1</sup>, S. Kato<sup>2</sup>, D. Nishizaki<sup>2</sup>, H. Miyashita<sup>3</sup>, J. Adashek<sup>4</sup>, S. Lee<sup>2</sup>, M. Nikanjam<sup>2</sup>, R. Eskander<sup>5</sup>, H. Patel<sup>2</sup>, G. Botta<sup>2</sup>, M. Nesline<sup>6</sup>, S. Pabla<sup>6</sup>, J. Conroy<sup>6</sup>, P. Depietro<sup>6</sup>, J. Sicklick<sup>2</sup>, R. Kurzrock<sup>7</sup>, <sup>1</sup>Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, JP, <sup>2</sup>University of California San Diego, La Jolla, US, <sup>3</sup>Dartmouth Cancer Center, Lebanon, US, <sup>4</sup>Johns Hopkins Hospital, Baltimore, US, <sup>5</sup>University of California San Diego - UCSD, La Jolla, US, <sup>6</sup>OmniSeq Inc., Buffalo, US, <sup>7</sup>Froedtert Hospital & Medical College of Wisconsin, Milwaukee, US
- 11:20 - 11:30 **Invited Discussant 404MO and 405MO**  
A. Hansen, Princess Alexandra Hospital - Metro South Health, Brisbane, AU
- 11:30 - 11:35 **Q&A and discussion**  
A. Speakers, Lugano, CH
- 11:35 - 11:40 **74MO - Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study**  
D.-Y. Oh<sup>1</sup>, F. Meric-Bernstam<sup>2</sup>, V. Makker<sup>3</sup>, A. Oaknin<sup>4</sup>, S. Banerjee<sup>5</sup>, A. Gonzalez Martin<sup>6</sup>, K. Jung<sup>7</sup>, I. Lugowska<sup>8</sup>, L. Manso<sup>9</sup>, A. Manzano<sup>10</sup>, B. Melichar<sup>11</sup>, S. Siena<sup>12</sup>, D. Stroyakovskiy<sup>13</sup>, A. Fielding<sup>14</sup>, Y. Ma<sup>15</sup>, S. Puvvada<sup>14</sup>, J.-Y. Lee<sup>16</sup>, <sup>1</sup>Seoul National University Hospital, Seoul, KR, <sup>2</sup>University of Texas MD Anderson Cancer Center, Houston, US, <sup>3</sup>Memorial Sloan-Kettering Cancer Center, New York City, US, <sup>4</sup>Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Barcelona, ES, <sup>5</sup>The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, GB, <sup>6</sup>Cancer Center Clínica Universidad de Navarra, Madrid, ES, <sup>7</sup>University of Ulsan College of Medicine, Seoul, KR, <sup>8</sup>Maria Skłodowska-Curie National Research Institute and Oncology Centre, Warsaw, PL, <sup>9</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>10</sup>Hospital Clinico San Carlos, Madrid, ES, <sup>11</sup>University Hospital, Palacký University Medical School, Olomouc, CZ, <sup>12</sup>Università degli Studi di Milano, Piazza Ospedale Maggiore, Milan, IT, <sup>13</sup>Moscow City Oncology Hospital No. 62, Moscow, RU, <sup>14</sup>AstraZeneca, Gaithersburg, US, <sup>15</sup>AstraZeneca, Cambridge, GB, <sup>16</sup>Yonsei University College of Medicine, Seoul, KR
- 11:40 - 11:45 **75MO - Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in**

**patients (pts) with DLL3; tumors: Focus on Asian pts**

Y. Kuboki<sup>1</sup>, V. Gambardella<sup>2</sup>, J. Capdevila Castillon<sup>3</sup>, O. Alese<sup>4</sup>, D. Morgensztern<sup>5</sup>, C.M. Sayehli<sup>6</sup>, M.F. Sanmamed<sup>7</sup>, E. Arriola<sup>8</sup>, J. Wolf<sup>9</sup>, T. Owonikoko<sup>10</sup>, M. Studeny<sup>11</sup>, M. Bouzaggou<sup>12</sup>, E. Song<sup>13</sup>, M. Wermke<sup>14</sup>, <sup>1</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>2</sup>Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, ES, <sup>3</sup>Vall d'Hebron University Hospital & Vall d'Hebron Institute of Oncology, Barcelona, ES, <sup>4</sup>Winship Cancer Institute of Emory University, Atlanta, US, <sup>5</sup>Washington University School of Medicine, St. Louis, US, <sup>6</sup>Medical Clinic and Polyclinic II of the University Hospital, Wuerzburg, DE, <sup>7</sup>Clínica Universidad de Navarra, Pamplona, ES, <sup>8</sup>Hospital del Mar-CIBERONC (Centro de Investigación Biomédica en Red de Oncología), 08003 Barcelona, Spain; Cancer Research Program, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), 08003, BARCELONA, ES, <sup>9</sup>University Hospital of Cologne, Cologne, DE, <sup>10</sup>University of Pittsburgh School of Medicine, Pittsburgh, US, <sup>11</sup>Boehringer Ingelheim International GmbH, Ingelheim, DE, <sup>12</sup>Boehringer Ingelheim France S.A.S., Reims, FR, <sup>13</sup>Boehringer Ingelheim (China) Investment Co., Shanghai, CN, <sup>14</sup>TU Dresden University of Technology, Dresden, DE

11:45 - 11:50

**76MO - Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas**

T.W.-W. Chen<sup>1</sup>, R. Sanfilippo<sup>2</sup>, R. Jones<sup>3</sup>, S. Schuetze<sup>4</sup>, A. Sebio Garcia<sup>5</sup>, R. Alvarez<sup>6</sup>, N. Bui<sup>7</sup>, J.-H. Ahn<sup>8</sup>, H.H.F. Loong<sup>9</sup>, C.-C. Yen<sup>10</sup>, J.Y. Hong<sup>11</sup>, H.S. Kim<sup>12</sup>, S. Patel<sup>13</sup>, R. Bryce<sup>14</sup>, F. Xu<sup>15</sup>, B. Zhang<sup>14</sup>, N. Shah<sup>16</sup>, R. Doebele<sup>15</sup>, G. Schwartz<sup>17</sup>, M. Gounder<sup>18</sup>, <sup>1</sup>NTU - National Taiwan University - College of Medicine, Taipei City, TW, <sup>2</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano, Milan, IT, <sup>3</sup>The Royal Marsden Hospital - Chelsea, London, GB, <sup>4</sup>University Hospital - Michigan Medicine, Ann Arbor, US, <sup>5</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>6</sup>Hospital General Universitario Gregorio Marañon, Madrid, ES, <sup>7</sup>Stanford Cancer Center Palo Alto, Palo Alto, US, <sup>8</sup>Asan Medical Center - University of Ulsan, Seoul, KR, <sup>9</sup>The Chinese University of Hong Kong, Sha Tin, HK, <sup>10</sup>Taipei Veterans General Hospital, Taipei City, TW, <sup>11</sup>Samsung Medical Center (SMC), Seoul, KR, <sup>12</sup>Severance Hospital, Seoul, KR, <sup>13</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US, <sup>14</sup>Rain Oncology Inc., Newark, US, <sup>15</sup>Rain Oncology Inc, Newark, US, <sup>16</sup>Rain Oncology, Inc., Newark, US, <sup>17</sup>Case Comprehensive Cancer Center, Cleveland, US, <sup>18</sup>Memorial Sloan Kettering Cancer Center, New York, US

11:50 - 11:55

**77MO - A first-in-human, open-label, dose-escalation study of ERK1/2 inhibitor HMPL-295 in patients with advanced solid tumors**

X. Yu<sup>1</sup>, J. Zhang<sup>1</sup>, R. Liu<sup>1</sup>, Y. Deng<sup>2</sup>, Y. Cai<sup>2</sup>, Y. Sun<sup>3</sup>, Q. Dang<sup>3</sup>, W. Hong<sup>4</sup>, Z. Song<sup>4</sup>, S. Guo<sup>5</sup>, S. Gao<sup>1</sup>, W. Su<sup>6</sup>, M. Shi<sup>6</sup>, S. Fan<sup>6</sup>, B. Zhang<sup>6</sup>, B. Pan<sup>6</sup>, Y. Ren<sup>6</sup>, J. Wang<sup>6</sup>, C. Zhong<sup>6</sup>, L. Ma<sup>6</sup>, <sup>1</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>2</sup>The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN, <sup>3</sup>Shandong Cancer Hospital and Institute, Jinan, CN, <sup>4</sup>Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, CN, <sup>5</sup>The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, CN, <sup>6</sup>HUTCHMED (China) Limited, Shanghai, CN

11:55 - 12:05

**Invited Discussant 74MO, 75MO, 76MO and 77MO**

I. Braña, Vall d'Hebron University Hospital, Barcelona, ES

12:05 - 12:10 **Q&A and discussion**  
A. Speakers, Lugano, CH

**10:45 - 11:55** **Type: Proffered paper session** **Hall 406**  
**Title: Proffered Paper session: Thoracic cancer**  
 Chair: Ben Solomon, AU; Lizza Hendriks, NL

10:45 - 10:55 **LBA10 - Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis**  
 S. Lu<sup>1</sup>, B.C. Cho<sup>2</sup>, J.-S. Lee<sup>3</sup>, S.-H. Lee<sup>4</sup>, P. Danchaivijitr<sup>5</sup>, B. Liu<sup>6</sup>, A. Alip<sup>7</sup>, H. Xiong<sup>8</sup>, S.H. How<sup>9</sup>, G.-C. Chang<sup>10</sup>, J.C.-H. Yang<sup>11</sup>, H. Yoshioka<sup>12</sup>, K. Xia<sup>13</sup>, M. Martinez<sup>14</sup>, J. Bauml<sup>13</sup>, S. Sethi<sup>13</sup>, H. Hayashi<sup>15</sup>, <sup>1</sup>Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, <sup>2</sup>Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, <sup>3</sup>Seoul National University Bundang Hospital, Seongnam, KR, <sup>4</sup>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, <sup>5</sup>Siriraj Hospital, Mahidol University, Bangkok, TH, <sup>6</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>7</sup>Faculty of Medicine, University of Malaya, Kuala Lumpur, MY, <sup>8</sup>Huizhou Municipal Central Hospital of Guangdong Province, Huizhou, CN, <sup>9</sup>International Islamic University Malaysia, Pahang, MY, <sup>10</sup>National Chung Hsing University, Chung Shan Medical University Hospital, and Chung Shan Medical University, Taichung, TW, <sup>11</sup>National Taiwan University Cancer Center, Taipei, TW, <sup>12</sup>Kansai Medical University Hospital, Osaka, JP, <sup>13</sup>Janssen R&D, Spring House, US, <sup>14</sup>Janssen R&D, Raritan, US, <sup>15</sup>Kindai University Faculty of Medicine, Osaka, JP

10:55 - 11:05 **LBA11 - Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis**  
 J.-Y. Shih<sup>1</sup>, J. Wang<sup>2</sup>, Y. Wang<sup>3</sup>, J. Wang<sup>4</sup>, S.-H. Lee<sup>5</sup>, K. Azuma<sup>6</sup>, T. Takahashi<sup>7</sup>, J.-L. Tan<sup>8</sup>, C.C. Lin<sup>9</sup>, S. Ganguly<sup>10</sup>, V. Lee<sup>11</sup>, P.-L. Chu<sup>12</sup>, S. Shah<sup>13</sup>, B. Diorio<sup>14</sup>, J. Bauml<sup>13</sup>, B.C. Cho<sup>15</sup>, <sup>1</sup>National Taiwan University Hospital, Taipei City, TW, <sup>2</sup>Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, <sup>3</sup>West China Hospital, Sichuan University, Chengdu, CN, <sup>4</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>5</sup>Sungkyunkwan University School of Medicine, Seoul, KR, <sup>6</sup>Kurume University School of Medicine, Kurume, JP, <sup>7</sup>Shizuoka Cancer Center, Nagaizumi, JP, <sup>8</sup>University of Malaya, Kuala Lumpur, MY, <sup>9</sup>College of Medicine, National Cheng Kung University, Tainan, TW, <sup>10</sup>Tata Medical Center, Kolkata, IN, <sup>11</sup>The University of Hong Kong, Pok Fu Lam, HK, <sup>12</sup>Janssen R&D, Raritan, US, <sup>13</sup>Janssen R&D, Spring House, US, <sup>14</sup>Janssen R&D, Titusville, US, <sup>15</sup>Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR

11:05 - 11:15 **Invited Discussant LBA10 and LBA11**  
N. Reguart Aransay, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

11:15 - 11:25 **Q&A and discussion**  
A. Speakers, Lugano, CH

- 11:25 - 11:35 **LBA12 - Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Initial results from a registrational phase II study**  
 Q. Zhou<sup>1</sup>, X. Meng<sup>2</sup>, L. Sun<sup>3</sup>, D. Huang<sup>4</sup>, N. Yang<sup>5</sup>, Y. Yu<sup>6</sup>, M. Zhao<sup>7</sup>, W. Zhuang<sup>8</sup>, Y. Hu<sup>9</sup>, Y. Pan<sup>10</sup>, M. Sun<sup>11</sup>, J. Shan<sup>12</sup>, R.-H. Guo<sup>13</sup>, Q. Chu<sup>14</sup>, C. Xu<sup>1</sup>, J. Lin<sup>1</sup>, J. Huang<sup>15</sup>, M. Huang<sup>15</sup>, Y. Shen<sup>15</sup>, Y.-L. Wu<sup>1</sup>, <sup>1</sup>Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, CN, <sup>2</sup>Shandong First Medical University Affiliated Cancer Hospital, Jinan, CN, <sup>3</sup>The First Affiliated Hospital of Nanchang University, Nanchang, CN, <sup>4</sup>Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, <sup>5</sup>Hunan Cancer Hospital, Changsha, CN, <sup>6</sup>Cancer Hospital affiliated to Harbin Medical University, Harbin, CN, <sup>7</sup>The First Affiliated Hospital of China Medical University, Shenyang, CN, <sup>8</sup>Fujian Cancer Hospital, Fuzhou, CN, <sup>9</sup>The First Medical Center of the Chinese People's Liberation Army General Hospital, Beijing, CN, <sup>10</sup>Anhui Provincial Hospital, Hefei, CN, <sup>11</sup>Central Hospital Affiliated to Shandong First Medical University, Jinan, CN, <sup>12</sup>Army Specialty Medical Center of PLA, Chongqing, CN, <sup>13</sup>Jiangsu Province Hospital, Nanjing, CN, <sup>14</sup>Tongji Hospital Affiliated to Tongji Medical College Huat, Wuhan, CN, <sup>15</sup>Innovent Biologics, Inc., Suzhou, Jiangsu, Suzhou, CN
- 11:35 - 11:45 **Invited Discussant LBA12**  
J. Remon Masip, Institut Gustave Roussy, Villejuif, Cedex, FR
- 11:45 - 11:55 **Q&A and discussion**  
A. Speakers, Lugano, CH
- 10:45 - 12:15** **Type: Educational session** **Hall 407**  
**Title: Implication of lymphoma classification in 2023**  
 Chair: Koji Izutsu, JP; Andrew Davies, GB
- 10:45 - 11:05 **T cell lymphomas**  
M. Sakata-Yanagimoto, University of Tsukuba, Tsukuba, JP
- 11:05 - 11:25 **Treatment of T cell lymphomas**  
W.S. Kim, Samsung Medical Center (SMC), Seoul, KR
- 11:25 - 11:45 **Pathology aggressive B cell lymphomas**  
C.L. Cheng, SGH - Singapore General Hospital, Singapore, SG
- 11:45 - 12:05 **Treatment of aggressive B cell lymphomas**  
A. Davies, Southampton General Hospital - University Hospital Southampton NHS Trust, Southampton, GB
- 12:05 - 12:15 **Q&A and discussion**  
A. Speakers, Lugano, CH



**12:30 - 14:00**    **Type: Industry satellite symposium**    **Hall**  
**Title: F. Hoffmann-La Roche Ltd. - Shaping the future of personalised**    **405**  
**healthcare for cancer patients**

Chair: Herbert Ho Fung Loong, HK; Jee Hyun Kim, KR

12:30 - 12:35    **Welcome & Introduction**

H.H.F. Loong, The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK

12:35 - 12:50    **CUPISCO as an innovative example in precision oncology**

L. Mileskin, Peter MacCallum Cancer Center, Melbourne, AU

12:50 - 13:05    **Changing the trajectory for cancer patients with liquid biopsy**

H.H.F. Loong, The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK

13:05 - 13:15    **Q&A**

A. Speakers, Lugano, CH

13:15 - 13:30    **Translating scientific evidence into tumour agnostic drug approvals**

J.H. Kim, Seoul National University Bundang Hospital, Seongnam, KR

13:30 - 13:45    **Shaping public healthcare systems to accelerate treatment access**

N. Pavlakis, RNSH - Royal North Shore Hospital, St Leonards, AU

13:45 - 13:55    **Q&A**

A. Speakers, Lugano, CH

13:55 - 14:00    **Call to action**

J.H. Kim, Seoul National University Bundang Hospital, Seongnam, KR

**12:30 - 14:00** **Type: Industry satellite symposium** **Hall 404**  
**Title: Amgen - The future of advanced GI cancer therapies: New approaches on the horizon?**  
 Chair: Matthew Chau Hsien Ng, SG

12:30 - 12:40 **Welcome and introduction**  
M.C.H. Ng, NCCS - National Cancer Centre Singapore, Singapore, SG

12:40 - 13:00 **Navigating RAS wild-type mCRC treatment with targeted therapies**  
T. Yoshino, National Cancer Center Hospital East, Kashiwa, JP

13:00 - 13:20 **Novel GI cancer therapies: Focus on KRAS mutations**  
T. Price, The Queen Elizabeth Hospital - Emergency Department, Woodville, AU

13:20 - 13:40 **Exploring new actionable targets in advanced gastric and GEJ cancers**  
S.Y. Rha, Yonsei University, Seoul, KR

13:40 - 14:00 **Panel discussion and Q&A**  
A. Speakers, Lugano, CH

**12:30 - 14:00** **Type: Industry satellite symposium** **Hall 401**  
**Title: Seagen - What's next for ADCs in oncology?**  
 Chair: Solange Peters, CH

12:30 - 12:35 **Welcome and introduction**  
S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

12:35 - 12:55 **State of the art and perspectives**  
S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

12:55 - 13:15 **Advances in integrin targeting**  
K. O'Byrne, Princess Alexandra Hospital - Metro South Health, Woolloongabba, AU

13:15 - 13:35 **Multimodal immune targeting with ADCs**  
E. Calvo, CIOCC - Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid, ES

13:35 - 14:00 **Panel discussion, live Q&A, and conclusions**  
A. Speakers, Lugano, CH

<b>12:30 - 14:00</b>	<b>Type: Industry satellite symposium</b> <b>Title: Astellas - Personalising novel therapeutics for advanced gastric cancer</b> Chair: Raghav Sundar, SG	<b>Hall 402</b>
12:30 - 12:40	<b>Transformation of gastric cancer management in the past decade (from BSC to chemo to targeted + IO)</b> <u>R. Sundar</u> , NUHS - National University Health System, Singapore, SG	
12:40 - 13:00	<b>Novel targeted therapy approaches in gastric cancer</b> <u>E. Smyth</u> , Oxford University Hospitals NHS Foundation Trust - Churchill Hospital, Oxford, GB	
13:00 - 13:20	<b>Claudin as a therapeutic target in gastric cancer</b> <u>K. Shitara</u> , National Cancer Center Hospital East, Kashiwa, JP	
13:20 - 13:40	<b>Biomarker testing in gastric cancer: Solving practical issues and surmounting challenges</b> <u>M. Fassan</u> , Azienda Universitaria Ospedaliera di Padova, Padova, IT	
13:40 - 13:55	<b>Panel discussion on the challenges of the management of gastric cancer</b> <u>A. Speakers</u> , Lugano, CH	
13:55 - 14:00	<b>Conclusion</b> <u>R. Sundar</u> , NUHS - National University Health System, Singapore, SG	

**12:30 - 14:00**    **Type: Industry satellite symposium**    **Hall 407**  
**Title: Merck - Raising the bar: Advancing bladder cancer treatment**  
 Chair: Ravindran Kanesvaran, SG

12:30 - 12:40    **Welcome and introduction**

R. Kanesvaran, NCCS - National Cancer Centre Singapore, Singapore, SG

12:40 - 13:00    **Advanced urothelial cancer treatment: Lessons from clinical practice and RWE**

E. Kikuchi, St. Marianna University School of Medicine Yokohama City Seibu Hospital, Yokohama, JP

13:00 - 13:20    **Treatment eligibility in urothelial cancer**

V. Talwar, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN

13:20 - 13:40    **Optimal treatment sequencing options in urothelial cancer**

S. Sridhar, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

13:40 - 14:00    **Audience Q&A Conclusion**

R. Kanesvaran, NCCS - National Cancer Centre Singapore, Singapore, SG

**12:30 - 13:00**    **Type: Young oncologists (YO) session**    **Discussion hub (exhibition area)**  
**Title: Meet your mentor session 1: How to set up in clinical trials**

Chair: Elizabeth Connolly, AU; Hongcheng Zhu, CN; Matteo Lambertini, IT

12:30 - 13:00    **Mentors**

T.S.K. Mok<sup>1</sup>, M.L.K. Chua<sup>2</sup>, T. Amaral<sup>3</sup>, <sup>1</sup>Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK, <sup>2</sup>NCCS - National Cancer Centre Singapore, Singapore, SG, <sup>3</sup>Skin Cancer Clinical Trials Center, University of Tuebingen, Tuebingen, DE

**14:15 - 15:45** **Type: Educational session** **Hall 405**  
**Title: Immunotherapy in nasopharyngeal carcinoma**  
 Chair: Caroline Even, FR; Brigette Ma, HK

14:15 - 14:40 **New approaches in the management of locoregionally advanced disease**  
J. Ma, Sun Yat-sen University Cancer Center, Guangzhou, CN

14:40 - 15:05 **Beyond first-line recurrent/metastatic disease**  
D.W.-T. Lim, NCCS - National Cancer Centre Singapore, Singapore, SG

15:05 - 15:30 **Biomarkers beyond PDL1**  
L. Licitra, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

15:30 - 15:45 **Q&A and discussion**  
A. Speakers, Lugano, CH

**14:15 - 15:45** **Type: Educational session** **Hall 404**  
**Title: Challenges in melanoma treatment**  
 Chair: Karijn Suijkerbuijk, NL

14:15 - 14:40 **Adjuvant treatment in high-risk stage II melanoma: Do we still need SLNB?**  
T. Amaral, Skin Cancer Clinical Trials Center, University of Tuebingen, Tübingen, DE

14:40 - 15:05 **Advances in the management BRAF mutant melanoma**  
H. Gogas, National and Kapodistrian University of Athens - School of Medicine, Athens, GR

15:05 - 15:30 **Managing advanced acral and mucosal melanoma**  
K. Suijkerbuijk, UMC-University Medical Center Utrecht, Utrecht, NL

15:30 - 15:45 **Q&A and discussion**  
A. Speakers, Lugano, CH

**14:15 - 15:45** **Type: Mini oral session** **Hall 401**  
**Title: Mini oral session: Genitourinary tumours**  
 Chair: Jan Oldenburg, NO; Marniza Saad, MY; Yuji Miura, JP

14:15 - 14:20 **258MO - Niraparib plus abiraterone acetate plus prednisone (NIRA&#x2b;AAP) as first-line treatment in patients with BRCA&#x2b; metastatic castration-resistant prostate cancer (mCRPC): Second interim analysis in the Asian subgroup of the MAGNITUDE study**  
M. Saad<sup>1</sup>, K.N. Chi<sup>2</sup>, S. Sandhu<sup>3</sup>, G. Attard<sup>4</sup>, D. Ye<sup>5</sup>, L. Li<sup>6</sup>, W. Jung<sup>7</sup>, S.-T. Pang<sup>8</sup>, P. Francis<sup>9</sup>, S. Li<sup>10</sup>, S. Dibaj<sup>11</sup>, J. Zhang<sup>12</sup>, W. Kim<sup>13</sup>, A. Lopez-Gitlitz<sup>13</sup>, D. Wu<sup>13</sup>, A. Singh<sup>14</sup>, R. De Vries<sup>15</sup>, L. Zhang<sup>16</sup>, J.Y. Lee<sup>17</sup>, <sup>1</sup>UMMC - University Malaya Medical Centre, Kuala Lumpur, MY, <sup>2</sup>BC Cancer Agency - Vancouver, Vancouver, CA, <sup>3</sup>Peter MacCallum Cancer

Centre, Melbourne, AU, <sup>4</sup>University College London, London, GB, <sup>5</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>6</sup>The First Affiliated Hospital of Xi'an Jiaotong University, Xi' An, CN, <sup>7</sup>Keimyung University Dongsan Hospital, Daegu, KR, <sup>8</sup>Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW, <sup>9</sup>Johnson and Johnson, Raritan, US, <sup>10</sup>Janssen R&D US, Spring House, US, <sup>11</sup>Janssen R&D US, San Diego, US, <sup>12</sup>Johnson & Johnson - Janssen R&D Spring House, Spring House, US, <sup>13</sup>Janssen Research and Development, Los Angeles, US, <sup>14</sup>Janssen, Singapore, SG, <sup>15</sup>Janssen Cilag Australia, North Ryde New South, AU, <sup>16</sup>Janssen China, Beijing, CN, <sup>17</sup>Yeouido St Mary's Hospital of the Catholic University of Korea, Seoul, KR

- 14:20 - 14:25 **260MO - Impact of starting treatment choice in metastatic castration-sensitive prostate cancer (mCSPC)**  
M. Shiota<sup>1</sup>, S. Mundle<sup>2</sup>, M. Nematian-Samani<sup>3</sup>, J. Hwang<sup>4</sup>, X. Wang<sup>5</sup>, Y. Liu<sup>6</sup>, <sup>1</sup>Kyushu University - Faculty of Medical Sciences, Fukuoka, JP, <sup>2</sup>Janssen Research & Development, Raritan, US, <sup>3</sup>Janssen-Cilag GmbH Germany, Neuss, DE, <sup>4</sup>Janssen Pharmaceutical Kabushiki Kaisha, Tokyo, JP, <sup>5</sup>Janssen Pharmaceuticals, Titusville, US, <sup>6</sup>Janssen Pharmaceuticals, LLC, Raritan, US
- 14:25 - 14:35 **Invited Discussant 258MO and 260MO**  
J. Oldenburg, University of Oslo, Oslo, NO
- 14:35 - 14:40 **Q&A and discussion**  
A. Speakers, Lugano, CH
- 14:40 - 14:45 **261MO - Effect of liver and metabolic toxicity on survival and quality of life in patients with high-volume, metastatic hormone-sensitive prostate cancer receiving rezvilutamide in the CHART trial**  
 S. Jiang<sup>1</sup>, D. Ye<sup>2</sup>, H. Luo<sup>3</sup>, P. Dong<sup>4</sup>, Z. Wang<sup>5</sup>, N.-Z. Xing<sup>6</sup>, T. Ma<sup>7</sup>, Z. Wang<sup>8</sup>, X. Gu<sup>9</sup>, G. Zhou<sup>10</sup>, X. Xue<sup>11</sup>, Z. Sun<sup>12</sup>, J. Guo<sup>13</sup>, Y. Yang<sup>14</sup>, C. Wang<sup>15</sup>, G. Shan<sup>16</sup>, A. Zhang<sup>17</sup>, D. Ding<sup>18</sup>, J. Lian<sup>19</sup>, W. Wang<sup>19</sup>, <sup>1</sup>Hunan Cancer Hospital, Changsha, CN, <sup>2</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>3</sup>Chongqing University Cancer Hospital, Chongqing, CN, <sup>4</sup>Sun Yat-Sen University Cancer Center, Guangzhou, CN, <sup>5</sup>Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN, <sup>6</sup>Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN, <sup>7</sup>Affiliated Hospital of Hebei University, Baoding, CN, <sup>8</sup>Second Hospital of Lanzhou University, Lanzhou, CN, <sup>9</sup>China-Japan Union Hospital of Jilin University/Third Hospital of Jilin University, Changchun, CN, <sup>10</sup>Northern Jiangsu People's Hospital, Yangzhou, CN, <sup>11</sup>The First Affiliated Hospital of Fujian Medical University, Fuzhou, CN, <sup>12</sup>Huadong Hospital affiliated to Fudan University, Shanghai, CN, <sup>13</sup>Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, <sup>14</sup>Beijing Cancer Hospital, Beijing, CN, <sup>15</sup>The First Hospital of Jilin University, Changchun, CN, <sup>16</sup>Liaoning Cancer Hospital & Institute, Shenyang, CN, <sup>17</sup>The Fourth Hospital of Hebei Medical University, Shijiazhuang, CN, <sup>18</sup>Henan Provincial People's Hospital, Zhengzhou, CN, <sup>19</sup>Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, CN
- 14:45 - 14:50 **262MO - Prognostic significance of deep and rapid prostate-specific antigen (PSA) response with docetaxel (DOC) or abiraterone (ABI): A territory-wide real-world analysis of 574 Asian metastatic hormone-sensitive prostate cancer (mHSPC) patients**

D. Poon<sup>1</sup>, B. Lam<sup>2</sup>, V. Tsang<sup>2</sup>, M.P. Lee<sup>2</sup>, C.L. Tz<sup>3</sup>, B. Ng<sup>4</sup>, B. Wo<sup>5</sup>, K.C. Leung<sup>5</sup>, H.C. Lam<sup>6</sup>, W.H. Mui<sup>5</sup>, T. Chan<sup>7</sup>, S. Siu<sup>8</sup>, K. Chan<sup>3</sup>, <sup>1</sup>The Chinese University of Hong Kong, Hong Kong, HK, <sup>2</sup>Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK, <sup>3</sup>Pamela Youde Nethersole Eastern Hospital, Hong Kong, HK, <sup>4</sup>Princess Margaret Hospital, Kowloon, HK, <sup>5</sup>Tuen Mun Hospital, Tuen Mun, HK, <sup>6</sup>HKIOC - Hong Kong Integrated Oncology Centre, Hong Kong, HK, <sup>7</sup>Queen Elizabeth Hospital, Kowloon, HK, <sup>8</sup>The University of Hong Kong - Queen Mary Hospital, Hong Kong, HK

14:50 - 14:55 **263MO - Enzalutamide versus abiraterone plus prednisolone for Japanese non-metastatic castration-resistant prostate cancer patients: Sub-analysis from ENABLE for PCa, a multicenter, randomized controlled trial**

K. Izumi<sup>1</sup>, S. Takahara<sup>2</sup>, A. Mizokami<sup>2</sup>, <sup>1</sup>Kanazawa University Hospital, Kanazawa, JP, <sup>2</sup>Kanazawa University, Kanazawa, JP

14:55 - 15:05 **Invited Discussant 261MO, 262MO and 263MO**

M. Saad, UMMC - University Malaya Medical Centre, Kuala Lumpur, MY

15:05 - 15:10 **Q&A and discussion**

A. Speakers, Lugano, CH

15:10 - 15:15 **210MO - Low dose nivolumab with TKI in mRCC: Dosing strategies, de-escalation and survival among self-paying patients in India**

A. John<sup>1</sup>, J.T. Georgy<sup>1</sup>, A. Joel<sup>1</sup>, D.B. Thumaty<sup>1</sup>, J.P. Wisely<sup>1</sup>, N. Tj<sup>2</sup>, S. Kumar<sup>2</sup>, R.T. Chacko<sup>1</sup>, R.S. Ninan<sup>1</sup>, A. Chandramohan<sup>1</sup>, B. Yadav<sup>2</sup>, A. Singh<sup>1</sup>, <sup>1</sup>CMC - Christian Medical College Hospital, Vellore, IN, <sup>2</sup>CMC - Christian Medical College Hospital Vellore, Vellore, IN

15:15 - 15:20 **211MO - EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV&#x2b;P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)**

T. Powles<sup>1</sup>, B. Perez Valderrama<sup>2</sup>, S. Gupta<sup>3</sup>, J. Bedke<sup>4</sup>, E. Kikuchi<sup>5</sup>, J. Hoffman-Censits<sup>6</sup>, G. Iyer<sup>7</sup>, C. Vulsteke<sup>8</sup>, S.H. Park<sup>9</sup>, S.J. Shin<sup>10</sup>, D. Castellano Gauna<sup>11</sup>, G. Fornarini<sup>12</sup>, J.-R. Li<sup>13</sup>, M. Gumus<sup>14</sup>, N. Mar<sup>15</sup>, S. Narayanan<sup>16</sup>, X. Yu<sup>16</sup>, S. Gorla<sup>17</sup>, B. Homet Moreno<sup>18</sup>, M. Van Der Heijden<sup>19</sup>, <sup>1</sup>St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, <sup>2</sup>Hospital Universitario Virgen del Rocio, Seville, ES, <sup>3</sup>Taussig Cancer Center-Cleveland Clinic, Cleveland, US, <sup>4</sup>Klinikum Stuttgart - Katharinenhospital (KH), Stuttgart, DE, <sup>5</sup>St. Marianna University School of Medicine Yokohama City Seibu Hospital, Yokohama, JP, <sup>6</sup>Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, US, <sup>7</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>8</sup>AZ Maria Middelaes AZMMSJ, Gent, BE, <sup>9</sup>Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, <sup>10</sup>Yonsei University College of Medicine, Seoul, KR, <sup>11</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>12</sup>IRCCS Ospedale Policlinico San Martino, Genova, IT, <sup>13</sup>Taichung Veterans General Hospital, Taichung City, TW, <sup>14</sup>Istanbul Medeniyet University, Prof.Dr. Suleyman Yalcin City Hospital, Istanbul, TR, <sup>15</sup>UCI Health - University of California Irvine, Orange, US, <sup>16</sup>Seagen Inc., Bothell, US, <sup>17</sup>Astellas Pharma USA, Northbrook, US, <sup>18</sup>Merck & Co., Inc., Kenilworth, US, <sup>19</sup>Netherlands Cancer Institute, Amsterdam, NL

15:20 - 15:30 **Invited Discussant 210MO and 211MO**

Y. Miura, Toranomon Hospital, Minato-ku, JP

15:30 - 15:35 **Q&A and discussion**

A. Speakers, Lugano, CH

**14:15 - 15:45 Type: Educational session**

**Hall 402**

**Title: Supporting shared decision making in face of uncertainty**

Chair: Grace Yang, SG; Angela Halley, GB

14:15 - 14:35 **Anticancer treatment at the end of life: When to stop, when to proceed**

G. Kreye, Universitätsklinikum Krems, Krems an der Donau, AT

14:35 - 14:55 **Supporting caregivers of patients with advanced cancer**

S. Kaasa, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO

14:55 - 15:15 **Identifying supportive and palliative care needs for patients undergoing CAR-T therapy**

A. Halley, The Royal Marsden Hospital - Chelsea, London, GB

15:15 - 15:35 **Advance care planning and serious illness conversations**

R. Lo, CUHK - Chinese University of Hong Kong, Sha Tin, HK

15:35 - 15:55 **Q&A and discussion**

A. Speakers, Lugano, CH

**14:15 - 15:25 Type: Proffered paper session**

**Hall 406**

**Title: Proffered Paper session: Gastrointestinal tumours**

Chair: Hanneke van Laarhoven, NL; TAE WON KIM, KR

14:15 - 14:25 **1290 - Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study**

D.-Y. Oh<sup>1</sup>, Y. Janjigian<sup>2</sup>, S.-E. Al-Batran<sup>3</sup>, Z. Wainberg<sup>4</sup>, E. Van Cutsem<sup>5</sup>, D. Molena<sup>2</sup>, K. Muro<sup>6</sup>, W.J. Hyung<sup>7</sup>, L. Wyrwicz<sup>8</sup>, T. Omori<sup>9</sup>, M. Moehler<sup>10</sup>, M. Garrido<sup>11</sup>, S. Cunha Sousa Oliveira<sup>12</sup>, M. Liberman<sup>13</sup>, V. Castro Oliden<sup>14</sup>, M. Bilici<sup>15</sup>, J. Kurland<sup>16</sup>, I. Xynos<sup>17</sup>, H. Mann<sup>17</sup>, J. Tabernero<sup>18</sup>, <sup>1</sup>Seoul National University Hospital; Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, <sup>2</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>3</sup>Krankenhaus Nordwest, University Cancer Center, Frankfurt, DE, <sup>4</sup>David Geffen School of Medicine at UCLA, Los Angeles, US, <sup>5</sup>University Hospitals Leuven and KU Leuven, Leuven, BE, <sup>6</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>7</sup>Yonsei University College of Medicine, Seoul, KR, <sup>8</sup>Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, <sup>9</sup>Osaka International Cancer Institute, Osaka, JP, <sup>10</sup>Johannes Gutenberg-University Clinic, Mainz, DE, <sup>11</sup>SAGA Clinical Trial Centre and Universidad Mayor, Santiago, CL, <sup>12</sup>Northern Riograndense League Against



Cancer, Natal, BR, <sup>13</sup>Centre Hospitalier de l'Université de Montréal, Centre de Recherche du CHUM, Montréal, CA, <sup>14</sup>National Institute of Neoplastic Diseases (INEN), Lima, PE, <sup>15</sup>Atatürk University Faculty of Medicine, Erzurum, TR, <sup>16</sup>AstraZeneca, Gaithersburg, US, <sup>17</sup>AstraZeneca, Cambridge, GB, <sup>18</sup>Vall d'Hebron Hospital Campus & Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, ES

- 14:25 - 14:35 **1300 - The phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2<sup>+</sup>; metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma**  
S.Y. Rha<sup>1</sup>, A. Kawazoe<sup>2</sup>, Y. Bai<sup>3</sup>, J. Xu<sup>4</sup>, S. Lonardi<sup>5</sup>, J.-P. Metges<sup>6</sup>, P. Yanez Weber<sup>7</sup>, L. Wyrwicz<sup>8</sup>, L. Shen<sup>9</sup>, Y. Ostapenko<sup>10</sup>, M. Bilici<sup>11</sup>, H.C. Chung<sup>1</sup>, K. Shitara<sup>2</sup>, S. Qin<sup>12</sup>, E. Van Cutsem<sup>13</sup>, J. Tabernero<sup>14</sup>, K. Li<sup>15</sup>, C.-S. Shih<sup>15</sup>, P. Bhagia<sup>15</sup>, Y. Janjigian<sup>16</sup>, <sup>1</sup>Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, <sup>2</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>3</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>4</sup>The Fifth Medical Center, Chinese PLA General Hospital, Beijing, CN, <sup>5</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>6</sup>University Hospital of Brest, Brest, FR, <sup>7</sup>Universidad de La Frontera, James Lind Cancer Research Center, Temuco, CL, <sup>8</sup>Maria Sklodowska Curie National Cancer Research Institute, Warsaw, PL, <sup>9</sup>Peking University Cancer Hospital and Institute, Beijing, CN, <sup>10</sup>Clinic of National Cancer Institute, Kyiv, UA, <sup>11</sup>Atatürk University Faculty of Medicine, Erzurum, TR, <sup>12</sup>Cancer Center of People's Liberation Army, Nanjing, CN, <sup>13</sup>University Hospitals Gasthuisberg and KU Leuven, Leuven, BE, <sup>14</sup>Vall d'Hebron Hospital Campus & Institute of Oncology (VHIO), Barcelona, ES, <sup>15</sup>Merck & Co., Inc., Rahway, US, <sup>16</sup>Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College, New York, US
- 14:35 - 14:40 **Invited Discussant - surgical perspective of 1290 and 1300**  
J. So, NUHS - National University Health System, Singapore, SG
- 14:40 - 14:50 **Invited Discussant 1290 and 1300**  
E. Smyth, Oxford University Hospitals NHS Foundation Trust - Churchill Hospital, Oxford, GB
- 14:50 - 15:00 **Q&A and discussion**  
A. Speakers, Lugano, CH
- 15:00 - 15:10 **890 - Long-term outcomes of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): A randomized, multicenter, prospective, phase III trial**  
Z. Pan<sup>1</sup>, R. Zhang<sup>1</sup>, X. Wu<sup>1</sup>, D.-S. Wan<sup>1</sup>, J.-Z. Lin<sup>1</sup>, P.-R. Ding<sup>1</sup>, L. Liao<sup>1</sup>, J. Lei<sup>2</sup>, Z. Lu<sup>1</sup>, L. Li<sup>1</sup>, G. Chen<sup>1</sup>, L.-H. Kong<sup>1</sup>, F. Wang<sup>1</sup>, W. Fan<sup>1</sup>, W. Jiang<sup>1</sup>, W. Zhou<sup>1</sup>, C. Li<sup>1</sup>, Y. Li<sup>1</sup>, J. Peng<sup>1</sup>, <sup>1</sup>Sun Yat-sen University Cancer Center, Guangzhou, CN, <sup>2</sup>The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN
- 15:10 - 15:20 **Invited Discussant 890**  
J. Taieb, Hopital European George Pompidou, Paris, FR

15:20 - 15:25	<b>Q&amp;A and discussion</b> <u>A. Speakers</u> , Lugano, CH	
<b>14:15 - 15:45</b>	<b>Type: Educational session</b> <b>Title: 'Levelling up': Reducing inequalities in outcomes through the use of global standards</b> Chair: <u>Jean-Yves Blay</u> , FR; <u>Ravindran Kanesvaran</u> , SG	<b>Hall 407</b>
14:15 - 14:30	<b>Setting the scene: Overview of key inequalities in the Asia-Pacific (AP) region and worldwide</b> <u>R. Kanesvaran</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
14:30 - 14:50	<b>Inequities in access to standards of care in the AP region</b> <u>M. Shah</u> , Tata Memorial Centre, Mumbai, IN	
14:50 - 15:10	<b>The strategies of ERN to reduce inequities in EU (example of Genturis or Euracan)</b> <u>P.G. Casali</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT	
15:10 - 15:30	<b>Measuring inequities in a single country</b> <u>A. Kawai</u> , NCCH - National Cancer Center Hospital-Tsukiji Campus, Tokyo, JP	
15:30 - 15:45	<b>Clinical Practice Guidelines (CPG) as tools to reduce inequities in the AP region</b> <u>L.-T. Chen</u> , National Health Research Institutes - National Institute of Cancer Research, Tainan City, TW	
<b>15:50 - 17:00</b>	<b>Type: Special session</b> <b>Title: ESMO Women for Oncology Forum: How can we bring about progress towards gender equity?</b> Chair: <u>Janice Wing-Hang Tsang</u> , HK	<b>Discussion hub (exhibition area)</b>
15:50 - 17:00	<b>Panellists</b> <u>E. Lim</u> <sup>1</sup> , <u>M. Md Yusof</u> <sup>2</sup> , <u>D. Mukherji</u> <sup>3</sup> , <u>J.H. Kim</u> <sup>4</sup> , <sup>1</sup> NCCS - National Cancer Centre Singapore, Singapore, SG, <sup>2</sup> Pantai Hospital Kuala Lumpur, Kuala Lumpur, MY, <sup>3</sup> Clemenceau Medical Center, Dubai, AE, <sup>4</sup> Seoul National University Bundang Hospital, Seongnam, KR	

<b>16:00 - 17:00</b>	<b>Type: Industry satellite symposium</b> <b>Title: GSK - Evolving role of immune checkpoint inhibitors (ICIs) in solid tumors: Expert perspectives</b> Chair: Wen Son Hsieh, SG	<b>Hall 405</b>
16:00 - 16:05	<b>Breakthrough evolution in treatment landscape for solid tumors with ICIs</b> <u>W.S. Hsieh</u> , Icon Cancer Centre - Mount Elizabeth Medical Clinic, Singapore, SG	
16:05 - 16:20	<b>Key considerations in advanced/recurrent treatment of EC</b> <u>D.S. Tan</u> , NUHS - National University Health System, Singapore, SG	
16:20 - 16:35	<b>Perspective on single-agent PD-1 blockade in dMMR CRC/solid tumors</b> <u>T. Yoshino</u> , National Cancer Center Hospital East, Kashiwa, JP	
16:35 - 16:50	<b>Novel checkpoint combinations for advanced NSCLC</b> <u>B.C. Cho</u> , Yonsei University, Seoul, KR	
16:50 - 17:00	<b>General Q&amp;A and closing</b> <u>A. Speakers</u> , Lugano, CH	
<b>16:00 - 17:00</b>	<b>Type: Industry satellite symposium</b> <b>Title: AstraZeneca - Across the HR spectrum: Exploring the optimisation and personalisation of HR-positive, HER2-negative mBC care</b> Chair: Rebecca Dent, SG	<b>Hall 404</b>
16:00 - 16:05	<b>Welcome and introduction of faculty</b> <u>R. Dent</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
16:05 - 16:20	<b>The HR spectrum: Where we are now</b> <u>N. Harbeck</u> , Ludwig Maximilians University - Grosshadern, Munich, DE	
16:20 - 16:35	<b>Emerging treatments in HR-positive HER2-negative mBC: What's on the horizon?</b> <u>S. Loi</u> , Peter MacCallum Cancer Centre, Melbourne, AU	
16:35 - 16:55	<b>Optimising patient care: Evolving treatment strategies</b> <u>R. Dent</u> <sup>1</sup> , <u>N. Harbeck</u> <sup>2</sup> , <u>S. Loi</u> <sup>3</sup> , <sup>1</sup> NCCS - National Cancer Centre Singapore, Singapore, SG, <sup>2</sup> Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>3</sup> Peter MacCallum Cancer Centre, Melbourne, AU	
16:55 - 17:00	<b>Summary and closing remarks</b> <u>R. Dent</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	

**16:00 - 17:00** **Type: Industry satellite symposium** **Hall 401**  
**Title: F. Hoffmann-La Roche Ltd. - HCC illuminated: Exploring future frontiers with systemic immunotherapies**  
 Chair: Han Chong Toh, SG

16:00 - 16:05 **Welcome and opening remarks**  
H.C. Toh, NCCS - National Cancer Centre Singapore, Singapore, SG

16:05 - 16:25 **Plenary presentation: Expanding role of systemic immunotherapy in the management of HCC**  
A.-L. Cheng, NTUH - National Taiwan University Hospital, Taipei City, TW

16:25 - 16:40 **Case discussion: Systemic therapy, locoregional therapy or both?**  
H. Sun, Zhongshan Hospital of Fudan University, Shanghai, CN

16:40 - 16:55 **Case discussion: Adjuvant therapy in HCC, who and how?**  
P. Chow, NCCS - National Cancer Centre Singapore, Singapore, SG

16:55 - 17:00 **Audience Q&A/Closing remarks**  
H.C. Toh, NCCS - National Cancer Centre Singapore, Singapore, SG

**16:00 - 17:00** **Type: Industry satellite symposium** **Hall 402**  
**Title: MSD - Advances of immunotherapy in gynecological and genitourinary cancers**  
 Chair: Natalie Ngoi, SG; Darren Poon, HK

16:00 - 16:05 **Opening remarks**  
N. Ngoi<sup>1</sup>, D. Poon<sup>2</sup>, <sup>1</sup>NUHS - National University Health System, Singapore, SG, <sup>2</sup>The Chinese University of Hong Kong, Hong Kong, HK

16:05 - 16:25 **Recent advances in advanced urothelial cancers: Time for a new standard of care?**  
T. Friedlander, UCSF - University of California San Francisco, San Francisco, US

16:25 - 16:45 **Advances of immunotherapy in cervical cancer treatment**  
C. Scott, Walter and Eliza Hall Institute WEHI, Parkville, AU

16:45 - 16:55 **Q&A and discussion**

16:55 - 17:00 **Closing**  
N. Ngoi<sup>1</sup>, D. Poon<sup>2</sup>, <sup>1</sup>NUHS - National University Health System, Singapore, SG, <sup>2</sup>The Chinese University of Hong Kong, Hong Kong, HK

**16:00 - 17:00**    **Type: Industry satellite symposium**    **Hall 407**  
**Title: Ipsen Pharma - Exploring optimal management of advanced RCC, HCC and RAI-DTC**  
Chair: Seng-Weng Wong, SG

16:00 - 16:05    **Welcome and opening**  
S.-W. Wong, The Cancer Centre, Singapore Medical Group, Singapore, SG

16:05 - 16:15    **Advances in management of advanced RCC**  
C.G. Kim, Yonsei Cancer Center Yonsei University, Seoul, KR

16:15 - 16:25    **Optimal sequencing in the hepatocellular carcinoma**  
S. Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK

16:25 - 16:35    **Treatment sequencing in RAI-DTC**  
J. Capdevila Castillon, Vall d'Hebron University Hospital, Barcelona, ES

16:35 - 16:55    **Q&A**  
A. Speakers, Lugano, CH

16:55 - 17:00    **Closing**  
S.-W. Wong, The Cancer Centre, Singapore Medical Group, Singapore, SG

<b>17:15 - 18:30</b>	<b>Type: Collaborative session</b> <b>Title: Collaborative session: The evolving screening and treatment paradigm in patients with hepatobiliary cancers</b> Chair: Demetris Papamichael, CY; Connie Diakos, AU	<b>Hall 405</b>
17:15 - 17:30	<b>Breakthroughs in prevention and screening of hepato biliary cancers</b> <u>D. Papamichael</u> , Bank of Cyprus Oncology Centre, Nicosia, CY	
17:30 - 17:45	<b>Strategies of molecular profiling of hepato biliary cancers: Perceived value and ongoing research</b> <u>C. Diakos</u> , RNSH - Royal North Shore Hospital, St Leonards, AU	
17:45 - 18:00	<b>Targeting key oncodrivers in hepato biliary cancers: State of the art</b> <u>L.-T. Chen</u> , National Health Research Institutes - National Institute of Cancer Research, Tainan City, TW	
18:00 - 18:15	<b>Tackling survivorship issues in patients with hepato biliary cancers</b> <u>A. Wong</u> , Te Whatu Ora-Capital, Coast and Hutt Valley, Wellington, NZ	
18:15 - 18:30	<b>Q&amp;A and discussion</b> <u>A. Speakers</u> , Lugano, CH	
<b>17:15 - 18:30</b>	<b>Type: Collaborative session</b> <b>Title: Collaborative session: Cellular therapies for precision oncology: What is the way forward?</b> Chair: Jean-Yves Blay, FR; Junichiro Yuda, JP	<b>Hall 404</b>
17:15 - 17:30	<b>Cell-based therapeutics: The concept and progress in ongoing research</b> <u>J. Yuda</u> , Japan Society of Clinical Oncology, Tokyo, JP	
17:30 - 17:45	<b>Implementing cell-based therapies in reference centers and networks: Bottlenecks and opportunities</b> <u>H.C. Toh</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
17:45 - 18:00	<b>Challenges in the development and regulatory approval of cell-based therapies in Asia</b> <u>M. Li</u> , The Chinese University of Hong Kong, Sha Tin, HK	
18:00 - 18:15	<b>Cell-based therapies and the new EU Pharmaceutical Regulation proposal</b> <u>J.-Y. Blay</u> , Centre Léon Bérard, Lyon, FR	
18:15 - 18:30	<b>Q&amp;A and discussion</b> <u>A. Speakers</u> , Lugano, CH	

**17:15 - 18:30** **Type: Collaborative session** **Hall 401**  
**Title: Collaborative session: Optimising drug development in Asia Pacific**  
 Chair: Brigette Ma, HK; Qian Chu, CN

17:15 - 17:17 **Introduction**  
B. Ma, The Chinese University of Hong Kong, Sha Tin, HK

17:17 - 17:32 **Early phase oncology drug development in Asia Pacific**  
Q. Chu, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN

17:32 - 17:47 **The optimal positioning and use of platform trial designs in drug development in oncology**  
B. Sirohi, BALCO Medical Centre - Vedanta Medical Research Foundation, Naya Raipur, IN

17:47 - 18:02 **Empowering networks and community hospitals for participation in cancer phase III trials**  
N. Ngamphaiboon, Mahidol University - Faculty of Medicine - Ramathibodi Hospital, Bangkok, TH

18:02 - 18:17 **Assessing the clinical value of new cancer therapeutics in real life settings: Tools and challenges**  
B. Ma, The Chinese University of Hong Kong, Sha Tin, HK

18:17 - 18:30 **Q&A and discussion**  
A. Speakers, Lugano, CH

**17:15 - 18:00** **Type: Challenge your Expert** **Summit 2**  
**Title: Challenge your Expert roundtables: Limited availability only**

17:15 - 17:15 **Table 1: Optimising therapy for pre-menopausal patients with early breast cancer**  
P. Dubsy<sup>1</sup>, S. Saji<sup>2</sup>, <sup>1</sup>Hirslanden Klinik St. Anna, Lucerne, CH, <sup>2</sup>Fukushima Medical University, Fukushima, JP

17:15 - 17:15 **Table 2: Improving prognosis in HR+/HER2- metastatic breast cancer**  
S.-A. Im<sup>1</sup>, M. Md Yusof<sup>2</sup>, <sup>1</sup>SNUH - Seoul National University Hospital, Seoul, KR, <sup>2</sup>Pantai Hospital Kuala Lumpur, Kuala Lumpur, MY

17:15 - 17:15 **Table 3: Standards and advances for isocitrate dehydrogenase (IDH)-mutant gliomas**  
E. Razis, Hygeia Hospital, Marousi, GR

17:15 - 17:15 **Table 4: How to successfully run a molecular tumour board**

M. Krebs<sup>1</sup>, C.-C. Lin<sup>2</sup>, <sup>1</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>2</sup>NTUH - National Taiwan University Hospital, Taipei City, TW

- 17:15 - 17:15 **Table 5: Novel application of circulating tumor DNA (ctDNA) and other biomarkers in individualising therapy for gastrointestinal cancers**  
J. Tie<sup>1</sup>, T. Yoshino<sup>2</sup>, <sup>1</sup>Peter MacCallum Cancer Centre, Melbourne, AU, <sup>2</sup>National Cancer Center Hospital East, Kashiwa, JP
- 17:15 - 17:15 **Table 6: Escalation or de-escalation of first-line therapy in metastatic clear cell renal cell carcinoma (mRCC)?**  
L. Albiges<sup>1</sup>, L. Pickering<sup>2</sup>, <sup>1</sup>Institut Gustave Roussy, Villejuif, Cedex, FR, <sup>2</sup>The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB
- 17:15 - 17:15 **Table 7: How do you select which patient gets PARPi in first-line?**  
K. Fujiwara<sup>1</sup>, D.S. Tan<sup>2</sup>, <sup>1</sup>Saitama Medical University International Medical Center, Saitama, JP, <sup>2</sup>NUHS - National University Health System, Singapore, SG
- 17:15 - 17:15 **Table 8: Follicular lymphoma**  
C. Buske, Ulm Medical University, Ulm, DE
- 17:15 - 17:15 **Table 9: Treatment options for relapsing/metastatic head and neck cancer (RM HNC) after platinum and immunotherapy**  
C. Resteghini, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT
- 17:15 - 17:15 **Table 10: Predicting response to immune checkpoint inhibitors**  
D.S.W. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG
- 17:15 - 17:15 **Table 11: Managing immune related adverse events without compromising immune checkpoint inhibitors (ICI) response**  
K. Suijkerbuijk, UMC-University Medical Center Utrecht, Utrecht, NL
- 17:15 - 17:15 **Table 12: Desmoid fibromatosis: To treat or not to treat**  
A. Gronchi, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT
- 17:15 - 17:15 **Table 13: Palliative emergencies in oncology: What every oncologist should know**  
J. Wood, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB
- 17:15 - 17:15 **Table 14: Controversies in the management of EGFR+ non-small cell lung cancer (NSCLC)**  
T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK



02-12-2023

**09:00 - 10:00**    **Type: Proffered paper session**    **Hall 405**  
**Title: Proffered Paper session: Genitourinary tumours**  
 Chair: Lisa Pickering, GB; Deborah Mukherji, AE

09:00 - 09:10    **2550 - Darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) in the phase III ARASENS study**

S. Wang<sup>1</sup>, C. Fu<sup>2</sup>, Y. Li<sup>3</sup>, J. Xing<sup>4</sup>, L. Zhou<sup>5</sup>, Y. Yang<sup>6</sup>, H. Wang<sup>1</sup>, M.R. Smith<sup>7</sup>, B. Tombal<sup>8</sup>, M. Hussain<sup>9</sup>, Y. Niu<sup>10</sup>, L. Cai<sup>10</sup>, Q. Liu<sup>10</sup>, N. Littleton<sup>11</sup>, R. Li<sup>12</sup>, D. Ye<sup>1</sup>, <sup>1</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>2</sup>Liaoning Cancer Hospital & Institute, Shenyang, CN, <sup>3</sup>Hubei Cancer Hospital, Wuhan, CN, <sup>4</sup>The First Affiliated Hospital of Xiamen University, Xiamen, CN, <sup>5</sup>Peking University First Hospital, Beijing, CN, <sup>6</sup>Beijing Cancer Hospital, Beijing, CN, <sup>7</sup>Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, US, <sup>8</sup>Division of Urology, IREC, Cliniques Universitaires Saint Luc, UCLouvain, Brussels, BE, <sup>9</sup>Northwestern University, Feinberg School of Medicine, Chicago, IL, US, <sup>10</sup>Bayer Healthcare Co Ltd, Beijing, CN, <sup>11</sup>Bayer Ltd, Dublin, IE, <sup>12</sup>Bayer HealthCare Pharmaceuticals Inc., Whippany, US

09:10 - 09:20    **2560 - Prostate-specific antigen response to different real-world treatments in high-risk metastatic hormone-naïve prostate cancer in J-ROCK registry study**

A. Mizokami<sup>1</sup>, R. Matsumoto<sup>2</sup>, K. Fujimoto<sup>3</sup>, H. Miyake<sup>4</sup>, H. Uemura<sup>5</sup>, H. Uemura<sup>6</sup>, S. Kawakami<sup>7</sup>, K. Nakamura<sup>8</sup>, S. Maekawa<sup>9</sup>, K. Shibayama<sup>10</sup>, Y. Tajima<sup>10</sup>, T. Kamoto<sup>11</sup>, H. Matsuyama<sup>12</sup>, <sup>1</sup>Kanazawa University, Kanazawa, JP, <sup>2</sup>Chutoen General Medical Center, Kakegawa, JP, <sup>3</sup>Nara Medical University, Nara, JP, <sup>4</sup>Hamamatsu University School of Medicine, Hamamatsu, JP, <sup>5</sup>Yokohama City University Medical Center, Yokohama, JP, <sup>6</sup>Kindai University - Faculty of Medicine, Osaka, JP, <sup>7</sup>Saitama Medical Center, Saitama Medical University, Kawagoe, JP, <sup>8</sup>Kimitsu Chuo Hospital, Kisarazu, JP, <sup>9</sup>Iwate Medical University School of Medicine, Shiwa-gun, Iwate, JP, <sup>10</sup>Janssen Pharmaceutical K.K., Chiyoda-ku, JP, <sup>11</sup>University of Miyazaki Hospital, Miyazaki, JP, <sup>12</sup>Yamaguchi University Graduate School of Medicine, Ube, JP

09:20 - 09:30    **2570 - Association of enzalutamide (ENZA) duration of treatment (DOT) and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis from PREVAIL**

E. Chiong<sup>1</sup>, C.S. Kim<sup>2</sup>, Y.D. Choi<sup>3</sup>, B. Tombal<sup>4</sup>, M. Lian<sup>5</sup>, G. Gourgioti<sup>6</sup>, A. Dhar<sup>7</sup>, Z. Xiao<sup>5</sup>, F. Zohren<sup>8</sup>, T. Beer<sup>9</sup>, <sup>1</sup>NUH - National University Hospital (S) Pte. Ltd., Singapore, SG, <sup>2</sup>Ewha Womans University Mokdong Hospital, Seoul, KR, <sup>3</sup>Yonsei University, Seoul, KR, <sup>4</sup>Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE, <sup>5</sup>Astellas China Investment Co. Ltd., Beijing, China, Beijing, CN, <sup>6</sup>Astellas Pharma Europe Ltd, Addlestone, GB, <sup>7</sup>Astellas Pharma Singapore Pte. Ltd., Singapore, SG, <sup>8</sup>Pfizer, Cambridge, US, <sup>9</sup>OHSU - Center for Health & Healing Building 2, Portland, US

09:30 - 09:45    **Invited Discussant 2550, 2560 and 2570**  
D. Mukherji, Clemenceau Medical Center, Dubai, AE

09:45 - 09:55    **Q&A and discussion**

A. Speakers, Lugano, CH

**09:00 - 10:20** **Type: Proffered paper session** **Hall 404**  
**Title: Proffered Paper session: Head and neck cancer**  
 Chair: Naomi Kiyota, JP; Darren Wan-Teck Lim, SG

- 09:00 - 09:10 **3530 - Efficacy and safety of ENZ-124 versus innovator cetuximab in combination with platinum-based chemotherapy in patients with recurrent locoregional or metastatic squamous cell carcinoma of the head and neck (SCCHN)**
- N. Dhamne<sup>1</sup>, M. Jain<sup>2</sup>, R. Nagarkar<sup>3</sup>, S.K. Das Majumdar<sup>4</sup>, C. Deshmukh<sup>5</sup>, R. Dana<sup>6</sup>, P. Ganesan<sup>7</sup>, K. Chatterjee<sup>8</sup>, S. Chatterjee<sup>9</sup>, K. Prabhash<sup>10</sup>, A. Sharma<sup>11</sup>, V.K. Mahobia<sup>12</sup>, R. Kumar<sup>13</sup>, P. S.S.<sup>14</sup>, M. A<sup>15</sup>, P.K. Chaitnya<sup>16</sup>, V. Choudhary<sup>17</sup>, H. Malhotra<sup>18</sup>, S. Aagre<sup>19</sup>, V. Maniar<sup>20</sup>, <sup>1</sup>Kolhapur Cancer Centre, Kolhapur, IN, <sup>2</sup>KEM Hopistal Research Centre, Day Care Centre, Banoo Coyaji Building, Pune, Pune, IN, <sup>3</sup>HCG Manavata Cancer Centre, Nasik, IN, <sup>4</sup>AIIMS-All India Institute of Medical Sciences - Bhubaneswar, Bhubaneswar, IN, <sup>5</sup>Deenanath Mangeshkar Hospital & Research Centre, Pune, IN, <sup>6</sup>SMS Hospital, Jaipur, IN, <sup>7</sup>JIPMER - Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IN, <sup>8</sup>Belle Vue Clinic, Kolkata, IN, <sup>9</sup>TMC - Tata Medical Center, Kolkata, IN, <sup>10</sup>Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN, <sup>11</sup>AIIMS - All India Institute of Medical Sciences, New Delhi, IN, <sup>12</sup>GMC - Government Medical College and Hospital Nagpur (MS), Nagpur, IN, <sup>13</sup>RCC - Regional Cancer Centre, Thiruvananthapuram, Thiruvananthapuram, IN, <sup>14</sup>Mysore Medical College and Research Institute, Mysore, IN, <sup>15</sup>Malabar Cancer Centre, Thalassery, IN, <sup>16</sup>MNJ Institute of Oncology & Regional Cancer Center, Hyderabad, IN, <sup>17</sup>Rashtrasant Tukadoji Regional Cancer Hospital and Rsearch Centre, 44F3+HJ4, Rameshwari, Nagpur, Maharashtra, Nagpur, IN, <sup>18</sup>MGMCH - Mahatma Gandhi Medical College & Hospital, Jaipur, IN, <sup>19</sup>Aayush Hospital, 102-1, First floor, Laxman Archade, Mumbai, IN, <sup>20</sup>MOC - Mumbai Oncocare Centre, Mumbai, IN
- 09:10 - 09:20 **3540 - A phase Ib/II study of nanatinostat (Nstat) plus valganciclovir (VGCV) in EBV<#x2b> solid tumors and with pembrolizumab (PEM) in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC)**
- A.D. Colevas<sup>1</sup>, L. Siu<sup>2</sup>, D.W.-T. Lim<sup>3</sup>, B. Gao<sup>4</sup>, P.J. Voon<sup>5</sup>, S. Khan<sup>6</sup>, L. Eng<sup>7</sup>, M.-J. Ahn<sup>8</sup>, V. Lee<sup>9</sup>, H.M. Wang<sup>10</sup>, M.-H. Yang<sup>11</sup>, D. Bowles<sup>12</sup>, R. Ferrarotto<sup>13</sup>, A. Elguindy<sup>14</sup>, A. Katkov<sup>14</sup>, K. MCGovern<sup>14</sup>, B. Ma<sup>15</sup>, <sup>1</sup>Stanford University School of Medicine, Stanford, US, <sup>2</sup>Princess Margaret Cancer Centre, Toronto, CA, <sup>3</sup>NCCS - National Cancer Centre Singapore, Singapore, SG, <sup>4</sup>Blacktown Hospital, Blacktown, AU, <sup>5</sup>Sarawak General Hospital, Kuching, MY, <sup>6</sup>Stanford University Medical Center, Stanford, US, <sup>7</sup>UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, <sup>8</sup>Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, <sup>9</sup>The University of Hong Kong - Li Ka Shing Faculty of Medicine, Hong Kong, HK, <sup>10</sup>Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW, <sup>11</sup>Taipei Veterans General Hospital, Taipei City, TW, <sup>12</sup>UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US, <sup>13</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US, <sup>14</sup>Viracta Therapeutics, Inc., Cardiff-by-the-Sea, US, <sup>15</sup>The Chinese University of Hong Kong, Sha Tin, HK

09:20 - 09:30 **Invited Discussant 3530 and 3540**

S. Oosting, UMCG - University Medical Center Groningen, Groningen, NL

09:30 - 09:40 **Q&A and discussion**

A. Speakers, Lugano, CH

09:40 - 09:50 **3550 - Artificial intelligence-powered spatial analysis of tumor microenvironment (TME) in nasopharyngeal carcinoma (NPC) patients treated with immune checkpoint inhibitors (ICI)**

B. Keam<sup>1</sup>, D.W.-T. Lim<sup>2</sup>, C.-Y. Ock<sup>3</sup>, T. Lee<sup>3</sup>, C. Oum<sup>3</sup>, H.-F. Kao<sup>4</sup>, J.P.S. Yeong<sup>2</sup>, B.-C. Goh<sup>5</sup>, S.H. Tan<sup>2</sup>, E. Hui<sup>6</sup>, H.A. Jung<sup>7</sup>, K.U. Park<sup>8</sup>, S.-H. Cho<sup>9</sup>, K.-W. Lee<sup>10</sup>, A.T.C. Chan<sup>6</sup>, B. Ma<sup>6</sup>,  
<sup>1</sup>Seoul National University Hospital, Seoul, KR, <sup>2</sup>NCCS - National Cancer Centre Singapore, Singapore, SG, <sup>3</sup>Lunit Inc., Seoul, KR, <sup>4</sup>NTUH - National Taiwan University Hospital, Taipei City, TW, <sup>5</sup>NCIS - National University Cancer Institute Singapore, Singapore, SG, <sup>6</sup>CUHK - Chinese University of Hong Kong, Sha Tin, HK, <sup>7</sup>Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, <sup>8</sup>Dongsan Medical Center Kemyung University Hospital, Daegu, KR, <sup>9</sup>Chonnam National University Medical School & Chonnam National University Hwasun Hospital, Hwasun, KR, <sup>10</sup>Seoul National University Bundang Hospital, Seongnam, KR

09:50 - 10:00 **3560 - Construction of an immune-related adverse events prediction model for teripulimab in the treatment of recurrent metastatic nasopharyngeal carcinoma and its analysis with survival prognosis**

Q.Y. Chen<sup>1</sup>, R. Liu<sup>2</sup>, S.-S. Guo<sup>1</sup>, P. Wang<sup>1</sup>, L. Mei<sup>3</sup>, R. Sun<sup>1</sup>, <sup>1</sup>Sun Yat-sen University Cancer Center, Guangzhou, CN, <sup>2</sup>Sun Yat-sen University Cancer Center, Guangzhou, CN, <sup>3</sup>Sun Yat-Sen University, Guangzhou, CN

10:00 - 10:10 **Invited Discussant 3550 and 3560**

M.-H. Yang, Taipei Veterans General Hospital, Taipei City, TW

10:10 - 10:20 **Q&A and discussion**

A. Speakers, Lugano, CH

**09:00 - 10:20 Type: Proffered paper session Hall 401**  
**Title: Proffered Paper session: Breast cancer**  
 Chair: Peter Dubsy, CH; Giuseppe Curigliano, IT

09:00 - 09:10 **LBA4 - Sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in Asian patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR<sup>+</sup>/HER2<sup>-</sup>) metastatic breast cancer (mBC): Results from the phase III EVER-002 study**

B. Xu<sup>1</sup>, F. Ma<sup>1</sup>, S. Wang<sup>2</sup>, M. Yan<sup>3</sup>, W. Li<sup>4</sup>, J. Sohn<sup>5</sup>, J. Tang<sup>6</sup>, X. Wang<sup>7</sup>, Y. Wang<sup>8</sup>, S.-A. Im<sup>9</sup>, D. Jiang<sup>10</sup>, T. Valdez<sup>11</sup>, Y. Zhang<sup>11</sup>, K. Komatsubara<sup>11</sup>, W.-P. Chung<sup>12</sup>, <sup>1</sup>Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, CN, <sup>2</sup>Sun Yat-sen University Cancer Center, Guangzhou, CN, <sup>3</sup>Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, <sup>4</sup>The First Hospital of Jilin University, Changchun, CN, <sup>5</sup>Yonsei Cancer Center, Seoul, KR, <sup>6</sup>The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN, <sup>7</sup>Zhejiang Cancer Hospital, Hangzhou, CN, <sup>8</sup>Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China, Guangzhou, CN, <sup>9</sup>SNUH -

Seoul National University Hospital, Seoul, KR, <sup>10</sup>Gilead Sciences, Inc., Shanghai, CN, <sup>11</sup>Gilead Sciences, Inc., Foster City, US, <sup>12</sup>National Cheng Kung University, Tainan City, TW

- 09:10 - 09:20 **540 - Safety outcomes by UGT1A1 status in the phase III TROPiCS-02 study of sacituzumab govitecan (SG) in HR+/HER2- metastatic breast cancer (mBC)**  
V. Heong<sup>1</sup>, F. Marmé<sup>2</sup>, H. Rugo<sup>3</sup>, S. Tolaney<sup>4</sup>, A. Bardia<sup>5</sup>, P. Schmid<sup>6</sup>, W. Verret<sup>7</sup>, T. Valdez<sup>7</sup>, H. Wang<sup>8</sup>, J. Cortes<sup>9</sup>, <sup>1</sup>National Healthcare Group - Tan Tock Seng Hospital, Singapore, SG, <sup>2</sup>UMM - Universitaetsklinikum Mannheim - Medizinische Fakultät, Mannheim, DE, <sup>3</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>4</sup>Dana Farber Cancer Institute, Boston, US, <sup>5</sup>Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US, <sup>6</sup>Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB, <sup>7</sup>Gilead Sciences, Inc., Miami, US, <sup>8</sup>Gilead Sciences, Inc. - Headquarters, Foster City, US, <sup>9</sup>MEDSIR - Medica Scientia Innovation Research, Barcelona, ES
- 09:20 - 09:30 **Invited Discussant one LBA4 and 540**  
S. Dawood, Mediclinic City Hospital, Dubai, AE
- 09:30 - 09:40 **Q&A and discussion**  
A. Speakers, Lugano, CH
- 09:40 - 09:50 **LBA5 - Capivasertib (C) &#x2b; fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR&#x2b;/HER2&#x2013; advanced breast cancer (ABC): Phase III CAPitello-291 trial Chinese cohort**  
X. Hu<sup>1</sup>, Q. Zhang<sup>2</sup>, T. Sun<sup>3</sup>, H. Xiong<sup>4</sup>, W. Li<sup>5</sup>, Y. Teng<sup>6</sup>, Y.-S. Lu<sup>7</sup>, L.-M. Tseng<sup>8</sup>, M. Yan<sup>9</sup>, H. Li<sup>10</sup>, D. Pang<sup>11</sup>, S.C. Chen<sup>12</sup>, W. Chen<sup>13</sup>, O. Jiang<sup>14</sup>, J. Wang<sup>15</sup>, X. Wu<sup>16</sup>, E. Fan<sup>17</sup>, L. Jiang<sup>17</sup>, X. Zeng<sup>17</sup>, N. Turner<sup>18</sup>, <sup>1</sup>Shanghai Cancer Center, Fudan University, Shanghai, CN, <sup>2</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>3</sup>Liaoning Cancer Hospital, Shenyang, CN, <sup>4</sup>Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, CN, <sup>5</sup>The First Hospital of Jilin University, Changchun, CN, <sup>6</sup>The First Hospital of China Medical University, Shenyang, CN, <sup>7</sup>National Taiwan University Hospital, Taipei, TW, <sup>8</sup>Taipei Veterans General Hospital, Taipei, TW, <sup>9</sup>The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, <sup>10</sup>Affiliated Tumor Hospital of Guangzhou Medical University, Guang Zhou Shi, Guangzhou, CN, <sup>11</sup>The First People's Hospital of Foshan, Foshan, CN, <sup>12</sup>Chang Gung Medical Foundation Linkuo Branch, Taoyuan, TW, <sup>13</sup>The Third Hospital of Nanchang, Nanchang, CN, <sup>14</sup>The Second People's Hospital of Neijiang, Neijiang, CN, <sup>15</sup>Linyi Cancer Hospital, Linyi, CN, <sup>16</sup>Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan Clinical Research Center for Breast Cancer, Wuhan, CN, <sup>17</sup>AstraZeneca, Shanghai, CN, <sup>18</sup>Royal Marsden Hospital, Institute of Cancer Research, London, GB
- 09:50 - 10:00 **550 - Phase I study of H3B-6545 in patients (pts) with estrogen receptor-positive (ER&#x2b;) breast cancer**  
M. Ono<sup>1</sup>, T. Kogawa<sup>1</sup>, S. Kitano<sup>1</sup>, T. Shimoi<sup>2</sup>, K. Yamamoto<sup>2</sup>, S. Kobayashi<sup>3</sup>, Y. Ichikawa<sup>3</sup>, K. Yamaguchi<sup>3</sup>, Y. Otake<sup>3</sup>, S. Hojo<sup>3</sup>, K. Yonemori<sup>2</sup>, <sup>1</sup>The Cancer Institute Hospital of

Japanese Foundation for Cancer Research, Tokyo, JP, <sup>2</sup>National Cancer Center Hospital, Tokyo, JP, <sup>3</sup>Eisai Co., Ltd., Tokyo, JP

10:00 - 10:10 **Invited Discussant one LBA5 and 550**

S.C. Lee, Cancer Science Institute (CSI) - National University of Singapore (NUS), Singapore, SG

10:10 - 10:20 **Q&A and discussion**

A. Speakers, Lugano, CH

**09:00 - 10:30 Type: Collaborative session**

**Hall 402**

**Title: In collaboration with AACR: Early detection of cancer**

Chair: Elizabeth Smyth, GB; Yu Shyr, US

09:00 - 09:20 **Emerging multi-cancer detection technologies in liquid biopsies**

C. Swanton, Francis Crick Institute, London, GB

09:20 - 09:40 **Novel study design and analysis for integrating multi-omics technologies for early detection of cancer**

Y. Shyr, Vanderbilt University - Department of Biostatistics, Nashville, US

09:40 - 10:00 **Novel metabolic imaging approaches for early cancer detection**

S. Adeleke, Guy's Hospital, London, GB

10:00 - 10:20 **Genomic technologies for cancer risk prognostication and early detection**

M. Diehn, Stanford University, Stanford, US

10:20 - 10:30 **Q&A and discussion**

A. Speakers, Lugano, CH

**09:00 - 10:30 Type: Mini oral session**

**Hall 406**

**Title: Mini oral session 1: Thoracic cancer**

Chair: Lizza Hendriks, NL; Beung Chul Ahn, KR

09:00 - 09:05 **508MO - Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study**

L. Paz-Ares<sup>1</sup>, M.-J. Ahn<sup>2</sup>, E. Felip<sup>3</sup>, S. Handzhiev<sup>4</sup>, I. Korantzis<sup>5</sup>, H. Izumi<sup>6</sup>, K. Ohashi<sup>7</sup>, M. Majem Tarruella<sup>8</sup>, J. Wolf<sup>9</sup>, M. Reck<sup>10</sup>, H.-D. Hummel<sup>11</sup>, F. Blackhall<sup>12</sup>, A.-M. Dingemans<sup>13</sup>, T. Owonikoko<sup>14</sup>, S. Ramalingam<sup>15</sup>, J. Sands<sup>16</sup>, T. Jiang<sup>17</sup>, S. Mukherjee<sup>18</sup>, E. Anderson<sup>17</sup>, B.C. Cho<sup>19</sup>, <sup>1</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>2</sup>Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>Universitätsklinikum Krems, Krems an der Donau, AT, <sup>5</sup>St Luke's Hospital-Agios Loukas Clinic, Thessaloniki, GR, <sup>6</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>7</sup>Okayama University Hospital, Okayama, JP, <sup>8</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>9</sup>University Hospital of Cologne, Cologne, DE, <sup>10</sup>German Center for Lung Research, Grosshansdorf, DE, <sup>11</sup>University of Würzburg,

Wuerzburg, DE, <sup>12</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>13</sup>Erasmus MC - University Medical Center, Rotterdam, NL, <sup>14</sup>University of Pittsburgh, Pittsburgh, US, <sup>15</sup>Winship Cancer Institute of Emory University, Atlanta, US, <sup>16</sup>Dana-Farber Cancer Institute, Harvard Medical School, Boston, US, <sup>17</sup>AMGEN (Headquarters) - USA, Thousand Oaks, US, <sup>18</sup>Amgen, Thousand Oaks, US, <sup>19</sup>Yonsei University, Seoul, KR

09:05 - 09:10

**509MO - Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01**

M.-J. Ahn<sup>1</sup>, A. Lisberg<sup>2</sup>, L. Paz-Ares<sup>3</sup>, R. Cornelissen<sup>4</sup>, N. Girard<sup>5</sup>, E. Pons-Tostivint<sup>6</sup>, D. Vicente Baz<sup>7</sup>, S. Sugawara<sup>8</sup>, M. Cobo Dols<sup>9</sup>, M. Pérol<sup>10</sup>, C. Mascaux<sup>11</sup>, E. Poddubskaya<sup>12</sup>, S. Kitazono<sup>13</sup>, H. Hayashi<sup>14</sup>, J. Sands<sup>15</sup>, R. Hall<sup>16</sup>, Y. Zhang<sup>17</sup>, H. Zebger-Gong<sup>18</sup>, D. Uema<sup>19</sup>, I. Okamoto<sup>20</sup>, <sup>1</sup>Samsung Medical Center, Seoul, KR, <sup>2</sup>David Geffen School of Medicine at UCLA, Los Angeles, US, <sup>3</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>4</sup>Erasmus MC - University Medical Center, Rotterdam, NL, <sup>5</sup>Institut Curie, Paris, FR, <sup>6</sup>University Hospital of Nantes, Nantes, Cedex, FR, <sup>7</sup>Hospital Universitario Virgen Macarena, Seville, ES, <sup>8</sup>Sendai Kousei Hospital, Sendai, JP, <sup>9</sup>Medical Oncology Intercenter Unit. Regional and Virgen de la Victoria University Hospitals. IBIMA, Malaga, ES, <sup>10</sup>Centre Léon Bérard, Lyon, FR, <sup>11</sup>University Hospital of Strasbourg, Strasbourg, FR, <sup>12</sup>Vitamed LLC, Moscow, RU, <sup>13</sup>The Cancer Institute Hospital of JFCR, Koto-ku, JP, <sup>14</sup>Kindai University, Osaka, JP, <sup>15</sup>Dana-Farber Cancer Institute, Harvard Medical School, Boston, US, <sup>16</sup>The University of Virginia, Charlottesville, US, <sup>17</sup>Daiichi Sankyo, Inc., Basking Ridge, US, <sup>18</sup>Daiichi Sankyo Europe GmbH, Munich, DE, <sup>19</sup>Daiichi Sankyo USA, Parsippany, US, <sup>20</sup>Kyushu University, Fukuoka, JP

09:10 - 09:15

**510MO - Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer (mNSCLC): Subgroup analysis of DESTINY-Lung02 (DL-02)**

K. Goto<sup>1</sup>, Y. Goto<sup>2</sup>, T. Kubo<sup>3</sup>, K. Ninomiya<sup>3</sup>, S.-W. Kim<sup>4</sup>, M.-J. Ahn<sup>5</sup>, K. Nakagawa<sup>6</sup>, H. Hayashi<sup>6</sup>, J. Shimizu<sup>7</sup>, D.-W. Kim<sup>8</sup>, J.C.-H. Yang<sup>9</sup>, C.-H. Kuo<sup>10</sup>, K.H. Lee<sup>11</sup>, T.-Y. Yang<sup>12</sup>, K. Pereira<sup>13</sup>, A. Taguchi<sup>14</sup>, A. Ali<sup>15</sup>, F.-C. Cheng<sup>13</sup>, R. Yonemochi<sup>13</sup>, P. Jänne<sup>16</sup>, <sup>1</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>2</sup>National Cancer Center Hospital, Tokyo, JP, <sup>3</sup>Okayama University Hospital, Okayama, JP, <sup>4</sup>Asan Medical Center, University of Ulsan, Seoul, KR, <sup>5</sup>Samsung Medical Center, Seoul, KR, <sup>6</sup>Kindai University Hospital, Osaka, JP, <sup>7</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>8</sup>SNUH - Seoul National University Hospital, Seoul, KR, <sup>9</sup>National Taiwan University Hospital, Taipei, TW, <sup>10</sup>Chang Gung Memorial Hospital, Taipei, TW, <sup>11</sup>Chungbuk National University Hospital, Cheongju, KR, <sup>12</sup>Taichung Veterans General Hospital, Taichung City, TW, <sup>13</sup>Daiichi Sankyo, Inc., Basking Ridge, US, <sup>14</sup>Daiichi Sankyo Co., Ltd., Chuo-ku, JP, <sup>15</sup>Daiichi Sankyo Europe GmbH, Munich, DE, <sup>16</sup>Dana Farber Cancer Institute, Boston, US

09:15 - 09:25

**Invited Discussant 508MO, 509MO and 510MO**

L. Hendriks, Maastricht University Medical Center (MUMC), Maastricht, NL

09:25 - 09:30

**Q&A and discussion**

A. Speakers, Lugano, CH

- 09:30 - 09:35 **LBA13 - Dostarlimab &#x2b; chemotherapy (CT) vs pembrolizumab &#x2b; CT in metastatic non-squamous non-small cell lung cancer (NSCLC): Updated Asian subgroup analyses of the PERLA trial**  
 D.H. Lee<sup>1</sup>, J.S. Ahn<sup>2</sup>, S.-H. Lin<sup>3</sup>, M. Ulanska<sup>4</sup>, G.A. Lopez<sup>5</sup>, C.-F. Chian<sup>6</sup>, L. Cho<sup>7</sup>, Z. Szijgyarto<sup>8</sup>, N. Stjepanovic<sup>9</sup>, S.M. Lim<sup>10</sup>, <sup>1</sup>University of Ulsan, College of Medicine, Asan Medical Center, Seoul, KR, <sup>2</sup>Samsung Medical Center, Sungkyunkwan University, Seoul, KR, <sup>3</sup>Changhua Christian Hospital, Changhua, TW, <sup>4</sup>Centrum Terapii Wspolczesnej, Łódź, PL, <sup>5</sup>CEMER Medical Centre, Vicente López, AR, <sup>6</sup>Tri-Service General Hospital, National Defense Medical Center, Taipei, TW, <sup>7</sup>GSK, Colleagueville, US, <sup>8</sup>GSK, Stevenage, GB, <sup>9</sup>GSK, Baar, CH, <sup>10</sup>Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, KR
- 09:35 - 09:40 **511MO - A phase I study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced non-small cell lung cancer (NSCLC)**  
J. Feng<sup>1</sup>, M. Shi<sup>1</sup>, J. Chen<sup>2</sup>, K. Li<sup>2</sup>, X. Li<sup>3</sup>, M. Sun<sup>4</sup>, B. Li<sup>5</sup>, G. Wen<sup>6</sup>, Y. Fang<sup>7</sup>, X. Min<sup>8</sup>, L. Lin<sup>9</sup>, Y. Liu<sup>10</sup>, Q. Wang<sup>11</sup>, S. Lu<sup>12</sup>, B. Zhu<sup>13</sup>, Y.-K. Shi<sup>14</sup>, H. Yu<sup>15</sup>, Y. Peng<sup>16</sup>, F. Liang<sup>17</sup>, P. Liu<sup>17</sup>, <sup>1</sup>Jiangsu Cancer Hospital, Nanjing, CN, <sup>2</sup>Hunan Cancer Hospital, Changsha, CN, <sup>3</sup>The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, <sup>4</sup>Jinan Central Hospital, Shandong First Medical University Affiliated Central Hospital, Jinan, CN, <sup>5</sup>Beijing Chest Hospital, Beijing, CN, <sup>6</sup>The First Affiliated Hospital of Nanchang University, Nanchang, CN, <sup>7</sup>Sir Run Run Shaw Hospital, Hangzhou, CN, <sup>8</sup>Anhui Chest Hospital, Hefei, CN, <sup>9</sup>The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, CN, <sup>10</sup>The First Affiliated Hospital of China Medical University, Shenyang, CN, <sup>11</sup>Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, <sup>12</sup>Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CN, <sup>13</sup>The Second Affiliated Hospital of Army Military Medical University, Chongqing, CN, <sup>14</sup>Chinese Academy of Medical Sciences, Cancer Hospital, Beijing, CN, <sup>15</sup>Chongqing Cancer Hospital, Chongqing, CN, <sup>16</sup>Xinxiang Central Hospital, Xinxiang, CN, <sup>17</sup>Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, CN
- 09:40 - 09:50 **Invited Discussant LBA13 and 511MO**  
B.C. Ahn, NCC - National Cancer Center, Goyang, KR
- 09:50 - 09:55 **Q&A and discussion**  
A. Speakers, Lugano, CH

**09:00 - 10:30**    **Type: Educational session**    **Hall 407**  
**Title: New treatment options for sarcomas**  
 Chair: Silvia Stacchiotti, IT; Herbert Ho Fung Loong, HK

09:00 - 09:25    **What is new in treatments for liposarcoma**  
H.H.F. Loong, The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK

09:25 - 09:50    **What is new in treatments for ultra-rare sarcomas**  
S. Stacchiotti, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

09:50 - 10:15    **What is new in treatments for tenosynovial giant cell tumor (TGCT)**  
E. Connolly, Chris O'Brien Lifehouse, Sydney, AU

10:15 - 10:30    **Q&A and discussion**  
A. Speakers, Lugano, CH

**10:45 - 12:15**    **Type: Proffered paper session**    **Hall 406**  
**Title: Presidential Symposium**  
 Chair: Brigette Ma, HK; Laurence Albiges, FR

10:45 - 10:55    **5070 - EXCLAIM-2: Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) and locally advanced/metastatic NSCLC**  
P. Jänne<sup>1</sup>, B.-C. Wang<sup>2</sup>, B.C. Cho<sup>3</sup>, J. Zhao<sup>4</sup>, J. Li<sup>5</sup>, M. Hochmair<sup>6</sup>, S. Peters<sup>7</sup>, B. Besse<sup>8</sup>, T. Kato<sup>9</sup>, Y.-L. Wu<sup>10</sup>, D. Nguyen<sup>11</sup>, J. Lin<sup>12</sup>, J. Lin<sup>12</sup>, F. Vranceanu<sup>12</sup>, M. Lin<sup>12</sup>, R. Fram<sup>12</sup>, T.S.K. Mok<sup>13</sup>, <sup>1</sup>Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, US, <sup>2</sup>Guangdong Provincial People's Hospital, Guangzhou, CN, <sup>3</sup>Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei New II Han Institute for Integrative Lung Cancer Research, Seoul, KR, <sup>4</sup>Beijing Cancer Hospital, Beijing, CN, <sup>5</sup>Sichuan Cancer Hospital, Chengdu, CN, <sup>6</sup>Klinik Floridsdorf, Vienna Healthcare Group, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna, AT, <sup>7</sup>Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, CH, <sup>8</sup>Institut Gustave Roussy, Villejuif, FR, <sup>9</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>10</sup>Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine South China University of Technology, Guangzhou, CN, <sup>11</sup>City of Hope National Medical Center, Duarte, US, <sup>12</sup>Takeda Development Center Americas, Inc., Lexington, US, <sup>13</sup>The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, CN

10:55 - 11:05    **Invited Discussant 5070**  
R. Soo, NCIS - National University Cancer Institute Singapore, Singapore, SG

11:05 - 11:15    **Q&A and discussion**  
A. Speakers, Lugano, CH



- 11:15 - 11:25 **LBA1 - Efficacy and safety of adjuvant alectinib vs platinum-based chemotherapy (CT) in patients (pts) from Asia with resected, early-stage ALK+ non-small cell lung cancer (NSCLC): A sub analysis of ALINA**  
J.S. Ahn<sup>1</sup>, Y.-L. Wu<sup>2</sup>, R. Dziadziuszko<sup>3</sup>, F. Barlesi<sup>4</sup>, M. Nishio<sup>5</sup>, D.H. Lee<sup>6</sup>, J.-S. Lee<sup>7</sup>, W.-Z. Zhong<sup>2</sup>, H. Horinouchi<sup>8</sup>, W. Mao<sup>9</sup>, S. Lu<sup>10</sup>, Q. Wang<sup>11</sup>, C.-T. Yang<sup>12</sup>, K. Korphaisarn<sup>13</sup>, T. Xu<sup>14</sup>, L. Bu<sup>14</sup>, A. Scalori<sup>15</sup>, P. Petric<sup>16</sup>, K. Redhead<sup>15</sup>, B. Solomon<sup>17</sup>, <sup>1</sup>Samsung Medical Center, Seoul, KR, <sup>2</sup>Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, CN, <sup>3</sup>Medical University of Gdansk, Gdansk, PL, <sup>4</sup>International Center for Thoracic Cancers (CICT), Gustave Roussy, Villejuif, FR, <sup>5</sup>Japanese Foundation for Cancer Research, Tokyo, JP, <sup>6</sup>University of Ulsan College of Medicine, Asan Medical Center, Seoul, KR, <sup>7</sup>Seoul National University Bundang Hospital, Seongnam, KR, <sup>8</sup>National Cancer Center Hospital, Tokyo, JP, <sup>9</sup>Chinese Academy of Sciences, Zhejiang, CN, <sup>10</sup>Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, <sup>11</sup>Zhongshan Hospital, Fudan University, Shanghai, CN, <sup>12</sup>Chang Gung Memorial Hospital, Taoyuan City, TW, <sup>13</sup>Siriraj Hospital, Mahidol University, Bangkok, TH, <sup>14</sup>Roche (China) Holding Ltd., Shanghai, CN, <sup>15</sup>Roche Products Ltd., Welwyn Garden City, GB, <sup>16</sup>F. Hoffmann-La Roche Ltd., Basel, CH, <sup>17</sup>Peter MacCallum Cancer Center, Melbourne, AU
- 11:25 - 11:35 **Invited Discussant LBA1**  
S. Popat, The Royal Marsden Hospital - NHS Foundation Trust, London, GB
- 11:35 - 11:45 **Q&A and discussion**  
A. Speakers, Lugano, CH
- 11:45 - 11:55 **2080 - Asian subgroup analysis of the THOR phase III study: Erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer and selected fibroblast growth factor receptor alterations**  
N. Matsubara<sup>1</sup>, Y. Loriot<sup>2</sup>, E. Burgess<sup>3</sup>, S.H. Park<sup>4</sup>, R. Huddart<sup>5</sup>, J.H. Ku<sup>6</sup>, B. Tran<sup>7</sup>, S. Triantos<sup>8</sup>, K. Deprince<sup>9</sup>, S. Mukhopadhyay<sup>10</sup>, R. Hemaya<sup>11</sup>, J. Zhuo<sup>12</sup>, A. Siefker-Radtke<sup>13</sup>, <sup>1</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>2</sup>INSERM U981, Gustave Roussy Universite Paris-Saclay, Villejuif, Cedex, FR, <sup>3</sup>Levine Cancer Institute, Charlotte, US, <sup>4</sup>Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, <sup>5</sup>Royal Marsden Hospital Institute of Cancer Research, Sutton, GB, <sup>6</sup>Seoul National University Hospital, Seoul, KR, <sup>7</sup>Peter MacCallum Cancer Centre, Melbourne, AU, <sup>8</sup>Janssen Research & Development, Spring House, US, <sup>9</sup>Janssen Research & Development, Beerse, BE, <sup>10</sup>Janssen Research & Development, Raritan, US, <sup>11</sup>Janssen Medical Affairs Asia Pacific, Melbourne, AU, <sup>12</sup>Janssen China R&D, Shanghai, CN, <sup>13</sup>The M. D. Anderson Cancer Center, Houston, US
- 11:55 - 12:05 **Invited Discussant 2080**  
E. Grande, MD Anderson Cancer Center Madrid, Madrid, ES
- 12:05 - 12:15 **Q&A and discussion**  
A. Speakers, Lugano, CH

**12:45 - 14:15**    **Type: Industry satellite symposium**    **Hall 405**  
**Title: AstraZeneca - Navigating the evolving immunotherapy landscape of hepatobiliary and gastric/gastroesophageal cancers**

Chair: Do-Youn Oh, KR

- 12:45 - 12:50    **Welcome and introductions**  
D.-Y. Oh, Seoul National University Hospital, Seoul, KR
- 12:50 - 13:00    **Combination therapy approaches in BTC: Current SoC and future outlook**  
D.-Y. Oh, Seoul National University Hospital, Seoul, KR
- 13:00 - 13:15    **Case-study discussion: Patient management and considerations for the treatment of advanced BTC**  
D.-Y. Oh, Seoul National University Hospital, Seoul, KR
- 13:15 - 13:25    **Considerations for HCC patient care**  
S. Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK
- 13:25 - 13:40    **Case study discussion: Clinical decision-making in HCC**  
S. Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK
- 13:40 - 13:50    **Therapeutic approaches in resectable GC/GEJC**  
E. Smyth, Oxford University Hospitals NHS Foundation Trust - Churchill Hospital, Oxford, GB
- 13:50 - 14:05    **Case study discussion: Peri-operative management of patients with resectable GC/GEJC**  
E. Smyth, Oxford University Hospitals NHS Foundation Trust - Churchill Hospital, Oxford, GB
- 14:05 - 14:15    **Audience Q&A**

**12:45 - 14:15**    **Type: Industry satellite symposium**    **Hall 404**  
**Title: MSD - Recent advances in immuno-oncology in GI tumors**  
 Chair: Han Chong Toh, SG

12:45 - 12:47    **Welcome and introduction**  
H.C. Toh, NCCS - National Cancer Centre Singapore, Singapore, SG

12:47 - 13:12    **Role of immunotherapy in gastric cancer**  
S.Y. Rha, Yonsei University, Seoul, KR

13:12 - 13:37    **Past, present & future: Clinical management of advanced biliary tract cancers**  
M. Ikeda, National Cancer Center Hospital East, Kashiwa, JP

13:37 - 13:57    **Changing landscape in CRC: Where are we today?**  
P. Gibbs, WEHI - Walter and Eliza Hall Institute of Medical Research, Parkville, AU

13:57 - 14:12    **Q&A session**

14:12 - 14:15    **Closing remarks**  
H.C. Toh, NCCS - National Cancer Centre Singapore, Singapore, SG

**12:45 - 14:15**    **Type: Industry satellite symposium**    **Hall 401**  
**Title: BMS - Expanding the role of immuno-oncology in GI cancers: Best practices and clinical questions**  
 Chair: Wei Peng Yong, SG

12:45 - 12:50    **Welcome and introduction**  
W.P. Yong, NUHS - National University Health System, Singapore, SG

12:50 - 13:20    **Update on immuno-oncology for the treatment of gastric and esophageal cancers**  
K. Kato, National Cancer Center - Tsukiji Campus, Chuo-ku, JP

13:20 - 13:50    **Update on immuno-oncology for the treatment of colorectal cancer**  
N. Tebbutt, Darebin Street Specialist Medical Centre, Heidelberg, AU

13:50 - 14:10    **Roundtable case discussion, Q&A, and summary**  
A. Speakers, Lugano, CH

14:10 - 14:15    **Close**  
W.P. Yong, NUHS - National University Health System, Singapore, SG

<b>12:45 - 14:15</b>	<b>Type: Industry satellite symposium</b> <b>Title: Pfizer - Raising the bar for patients with ALK+ NSCLC</b> Chair: Solange Peters, CH	<b>Hall 402</b>
12:45 - 12:50	<b>Raising the bar for patients with ALK+ NSCLC: Welcome &amp; opening</b> <u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
12:50 - 13:00	<b>Evolution of 1L treatment in ALK+ NSCLC</b> <u>B. Solomon</u> , Peter MacCallum Cancer Center, Melbourne, AU	
13:00 - 13:10	<b>Optimizing CNS management in ALK+ NSCLC</b> <u>R. Soo</u> , NCIS - National University Cancer Institute Singapore, Singapore, SG	
13:10 - 13:40	<b>Open forum discussion</b> <u>A. Speakers</u> , Lugano, CH	
13:40 - 13:50	<b>Therapy management in the real world</b> <u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
13:50 - 14:10	<b>Open forum discussion</b> <u>A. Speakers</u> , Lugano, CH	
14:10 - 14:15	<b>Summary &amp; closing</b> <u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	

**12:45 - 14:15** **Type: Industry satellite symposium** **Hall 407**  
**Title: Daiichi Sankyo Co., Ltd. - The multi-tumor toolkit: ADCs in cancer therapy**  
 Chair: Tony S.K. Mok, HK

12:45 - 12:55 **ADC technology in cancer therapy**  
T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

12:55 - 13:20 **The role of ADCs in the lung treatment landscape**  
D.W.-T. Lim, NCCS - National Cancer Centre Singapore, Singapore, SG

13:20 - 13:40 **The impact of ADCs on the breast cancer treatment landscape**  
Y.-S. Lu, NTUH - National Taiwan University Hospital, Taipei City, TW

13:40 - 13:55 **The current state and future potential of ADCs in gastrointestinal cancers**  
R. Sundar, NUHS - National University Health System, Singapore, SG

13:55 - 14:15 **Multi-tumor panel roundtable discussion and Q&A**

**12:45 - 13:15** **Type: Young oncologists (YO) session** **Discussion hub (exhibition area)**  
**Title: Meet your mentor session 2: How to get involved in research**  
 Chair: Elizabeth Connolly, AU; Hongcheng Zhu, CN; Matteo Lambertini, IT

12:45 - 13:15 **Mentors**  
J. Ma<sup>1</sup>, H.H.F. Loong<sup>2</sup>, J. Tie<sup>3</sup>, <sup>1</sup>Sun Yat-sen University Cancer Center, Guangzhou, CN, <sup>2</sup>The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK, <sup>3</sup>Peter MacCallum Cancer Centre, Melbourne, AU

**13:45 - 14:15** **Type: Special session** **Discussion hub (exhibition area)**  
**Title: Radiation oncology: Lunch time with your mentors for an informal discussion**  
 Chair: Françoise Mornex, FR; Melvin Lee Kiang Chua, SG; Shankar Siva, AU

**14:30 - 16:00** **Type: Mini oral session** **Hall 405**  
**Title: Mini oral session 1: Gastrointestinal tumours**  
 Chair: TAE WON KIM, KR; Iain Tan, SG; Angela Lamarca, ES

14:30 - 14:35 **LBA7 - Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the KEYNOTE-177 study Asia subgroup**  
T. Yoshino<sup>1</sup>, T. André<sup>2</sup>, T.W. Kim<sup>3</sup>, W.P. Yong<sup>4</sup>, K.-K. Shiu<sup>5</sup>, B. Vittrup Jensen<sup>6</sup>, L.H. Jensen<sup>7</sup>, C. Punt<sup>8</sup>, D. Smith<sup>9</sup>, R. Garcia-Carbonero<sup>10</sup>, J. Alcaide-Garcia<sup>11</sup>, P. Gibbs<sup>12</sup>, C. De La Fouchardiere<sup>13</sup>, F. Rivera<sup>14</sup>, M.E. Elez Fernandez<sup>15</sup>, D. Le<sup>16</sup>, Y. Zuo<sup>17</sup>, D. Fogelman<sup>18</sup>, D. Adelberg<sup>18</sup>, L. Diaz<sup>19</sup>, <sup>1</sup>National Cancer Center Hospital East, Kashiwa, Chiba, JP, <sup>2</sup>Sorbonne University, Hopital Saint-Antoine, INSERM 938, SIRIC CURAMUS,

Paris, FR, <sup>3</sup>Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, <sup>4</sup>NUHS - National University Health System, Singapore, SG, <sup>5</sup>University College Hospital NHS Foundation Trust, London, GB, <sup>6</sup>Herlev and Gentofte Hospital, Herlev, DK, <sup>7</sup>University Hospital of Southern Denmark, Vejle, DK, <sup>8</sup>Amsterdam University Medical Center, Utrecht, NL, <sup>9</sup>Hopital Haut Leveque, Centre Hospitalier Universitaire de Bordeaux, Pessac, FR, <sup>10</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>11</sup>Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Malaga, ES, <sup>12</sup>Western Hospital, Footscray, AU, <sup>13</sup>Centre Leon Berard, Lyon, FR, <sup>14</sup>Hospital Universitario Marqués de Valdecilla, Santander, ES, <sup>15</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>16</sup>Sidney Kimmel Comprehensive Cancer Center, Baltimore, US, <sup>17</sup>MSD China, Beijing, CN, <sup>18</sup>Merck & Co., Inc., Rahway, US, <sup>19</sup>Memorial Sloan Kettering Cancer Center, New York, US

14:35 - 14:40

**90MO - Panitumumab (PAN) vs bevacizumab (BEV) in metastatic colorectal cancer (mCRC) by microsatellite stable (MSS), RAS/BRAF, and HER2 amplification (HER2amp) status: Phase III PARADIGM biomarker study**

T. Kato<sup>1</sup>, K. Muro<sup>2</sup>, J. Watanabe<sup>3</sup>, K. Shitara<sup>4</sup>, K. Yamazaki<sup>5</sup>, H. Ohori<sup>6</sup>, M. Shiozawa<sup>7</sup>, H. Yasui<sup>5</sup>, E. Oki<sup>8</sup>, T. Sato<sup>9</sup>, T. Naitoh<sup>9</sup>, Y. Komatsu<sup>10</sup>, J. Soeda<sup>11</sup>, K. Yamamoto<sup>12</sup>, R. Yamashita<sup>13</sup>, K. Akagi<sup>14</sup>, A. Ochiai<sup>15</sup>, H. Uetake<sup>16</sup>, K. Tsuchihara<sup>13</sup>, T. Yoshino<sup>4</sup>, <sup>1</sup>National Hospital Organization Osaka National Hospital, Osaka, JP, <sup>2</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>3</sup>Yokohama City University Medical Center, Yokohama, JP, <sup>4</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>5</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>6</sup>Japanese Red Cross Ishinomaki Hospital, Miyagi, JP, <sup>7</sup>Kanagawa Cancer Center, Kanagawa, JP, <sup>8</sup>Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, <sup>9</sup>Kitasato University School of Medicine, Sagamihara, JP, <sup>10</sup>Hokkaido University Hospital Cancer Center, Sapporo, JP, <sup>11</sup>Takeda Pharmaceutical Company Ltd., Tokyo, JP, <sup>12</sup>Yokohama City University School of Medicine, Yokohama, JP, <sup>13</sup>National Cancer Center, Chiba, JP, <sup>14</sup>Saitama Cancer Center, Saitama, JP, <sup>15</sup>Tokyo University of Science, Tokyo, JP, <sup>16</sup>National Hospital Organization, Disaster Medical Center, Tokyo, JP

14:40 - 14:50

**Invited Discussant one LBA7 and 90MO**

T.W. Kim, Asan Medical Center / Asan Cancer Institute, Seoul, KR

14:50 - 14:55

**Q&A and discussion**

A. Speakers, Lugano, CH

14:55 - 15:00

**91MO - Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study**

Y. Kuboki<sup>1</sup>, F. Pietrantonio<sup>2</sup>, L. Salvatore<sup>3</sup>, T. Esaki<sup>4</sup>, D. Modest<sup>5</sup>, D. Paez<sup>6</sup>, J. Taieb<sup>7</sup>, E. Ruiz<sup>8</sup>, T.W. Kim<sup>9</sup>, F. Meriggi<sup>10</sup>, D. Cunningham<sup>11</sup>, K.-H. Yeh<sup>12</sup>, E. Chan<sup>13</sup>, J. Chao<sup>14</sup>, N. Strydom<sup>15</sup>, Y. Saportas<sup>16</sup>, Q. Tran<sup>16</sup>, C. Cremolini<sup>17</sup>, M. Fakih<sup>18</sup>, <sup>1</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>2</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>3</sup>Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, <sup>4</sup>National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, <sup>5</sup>Charité - Universitaetsmedizin Berlin, Berlin, DE, <sup>6</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>7</sup>Hopital European George Pompidou, Paris, FR, <sup>8</sup>INCAN - Instituto Nacional de Cancerologia, Ciudad de Mexico, MX, <sup>9</sup>Asan Medical Center - University of

Ulsan College of Medicine, Seoul, KR, <sup>10</sup>Fondazione Poliambulanza Istituto Ospedaliero, Brescia, IT, <sup>11</sup>The Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB, <sup>12</sup>NTUH - National Taiwan University Hospital, Taipei City, TW, <sup>13</sup>Amgen Inc., Thousand Oaks, US, <sup>14</sup>AMGEN - USA, Seattle, US, <sup>15</sup>Amgen Inc - SSF, South San Francisco, US, <sup>16</sup>AMGEN (Headquarters) - USA, Thousand Oaks, US, <sup>17</sup>AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT, <sup>18</sup>City of Hope Comprehensive Cancer Center, Duarte, US

- 15:00 - 15:05 **92MO - Sotorasib (Soto) & panitumumab (Pmab) and FOLFIRI in previously treated KRASG12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy for CodeBreak 101 phase Ib expansion cohort**  
T. Masuishi<sup>1</sup>, J. Strickler<sup>2</sup>, J.-P. Machiels<sup>3</sup>, D. Hong<sup>4</sup>, R. Greil<sup>5</sup>, E. Chan<sup>6</sup>, J. Hippenmeyer<sup>7</sup>, Y. Saportas<sup>8</sup>, P. Cardona<sup>8</sup>, C. Xia<sup>8</sup>, Y. Kuboki<sup>9</sup>, <sup>1</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>2</sup>Duke Cancer Center, Durham, US, <sup>3</sup>Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE, <sup>4</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>5</sup>Paracelsus Medizinische Privatuniversität, Salzburg, AT, <sup>6</sup>Amgen, Thousand Oaks, US, <sup>7</sup>Amgen (Europe) GmbH, Zug, CH, <sup>8</sup>AMGEN (Headquarters) - USA, Thousand Oaks, US, <sup>9</sup>National Cancer Center Hospital East, Kashiwa, JP
- 15:05 - 15:15 **Invited Discussant 91MO and 92MO**  
I. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG
- 15:15 - 15:20 **Q&A and discussion**  
A. Speakers, Lugano, CH
- 15:20 - 15:25 **132MO - Zanidatamab (ZW25; Zani) in patients (pts) with previously treated advanced human epidermal growth factor receptor 2 (HER2)-amplified biliary tract cancer (BTC): Asia subgroup analysis of the phase Iib HERIZON-BTC-01 study**  
H. Sun<sup>1</sup>, J.W. Kim<sup>2</sup>, H.J. Choi<sup>3</sup>, H.-M. Chang<sup>4</sup>, L. Bao<sup>5</sup>, J. Ying<sup>6</sup>, F. Xie<sup>7</sup>, M.A. Lee<sup>8</sup>, K. Dong Uk<sup>9</sup>, T. Song<sup>10</sup>, H. Pan<sup>11</sup>, G. Yu<sup>12</sup>, K. Li<sup>13</sup>, Q. Yan<sup>14</sup>, X. Wu<sup>15</sup>, Y. Bao<sup>16</sup>, P. Garfin<sup>15</sup>, J. Ma<sup>17</sup>, J. Fan<sup>1</sup>, D.-Y. Oh<sup>18</sup>, <sup>1</sup>Affiliated Zhongshan Hospital of Fudan University, Shanghai, CN, <sup>2</sup>Seoul National University Bundang Hospital, Seoul, KR, <sup>3</sup>Severance Hospital Yonsei University Health System, Seoul, KR, <sup>4</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>5</sup>Hubei Cancer Hospital, Wuhan City, CN, <sup>6</sup>Zhejiang Cancer Hospital, Hangzhou, CN, <sup>7</sup>Eastern Hepatobiliary Surgery Hospital, Affiliated to Naval Medical University, Shanghai, CN, <sup>8</sup>The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, KR, <sup>9</sup>Pusan National University Hospital, Busan, KR, <sup>10</sup>Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, <sup>11</sup>Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, CN, <sup>12</sup>Weifang People's Hospital, Weifang, CN, <sup>13</sup>Shandong Provincial Third Hospital, Cheeloo College of Medicine, Shandong University, Shandong, CN, <sup>14</sup>Huzhou Central Hospital, Huzhou, CN, <sup>15</sup>Jazz Pharmaceuticals, Palo Alto, US, <sup>16</sup>BeiGene (Shanghai) Co., Ltd., Shanghai, CN, <sup>17</sup>BeiGene (Beijing) Co., Ltd., Beijing, CN, <sup>18</sup>Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR
- 15:25 - 15:30 **133MO - Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966**

R. Finn<sup>1</sup>, M. Ueno<sup>2</sup>, C. Yoo<sup>3</sup>, Z. Ren<sup>4</sup>, J. Furuse<sup>2</sup>, R.K. Kelley<sup>5</sup>, S. Chan<sup>6</sup>, J. Edeline<sup>7</sup>, H.J. Klumpen<sup>8</sup>, T. Yau<sup>9</sup>, S.C. Oh<sup>10</sup>, M. Ozaka<sup>11</sup>, J.G. Kim<sup>12</sup>, J.O. Park<sup>13</sup>, A. Vogel<sup>14</sup>, J. Valle<sup>15</sup>, L. Yu<sup>16</sup>, U. Malhotra<sup>17</sup>, A. Siegel<sup>17</sup>, S. Qin<sup>18</sup>, <sup>1</sup>UCLA - David Geffen School of Medicine, Los Angeles, US, <sup>2</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>3</sup>Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, <sup>4</sup>Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, <sup>5</sup>UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US, <sup>6</sup>The Chinese University of Hong Kong - Sino Building, Sha Tin, HK, <sup>7</sup>Centre Eugene - Marquis, Rennes, FR, <sup>8</sup>Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, <sup>9</sup>The University of Hong Kong - Queen Mary Hospital, Hong Kong, HK, <sup>10</sup>Korea University, Seoul, KR, <sup>11</sup>The Cancer Institute Hospital of JFCR, Koto-ku, JP, <sup>12</sup>Kyungpook National University Chilgok Hospital, Daegu, KR, <sup>13</sup>Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, <sup>14</sup>MHH - Medizinische Hochschule Hannover, Hannover, DE, <sup>15</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>16</sup>Merck & Co. Inc., Riverside, US, <sup>17</sup>Merck & Co, Rahway, US, <sup>18</sup>Nanjing Jingdu Hospital, Nanjing, CN

15:30 - 15:40 **Invited Discussant 132MO and 133MO**

A. Lamarca, Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES

15:40 - 15:45 **Q&A and discussion**

A. Speakers, Lugano, CH

**14:30 - 16:00 Type: Mini oral session**

**Hall 404**

**Title: Mini oral session: Head and neck cancer**

Chair: Pei Jye Voon, MY; Bhumsuk Keam, KR

14:30 - 14:35 **357MO - Comparison of long-term quality of life between survivors of adolescent and adult nasopharyngeal carcinoma**

J. Jin<sup>1</sup>, Q.Y. Chen<sup>1</sup>, L. Liu<sup>2</sup>, S.-S. Guo<sup>1</sup>, D.X. Wen<sup>1</sup>, J.Y. Lin<sup>1</sup>, J.H. Yang<sup>1</sup>, R. Li<sup>1</sup>, <sup>1</sup>Sun Yat-sen University Cancer Center, Guangzhou, CN, <sup>2</sup>Sun Yat-Sen University Cancer Center, Guangzhou, CN

14:35 - 14:40 **358MO - Quality-adjusted life-year and life-year estimates for patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the combined positive score 1-19 subgroup treated with pembrolizumab &#x2b;/- chemotherapy vs cetuximab-containing regimens**

P. Ivanyi<sup>1</sup>, A. Bullement<sup>2</sup>, M. Schlichting<sup>3</sup>, J. Naik<sup>2</sup>, C. Pescott<sup>3</sup>, <sup>1</sup>MHH - Medizinische Hochschule Hannover, Hannover, DE, <sup>2</sup>Delta Hat, Nottingham, GB, <sup>3</sup>Merck KGaA - Headquarters Merck Group, Darmstadt, DE

14:40 - 14:50 **Invited Discussant 357MO and 358MO**

P.J. Voon, Hospital Umum Sarawak, Kuching, MY

14:50 - 15:00 **Q&A and discussion**

A. Speakers, Lugano, CH

15:00 - 15:05 **359MO - Phase I dose-escalation study of nab-paclitaxel combined with cisplatin**



**and capecitabine as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma**

S.-S. Guo<sup>1</sup>, Q.Y. Chen<sup>1</sup>, L. Liu<sup>1</sup>, R. Sun<sup>1</sup>, P. Wang<sup>1</sup>, D. Li<sup>2</sup>, <sup>1</sup>Sun Yat-sen University Cancer Center, Guangzhou, CN, <sup>2</sup>State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, CN

15:05 - 15:10 **360MO - Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC): A prospective phase II study**

L. Gui<sup>1</sup>, X. Chen<sup>2</sup>, X. He<sup>1</sup>, J. Yang<sup>3</sup>, P. Liu<sup>1</sup>, Y. Qin<sup>1</sup>, Y.-K. Shi<sup>4</sup>, <sup>1</sup>Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, <sup>2</sup>National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, CN, <sup>3</sup>CAMS-PUMC - Chinese Academy of Medical Sciences and Peking Union Medical College - Dongdan Campus, Beijing, CN, <sup>4</sup>Chinese Academy of Medical Sciences - National Cancer Center, Cancer Hospital, Beijing, CN

15:10 - 15:15 **361MO - Characterizing the role of NSD family of histone methyltransferases in the head and neck squamous cell carcinoma tumor immune microenvironment**

Y. Bumber<sup>1</sup>, S.K. Deshmukh<sup>2</sup>, S. Wu<sup>2</sup>, J. Xiu<sup>3</sup>, A. Farrell<sup>2</sup>, A. Desai<sup>4</sup>, C. Kim<sup>5</sup>, F. Abdulla<sup>2</sup>, A. Vanderwalde<sup>2</sup>, T. Wise-Draper<sup>6</sup>, J. Johnson<sup>7</sup>, <sup>1</sup>Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, US, <sup>2</sup>Caris Life Sciences - Headquarters, Irving, US, <sup>3</sup>Caris Life Sciences, Phoenix, US, <sup>4</sup>UAB Medicine - UAB Hospital, Birmingham, US, <sup>5</sup>Lombardi Cancer Center Georgetown University, Washington, US, <sup>6</sup>Vontz Center for Molecular Studies, Cincinnati, US, <sup>7</sup>Thomas Jefferson University, Philadelphia, US

15:15 - 15:30 **Invited Discussant 359MO, 360MO and 361MO**

B. Keam, Seoul National University Hospital, Seoul, KR

15:30 - 15:45 **Q&A and discussion**

A. Speakers, Lugano, CH

**14:30 - 16:00** **Type: Multidisciplinary Tumour Board** **Hall 401**  
**Title: Demystifying the treatment of uterine leiomyosarcoma (uLMS)**  
 Chair: Smruti Koppikar, IN; Clare Scott, AU

14:30 - 14:35 **A case of early stage LMS that will recur as a single lesion 7 months later**  
S. Koppikar, Bombay Hospital and Medical Research Center, Mumbai, IN

14:35 - 14:50 **The role of surgery**  
A. Maheshwari, Tata Memorial Hospital Centre, Mumbai, IN

14:50 - 15:05 **Defining the role of chemotherapy: When and which**  
S. Koppikar, Bombay Hospital and Medical Research Center, Mumbai, IN

15:05 - 15:20 **Should all patients receive radiotherapy?**  
A. Miah, The Royal Marsden Hospital - Chelsea, London, GB

15:20 - 15:35 **Is there hope from molecular therapies?**  
C. Scott, Walter and Eliza Hall Institute WEHI, Parkville, AU

15:35 - 16:00 **Q&A and discussion**  
A. Speakers, Lugano, CH

**14:30 - 15:50** **Type: Mini oral session** **Hall 402**  
**Title: Mini oral session: Supportive and palliative care**  
 Chair: Raymond Lo, HK; Jayne Wood, GB; Grace Yang, SG

14:30 - 14:35 **430MO - Impact of Nada yoga music therapy on anxiety and quality of life in ovarian cancer patients: A randomized controlled trial**  
S. Malik<sup>1</sup>, A. Sehrawat<sup>1</sup>, R. Kumari<sup>1</sup>, S.L. Barnwal<sup>2</sup>, S. Kalra<sup>3</sup>, R. Singh<sup>4</sup>, P. Bhardwaj<sup>1</sup>, T. Dogra<sup>1</sup>, S. Gupta<sup>1</sup>, S. Saini<sup>5</sup>, N. Sinha<sup>1</sup>, J. Chaturvedi<sup>1</sup>, <sup>1</sup>All India Institute of Medical Sciences Rishikesh, Rishikesh, IN, <sup>2</sup>Dev Sanskriti Vishwavidyalaya, Haridwar, IN, <sup>3</sup>IITJ - Indian Institute of Technology Jodhpur, Jodhpur, IN, <sup>4</sup>Mohan Lal Sukhadia University, Udaipur, IN, <sup>5</sup>Cancer Research Institute, Swami Rama Himalayan University, Dehradun, IN

14:35 - 14:40 **431MO - Cost-effective evaluation of homemade diet recipe in head and neck cancer patients during radiotherapy from low-middle-income group countries**  
P. Kalbande, Shri Siddivinayak ganpati cancer hospital cancer, Miraj, IN

14:40 - 14:45 **432MO - Barriers and facilitators of home-based exercise intervention participation in Indonesian breast cancer patients: A nested qualitative study using COM-B model**  
Y. Astari<sup>1</sup>, S. Hutajulu<sup>2</sup>, Y. Prabandari<sup>3</sup>, M. Mozhaf<sup>4</sup>, M. Hardianti<sup>2</sup>, A. Hartopo<sup>2</sup>, M. Allsop<sup>5</sup>, S. Burke<sup>5</sup>, <sup>1</sup>Dr. Sardjito General Hospital, Yogyakarta, ID, <sup>2</sup>Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, ID, <sup>3</sup>Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah

Mada, Yogyakarta, ID, <sup>4</sup>Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, ID, <sup>5</sup>The University of Leeds, Leeds, GB

- 14:45 - 14:55 **Invited Discussant 430MO, 431MO and 432MO**  
R. Lo, CUHK - Chinese University of Hong Kong, Sha Tin, HK
- 14:55 - 15:00 **Q&A and discussion**  
A. Speakers, Lugano, CH
- 15:00 - 15:05 **433MO - Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: A multi-center study**  
Q. Liu<sup>1</sup>, M. Liu<sup>1</sup>, Z. Zou<sup>2</sup>, J. Lin<sup>1</sup>, Y. Wang<sup>1</sup>, N. Zhang<sup>1</sup>, L. Zhao<sup>1</sup>, J. Zhou<sup>3</sup>, H. Zhou<sup>4</sup>, X. Zhou<sup>5</sup>, X. Jiao<sup>6</sup>, Y. Yu<sup>1</sup>, T. Liu<sup>1</sup>, <sup>1</sup>Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, <sup>2</sup>Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, CN, <sup>3</sup>Shanghai Construction Group (SCG) Hospital, Shanghai, CN, <sup>4</sup>Xuhui District Central Hospital of Shanghai, Shanghai, CN, <sup>5</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>6</sup>Changzheng Hospital, Shanghai, CN
- 15:05 - 15:10 **434MO - Increased eosinophil is a universal biomarker for immune-related adverse events induced by immune checkpoint inhibitors in various cancer patients: A retrospective multidisciplinary study**  
Y. Tasaki<sup>1</sup>, Y. Sugiyama<sup>1</sup>, I. Nanami<sup>1</sup>, M. Yoshihisa<sup>1</sup>, M. Iida<sup>1</sup>, K. Odagiri<sup>1</sup>, Y. Kimura<sup>1</sup>, Y. Hotta<sup>1</sup>, T. Naiki<sup>1</sup>, S. Hamamoto<sup>1</sup>, T. Yasui<sup>2</sup>, Y. Hibi<sup>1</sup>, <sup>1</sup>Nagoya City University Hospital, Nagoya, JP, <sup>2</sup>Nagoya City University Graduate School of Medical Sciences and Medical School, Nagoya, JP
- 15:10 - 15:20 **Invited Discussant 433MO and 434MO**  
J. Wood, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB
- 15:20 - 15:25 **Q&A and discussion**  
A. Speakers, Lugano, CH
- 15:25 - 15:30 **394MO - Structure of QOLTI-F in Chinese-speaking carers of palliative care patients**  
K.C.T. Li<sup>1</sup>, D.Y. Leung<sup>2</sup>, R. Lo<sup>3</sup>, <sup>1</sup>Shatin Hospital, Hong Kong, HK, <sup>2</sup>The Hong Kong Polytechnic University, Kowloon, HK, <sup>3</sup>The Chinese University of Hong Kong, Shatin, HK
- 15:30 - 15:35 **395MO - Prognostic models for survival predictions in advanced cancer patients: A systematic review and meta-analysis**  
M.Y. Fung<sup>1</sup>, Y.L. Wong<sup>1</sup>, K.M. Cheung<sup>2</sup>, K. Bao<sup>2</sup>, W. Sung<sup>2</sup>, <sup>1</sup>CUHK - Chinese University of Hong Kong, Sha Tin, HK, <sup>2</sup>Queen Elizabeth Hospital, Kowloon, HK
- 15:35 - 15:45 **Invited Discussant 394MO and 395MO**  
G. Yang, NCCS - National Cancer Centre Singapore, Singapore, SG

15:45 - 15:50 **Q&A and discussion**  
A. Speakers, Lugano, CH

**14:30 - 16:00** **Type: Educational session** **Hall 406**  
**Title: Epidermal growth factor receptor (EGFR) mutations in early stage non-small cell lung cancer: Do we know it all?**  
 Chair: Noemi Reguart Aransay, ES; Daniel Shao Weng Tan, SG

14:30 - 14:45 **Broader overview of screening in never smokers**  
C.L. Lam, The University of Hong Kong - Queen Mary Hospital, Hong Kong, HK

14:45 - 15:00 **Molecular testing/minimal residual disease (MRD)**  
D.S.W. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG

15:00 - 15:15 **EGFR tyrosine kinase inhibitors (TKIs): Which one? How long? When?**  
M. Tsuboi, National Cancer Center Hospital East, Kashiwa, JP

15:15 - 15:30 **Chemotherapy and immunotherapy: Any role to play at all?**  
L. Hendriks, Maastricht University Medical Center (MUMC), Maastricht, NL

15:30 - 15:45 **Integrating radiation in early stage EGFR**  
R. Dziadziuszko, Medical University of Gdansk, Gdansk, PL

15:45 - 16:00 **Q&A and discussion**  
A. Speakers, Lugano, CH

**14:30 - 16:00** **Type: Educational session** **Hall 407**  
**Title: Latest updates in drug development**  
 Chair: Matthew Krebs, GB; Chia-Chi Lin, TW

14:30 - 15:00 **New therapies targeting RAS-RAF signalling in solid tumours**  
J. Desai, Peter MacCallum Cancer Centre, Melbourne, AU

15:00 - 15:30 **New antibody drug conjugate (ADC) targets on the horizon**  
D.-Y. Oh, Seoul National University Hospital, Seoul, KR

15:30 - 16:00 **Q&A and discussion**  
A. Speakers, Lugano, CH

16:15 - 17:45	<p><b>Type: Special session</b>  <b>Title: Practicing oncology across the globe: ESMO Clinical Practice Guidelines and Pan Asian adaptations (in collaboration with JSMO and KSMO)</b></p>	Hall 405
	Chair: Kohei Shitara, JP; Giuseppe Curigliano, IT	
16:15 - 16:30	<p><b>A clinical case and analysis of its management according to the recent PAGA: Early breast cancer</b>  <u>K.H. Park</u>, Korea University Anam Hospital, Seoul, KR</p>	
16:30 - 16:45	<p><b>Differences between the parent guideline (CPG) and the PAGA: Genetics, biology and practice differences between West and Asia</b>  <u>N. Harbeck</u>, Ludwig Maximilians University - Grosshadern, Munich, DE</p>	
16:45 - 17:00	<p><b>Q&amp;A and discussion</b>  <u>A. Speakers</u>, Lugano, CH</p>	
17:00 - 17:15	<p><b>A clinical case and analysis of its management according to the recent PAGA: Gastric cancer</b>  <u>K. Shitara</u>, National Cancer Center Hospital East, Kashiwa, JP</p>	
17:15 - 17:30	<p><b>Differences between the parent guideline (CPG) and the PAGA: Genetics, biology and practice differences between West and Asia</b>  <u>E. Smyth</u>, Oxford University Hospitals NHS Foundation Trust - Churchill Hospital, Oxford, GB</p>	
17:30 - 17:45	<p><b>Q&amp;A and discussion</b>  <u>A. Speakers</u>, Lugano, CH</p>	

<b>16:15 - 17:45</b>	<p><b>Type: Educational session</b>  <b>Title: Novel therapies shaping the treatment landscape of gynecologic malignancies: Immunotherapy and ADCs</b>            Chair: Alexandra Leary, FR; Kathleen Moore, US; Rebecca Kristeleit, GB</p>	<b>Hall 404</b>
16:15 - 16:25	<p><b>Predictive biomarkers of response to immunotherapy and ADC in gynecological cancer</b>  <u>A. Leary</u>, Institut Gustave Roussy, Villejuif, FR</p>	
16:25 - 16:50	<p><b>Immunotherapy in gynecologic malignancies: Current role and future prospects</b>  <u>A. Leary</u>, Institut Gustave Roussy, Villejuif, FR</p>	
16:50 - 17:15	<p><b>ADCs in gynaecological malignancies</b>  <u>K. Moore</u>, Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US</p>	
17:15 - 17:30	<p><b>Managing the toxicities of novel compounds</b>  <u>R. Kristeleit</u>, Guy's and St Thomas' NHS Foundation Trust, London, GB</p>	
17:30 - 17:45	<p><b>Q&amp;A and discussion</b>  <u>A. Speakers</u>, Lugano, CH</p>	
<b>16:15 - 17:45</b>	<p><b>Type: Educational session</b>  <b>Title: Learnings from Europe: Policy options to improve primary, secondary &amp; tertiary cancer prevention in the Asia &amp; Pacific region</b>            Chair: Jean-Yves Blay, FR; Hemant Malhotra, IN</p>	<b>Hall 401</b>
16:15 - 16:30	<p><b>Setting the scene: EU's Beating Cancer Plan &amp; overview of cancer incidence in the Asia-Pacific region</b>  <u>J.-Y. Blay</u>, Centre Léon Bérard, Lyon, FR</p>	
16:30 - 16:50	<p><b>Tobacco cessation/lifestyle changes</b>  <u>P. Garrido Lopez</u>, Hospital Universitario Ramon y Cajal, Madrid, ES</p>	
16:50 - 17:10	<p><b>Air quality</b>  <u>C. Swanton</u>, Francis Crick Institute, London, GB</p>	
17:10 - 17:30	<p><b>Screening</b>  <u>T.W.-W. Chen</u>, NTU - National Taiwan University - College of Medicine, Taipei City, TW</p>	
17:30 - 17:45	<p><b>Conclusions: How to transfer these solutions to Asia</b>  <u>C. Karapetis</u>, Flinders Centre for Innovation in Cancer, Bedford Park, AU</p>	
<b>16:15 - 17:45</b>	<p><b>Type: Mini oral session</b>  <b>Title: Young Oncologists clinical cases discussion: Adaptive management for complex oncology cases</b></p>	<b>Hall 402</b>

Chair: Matteo Lambertini, IT; Elizabeth Connolly, AU; Hongcheng Zhu, CN

- 16:15 - 16:20 **YO2 - A Rare Case of Breast Cancer in A Postpartum Female with Reoccurrence of Breast Cancer During Pregnancy**  
J. Gill, Gandhi Medical College, Bhopal, IN
- 16:20 - 16:25 **YO31 - "Their voices are louder than yours, doctor" Unspoken challenges managing breast cancer in a schizophrenic patient: a case report.**  
J. Elias<sup>1</sup>, M. Nik Eezamuddeen<sup>2</sup>, <sup>1</sup>UMMC - University Malaya Medical Centre, Kuala Lumpur, MY, <sup>2</sup>UKM - Universiti Kebangsaan Malaysia - Faculty of Medicine, Cheras, MY
- 16:25 - 16:35 **Invited Discussant YO2 and YO31**  
M. Lambertini, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT
- 16:35 - 16:40 **Q&A and discussion**  
A. Speakers, Lugano, CH
- 16:40 - 16:45 **YO5 - Solitary Cardiac Metastasis in BRAFV600E Mutation Colon Cancer**  
M. Wang, Y.X. Gwee, C.E. Chee, G. Chan, NCIS - National University Cancer Institute Singapore, Singapore, SG
- 16:45 - 16:50 **YO26 - The efficacy and safety of aumolertinib plus alectinib in NSCLC patients harboring EGFR 19 Del and ALK fusion co-mutations: a case report**  
Y. Qin<sup>1</sup>, D. Yang<sup>2</sup>, X. Mu<sup>2</sup>, <sup>1</sup>Zhengzhou Hospital of Traditional Chinese Medicine, Zhengzhou, CN, <sup>2</sup>Peking University People's Hospital, Beijing, CN
- 16:50 - 17:00 **Invited Discussant YO5 and YO26**  
H. Zhu, Fudan University Shanghai Cancer Center, Shanghai, CN
- 17:00 - 17:05 **Q&A and discussion**  
A. Speakers, Lugano, CH
- 17:05 - 17:10 **YO16 - Chemotherapy-resistant epithelioid trophoblastic tumor successfully treated by immunotherapy with further response after dose escalation: a case report**  
L. Nguyen<sup>1</sup>, T.H. Nguyen<sup>2</sup>, T. Nguyen<sup>2</sup>, H. Phung Thi<sup>1</sup>, <sup>1</sup>K Hospital - Vietnam National Cancer Hospital - BASE 3, Hanoi, VN, <sup>2</sup>K Hospital - Vietnam National Cancer Hospital - BASE 1, Hanoi, VN
- 17:10 - 17:15 **YO20 - In-depth analysis of unknown NTRK1-fusion gene detected in DNA-based comprehensive genomic profiling.**  
N. Suzuki<sup>1</sup>, M. Idogawa<sup>2</sup>, M. Emori<sup>2</sup>, K. Murase<sup>2</sup>, Y. Arihara<sup>2</sup>, H. Nakamura<sup>2</sup>, M. Usami<sup>2</sup>, I. Kinoshita<sup>3</sup>, S. Sugita<sup>2</sup>, T. Tokino<sup>2</sup>, T. Hasegawa<sup>2</sup>, A. Sakurai<sup>2</sup>, K. Takada<sup>2</sup>, <sup>1</sup>Japanese Red Cross Date General Hospital, Suenaga-cho, JP, <sup>2</sup>Sapporo Medical University School of Medicine, Sapporo, JP, <sup>3</sup>Hokkaido University Hospital, Sapporo, JP

17:15 - 17:25 **Invited Discussant YO16 and YO20**  
E. Connolly, Chris O'Brien Lifehouse, Sydney, AU

17:25 - 17:30 **Q&A and discussion**  
A. Speakers, Lugano, CH

**16:15 - 17:45** **Type: Educational session** **Hall 406**  
**Title: What's new in 2023? (Investigational immunotherapy)**  
Chair: Sapna Patel, US; Han Chong Toh, SG

16:15 - 16:40 **Vaccines for cancer treatment: Finally primetime?**  
H.C. Toh, NCCS - National Cancer Centre Singapore, Singapore, SG

16:40 - 17:05 **Why adjuvant when there is neoadjuvant?**  
S. Patel, MD Anderson Cancer Center, Houston, US

17:05 - 17:30 **Genetically-engineered cellular therapies: Expanding indications?**  
A. Furness, The Royal Marsden Hospital - Chelsea, London, GB

17:30 - 17:45 **Q&A and discussion**  
A. Speakers, Lugano, CH



<b>16:15 - 18:00</b>	<b>Type: Special session</b> <b>Title: Radiation oncology session 1 - Oligometastases: State of the art 2023</b> Chair: Kevin Chua, SG; Francoise Mornex, FR	<b>Hall 407</b>
16:15 - 16:35	<b>Leveraging a biology-based and multidisciplinary approach for treating oligometastatic and metastatic cancer</b> <u>J. Tsai</u> , Princess Margaret Cancer Centre, Toronto, CA	
16:35 - 16:55	<b>Single or fractionated radiosurgery for oligometets? What have we learnt from SAFRON trial experience</b> <u>S. Siva</u> , Peter MacCallum Cancer Centre, Melbourne, AU	
16:55 - 17:15	<b>Real world consensus status on oligometastasis management: Korean caregivers perspective</b> <u>E.K. Chie</u> , Seoul National University College of Medicine, Seoul, KR	
17:15 - 17:35	<b>Role of new generation TKIs vs SRS in metastatic NSCLC</b> <u>V. Lee</u> , The University of Hong Kong - Li Ka Shing Faculty of Medicine, Hong Kong, HK	
17:35 - 17:45	<b>Clinical case 1</b> <u>F. Mornex</u> <sup>1</sup> , <u>X. Zhang</u> <sup>2</sup> , <sup>1</sup> Université Claude Bernard Lyon1, Lyon, FR, <sup>2</sup> NCCS - National Cancer Centre Singapore, Singapore, SG	
17:45 - 17:55	<b>Clinical case 2</b> <u>F. Mornex</u> <sup>1</sup> , <u>X. Zhang</u> <sup>2</sup> , <sup>1</sup> Université Claude Bernard Lyon1, Lyon, FR, <sup>2</sup> NCCS - National Cancer Centre Singapore, Singapore, SG	
17:55 - 18:00	<b>General discussion and conclusions</b> <u>A. Speakers</u> , Lugano, CH	
<b>17:50 - 18:45</b>	<b>Type: Poster viewing session</b> <b>Title: YO clinical cases: Poster Display</b>	<b>Discussion hub (exhibition area)</b>
17:50 - 17:50	<b>Breast cancer, early stage</b>	
17:50 - 17:50	<b>YO1 - Breast Cancer in an adult female with both BRCA 1 and BRCA 2 mutation: A Case Report</b> <u>M.M. Mesina</u> , St Lukes Medical Center, Quezon City, PH	
17:50 - 17:50	<b>Breast cancer, locally advanced</b>	
17:50 - 17:50	<b>YO3 - Cyclophosphamide induced severe hyponatremia with encephalopathy and</b>	

**seizure in a patient with locally advanced breast cancer**

S. Sharashenidze, N. Sharikadze, E. Giorgadze, K. Tsintsadze, K. Maisaia, M. Kepuladze, Mardaleishvili Medical Centre, Tbilisi, GE

17:50 - 17:50 **YO4 - How to evaluate the axilla after neoadjuvant Chemotherapy? Experience from a North Indian Tertiary care center**

S. De, Indraprastha Apollo Hospital, New Delhi, IN

17:50 - 17:50 **Gastrointestinal tumours, colorectal**

17:50 - 17:50 **YO6 - Cystic pneumatosis of the intestine is a rare cause non-surgical pneumoperitoneum**

M. Yunusovich, Samarkand Regional Centre of Oncology, Samarkand, UZ

17:50 - 17:50 **YO7 - Primary squamous cell carcinoma of the recto-sigmoid colon: Surgery, neo-adjuvant chemotherapy or neo-adjuvant radiation- treatment dilemma**

V. Goel, Star Hospitals, hyderabad, IN

17:50 - 17:50 **YO8 - Acute Blepharoptosis: A Rare Complication of Oxaliplatin-induced Neurotoxicity**

D. Khanikar<sup>1</sup>, H. Mittal<sup>1</sup>, A. Bhattacharyya<sup>1</sup>, K. Medhi<sup>1</sup>, C. Hazarika<sup>2</sup>, <sup>1</sup>Dr B.Barooah Cancer Institute (TMH Guwahati), Guwahati, IN, <sup>2</sup>Gauhati Medical College and Hospital, Guwahati, IN

17:50 - 17:50 **YO9 - Therapeutic monitoring of patients with BRAFV600E mutant (mut) metastatic colorectal cancer (mCRC) using droplet digital (dd) PCR assay - a case history.**

C.T.R. Lam<sup>1</sup>, W. Lai<sup>2</sup>, B. Ma<sup>2</sup>, A. Kong<sup>2</sup>, I. Tse<sup>2</sup>, W.K.J. Lam<sup>2</sup>, A. Chan<sup>2</sup>, <sup>1</sup>The Chinese University of Hong Kong, Hong Kong, HK, <sup>2</sup>CUHK - Chinese University of Hong Kong, Sha Tin, HK

17:50 - 17:50 **YO10 - Discordant response in metastatic colorectal cancer: How to tackle the heterogeneity?**

E. García, INCAN - Instituto Nacional de Cancerologia, Ciudad de Mexico, MX

17:50 - 17:50 **Gastrointestinal tumours, non-colorectal**

17:50 - 17:50 **YO11 - Metastatic Extrahepatic Cholangiocarcinoma with Dual BRCA Mutation (BRCA 1 c.5153-2A>G, BRCA 2 p.Asn986fs): Response to PARP Inhibitors and Implications for Precision Medicine**

P. Mandloi, V. Gupta, O. Suri, Artemis Hospital Gurgaon, Gurugram, IN

17:50 - 17:50 **YO12 - Conversion therapy form systemic therapy to locoregional therapy in advance stage Hepatocellular carcinoma with immunotherapy.**

C. Charonpongsuntorn, N. Teravaninthorn, Srinakharinwirot University - Faculty of Medicine - Ongkharak Campus, Nakhon Nayok, TH

- 17:50 - 17:50 **YO13 - "Disease response to adjuvant Taxane and Nivolumab in a MSI high case of carcinoma GE junction unresponsive to neoadjuvant chemotherapy: A case study"**  
T. Singh, S. Qureshi, Fortis Hospital, New Delhi, IN
- 17:50 - 17:50 **YO14 - Cholangioblastic Cholangiocarcinoma Rare Variant**  
G. Vrakornvoravuti<sup>1</sup>, G. Kerkarchachai<sup>2</sup>, <sup>1</sup>Faculty of Medicine vajira Hospital. Navamindradhiraj University, Bangkok, TH, <sup>2</sup>Vajira Hospital - Faculty of Medicine - Navamindradhiraj University, Bangkok, TH
- 17:50 - 17:50 **Genitourinary tumours, prostate**
- 17:50 - 17:50 **(Withdrawn)**
- 17:50 - 17:50 **Head and neck cancer, excluding thyroid**
- 17:50 - 17:50 **YO17 - Diffuse Large B-Cell Lymphoma Manifesting as Bilateral Earlobes Swelling in a 70-Year-Old Filipino: A Case Report**  
R.A. Trance, M.A. Ong, Antique Medical Center, San Jose, PH
- 17:50 - 17:50 **YO18 - Oropharyngeal Squamous Cell Carcinoma presenting with SSTR overexpression on 68Ga DOTATATE PET scan: A Case Report**  
L.F. Revillas<sup>1</sup>, J.G. Pandya<sup>2</sup>, <sup>1</sup>St Lukes Medical Center, Quezon City, PH, <sup>2</sup>St. Luke's Medical Center - Quezon City, Quezon City, PH
- 17:50 - 17:50 **YO19 - Gingival Squamous Cell Carcinoma Initially Presenting As Metastatic Submandibular Mass In A 55-Year-Old Filipino Woman: A Case Report**  
L.D. Parreño<sup>1</sup>, M.A. Ong<sup>2</sup>, <sup>1</sup>Antique Medical Center, Inc., San Jose de Buenavista, PH, <sup>2</sup>Iloilo Mission Hospital, Iloilo City, PH
- 17:50 - 17:50 **Precision medicine**
- 17:50 - 17:50 **YO21 - Navigating a challenging case of MET amplified gastric cancer via the Molecular Tumor Board**  
D. Lee<sup>1</sup>, S.F. Ang<sup>2</sup>, R. Sim<sup>2</sup>, Y.C.J. Lam<sup>2</sup>, D.S.W. Tan<sup>2</sup>, <sup>1</sup>University of Malaya Medical Centre, Kuala Lumpur, MY, <sup>2</sup>NCCS - National Cancer Centre Singapore, Singapore, SG
- 17:50 - 17:50 **YO22 - Lenvatinib as neoadjuvant therapy before total thyroidectomy in Follicular thyroid cancer**

W. Siriboonpipattana, S. Putraveepong, P. Watcharenwong, J. Chindaprasirt, A. Sookprasert, K. Wirasorn, T. Sanlung, Khon Kaen University - Faculty of Medicine - Srinagarind Hospital, Khon Kaen, TH

- 17:50 - 17:50 **YO23 - Sustained response with PD1-1 inhibitor (Pembrolizumab) and KRAS G12C mutation positive inhibitor (Sotorasib) in a case of metastatic squamous cell carcinoma with brain metastases.**  
M. Naseer R, HCG Bangalore Institute of Oncology Speciality Centre, Bangalore, IN
- 17:50 - 17:50 **Thoracic tumours, locally advanced**
- 17:50 - 17:50 **YO24 - Sunitinib for Clear cell carcinoma of Lung: Histology matters more than Primary Organ?**  
R. Nair, B. Devnani, AIIMS - All India Institute of Medical Sciences, Jodhpur, Jodhpur, IN
- 17:50 - 17:50 **YO25 - A Lung Squamous Cell Carcinoma ( LUSC ) Patient with Complex Gene Mutations and PD-L1 Expression Responded to Aumolertinib**  
H. Qiao, X. Hou, D. Zhao, P. Xie, The First Hospital of Lanzhou University/The First School of Clinical Medicine, Lanzhou, CN
- 17:50 - 17:50 **Thoracic tumours, metastatic**
- 17:50 - 17:50 **YO27 - BRAF mutant, PD-L1 positive metastatic musculoskeletal lesions from primary lung adenocarcinoma treated with combination Vemurafenib and Pembrolizumab**  
F.F. Sy, University of the Philippines - Philippine General Hospital, Manila, PH
- 17:50 - 17:50 **YO28 - VATS versus open thoracotomy for one stage bilateral lung metastasectomy**  
Y.-W. Liu, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, TW
- 17:50 - 17:50 **YO29 - Case report : Woman 41 Years Old with pericardium effusion metastatic due to lung adenocarcinoma Mutation EGFR Exon 21 L858R**  
T. Saputra, A. Infianto, R.D. Listiandoko, Lampung University, Bandar Lampung, ID
- 17:50 - 17:50 **YO30 - Uncommon Presentation of a Common Cancer**  
G. Vrakornvoravuti<sup>1</sup>, G. Kerkarchachai<sup>2</sup>, <sup>1</sup>Faculty of Medicine vajira Hospital. Navamindradhiraj University, Bangkok, TH, <sup>2</sup>Vajira Hospital - Faculty of Medicine - Navamindradhiraj University, Bangkok, TH
- 17:50 - 17:50 **General interest**
- 17:50 - 17:50 **YO33 - A triple-agent regimen combining immuno-, targeted-, and chemotherapy**

**showed favorable efficacy in advanced-stage epithelioid angiosarcoma**

Y. Wei, Y. Chai, D. Zhang, F. Qi, M. Dong, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN

17:50 - 17:50 **YO34 - Transbronchial Mediastinal Cryobiopsy for Challenging Mediastinal Tumors: The First Case Report in South Korea**

J. Kim, S. Jang, W. Ji, H.S. Hwang, H.-S. Park, Asan Medical Center - University of Ulsan, Seoul, KR

**17:50 - 18:45 Type: Poster viewing session  
Title: Poster Display**

**Exhibition area**

17:50 - 17:50 **5P - Clinicopathologic features and genomic profiling of occult breast cancer**

L. Tang, W. He, Y. Zhu, J. Liu, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN

17:50 - 17:50 **6P - Tumor cell-released autophagosomes (TRAPs) promote lung metastasis through inducing PD-L1 high expression of pulmonary vascular endothelial cells (PVECs) in breast cancer**

X. Wang, SEU - Southeast University - Sipailou Campus, Nanjing, CN

17:50 - 17:50 **7P - Tumor cell-released autophagosomes (TRAPs) promote breast cancer lung metastasis by modulating neutrophil extracellular traps formation**

X. Zhou, SEU - Southeast University - Sipailou Campus, Nanjing, CN

17:50 - 17:50 **9P - Clinicopathological features and prognosis of mucinous breast cancer: A retrospective analysis of 358 patients in Vietnam**

H. Hoang<sup>1</sup>, H. Phung Thi<sup>2</sup>, L. Nguyen<sup>2</sup>, T. Nguyen<sup>2</sup>, T. Nguyen<sup>1</sup>, A.T. Do<sup>3</sup>, H. Nguyen<sup>2</sup>, Q. Le<sup>2</sup>, T. Nguyen Thanh<sup>1</sup>, <sup>1</sup>HMU - Hanoi Medical University, Hanoi, VN, <sup>2</sup>K Hospital - Vietnam National Cancer Hospital - BASE 3, Hanoi, VN, <sup>3</sup>K Hospital - Vietnam National Cancer Hospital - BASE 1, Hanoi, VN

17:50 - 17:50 **10P - Comparison of 28-gene and 70-gene panel in risk-prediction of Chinese women with early-stage HR-positive and HER2-negative breast cancer**

L. Lei<sup>1</sup>, W. Cao<sup>1</sup>, Y. Yu<sup>1</sup>, G. Qiao<sup>2</sup>, J. Luo<sup>3</sup>, X. Xie<sup>4</sup>, Y. Tan<sup>5</sup>, X. Wang<sup>1</sup>, <sup>1</sup>Zhejiang Cancer Hospital, Hangzhou, CN, <sup>2</sup>Yantai Yuhuangding Hospital, Yantai, CN, <sup>3</sup>Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, CN, <sup>4</sup>The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, CN, <sup>5</sup>Jiangsu Sincere Diagnostics Co.,Ltd., Nanjing, CN

17:50 - 17:50 **11P - Multimodal analysis of methylation and fragmentomic profiles in plasma cell-free DNA for differentiation of benign and malignant breast tumors**

H. Nguyen, V. Van, C. Nguyen, H. Vo, L.S. Tran, Medical Genetics Institute, Ho Chi Minh City, VN

17:50 - 17:50 **12P - Plasma cell-free mRNA profiles enable early detection of breast cancer**

C. Nguyen, N. Nguyen, P. Nguyen, L.S. Tran, Gene Solutions Joint Stock Company, Ho Chi Minh City, VN

- 17:50 - 17:50 **13P - Relationship of distress and quality of life with gut microbiome composition in newly diagnosed breast cancer patients: A prospective, observational study**  
C.-C. Lee<sup>1</sup>, P.-S. Yang<sup>2</sup>, H.-W. Yang<sup>3</sup>, C.-J. Liu<sup>1</sup>, F. Lee<sup>1</sup>, W.-C. Ko<sup>4</sup>, Y.-C. Chang<sup>5</sup>, <sup>1</sup>MMH - Mackay Memorial Hospital - Taipei Branch, Taipei City, TW, <sup>2</sup>Mackay Memorial Hospital, Taipei City, TW, <sup>3</sup>Mackay Memorial Hospital - Tamsui Branch, New Taipei City, TW, <sup>4</sup>Hsinchu Mackay Memorial Hospital, Hsinchu City, TW, <sup>5</sup>Mackay Memorial Hospital - Taipei Branch, Taipei City, TW
- 17:50 - 17:50 **14P - Classification of molecular subtypes of breast cancer in whole-slide histopathological images using a novel deep learning algorithm**  
H.S. Kim<sup>1</sup>, K.-W. Min<sup>2</sup>, J.S. Kim<sup>3</sup>, <sup>1</sup>Hanyang University College of Medicine, Seoul, KR, <sup>2</sup>Uijeongbu Eulji Medical Center, Gyeonggi-do, KR, <sup>3</sup>Hanyang University - Seoul Campus, Seoul, KR
- 17:50 - 17:50 **15P - The regulation of pregnenolone in breast cancer**  
H.-G. Kang, D.S. Kim, J.S. Jeong, S.Y. Kim, H. Ahn, Y. Kim, Y. Heo, B.-S. An, Pusan National University - Busan Campus, Busan (Jangjeon-dong), KR
- 17:50 - 17:50 **16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment**  
J.-I. Lai<sup>1</sup>, Y. Antill<sup>2</sup>, K. Jung<sup>3</sup>, C. Shimizu<sup>4</sup>, M.L. Abesamis Tiambeng<sup>5</sup>, L.-M. Tseng<sup>1</sup>, E.M. Tan<sup>6</sup>, S. Qu<sup>7</sup>, C. Spiteri<sup>8</sup>, S.Y. Ihm<sup>9</sup>, D. Hsu<sup>10</sup>, <sup>1</sup>Taipei Veterans General Hospital, Taipei City, TW, <sup>2</sup>Frankston Hospital, Frankston, AU, <sup>3</sup>Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, <sup>4</sup>NCGM - National Center for Global Health and Medicine, Shinjuku-ku, JP, <sup>5</sup>Cardinal Santos Medical Center (CSMC), Manila, PH, <sup>6</sup>IQVIA Asia Pacific, Singapore, SG, <sup>7</sup>IQVIA, Shanghai, CN, <sup>8</sup>Merck Sharp & Dohme (Australia) Pty Ltd, Macquarie Park, AU, <sup>9</sup>MSD Korea Ltd., Seoul, KR, <sup>10</sup>MSD - Merck East Pharmaceutical Co., Ltd., Hong Kong, HK
- 17:50 - 17:50 **17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast cancerR (screening/ stage shifting) utilizing Integrated Mobile Clinics and pAtient Reported online Evaluations and Education**  
H.G. Luna<sup>1</sup>, G. Cristal Luna<sup>1</sup>, R. Rosario<sup>2</sup>, C. Ngelangel<sup>3</sup>, <sup>1</sup>National Kidney and Transplant Institute, Quezon City, PH, <sup>2</sup>Philippine Cancer Society, Manila, PH, <sup>3</sup>AHMC - Asian Hospital and Medical Center, Muntinlupa, PH
- 17:50 - 17:50 **18P - Optimizing premenopausal HR#x2b; HER2#x2013;ve eBC management in India: Insights from expert consensus**  
A.K. Vaid<sup>1</sup>, O. Pagani<sup>2</sup>, A. Ramesh<sup>3</sup>, A. Bharthuar<sup>4</sup>, C. Desai<sup>5</sup>, G. Biswas<sup>6</sup>, J. Wadhwa<sup>1</sup>, P. Mohapatra<sup>7</sup>, S. Gulia<sup>8</sup>, P. Sripada<sup>9</sup>, T. Sahoo<sup>10</sup>, V. Agarwal<sup>11</sup>, F. Dawer<sup>12</sup>, R. Desai<sup>13</sup>, K. Gaurav<sup>14</sup>, B. Kotak<sup>12</sup>, <sup>1</sup>Medanta - The Medicity, Gurugram, Gurugram, IN, <sup>2</sup>HRC - Hopital Riviera-Chablais - Site de Rennaz, Rennaz, CH, <sup>3</sup>Saveetha Medical College and Hospital, Chennai, IN, <sup>4</sup>Patel Cancer and Super-speciality Hospital, Jalandhar, IN, <sup>5</sup>Daiichi Sankyo, Inc., Basking Ridge, US, <sup>6</sup>Sparsh Hospitals & Critical Care At Old

Rajdhani Nursing Home, Bhubaneswar, IN, <sup>7</sup>Apollo Gleneagles Hospital, Kolkata, IN, <sup>8</sup>Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN, <sup>9</sup>Apollo Cancer Institute - Hyderabad, Hyderabad, IN, <sup>10</sup>Silverline Hospital, Bhopal, IN, <sup>11</sup>HCG Towers, Karnataka, IN, <sup>12</sup>Dr Reddy's Laboratories, Hyderabad, IN, <sup>13</sup>Dr. Reddy's Laboratories Ltd., Hyderabad, IN, <sup>14</sup>Dr. Reddy's Laboratories Limited, Hyderabad, IN

17:50 - 17:50 **19P - Referral patterns among breast cancer patients in county-level hospitals in China**

P. Lu<sup>1</sup>, Y. Ji<sup>1</sup>, H. Qu<sup>2</sup>, F. Zhou<sup>3</sup>, J. Wang<sup>4</sup>, Q. Wu<sup>5</sup>, G. Dai<sup>6</sup>, M. Liu<sup>7</sup>, W. He<sup>8</sup>, W. Liang<sup>9</sup>, Q. Meng<sup>10</sup>, Y. Ren<sup>11</sup>, G. Luo<sup>12</sup>, H. Wang<sup>13</sup>, J. Luo<sup>14</sup>, Z. Yu<sup>15</sup>, G. Hu<sup>16</sup>, J. Gao<sup>17</sup>, Y. Zhang<sup>18</sup>, C. Zhao<sup>19</sup>, <sup>1</sup>The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, CN, <sup>2</sup>Inner Mongolia Forestry General Hospital, Hulunbeier, CN, <sup>3</sup>The People's Hospital of Liuyang, Changsha, CN, <sup>4</sup>Honghe Prefecture Third People's Hospital, Honghe, CN, <sup>5</sup>Guiping People's Hospital, Guigang, CN, <sup>6</sup>Pingyu County People's Hospital, Zhumadian, CN, <sup>7</sup>Lixin County People's Hospital, Bozhou, CN, <sup>8</sup>Dingzhou City People's Hospital, Dingzhou, CN, <sup>9</sup>Huixian City People's Hospital, Xinxiang, CN, <sup>10</sup>Gongyi City People's Hospital, Zhengzhou, CN, <sup>11</sup>Taihe County People's Hospital, Fuyang, CN, <sup>12</sup>Xiantao First People's Hospital Affiliated To Yangtze University, Xiantao, CN, <sup>13</sup>Tengzhou Central People's Hospital, Tengzhou, CN, <sup>14</sup>Fengcheng People's Hospital, Yichun, CN, <sup>15</sup>Central Hospital of Qinghe, Xingtai, CN, <sup>16</sup>Dongyang People's Hospital, Jinhua, CN, <sup>17</sup>Zhuozhou City Hospital, Baoding, CN, <sup>18</sup>Changshu NO.2 People's Hospital, Suzhou, CN, <sup>19</sup>Ningcheng County People's Hospital, Chifeng, CN

17:50 - 17:50 **20P - Real-world treatment of HER2<sup>+</sup> and HR<sup>+</sup>/HER2<sup>-</sup> early breast cancer in county areas of China**

Y. Ji<sup>1</sup>, J. Wang<sup>2</sup>, G. Dai<sup>3</sup>, F. Zhou<sup>4</sup>, Q. Meng<sup>5</sup>, Q. Wu<sup>6</sup>, H. Qu<sup>7</sup>, H. Liu<sup>8</sup>, M. Liu<sup>9</sup>, Y. Tian<sup>10</sup>, X. Tan<sup>11</sup>, W. He<sup>12</sup>, Z. Qin<sup>13</sup>, H. Tang<sup>14</sup>, G. Luo<sup>15</sup>, Y. Liu<sup>16</sup>, Y. Ren<sup>17</sup>, J. Luo<sup>18</sup>, M. Wang<sup>19</sup>, P. Lu<sup>1</sup>, <sup>1</sup>The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, CN, <sup>2</sup>Honghe Prefecture Third People's Hospital, Honghe, CN, <sup>3</sup>Pingyu County People's Hospital, Zhumadian, CN, <sup>4</sup>The People's Hospital of Liuyang, Changsha, CN, <sup>5</sup>Gongyi City People's Hospital, Zhengzhou, CN, <sup>6</sup>Guiping People's Hospital, Guigang, CN, <sup>7</sup>Inner Mongolia Forestry General Hospital, Hulunbeier, CN, <sup>8</sup>Dingyuan General Hospital, Chuzhou, CN, <sup>9</sup>Lixin County People's Hospital, Bozhou, CN, <sup>10</sup>The People's Hospital of Yuechi County, Guang'an, CN, <sup>11</sup>Anyue County People's Hospital, Ziyang, CN, <sup>12</sup>Dingzhou City People's Hospital, Dingzhou, CN, <sup>13</sup>People's Hospital of Lixian, Changde, CN, <sup>14</sup>Central Hospital of Zhuanghe City, Dalian, CN, <sup>15</sup>Xiantao First People's Hospital Affiliated To Yangtze University, Xiantao, CN, <sup>16</sup>People's Hospital of Macheng City, Huanggang, CN, <sup>17</sup>Taihe County People's Hospital, Fuyang, CN, <sup>18</sup>Fengcheng People's Hospital, Yichun, CN, <sup>19</sup>Hebei Yanda Hospital, Langfang, CN

17:50 - 17:50 **21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date**

D. Verschoor<sup>1</sup>, P. Khlebnikov<sup>2</sup>, F. Meer<sup>2</sup>, P. Amini<sup>2</sup>, Q. Haas<sup>2</sup>, E. Segelov<sup>1</sup>, <sup>1</sup>University of Bern, Bern, CH, <sup>2</sup>Risklick AG, Bern, CH

17:50 - 17:50 **22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)**

H. Padmanabhan<sup>1</sup>, N.T. Hassan<sup>1</sup>, C.H. Yip<sup>2</sup>, N.A. Taib<sup>3</sup>, A. Abdul Aziz<sup>4</sup>, M.W. Wong<sup>5</sup>, W.K. Ho<sup>6</sup>, B.H. Ang<sup>1</sup>, V. Lee<sup>1</sup>, Y.Q. Lee<sup>1</sup>, M.-K. Thong<sup>3</sup>, S.Y. Yoon<sup>1</sup>, S.-H. Teo<sup>1</sup>, <sup>1</sup>Cancer Research Malaysia, Subang Jaya, MY, <sup>2</sup>Subang Jaya Medical Centre, Subang Jaya, MY, <sup>3</sup>University Malaya Medical Centre, Kuala Lumpur, MY, <sup>4</sup>Pantai Hospital Kuala Lumpur, Kuala Lumpur, MY, <sup>5</sup>Sunway Medical Centre, Petaling Jaya, MY, <sup>6</sup>University of Nottingham Malaysia, Semenyih, MY

17:50 - 17:50

**23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)**

S.C. Lee<sup>1</sup>, Y.H. Park<sup>2</sup>, C. Singer<sup>3</sup>, J. Balmaña<sup>4</sup>, R. Dent<sup>5</sup>, V. Tan<sup>5</sup>, N.A.M. Sari<sup>6</sup>, M. Md Yusof<sup>7</sup>, F.V. Que<sup>8</sup>, Y.-S. Lu<sup>9</sup>, N. Parinyanitikul<sup>10</sup>, C.P. Pham<sup>11</sup>, N.A. Taib<sup>12</sup>, S.-Y. Kong<sup>13</sup>, Y. Antill<sup>14</sup>, H.J. Kim<sup>15</sup>, <sup>1</sup>Cancer Science Institute (CSI) - National University of Singapore (NUS), Singapore, SG, <sup>2</sup>Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, <sup>3</sup>Comprehensive Cancer Center, Medical University of Vienna, Vienna, AT, <sup>4</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>5</sup>NCCS - National Cancer Centre Singapore, Singapore, SG, <sup>6</sup>Dr. Cipto Mangunkusumo Hospital/ University of Indonesia, Central Jakarta, ID, <sup>7</sup>Pantai Hospital Kuala Lumpur, Kuala Lumpur, MY, <sup>8</sup>St. Luke's Medical Center - Quezon City, Quezon City, PH, <sup>9</sup>NTUH - National Taiwan University Hospital, Taipei City, TW, <sup>10</sup>King Chulalongkorn Memorial Hospital - Thai Red Cross Society, Bangkok, TH, <sup>11</sup>Bach Mai Hospital, Hanoi, VN, <sup>12</sup>University of Malaya, Kuala Lumpur, MY, <sup>13</sup>National Cancer Center - Graduate School of Cancer Science and Policy, Goyang, KR, <sup>14</sup>Royal Melbourne Hospital, Melbourne, AU, <sup>15</sup>Asan Medical Center - University of Ulsan, Seoul, KR

17:50 - 17:50

**24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia**

V. Lee, Cancer Research Malaysia, Subang Jaya, MY

17:50 - 17:50

**25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan**

C.-C. Huang, G. Chen, L.-M. Tseng, B.-F. Chen, Taipei Veterans General Hospital, Taipei City, TW

17:50 - 17:50

**26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China**

B. Sun, Y. Wang, H. Wang, X. Zhang, M. Li, Tianjin Medical University Cancer Institute & Hospital, TianJin, CN

17:50 - 17:50

**27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes**

A. Tsuruga<sup>1</sup>, M. Hosonuma<sup>1</sup>, A. Sasaki<sup>1</sup>, H. Isobe<sup>1</sup>, N. Parinyanitikul<sup>2</sup>, G. Gong<sup>3</sup>, H.J. Lee<sup>3</sup>, R. Yoshida<sup>1</sup>, N. Hayashi<sup>1</sup>, S. Nakamura<sup>1</sup>, R. Seitz<sup>4</sup>, D. Hout<sup>4</sup>, N. Ueno<sup>5</sup>, H. Masuda<sup>1</sup>, <sup>1</sup>Showa University, Shinagawa-ku, JP, <sup>2</sup>King Chulalongkorn Memorial Hospital - Thai Red Cross Society, Bangkok, TH, <sup>3</sup>Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, <sup>4</sup>Oncocyte, Irvine, US, <sup>5</sup>University of Hawaii Cancer Center, Honolulu, US

17:50 - 17:50

**28P - One-week ultra-hypofractionated partial breast RT in early breast cancer:**



**3DCRT vs IMRT**

N. Zaynutdinov<sup>1</sup>, A. Abdujapparov<sup>1</sup>, F. Djuraev<sup>2</sup>, I. Vakhabov<sup>3</sup>, <sup>1</sup>Tashkent City Branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, Tashkent, UZ, <sup>2</sup>Tashkent Medical Park, Tashkent, UZ, <sup>3</sup>Tashkent Medical Academy, Tashkent, UZ

- 17:50 - 17:50 **30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics**  
T.-N. Wei, H.-L. Yeh, Taichung Veterans General Hospital, Taichung City, TW
- 17:50 - 17:50 **31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer**  
K.-T. Hwang, Seoul National University College of Medicine / SMG-SNU Boramae Medical Center, Seoul, KR
- 17:50 - 17:50 **32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study**  
M. Tada, Y. Kikawa, C. Hirai, H. Yanai, N. Shibata, T. Sugie, Kansai Medical University, Hirakata, JP
- 17:50 - 17:50 **34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer**  
N. Sinarajoo<sup>1</sup>, Y.C. Kong<sup>2</sup>, R. Kaur<sup>3</sup>, B.L. Sew<sup>4</sup>, M. Thiagarajan<sup>5</sup>, N.F. Bt Abdul Satar<sup>6</sup>, A. Ali<sup>7</sup>, F. Chong<sup>8</sup>, N.H. Zainal<sup>9</sup>, A. Abdul Aziz<sup>10</sup>, S. Jaya-Prakason<sup>2</sup>, H. Alagir Rajah<sup>2</sup>, N. Muniandy<sup>2</sup>, M. Danaee<sup>1</sup>, C.H. Yip<sup>11</sup>, N. Bhoo-Pathy<sup>1</sup>, <sup>1</sup>University Malaya Faculty of Medicine, Kuala Lumpur, MY, <sup>2</sup>University of Malaya Faculty of Medicine, Kuala Lumpur, MY, <sup>3</sup>Breast Cancer Welfare Association Malaysia, Selangor, MY, <sup>4</sup>Society for Cancer Advocacy & Awareness Kuching (SCAN), Kuching, MY, <sup>5</sup>General Hospital Kuala Lumpur, Kuala Lumpur, MY, <sup>6</sup>UMMC - University Malaya Medical Centre, Kuala Lumpur, MY, <sup>7</sup>Sarawak General Hospital, Kuching, MY, <sup>8</sup>Sabah Women and Children's Hospital (Likas Hospital), Kota Kinabalu, MY, <sup>9</sup>Hospital Tengku Ampuan Rahimah Klang, Klang, MY, <sup>10</sup>Pantai Hospital Kuala Lumpur, Kuala Lumpur, MY, <sup>11</sup>SJMC - Sime Darby Medical Centre Subang Jaya, Subang Jaya, MY
- 17:50 - 17:50 **35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy**  
W. Yeo<sup>1</sup>, C. Kwok<sup>2</sup>, T. Lau<sup>3</sup>, K. Lai<sup>3</sup>, L. Li<sup>3</sup>, E. Leung<sup>2</sup>, D. Chan<sup>2</sup>, H. Wong<sup>2</sup>, D. Lui<sup>2</sup>, H. So<sup>2</sup>, Y. Li<sup>1</sup>, H. Yeo<sup>1</sup>, E. Pang<sup>1</sup>, F. Mo<sup>1</sup>, <sup>1</sup>The Chinese University of Hong Kong, Shatin, HK, <sup>2</sup>Princess Margaret Hospital, Kowloon, HK, <sup>3</sup>CUHK - Chinese University of Hong Kong, Sha Tin, HK
- 17:50 - 17:50 **37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients**  
C. Hing<sup>1</sup>, E.Y. Tan<sup>2</sup>, E.-J. Sim<sup>2</sup>, E.L.S. Tang<sup>3</sup>, <sup>1</sup>NUS - National University of Singapore, Singapore, SG, <sup>2</sup>National Healthcare Group - Tan Tock Seng Hospital, Singapore, SG, <sup>3</sup>National Healthcare Group, Singapore- Woodlands Health, Singapore, SG

- 17:50 - 17:50 **38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data**  
L. Wenjie, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, CN
- 17:50 - 17:50 **39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer**  
S. Kang, Daegu Catholic University Hospital, SKT, KR
- 17:50 - 17:50 **40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer**  
J.W. Pan<sup>1</sup>, H. Makmur<sup>1</sup>, P.-S. Ng<sup>1</sup>, J.-Y. Tai<sup>1</sup>, S.N. Hasan<sup>1</sup>, C.H. Yip<sup>2</sup>, P. Rajadurai<sup>3</sup>, J. Lim<sup>1</sup>, S.-H. Teo<sup>1</sup>, <sup>1</sup>Cancer Research Malaysia, Subang Jaya, MY, <sup>2</sup>Subang Jaya Medical Centre, Subang Jaya, MY, <sup>3</sup>Monash University, Subang Jaya, MY
- 17:50 - 17:50 **41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome**  
S. Park<sup>1</sup>, W. Suh<sup>2</sup>, <sup>1</sup>The Catholic University of Korea - College of Medicine, Seoul, KR, <sup>2</sup>The Catholic University of Korea - Daejeon St. Mary's Hospital, Daejeon, KR
- 17:50 - 17:50 **42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling**  
H.-J. Chae<sup>1</sup>, J. Kim<sup>2</sup>, H.-K. Kim<sup>2</sup>, H. Yoo<sup>1</sup>, S. Lee<sup>1</sup>, Y.-J. Yu<sup>2</sup>, E.Y. Kim<sup>1</sup>, <sup>1</sup>ONCOZEN Co., Ltd, Seoul, KR, <sup>2</sup>Jeonbuk National University, School of Pharmacy, Jeonju-si, KR
- 17:50 - 17:50 **43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)**  
M. Wijaya<sup>1</sup>, S. Haryono<sup>2</sup>, F. Aldila<sup>3</sup>, S.G. Tanu<sup>3</sup>, J. Audrienna<sup>3</sup>, B. Rabbani<sup>3</sup>, K.N. Ramanto<sup>3</sup>, A. Fajarrahman<sup>3</sup>, S.S.M. Hasan<sup>3</sup>, S. Sormin<sup>1</sup>, F.A. Agatha<sup>1</sup>, K.I. Junusmin<sup>3</sup>, M. Amelia<sup>3</sup>, J. Haruman<sup>3</sup>, L. Sani<sup>3</sup>, E. Fernandez<sup>3</sup>, A. Irwanto<sup>3</sup>, A. Salim<sup>1</sup>, A. Winata<sup>1</sup>, S. Ali<sup>4</sup>, <sup>1</sup>SJH Initiatives, Jakarta, ID, <sup>2</sup>Mochtar Riady Comprehensive Cancer Center, Siloam Hospitals Semanggi, South Jakarta, ID, <sup>3</sup>PT Nalagenetik Riset Indonesia, Jakarta Selatan, ID, <sup>4</sup>Atma Jaya Catholic Univeristy of Indonesia, South Jakarta, ID
- 17:50 - 17:50 **44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer**  
A. Patel<sup>1</sup>, M. Sharma<sup>1</sup>, S. Joga<sup>1</sup>, S. Goel<sup>2</sup>, D.C. Doval<sup>1</sup>, V. Talwar<sup>1</sup>, S. Goyal<sup>1</sup>, U. Batra<sup>1</sup>, <sup>1</sup>Rajiv Gandhi Cancer Institute and Research Centre, Delhi, IN, <sup>2</sup>Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN
- 17:50 - 17:50 **45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer**  
A. Dharanikota, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad, IN

- 17:50 - 17:50 **46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly**  
T. Mistry, R. Pal, S. Ghosh, P. Nath, N. Alam, V.D. Nasare, Chittaranjan National Cancer Institute, Kolkata, IN
- 17:50 - 17:50 **47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities**  
A. Dharanikota, Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad, IN
- 17:50 - 17:50 **48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients**  
B. Rajendar<sup>1</sup>, J. Ram Vishnoi<sup>2</sup>, R. Yadav<sup>2</sup>, S. Misra<sup>3</sup>, <sup>1</sup>AIIMS - All India Institute of Medical Sciences, Jodhpur, JODHPUR, IN, <sup>2</sup>AIIMS - All India Institute of Medical Sciences, Jodhpur, Jodhpur, IN, <sup>3</sup>AIIMS - All India Institute of Medical Sciences, Jodhpur, New Delhi, IN
- 17:50 - 17:50 **49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India**  
M. Shah<sup>1</sup>, S. Rath<sup>2</sup>, S. Gulia<sup>2</sup>, P. Bhargava<sup>1</sup>, A. Sekar<sup>3</sup>, J. Bajpai<sup>2</sup>, T. Shet<sup>4</sup>, S. Desai<sup>2</sup>, R. Sarin<sup>5</sup>, R. Pathak<sup>2</sup>, P. Popat<sup>4</sup>, P. Parab<sup>2</sup>, Y. Kembhavi<sup>4</sup>, A. Patil<sup>2</sup>, N. Nair<sup>2</sup>, P. Rane<sup>4</sup>, S. Joshi<sup>5</sup>, R. Badwe<sup>1</sup>, S. Gupta<sup>2</sup>, <sup>1</sup>Tata Memorial Centre, Mumbai, IN, <sup>2</sup>Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN, <sup>3</sup>ACTREC Tata Memorial Centre, Mumbai, IN, <sup>4</sup>Tata Memorial Centre - Parel, Mumbai, IN, <sup>5</sup>Tata Memorial Hospital - Parel, Mumbai, IN
- 17:50 - 17:50 **50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis**  
A. Kardousha<sup>1</sup>, W. Shehada<sup>1</sup>, A. Basha<sup>1</sup>, S. Nasser<sup>1</sup>, M. El Mistiri<sup>2</sup>, A. Hamad<sup>1</sup>, S. Bujassoum<sup>2</sup>, S. Elazzazy<sup>1</sup>, <sup>1</sup>Hamad Medical Corporation (HMC) - National Center for Cancer Care and Research (Al Amal Hospital), Doha, QA, <sup>2</sup>Hamad Medical Corporation (HMC), Doha, QA
- 17:50 - 17:50 **51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations**  
S. Gahramanova, National Center of Oncology, Baku, AZ
- 17:50 - 17:50 **52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques**  
P. Singh, AIIMS - All India Institute of Medical Sciences - Patna, Patna, IN
- 17:50 - 17:50 **29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers**

S. Kahol, S. Mathur, AIIMS - All India Institute of Medical Sciences, New Delhi, IN

17:50 - 17:50 **Breast cancer, metastatic**

17:50 - 18:10 **36P - Fertility Preservation & HBOC Genetic Testing in Young Japanese Breast Cancer Patients: the Role of Insurance Coverage**

C. Hirai, C. Satoh, S. Shimada, M. Tada, H. Yanai, Y. Kikawa, T. Sugie, Kansai Medical University, Hirakata, JP

18:10 - 18:10 **53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care**

D. Manuain<sup>1</sup>, G.B. Prajogi<sup>2</sup>, T.B.M. Permata<sup>2</sup>, H. Handoko<sup>3</sup>, S.M. Sekarutami<sup>2</sup>, S. Gondhowiardjo<sup>2</sup>, <sup>1</sup>Universitas Indonesia, Central Jakarta, ID, <sup>2</sup>RSUPN Dr. Cipto Mangunkusumo, Central Jakarta, ID, <sup>3</sup>University of Indonesia - Faculty of Medicine, Central Jakarta, ID

18:10 - 18:10 **58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study**

H. Iwata<sup>1</sup>, Y. Naito<sup>2</sup>, M. Hattori<sup>1</sup>, A. Yoshimura<sup>1</sup>, K. Yonemori<sup>3</sup>, M. Aizawa<sup>4</sup>, Y. Mori<sup>4</sup>, J. Yoshimitsu<sup>4</sup>, Y. Umeyama<sup>4</sup>, T. Mukohara<sup>2</sup>, <sup>1</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>2</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>3</sup>National Cancer Center Hospital, Tokyo, JP, <sup>4</sup>Pfizer R&D Japan, Tokyo, JP

18:10 - 18:10 **59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience**

S. Lingaraju<sup>1</sup>, K. Raghavendracher<sup>1</sup>, G. Balaram<sup>1</sup>, R. Kodandapani<sup>1</sup>, V. Erappareddy<sup>1</sup>, V. Keriyappa<sup>1</sup>, S. Ghorpade<sup>1</sup>, S. Patil<sup>2</sup>, S. Chiradoni Thungappa<sup>2</sup>, S. Papaiah Susheela<sup>2</sup>, S. Belagutti Jayappa<sup>2</sup>, S. Bhattacharjee<sup>2</sup>, M. Naseer R<sup>2</sup>, R. Dasgupta<sup>2</sup>, D. Hattangdi<sup>1</sup>, T. Nanjaiah<sup>1</sup>, A. Ravichandran<sup>3</sup>, U. Bahadur<sup>3</sup>, B.S. Ajaikumar<sup>2</sup>, M. Ghosh<sup>1</sup>, <sup>1</sup>HCG HealthCare Global Enterprises Ltd, Bangalore, IN, <sup>2</sup>HCG Cancer Centre, Bangalore, IN, <sup>3</sup>Strand Life Sciences Pvt Ltd, Bangalore, IN

18:10 - 18:10 **60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer**

P.-S. Yang<sup>1</sup>, C.-C. Lee<sup>2</sup>, Y.-W. Su<sup>3</sup>, Y.-C. Chang<sup>4</sup>, H.B. Lam<sup>4</sup>, F. Lee<sup>3</sup>, <sup>1</sup>Mackay Memorial Hospital, Taipei City, TW, <sup>2</sup>Mackay Memorial Hospital, Taipei, TW, <sup>3</sup>MMH - Mackay Memorial Hospital - Taipei Branch, Taipei City, TW, <sup>4</sup>Mackay Memorial Hospital - Taipei Branch, Taipei City, TW

18:10 - 18:10 **61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)**

C. Wu, SEU - Southeast University - Sipailou Campus, Nanjing, CN

18:10 - 18:10 **62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -**

**negative disease: A phase II randomised clinical trial**

M. Saleh<sup>1</sup>, L. Kassem<sup>1</sup>, A. Abdel Hafeez<sup>1</sup>, P. Essam Eldin Shibel<sup>2</sup>, M. Hassan<sup>1</sup>, H. Azim<sup>1</sup>,  
<sup>1</sup>NEMROCK - Kasr Alainy Centre of Clinical Oncology & Nuclear Medicine, Cairo, EG,  
<sup>2</sup>Kasr Al-Ainy School of Medicine, Cairo University, Cairo, EG

- 18:10 - 18:10 **63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer**  
M. Ni<sup>1</sup>, L. Zhou<sup>2</sup>, Y. Lu<sup>3</sup>, L. Zhang<sup>4</sup>, X. Li<sup>5</sup>, M. Chen<sup>2</sup>, A. Yang<sup>6</sup>, L. Zhang<sup>2</sup>, F. Xu<sup>7</sup>, Z. Yuan<sup>2</sup>, S. Wang<sup>2</sup>, Y. Shi<sup>2</sup>, X. An<sup>8</sup>, <sup>1</sup>Sun Yat-sen University Cancer Center, Guangzhou, CN, <sup>2</sup>Sun Yat-Sen University Cancer Center, Guangzhou, CN, <sup>3</sup>Affiliated Tumor Hospital of Guangxi Medical University, Guangxi, CN, <sup>4</sup>Puning People's Hospital, Puning, CN, <sup>5</sup>Guangzhou Panyu Central Hospital, Guangzhou, CN, <sup>6</sup>Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, CN, <sup>7</sup>Sun Yat-sen University Cancer Center, Guangzhou, CN, <sup>8</sup>State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, CN
- 18:10 - 18:10 **64P - Unmet needs following metastatic breast cancer in a middle-income Asian country**  
N. Bhoo-Pathy<sup>1</sup>, Y.C. Kong<sup>1</sup>, M. Thiagarajan<sup>2</sup>, N.F. Bt Abdul Satar<sup>3</sup>, C.H. Yip<sup>4</sup>, M. Md Yusof<sup>5</sup>, R. Kaur<sup>6</sup>, <sup>1</sup>Universiti Malaya, Kuala Lumpur, MY, <sup>2</sup>Kuala Lumpur Hospital, Kuala Lumpur, MY, <sup>3</sup>UMMC - University Malaya Medical Centre, Kuala Lumpur, MY, <sup>4</sup>Subang Jaya Medical Centre, Subang Jaya, MY, <sup>5</sup>Pantai Hospital Kuala Lumpur, Kuala Lumpur, MY, <sup>6</sup>Breast Cancer Welfare Association Malaysia, Petaling Jaya, MY
- 18:10 - 18:10 **66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial**  
J. Zhang<sup>1</sup>, Z. Liu<sup>1</sup>, H. Ding<sup>2</sup>, L. Ma<sup>1</sup>, H. Lu<sup>3</sup>, Y. Shi<sup>4</sup>, F. Lin<sup>5</sup>, L. Zheng<sup>6</sup>, M. Wang<sup>7</sup>, G. Qiao<sup>1</sup>, Z. Deng<sup>1</sup>, L. Yu<sup>1</sup>, Y. Zhang<sup>1</sup>, Y. Yuan<sup>1</sup>, H. Lin<sup>1</sup>, <sup>1</sup>Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CN, <sup>2</sup>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CN, <sup>3</sup>Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CN, <sup>4</sup>Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CN, <sup>5</sup>Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, CN, <sup>6</sup>Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, CN, <sup>7</sup>Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, CN
- 18:10 - 18:10 **67P - Efficacy and safety of trastuzumab biosimilar in HER2-positive metastatic breast cancer: A multicenter phase III study**  
K. Mohan<sup>1</sup>, A. Prajapati<sup>2</sup>, R. Kothari<sup>3</sup>, S. Mondal<sup>4</sup>, S. R<sup>5</sup>, R. Nagarkar<sup>6</sup>, S. Kane<sup>7</sup>, A. Santa<sup>1</sup>, D. Dadke<sup>2</sup>, <sup>1</sup>Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad, IN, <sup>2</sup>Curateq Biologics Private Limited, Hyderabad, IN, <sup>3</sup>Narayana Multispecialty Hospital, Ahmedabad, IN, <sup>4</sup>Nilratan Sircar Medical College & Hospital, Kolkata, IN, <sup>5</sup>MNJ Institute of Oncology & Regional Cancer Center, Hyderabad, IN, <sup>6</sup>HCG Manavata Cancer Centre, Nashik, IN, <sup>7</sup>RST Regional Cancer Centre, Nagpur, IN
- 18:10 - 18:10 **68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER-positive breast cancer**

M. Arshad, KCL - King's College London, London, GB

- 18:10 - 18:10 **69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer**  
N. Jin, Y. Yin, W. Li, X. Huang, Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN
- 18:10 - 18:10 **70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial**  
K. Inoue<sup>1</sup>, J. Ninomiya<sup>2</sup>, K. Okubo<sup>3</sup>, T. Nakakuma<sup>4</sup>, H. Yamada<sup>5</sup>, K. Kimizuka<sup>6</sup>, T. Higuchi<sup>7</sup>, T. Saito<sup>7</sup>, <sup>1</sup>Saitama Cancer Center, Ina, JP, <sup>2</sup>Ninomiya Hospital, Soka, JP, <sup>3</sup>Toda Central General Hospital, Toda, JP, <sup>4</sup>Ageo Central General Hospital, Ageo, JP, <sup>5</sup>Sekishindo Hospital, Kawagoe, JP, <sup>6</sup>Kasukabe City Hospital, Kasukabe, JP, <sup>7</sup>Saitama Red Cross Hospital, Saitama, JP
- 18:10 - 18:10 **71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 - positive breast cancer: A real-world data of retrospective study**  
C. Li, Z. Yu, Shandong Cancer Hospital and Institute, Jinan, CN
- 18:10 - 18:10 **72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India**  
K. Patel, Sunshine Global Hospital, Surat, IN
- 18:10 - 18:10 **73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)&#x2b;/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3**  
H. Iwata<sup>1</sup>, E. Hamilton<sup>2</sup>, C. Ma<sup>3</sup>, M. De Laurentiis<sup>4</sup>, S. Hurvitz<sup>5</sup>, S. Wander<sup>6</sup>, M. Danso<sup>7</sup>, D. Lu<sup>8</sup>, J. Perkins<sup>9</sup>, Y. Liu<sup>8</sup>, L. Tran<sup>8</sup>, S. Anderson<sup>10</sup>, C. Chappay<sup>8</sup>, D. Yang<sup>8</sup>, M. Campone<sup>11</sup>, <sup>1</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>2</sup>Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US, <sup>3</sup>Washington University School of Medicine, St. Louis, US, <sup>4</sup>Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, IT, <sup>5</sup>Fred Hutchinson Cancer Center, Seattle, US, <sup>6</sup>Massachusetts General Hospital, Boston, US, <sup>7</sup>Brock Cancer Center, Virginia Oncology Associates, Norfolk, US, <sup>8</sup>Pfizer Inc, La Jolla, US, <sup>9</sup>Pfizer Inc, New York, US, <sup>10</sup>Arvinas Operations, Inc., New Haven, US, <sup>11</sup>Institut de Cancerologie de l'Ouest, Angers, FR
- 18:10 - 18:10 **Developmental therapeutics**
- 18:10 - 18:10 **78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors**  
C.J. Yen<sup>1</sup>, M.-C. Liu<sup>2</sup>, J. Fan<sup>3</sup>, C. Sun<sup>4</sup>, P. Peng<sup>4</sup>, X. Du<sup>4</sup>, J. Wang<sup>4</sup>, F. Wei<sup>4</sup>, Z. Gou<sup>4</sup>, X. Tan<sup>4</sup>, D. Wu<sup>4</sup>, F. Wu<sup>4</sup>, C.-L. Ho<sup>5</sup>, <sup>1</sup>NCKUH - National Cheng Kung University Hospital, Tainan City, TW, <sup>2</sup>Taipei Medical University Hospital, Taipei City, TW, <sup>3</sup>TransThera Sciences (US), Inc, Gaithersburg, US, <sup>4</sup>TransThera Sciences (Nanjing), Inc., Nanjing, CN,

<sup>5</sup>Tri-Service General Hospital - Neihu Branch, Taipei City, TW

- 18:10 - 18:10 **79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines**  
L.S. Tran, D. Tran, T. Nguyen, Medical Genetics Institute, Ho Chi Minh City, VN
- 18:10 - 18:10 **80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study**  
Y. Wu<sup>1</sup>, H. Jing<sup>1</sup>, J. Zhang<sup>1</sup>, X. Cao<sup>1</sup>, K. Li<sup>1</sup>, Y. Liu<sup>1</sup>, M. Meng<sup>1</sup>, H. Li<sup>2</sup>, W. Kang<sup>2</sup>, J. Li<sup>2</sup>, Q. Wang<sup>2</sup>, J. Zhu<sup>2</sup>, <sup>1</sup>Xuzhou Central Hospital, Xuzhou, CN, <sup>2</sup>Shanghai Henlius Biotech, Inc., Shanghai, CN
- 18:10 - 18:10 **81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors**  
Q. Liu, B. Liu, J. Wei, R. Li, J. Shao, L. Zhu, M. Tian, L. Yu, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, CN
- 18:10 - 18:10 **82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies**  
 J. Choo, S. Nathan Jeraj, G. Chan, R. Sundar, W.P. Yong, M. Lee, N. Ngoi, A. Wong, R. Soo, C.E. Chee, J. Lim, B.-C. Goh, S.C. Lee, D.S. Tan, NCIS - National University Cancer Institute Singapore, Singapore, SG
- 18:10 - 18:10 **83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors**  
Y. Shen<sup>1</sup>, S. Rahimian<sup>2</sup>, A. Qin<sup>3</sup>, Y. Qiu<sup>3</sup>, T. Fang<sup>1</sup>, X. Liang<sup>1</sup>, Y. Li<sup>1</sup>, Q. Tan<sup>3</sup>, R. Zhao<sup>3</sup>, X. Bai<sup>1</sup>, T. Liang<sup>1</sup>, <sup>1</sup>The First Affiliated Hospital, Zhejiang University School Of Medicine, Hangzhou, CN, <sup>2</sup>Virogin Biotech, Jonesville, US, <sup>3</sup>Virogin Biotech (Shanghai) Ltd., Shanghai, CN
- 18:10 - 18:10 **84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy**  
T. Nguyen, Q. Pham, L.S. Tran, Medical Genetics Institute, Ho Chi Minh City, VN
- 18:10 - 18:10 **85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies**  
A. Al Hanafy<sup>1</sup>, D. Aggour<sup>2</sup>, O. Sherif<sup>3</sup>, M. Alhanafy<sup>3</sup>, R. Ibrahim<sup>3</sup>, R. Hassanin<sup>3</sup>, A. Hegazy<sup>3</sup>, <sup>1</sup>MFM - Menoufia University - Faculty of Medicine, Shebeen El-Kom, EG, <sup>2</sup>Menoufia University, Shebeen El-Kom, EG, <sup>3</sup>Menoufeya University Faculty of Medicine, Cairo, EG
- 18:10 - 18:10 **86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study**  
C. Li<sup>1</sup>, D. Zhu<sup>2</sup>, Z. Fan<sup>3</sup>, Y. Chen<sup>4</sup>, Y. Chen<sup>5</sup>, Y. Li<sup>6</sup>, M. Ji<sup>7</sup>, P. Duan<sup>8</sup>, J. Su<sup>9</sup>, J. Yang<sup>10</sup>, Y. Tang<sup>11</sup>, M. Zhang<sup>12</sup>, S. Wang<sup>13</sup>, G. Yu<sup>14</sup>, Y. Huang<sup>15</sup>, R. Chen<sup>16</sup>, X. Hu<sup>17</sup>, L. Wang<sup>17</sup>, Q.

Wang<sup>17</sup>, J. Zhu<sup>17</sup>, <sup>1</sup>Nanfang Hospital, Southern Medical University, Guangzhou, CN, <sup>2</sup>Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, CN, <sup>3</sup>Beijing Cancer Hospital, Beijing, CN, <sup>4</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>5</sup>Fujian Cancer Hospital, Fuzhou, CN, <sup>6</sup>The First Affiliated Hospital of Nanchang University, Nanchang, CN, <sup>7</sup>The Second Affiliated Hospital of Xiamen Medical College, Xiamen, CN, <sup>8</sup>Chengdu Integrated TCM & Western Medicine Hospital, Chengdu, CN, <sup>9</sup>Xiangya Hospital of Central South University, Changsha, CN, <sup>10</sup>Tianjin Cancer Institute & Hospital, Tianjin, CN, <sup>11</sup>The First Affiliated Hospital of Kunming Medical University, Kunming, CN, <sup>12</sup>The Second Hospital of Anhui Medical University, Hefei, CN, <sup>13</sup>The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, CN, <sup>14</sup>Jiangmen Central Hospital, Jiangmen, CN, <sup>15</sup>Maoming People's Hospital, Maoming, CN, <sup>16</sup>Dermatology Hospital of Southern Medical University, Guangzhou, CN, <sup>17</sup>Shanghai Henlius Biotech, Inc., Shanghai, CN

18:10 - 18:10

**87TiP - Phase I expansion study of the tissue factor (TF) antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)**

S. Ulahannan<sup>1</sup>, M. Johnson<sup>2</sup>, M. Weiss<sup>3</sup>, A. Vandross<sup>4</sup>, S. Vidal-Cardenas<sup>5</sup>, M. Syed<sup>5</sup>, A. Tolcher<sup>6</sup>, <sup>1</sup>University of Oklahoma Health Sciences Center, Oklahoma City, US, <sup>2</sup>Sarah Cannon Research Institute, Nashville, US, <sup>3</sup>Washington University School of Medicine in St. Louis, St. Louis, US, <sup>4</sup>NEXT Oncology, Austin, US, <sup>5</sup>Exelixis, Inc., Alameda, US, <sup>6</sup>NEXT Oncology, San Antonio, US

18:10 - 18:10

**88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling**

N. Pavlakis<sup>1</sup>, M. Millward<sup>2</sup>, G. Richardson<sup>3</sup>, V. Anđelković<sup>4</sup>, G. Kichenadasse<sup>5</sup>, D. Thomas<sup>6</sup>, A. Mas Fernandez<sup>7</sup>, D. Thakkar<sup>7</sup>, T. Arbabzade<sup>8</sup>, C.H. Goey<sup>7</sup>, Q. Seet<sup>7</sup>, W. Toy<sup>7</sup>, K. Paszkiewicz<sup>7</sup>, P. Ingram<sup>7</sup>, J. Boyd-Kirkup<sup>7</sup>, K.Y. Kwek<sup>9</sup>, <sup>1</sup>GenesisCare North Shore, St Leonards, AU, <sup>2</sup>Linear Clinical Research, Nedlands, AU, <sup>3</sup>Cabrini Institute Research & Education, Malvern, AU, <sup>4</sup>Icon Cancer Centre South Brisbane, South Brisbane, AU, <sup>5</sup>Southern Oncology, Bedford Park, AU, <sup>6</sup>Omico: Australian Genomic Cancer Medicine Centre, Darlinghurst, AU, <sup>7</sup>Hummingbird Bioscience Pte. Ltd., Singapore, SG, <sup>8</sup>Hummingbird Bioscience Australia Pty Ltd, Melbourne, AU, <sup>9</sup>Hummingbird Bioscience Pte. Ltd., SINGAPORE, SG

18:10 - 18:10

**93P - Efficacy and safety of fruquintinib (F) vs placebo (P) vs BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2**

D. Kotani<sup>1</sup>, T. Yoshino<sup>1</sup>, A. Paulson<sup>2</sup>, T. Masuishi<sup>3</sup>, H. Hochster<sup>4</sup>, J. Krauss<sup>5</sup>, Y. Sunakawa<sup>6</sup>, A. Takashima<sup>7</sup>, K. Yamazaki<sup>8</sup>, H. Kawakami<sup>9</sup>, T. Nishina<sup>10</sup>, Y. Komatsu<sup>11</sup>, T. Esaki<sup>12</sup>, C. Eng<sup>13</sup>, N.A. Dasari<sup>14</sup>, Z. Yu<sup>15</sup>, L. Chen<sup>15</sup>, T. Yang<sup>16</sup>, W. Schelman<sup>16</sup>, T. Satoh<sup>17</sup>, <sup>1</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>2</sup>Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, US, <sup>3</sup>Aichi Cancer Center Hospital, Aichi, JP, <sup>4</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, US, <sup>5</sup>The University of Michigan Health Rogel Cancer Center, Ann Arbor, US, <sup>6</sup>St Marianna University School of Medicine, Kawasaki, JP, <sup>7</sup>National Cancer Center Hospital, Tokyo, JP, <sup>8</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>9</sup>Kindai University Faculty of Medicine, Osakasayama, JP, <sup>10</sup>National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, <sup>11</sup>Hokkaido University Hospital



Cancer Center, Sapporo, JP, <sup>12</sup>National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, <sup>13</sup>Vanderbilt-Ingram Cancer Center, Nashville, US, <sup>14</sup>University of Texas MD Anderson Cancer Center, Houston, US, <sup>15</sup>Takeda Pharmaceuticals, Lexington, US, <sup>16</sup>HUTCHMED International Corporation, Florham Park, US, <sup>17</sup>Osaka University Hospital, Osaka, JP

18:10 - 18:10

**94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)**

T. Kajiwara<sup>1</sup>, T. Nishina<sup>1</sup>, R. Yamashita<sup>2</sup>, Y. Nakamura<sup>3</sup>, M. Shiozawa<sup>4</sup>, S. Yuki<sup>5</sup>, H. Taniguchi<sup>6</sup>, H. Hara<sup>7</sup>, T. Ohta<sup>8</sup>, T. Esaki<sup>9</sup>, E. Shinozaki<sup>10</sup>, A. Takashima<sup>11</sup>, Y. Yamamoto<sup>12</sup>, K. Yamazaki<sup>13</sup>, T. Yoshino<sup>3</sup>, I. Hyodo<sup>1</sup>, <sup>1</sup>National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, <sup>2</sup>National Cancer Center, Kashiwa, JP, <sup>3</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>4</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>5</sup>Hokkaido University Hospital, Sapporo, JP, <sup>6</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>7</sup>Saitama Cancer Center, Kitaadachi-gun, JP, <sup>8</sup>Kansai Rosai Hospital, Amagasaki, JP, <sup>9</sup>National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, <sup>10</sup>Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JP, <sup>11</sup>National Cancer Center Hospital, Tokyo, JP, <sup>12</sup>University of Tsukuba, Tsukuba, JP, <sup>13</sup>Shizuoka Cancer Center, Shunto-gun, JP

18:10 - 18:10

**95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum**

S. Barik<sup>1</sup>, P. Mukherjee<sup>2</sup>, S.K. Das Majumdar<sup>3</sup>, D. Das<sup>4</sup>, D. Muduly<sup>2</sup>, B. Pattnaik<sup>2</sup>, T. Dutta<sup>2</sup>, S. Gupta<sup>2</sup>, M.R. Sahoo<sup>2</sup>, P. Sasmal<sup>2</sup>, S. Patra<sup>2</sup>, B. Sahoo<sup>2</sup>, H.K. Nayak<sup>2</sup>, A.K. Singh<sup>2</sup>, D.K. Parida<sup>2</sup>, <sup>1</sup>All India Institute of Medical Sciences, Bhubaneswar, Bhubaneswar, IN, <sup>2</sup>AIIMS - All India Institute of Medical Sciences - Bhubaneswar, Bhubaneswar, IN, <sup>3</sup>AIIMS-All India Institute of Medical Sciences - Bhubaneswar, Bhubaneswar, IN, <sup>4</sup>PGIMER - Post Graduate Institute of Medical Education and Research, Chandigarh, IN

18:10 - 18:10

**96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study**

J. Zhang<sup>1</sup>, Q. Dong<sup>1</sup>, Y. Wang<sup>1</sup>, Y. Diao<sup>1</sup>, X. Cui<sup>2</sup>, L. Man<sup>3</sup>, J. Zhang<sup>4</sup>, Y. Zhang<sup>5</sup>, T. Wu<sup>6</sup>, T. Chen<sup>7</sup>, Y. Dong<sup>3</sup>, J. Zhang<sup>8</sup>, Y. Huang<sup>9</sup>, S. Wang<sup>10</sup>, <sup>1</sup>Liaoning Cancer Hospital & Institute, Shenyang, CN, <sup>2</sup>Chaoyang Central Hospital, Chaoyang, CN, <sup>3</sup>Anshan Cancer Hospital, Anshan, CN, <sup>4</sup>Liaoyang Central Hospital of China Medical University, Liaoyang, CN, <sup>5</sup>The Second Department of Oncology, General Hospital of Fushun Mining Bureau of Liaoning Health Industry Group, FUSHUN, CN, <sup>6</sup>the Second Hospital of Dalian Medical University, DALIAN, CN, <sup>7</sup>Benxi Central Hospital, Benxi, CN, <sup>8</sup>Panjin Central Hospital, Panjin, CN, <sup>9</sup>Liaoyang county Central Hospital, liaoyang, CN, <sup>10</sup>Shengjing Hospital of China Medical University - Huaxiang Campus, Shenyang, CN

18:10 - 18:10

**97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)**

R.-H. Xu<sup>1</sup>, Z. Chen<sup>2</sup>, H.-W. Teng<sup>3</sup>, H. Pan<sup>4</sup>, H. Zhong<sup>5</sup>, A. Takashima<sup>6</sup>, T.-S. Yang<sup>7</sup>, Y.-M.

Yeh<sup>8</sup>, Y. Deng<sup>9</sup>, T.W. Kim<sup>10</sup>, T.-Y. Kim<sup>11</sup>, J.O. Park<sup>12</sup>, M.A. Lee<sup>13</sup>, S. Lee<sup>14</sup>, K.-H. Yeh<sup>15</sup>, T. Yoshino<sup>16</sup>, R. Fu<sup>17</sup>, R. Jain<sup>18</sup>, D. Adelberg<sup>18</sup>, A. Kawazoe<sup>16</sup>, <sup>1</sup>Sun Yat-sen University Cancer Center, Guangzhou, CN, <sup>2</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>3</sup>Taipei Veterans General Hospital, Taipei City, TW, <sup>4</sup>Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, CN, <sup>5</sup>Zhejiang Cancer Hospital - Cancer Research Institute, Hangzhou, CN, <sup>6</sup>National Cancer Center Hospital, Tokyo, JP, <sup>7</sup>Chang Gung Medical Foundation- Taipei Chang Gung Memorial Hospital, Kuei-Shan, TW, <sup>8</sup>NCKUH - National Cheng Kung University Hospital, Tainan, TW, <sup>9</sup>The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN, <sup>10</sup>Asan Medical Center, Seoul, KR, <sup>11</sup>SNUH - Seoul National University Hospital, Seoul, KR, <sup>12</sup>Samsung Medical Center (SMC), Seoul, KR, <sup>13</sup>The Catholic University of Korea - Seoul St. Mary's Hospital, Seoul, KR, <sup>14</sup>Korea University Anam Hospital, Seoul, KR, <sup>15</sup>NTUH - National Taiwan University Hospital and Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, TW, <sup>16</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>17</sup>MSD (China) Co., Ltd., Beijing, CN, <sup>18</sup>Merck & Co., Inc., Rahway, US

18:10 - 18:10

**98P - Real clinical impact of postoperative surgical complications after colon cancer surgery**

T. Aoyama<sup>1</sup>, K. Oba<sup>2</sup>, M. Honda<sup>3</sup>, S. Mayanagi<sup>4</sup>, H. Maeda<sup>5</sup>, M. Kanda<sup>6</sup>, K. Kashiwabara<sup>7</sup>, M. Muto<sup>8</sup>, J. Sakamoto<sup>9</sup>, T. Yoshikawa<sup>10</sup>, <sup>1</sup>Yokohama City University Hospital, Yokohama, JP, <sup>2</sup>The University of Tokyo Graduate School of Medicine, Tokyo, JP, <sup>3</sup>Fukushima Medical University, Fukushima, JP, <sup>4</sup>Shizuoka Cancer Center Hospital, Nagaizumi, JP, <sup>5</sup>Kochi Medical School Hospital, Nankoku, JP, <sup>6</sup>Nagoya University Graduate School of Medicine, Nagoya, JP, <sup>7</sup>The University of Tokyo Hospital, Bunkyo-ku, JP, <sup>8</sup>Japanese Foundation for Multidisciplinary Treatment of Cancer, Tokyo, JP, <sup>9</sup>Tokai Central Hospital, Kakamigahara, JP, <sup>10</sup>National Cancer Center Hospital, Tokyo, JP

18:10 - 18:10

**99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy**

R. Zhang<sup>1</sup>, Y. Zang<sup>2</sup>, M. Wu<sup>1</sup>, W. Fan<sup>1</sup>, X. Wang<sup>3</sup>, Z. Pan<sup>1</sup>, G. Chen<sup>1</sup>, W. Ma<sup>4</sup>, Y. Feng<sup>2</sup>, <sup>1</sup>Sun Yat-sen University Cancer Center, Guangzhou, CN, <sup>2</sup>BGI-Shenzhen - Headquarters, Shenzhen, CN, <sup>3</sup>Guangzhou Medical University, Guangzhou, CN, <sup>4</sup>Sun Yat-sen University Cancer Center, Guangzhou, CN

18:10 - 18:10

**100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis**

S.H. Tan<sup>1</sup>, E.U.H. Sim<sup>2</sup>, C. Guan<sup>1</sup>, M.A. Bujang<sup>1</sup>, W.H. Lai<sup>1</sup>, P.J. Voon<sup>1</sup>, <sup>1</sup>Sarawak General Hospital, Kuching, MY, <sup>2</sup>Universiti Malaysia Sarawak, Kota Samarahan, MY

18:10 - 18:10

**101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer**

K. Ouchi<sup>1</sup>, S. Wakayama<sup>1</sup>, S. Takahashi<sup>1</sup>, Y. Yamada<sup>2</sup>, Y. Komatsu<sup>3</sup>, K. Shimada<sup>4</sup>, T. Yamaguchi<sup>5</sup>, H. Shirota<sup>1</sup>, M. Takahashi<sup>1</sup>, C. Ishioka<sup>1</sup>, <sup>1</sup>Tohoku University Hospital, Sendai, JP, <sup>2</sup>NCGM - National Center for Global Health and Medicine, Shinjuku-ku, JP, <sup>3</sup>Hokkaido University Hospital, Sapporo, JP, <sup>4</sup>Showa University Kouto-Toyosu Hospital, Tokyo, JP, <sup>5</sup>Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, JP

- 18:10 - 18:10 **102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance**  
 L. Xie<sup>1</sup>, H. Qin<sup>2</sup>, M. Zhang<sup>3</sup>, G. Zhang<sup>1</sup>, H. Zhang<sup>4</sup>, L. Zhao<sup>2</sup>, W. Zhang<sup>1</sup>, Y. Wang<sup>3</sup>, X. Zhang<sup>2</sup>, B. Qian<sup>1</sup>, <sup>1</sup>Shanghai Jiao Tong University School of Medicine, Shanghai, CN, <sup>2</sup>Tianjin Union Medical Center, Nankai University, Tianjin, CN, <sup>3</sup>Tianjin Union Medical Center, Tianjin, CN, <sup>4</sup>TMUCIH - Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN
- 18:10 - 18:10 **103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A**  
 J. Wu<sup>1</sup>, L. Zhu<sup>2</sup>, C. Zhou<sup>1</sup>, M. Shi<sup>1</sup>, J. Chen<sup>3</sup>, L. Zhao<sup>1</sup>, Z. Han<sup>4</sup>, C. Wang<sup>5</sup>, J. Jiang<sup>1</sup>, J. Yan<sup>6</sup>, C. Wang<sup>6</sup>, X. Wei<sup>7</sup>, Y. Mao<sup>8</sup>, X. Yang<sup>9</sup>, Z. Qin<sup>10</sup>, X. Tang<sup>11</sup>, J. Zhang<sup>1</sup>, <sup>1</sup>Ruijin Hospital - Shanghai Jiao Tong University School of Medicine, Shanghai, CN, <sup>2</sup>Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN, <sup>3</sup>The Affiliated People's Hospital of Ningbo University, Ningbo, CN, <sup>4</sup>THE AFFILIATED HOSPITAL OF XUZHOU MEDICAL UNIVERSITY, Xuzhou, CN, <sup>5</sup>3rd People's Hospital of Yancheng, Yancheng, CN, <sup>6</sup>Jiading Central Hospital, Shanghai, CN, <sup>7</sup>Nanjing First Hospital, Nanjing, CN, <sup>8</sup>Wuxi Fourth People's Hospital, Jiangnan University, Wuxi, CN, <sup>9</sup>First Affiliated Hospital of Nanyang Medical College, Nanyang, CN, <sup>10</sup>Zhejiang Provincial People's Hospital, Hangzhou, CN, <sup>11</sup>Wuxi Branch of Ruijin Hospital, Wuxi, CN
- 18:10 - 18:10 **104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy**  
 W. Li, H. Zhang, Z. Gong, W. Zhang, T. Tong, W. Guo, Fudan University Shanghai Cancer Center, Shanghai, CN
- 18:10 - 18:10 **105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors**  
 W. Guo<sup>1</sup>, F. Bi<sup>2</sup>, J. Dong<sup>3</sup>, C. Jin<sup>4</sup>, Z. Niu<sup>5</sup>, Y. Wang<sup>6</sup>, M. Sun<sup>7</sup>, T. Wang<sup>8</sup>, D. Yu<sup>9</sup>, Y. He<sup>10</sup>, R. Zhang<sup>11</sup>, X. Yin<sup>12</sup>, W. Feng<sup>13</sup>, M. Zhang<sup>13</sup>, L. Li<sup>13</sup>, B. Zhang<sup>13</sup>, X. Kang<sup>13</sup>, <sup>1</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>2</sup>West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN, <sup>3</sup>Yunnan Cancer Hospital & The third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, CN, <sup>4</sup>Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, CN, <sup>5</sup>Shandong Cancer Hospital Affiliated to Shandong University, Jinan, CN, <sup>6</sup>Shanxi Cancer Hospital, Taiyuan, CN, <sup>7</sup>Central Hospital Affiliated to Shandong First Medical University, Jinan, CN, <sup>8</sup>Affiliated Hospital of Jiangnan University, Wuxi, CN, <sup>9</sup>The First Affiliated Hospital of Bengbu Medical College, Bengbu, CN, <sup>10</sup>Anhui Provincial Cancer Hospital, Hefei, CN, <sup>11</sup>The Fourth Hospital of Hebei Medical University/ Hebei Cancer Hospital, Shijiazhuang, CN, <sup>12</sup>Hunan Cancer Hospital, Changsha, CN, <sup>13</sup>Qilu Pharmaceutical Co., Ltd., Jinan, CN
- 18:10 - 18:10 **106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies**  
 Y. Yuan<sup>1</sup>, Y. Deng<sup>2</sup>, Y. Jin<sup>3</sup>, Y. Pan<sup>4</sup>, C. Wang<sup>5</sup>, Z. Wang<sup>6</sup>, Z. Zhang<sup>7</sup>, X. Meng<sup>8</sup>, Y. Hu<sup>9</sup>, M.

Zhao<sup>10</sup>, H. Wang<sup>11</sup>, N. Yang<sup>12</sup>, D. Wu<sup>13</sup>, X. Dong<sup>14</sup>, D. Huang<sup>15</sup>, M. Sun<sup>16</sup>, L. Liu<sup>17</sup>, D. Hua<sup>18</sup>, Z. Guo<sup>19</sup>, K. Ding<sup>1</sup>, <sup>1</sup>The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, CN, <sup>2</sup>The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN, <sup>3</sup>Sichuan Cancer Hospital, Chengdu, CN, <sup>4</sup>Anhui Provincial Hospital, Hefei, CN, <sup>5</sup>Hunan Traditional Chinese Medical College No.1 Affiliated Hospital, Zhuzhou, CN, <sup>6</sup>Tangshan People's Hospital, Tangshan, CN, <sup>7</sup>The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, CN, <sup>8</sup>Shandong Provincial Cancer Hospital, Jinan, CN, <sup>9</sup>Chinese PLA General Hospital, Beijing, CN, <sup>10</sup>The First Affiliated Hospital of China Medical University, Shenyang, CN, <sup>11</sup>Henan Cancer Hospital, Zhengzhou, CN, <sup>12</sup>Hunan Cancer Hospital, Changsha, CN, <sup>13</sup>Hubei Cancer Hospital, Wuhan, CN, <sup>14</sup>Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, CN, <sup>15</sup>Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, <sup>16</sup>Central Hospital Affiliated to Shandong First Medical University, Jinan, CN, <sup>17</sup>Qilu Hospital of Shandong University, Jinan, CN, <sup>18</sup>Wuxi People's Hospital, Wuxi, CN, <sup>19</sup>Fujian Cancer Hospital, Fuzhou, CN

18:10 - 18:10

**107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum**

S. Suresh<sup>1</sup>, K. Sekar<sup>1</sup>, V. R<sup>1</sup>, K. Kallur<sup>1</sup>, S. Swamy<sup>2</sup>, S. Ct<sup>1</sup>, S. Bj<sup>1</sup>, S. Patil<sup>3</sup>, A. Bs<sup>1</sup>, G. Lohith<sup>1</sup>, <sup>1</sup>HCG HealthCare Global Enterprises Ltd, Bangalore, IN, <sup>2</sup>HCG Cancer Center, Gulbarga, IN, <sup>3</sup>Bangalore Institute of Oncology, Bangalore, IN

18:10 - 18:10

**108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH**

L. Luan, J. Huang, Y. Hou, X. Wang, L. Zhang, W. Pan, J. Liu, A. Sujie, L. Zhang, C. Xu, Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN

18:10 - 18:10

**109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status**

A. Pretta<sup>1</sup>, P. Ziranu<sup>1</sup>, E. Perissinotto<sup>2</sup>, P. Ciraci<sup>3</sup>, L. Giuliani<sup>4</sup>, V. Pusceddu<sup>1</sup>, M.C. De Grandis<sup>2</sup>, A. Taravella<sup>3</sup>, M. Puzzone<sup>1</sup>, V.M. Piva<sup>2</sup>, C. Boccaccio<sup>3</sup>, E. Lai<sup>1</sup>, A. Prete<sup>5</sup>, K. Cerma<sup>2</sup>, F. Marmorino<sup>3</sup>, R. Giampieri<sup>4</sup>, S. Lonardi<sup>2</sup>, C. Cremolini<sup>3</sup>, F. Bergamo<sup>5</sup>, M. Scartozzi<sup>1</sup>, <sup>1</sup>University Hospital and University of Cagliari, Monserrato, IT, <sup>2</sup>Veneto Institute of Oncology IOV-IRCCS, Padova, Padova, IT, <sup>3</sup>Santa Chiara Hospital, University of Pisa, Pisa, IT, <sup>4</sup>AOU - Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi, Torrette di Ancona, IT, <sup>5</sup>Veneto Institute of Oncology IOV - IRCCS, Padua, IT

18:10 - 18:10

**110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer**

Y. Liu, W. Chang, J. Xu, Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN

18:10 - 18:10

**111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study**

Z. Wang, H. Fu, L. Huiyan, F. Wang, F. Wang, D. Wang, Y. Li, D. Li, Y. Jin, D. Zhang, Z. Lu, J. Chen, State Key Laboratory of Oncology in South China, Collaborative Innovation

Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, CN

- 18:10 - 18:10 **112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases**  
K. Kobayashi, Y. Inoue, A. Oba, Y. Ono, T. Sato, H. Ito, Y. Takahashi, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JP
- 18:10 - 18:10 **113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)**  
K. Ou<sup>1</sup>, X. Liu<sup>1</sup>, X. Ma<sup>1</sup>, L. Gao<sup>2</sup>, Q. Wang<sup>3</sup>, L. Yang<sup>1</sup>, <sup>1</sup>National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, <sup>2</sup>Cancer Hospital of Huanxing Chaoyang District Beijing, Beijing, CN, <sup>3</sup>Beijing Chaoyang District Third Ring Cancer Hospital/ National Mark Cancer Hospital, Beijing, CN
- 18:10 - 18:10 **114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer**  
Y.-H. Huang<sup>1</sup>, C.-T. Lee<sup>1</sup>, P. Lin<sup>1</sup>, R.-H. Chan<sup>1</sup>, P.-C. Chen<sup>1</sup>, B.-W. Lin<sup>1</sup>, M.-R. Shen<sup>1</sup>, S.-H. Chen<sup>2</sup>, Y.-M. Yeh<sup>1</sup>, <sup>1</sup>NCKUH - National Cheng Kung University Hospital, Tainan City, TW, <sup>2</sup>National Health Research Institutes - National Institute of Cancer Research, Tainan City, TW
- 18:10 - 18:10 **115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan**  
M.-C. Hsieh<sup>1</sup>, H.-P. Chen<sup>1</sup>, K.-M. Rau<sup>1</sup>, S.-E. Lin<sup>2</sup>, K.-W. Liu<sup>1</sup>, C.-C. Chiu<sup>2</sup>, C.-I. Chen<sup>1</sup>, L.-C. Song<sup>2</sup>, <sup>1</sup>E-DA Hospital, Kaohsiung City, TW, <sup>2</sup>E-DA Cancer Hospital - Yida Medical Foundation Corporation, Kaohsiung City, TW
- 18:10 - 18:10 **116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis**  
M. Chhayani<sup>1</sup>, M. Khealani<sup>2</sup>, S.K. Yadav<sup>2</sup>, S.J. Obulareddy<sup>3</sup>, H. Chhayani<sup>1</sup>, H.D. Desai<sup>4</sup>, T. Patel<sup>5</sup>, R. Patel<sup>6</sup>, <sup>1</sup>G.M.E.R.S. Medical College, Gandhinagar, IN, <sup>2</sup>Mayo Clinic Health System - Mankato Hospital, Mankato, US, <sup>3</sup>Winthrop P. Rockefeller Cancer Institute University of Arkansas for Medical Sciences, Little Rock, US, <sup>4</sup>Gujarat Adani Institute of Medical Sciences, Affiliated to K.S.K.V UNiversity, Bhuj, IN, <sup>5</sup>American University of Antigua College of Medicine, Antigua and Barbuda, Osbourn, AG, <sup>6</sup>Unc Health Blue Ridge, Morganton, USA 28655, Morganton,, US
- 18:10 - 18:10 **117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)**  
V. Wong<sup>1</sup>, J. Mckenzie<sup>1</sup>, S. Kosmider<sup>2</sup>, R. Wong<sup>3</sup>, Y.H. To<sup>4</sup>, J. Shapiro<sup>5</sup>, C. Dunn<sup>1</sup>, M. Burge<sup>6</sup>, W. Hong<sup>1</sup>, S. Caird<sup>7</sup>, S. Lim<sup>8</sup>, H.-L. Wong<sup>1</sup>, B. Lee<sup>9</sup>, B. Ma<sup>10</sup>, P. Gibbs<sup>1</sup>, <sup>1</sup>WEHI, Parkville, AU, <sup>2</sup>Footscray Hospital - Western Health, Footscray, AU, <sup>3</sup>Eastern Health - Box Hill Hospital - Main Entrance, Box Hill, AU, <sup>4</sup>WEHI - Walter and Eliza Hall Institute of Medical Research, Parkville, AU, <sup>5</sup>CabrinI Health - Malvern, Malvern, AU, <sup>6</sup>Royal Brisbane and Women's Hospital, Herston, AU, <sup>7</sup>Gold Coast University Hospital (GCUH),

Southport, AU, <sup>8</sup>Macarthur Cancer Therapy Centre, Campbelltown, AU, <sup>9</sup>Northern Health, Melbourne, AU, <sup>10</sup>Sir YK Pao Centre for Cancer, The Chinese University of Hong Kong, Sha Tin, HK

- 18:10 - 18:10 **119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?**  
A. Abdujapparov<sup>1</sup>, N. Zaynutdinov<sup>1</sup>, F. Djuraev<sup>2</sup>, <sup>1</sup>Tashkent City Branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology, Tashkent, UZ, <sup>2</sup>Tashkent Medical Park, Tashkent, UZ
- 18:10 - 18:10 **120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital**  
X. Yang<sup>1</sup>, G. Guo<sup>1</sup>, H. Zhou<sup>2</sup>, Z. Liu<sup>2</sup>, R. Li<sup>1</sup>, H. Shen<sup>1</sup>, X. Yin<sup>1</sup>, Y. Zeng<sup>1</sup>, W. Liu<sup>1</sup>, F. Xiang<sup>1</sup>, S. Jiang<sup>1</sup>, X. Qu<sup>1</sup>, <sup>1</sup>Hunan Cancer Hospital, Changsha, CN, <sup>2</sup>Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CN
- 18:10 - 18:10 **121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer**  
Y. Xu, J. Xu, Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN
- 18:10 - 18:10 **122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas**  
A. Khellaf<sup>1</sup>, M.F. Gonzalez<sup>1</sup>, A. Khellaf<sup>1</sup>, L. Lando<sup>2</sup>, Q.-H. Trinh<sup>1</sup>, <sup>1</sup>CHUM - Centre Hospitalier de l'Université de Montréal, Montreal, CA, <sup>2</sup>Barretos Cancer Hospital, Barretos, BR
- 18:10 - 18:10 **123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer**  
D. Hoon, S. Furuhashi, S. Mizuno, S. Ryu, Y. Naeini, A. Bilchik, M. Bustos, Providence Saint John's Cancer Institute, Santa Monica, US
- 18:10 - 18:10 **124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer**  
L. Arsa<sup>1</sup>, N. Ngamphaiboon<sup>1</sup>, A. Jinawath<sup>2</sup>, N. Sripaiboonkij<sup>2</sup>, N. Jinawath<sup>2</sup>, E. Sirachainan<sup>2</sup>, T. Siripoon<sup>2</sup>, <sup>1</sup>Mahidol University - Faculty of Medicine - Ramathibodi Hospital, Bangkok, TH, <sup>2</sup>Mahidol University - Faculty of Medicine Ramathibodi Hospital, Bangkok, TH
- 18:10 - 18:10 **125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice**  
A. Tryakin<sup>1</sup>, M. Fedyanin<sup>1</sup>, F. Moiseenko<sup>2</sup>, I. Khatkov<sup>3</sup>, L. Zhukova<sup>3</sup>, O. Mironov<sup>4</sup>, D. Stroyakovskiy<sup>5</sup>, N. Sokolov<sup>6</sup>, S. Orlova<sup>7</sup>, E. Mantsyrev<sup>8</sup>, A. Sultanbaev<sup>9</sup>, A. Teterich<sup>10</sup>, K. Babina<sup>11</sup>, D. Yukalchuk<sup>12</sup>, S. Borzyanitsa<sup>13</sup>, A. Isyangulova<sup>14</sup>, A. Saidullaeva<sup>15</sup>, I. Chernova<sup>16</sup>, E. Bobrova<sup>17</sup>, N. Fadeeva<sup>18</sup>, <sup>1</sup>National Medical Research Center of Oncology

named after N.N. Blokhin, Moscow, RU, <sup>2</sup>N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, RU, <sup>3</sup>SBIH "Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM", Moscow, RU, <sup>4</sup>Tambov Regional Clinical Oncology Dispensary, Tambov, RU, <sup>5</sup>Moscow Municipal Oncology Hospital No. 62, Istra, RU, <sup>6</sup>GBUZ Gkb Im. S.P. Botkin Clinical City Hospital, Moscow, RU, <sup>7</sup>Republican Clinical Oncology Center, Chuvash Republic, Cheboksary, RU, <sup>8</sup>Chelyabinsk Regional Oncology Hospital, Chelyabinsk, RU, <sup>9</sup>Republican Clinical Oncology Dispensary - Ufa, Ufa, RU, <sup>10</sup>Belgorod Oncology Dispensary, Belgorod, RU, <sup>11</sup>GBUZ Volgograd Regional Clinical Oncology Dispensary 1, Volgograd, RU, <sup>12</sup>Irkutsk Regional Oncology Dispensary, Irkutsk, RU, <sup>13</sup>Kuzbass Clinical Oncological Center, Kemerovo, RU, <sup>14</sup>GAUZ Republican Clinical Oncological Dispensary of Tatarstan Republic, Kazan, RU, <sup>15</sup>Tver Regional Clinical Oncological Hospital, Tver, RU, <sup>16</sup>Tomsk Regional Oncology Center, Tomsk, RU, <sup>17</sup>GBUZ Moscow Clinical Scientific Research Center named after A. S. Loginov DZM, Moscow, RU, <sup>18</sup>State Budgetary Healthcare Institution "Chelyabinsk Regional Clinical Oncology Dispensary", Chelyabinsk, RU

18:10 - 18:10

**126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neoadjuvant therapy (TNT): A retrospective analysis**

V. Pusceddu<sup>1</sup>, A. Pretta<sup>1</sup>, V. Palma<sup>2</sup>, M. Dettori<sup>3</sup>, P. Ziranu<sup>1</sup>, E. Palmas<sup>1</sup>, G. Moleda<sup>1</sup>, G. Sanna<sup>1</sup>, C. Codipietro<sup>1</sup>, C. Donisi<sup>1</sup>, D. Rizzo<sup>1</sup>, A.P. D'Agata<sup>1</sup>, F. Balconi<sup>1</sup>, S. Mariani<sup>1</sup>, E. Lai<sup>1</sup>, M. Puzzone<sup>1</sup>, L. Mascia<sup>3</sup>, G. Santabarbara<sup>4</sup>, M. Scartozzi<sup>1</sup>, <sup>1</sup>University Hospital and University of Cagliari, Monserrato, IT, <sup>2</sup>University Hospital Luigi Vanvitelli, Napoli, IT, <sup>3</sup>Ospedale Oncologico Armando Businco, Cagliari, IT, <sup>4</sup>Azienda Ospedaliera S. Giuseppe Moscati, Avellino, IT

18:10 - 18:10

**127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness**

T. Yoshino<sup>1</sup>, N. Hooda<sup>2</sup>, D. Younan<sup>3</sup>, K. Muro<sup>4</sup>, K. Shitara<sup>1</sup>, V. Heinemann<sup>5</sup>, B. O'Neil<sup>6</sup>, F. Rivera Herrero<sup>7</sup>, M. Peeters<sup>8</sup>, J. Soeda<sup>9</sup>, M. Suh<sup>2</sup>, H. Reichart<sup>2</sup>, K. Mezzi<sup>3</sup>, J. Fryzek<sup>2</sup>, V. Chia<sup>3</sup>, M. Rehn<sup>3</sup>, S. Stintzing<sup>10</sup>, <sup>1</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>2</sup>EpidStrategies, A Division of ToxStrategies, LLC., Rockville, US, <sup>3</sup>AMGEN (Headquarters) - USA, Thousand Oaks, US, <sup>4</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>5</sup>LMU Klinikum der Universität München, Munich, DE, <sup>6</sup>Community Health Network, Indianapolis, US, <sup>7</sup>Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, ES, <sup>8</sup>University of Antwerp, Wilrijk, BE, <sup>9</sup>Takeda Pharmaceutical Company Limited, Tokyo, JP, <sup>10</sup>Charité - Universitätsmedizin Berlin, Berlin, DE

18:10 - 18:10

**128TiP - A phase II study of cadonilimab &#x2b; FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)**

R. Lin<sup>1</sup>, S. Zhao<sup>1</sup>, L. Su<sup>1</sup>, Y. Hong<sup>2</sup>, J. Luo<sup>3</sup>, Y. Wei<sup>4</sup>, S. Zhao<sup>5</sup>, <sup>1</sup>Fujian Cancer Hospital, Fuzhou, CN, <sup>2</sup>Quanzhou First Hospital, Quanzhou, CN, <sup>3</sup>Fujian Rehabilitation hospital, fuzhou, CN, <sup>4</sup>Wuping County Hospital, longyan, CN, <sup>5</sup>Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, CN

18:10 - 18:10

**140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction**

**(mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies**

Y.-J. Bang<sup>1</sup>, L. Shen<sup>2</sup>, Y.-K. Kang<sup>3</sup>, Y. Chao<sup>4</sup>, S.H. Hwoei Fen<sup>5</sup>, P. Sunpaweravong<sup>6</sup>, D. Moran<sup>7</sup>, A. Guerrero<sup>7</sup>, R. Li<sup>7</sup>, J. Pavese<sup>7</sup>, M. Matsangou<sup>7</sup>, P. Bhattacharya<sup>7</sup>, K. Shitara<sup>8</sup>, R.-H. Xu<sup>9</sup>, <sup>1</sup>Seoul National University College of Medicine, Seoul, KR, <sup>2</sup>Peking University Cancer Hospital and Institute, Beijing, CN, <sup>3</sup>Asan Medical Center, University of Ulsan, Seoul, KR, <sup>4</sup>Taipei Veterans General Hospital, Taipei City, TW, <sup>5</sup>Penang Hospital, Penang, MY, <sup>6</sup>Prince of Songkla University, Songkhla, TH, <sup>7</sup>Astellas Pharma Global Development, Inc., Northbrook, US, <sup>8</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>9</sup>Sun Yat-Sen University Cancer Center, Guangzhou, CN

18:10 - 18:10 **141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit**

A. Cammarota<sup>1</sup>, I. Turgeman<sup>2</sup>, F. Aghayeva<sup>3</sup>, R. Woodford<sup>1</sup>, R. Grochot<sup>1</sup>, J. Choy<sup>1</sup>, A. De Burgh Williams<sup>1</sup>, H.-T. Arkenau<sup>4</sup>, E. Fontana<sup>1</sup>, <sup>1</sup>Sarah Cannon Research Institute SCRI UK, London, GB, <sup>2</sup>Haemek Medical Center, Afula, IL, <sup>3</sup>UCL - University College London, London, GB, <sup>4</sup>Ellipses Pharma Limited, London, GB

18:10 - 18:10 **142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study**

M. Persano<sup>1</sup>, S. Foti<sup>2</sup>, L. Fornaro<sup>3</sup>, S. Lonardi<sup>4</sup>, M. Niger<sup>5</sup>, E. Tamburini<sup>6</sup>, D. Lavacchi<sup>7</sup>, I.G. Rapposelli<sup>8</sup>, E. Martinelli<sup>9</sup>, I. Garajova<sup>10</sup>, F. Simionato<sup>11</sup>, S. Camera<sup>2</sup>, F. Rossari<sup>12</sup>, E. Amadeo<sup>2</sup>, F. Vitiello<sup>2</sup>, S. Cascinu<sup>2</sup>, L. Rimassa<sup>13</sup>, L. Antonuzzo<sup>14</sup>, A. Casadei Gardini<sup>2</sup>, <sup>1</sup>AOU di Cagliari - Ospedale Civile, Cagliari, IT, <sup>2</sup>IRCCS Ospedale San Raffaele, Milan, IT, <sup>3</sup>AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT, <sup>4</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>5</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>6</sup>Azienda Ospedaliera Cardinale Giovanni Panico, Tricase, IT, <sup>7</sup>Azienda Ospedaliera Universitaria Careggi, Firenze, IT, <sup>8</sup>IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS S.r.l., Meldola, IT, <sup>9</sup>Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, <sup>10</sup>Policlinico Sant'Orsola-Malpighi, Bologna, IT, <sup>11</sup>San Bartolomeo General Hospital, Vicenza, IT, <sup>12</sup>UniSR - Università Vita e Salute San Raffaele Milano, Milan, IT, <sup>13</sup>IRCCS Humanitas Research Hospital, Rozzano, IT, <sup>14</sup>AOUC - Azienda Ospedaliero-Universitaria Careggi, Firenze, IT

18:10 - 18:10 **143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial**

L. Xu, S. Ngai, Y. Pan, Y. Zhang, M.-S. Chen, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, CN

18:10 - 18:10 **144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project**

J.H. Kim, Y. Choi, J.W. Lee, J.W. Kim, S. Lee, Y.J. Choi, K.H. Park, Korea University Anam Hospital, Seoul, KR

18:10 - 18:10 **145P - Tislelizumab (TIS) &#x2b; chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)**



L. Chen<sup>1</sup>, Y. Liao<sup>2</sup>, T. Jiang<sup>3</sup>, M. Kang<sup>4</sup>, X. Mei<sup>5</sup>, L. Tan<sup>6</sup>, J. Liu<sup>7</sup>, Z. Zhang<sup>8</sup>, W. Yu<sup>9</sup>, L. Li<sup>9</sup>, H. Jiang<sup>10</sup>, <sup>1</sup>West China Hospital, Sichuan University, Chengdu, CN, <sup>2</sup>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, <sup>3</sup>Tangdu Hospital of the Fourth Military Medical University of the PLA, Xi'an, CN, <sup>4</sup>Fujian Medical University Union Hospital, Fuzhou, CN, <sup>5</sup>The First Affiliated Hospital of University of Science and Technology of China, Anhui Provincial Hospital, Hefei, CN, <sup>6</sup>Fudan University Zhongshan Hospital, Shanghai, CN, <sup>7</sup>Hebei Medical University Fourth Hospital, Shijiazhuang, CN, <sup>8</sup>BeiGene (Shanghai) Co. Ltd., Beijing, CN, <sup>9</sup>BeiGene (Beijing) Co. Ltd., Beijing, CN, <sup>10</sup>Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN

18:10 - 18:10

**146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study**

K.-W. Lee<sup>1</sup>, Y.-K. Kang<sup>2</sup>, M.-H. Chen<sup>3</sup>, H. Hirano<sup>4</sup>, Y. Sunakawa<sup>5</sup>, S. Kim<sup>6</sup>, C.-C. Lin<sup>7</sup>, W.P. Yong<sup>8</sup>, T. Kawakami<sup>9</sup>, T. Oshima<sup>10</sup>, Z. Li<sup>11</sup>, M. Hopkins<sup>12</sup>, A. Levin<sup>11</sup>, H. Wang<sup>11</sup>, L. Goldstein<sup>11</sup>, D. Zhou<sup>13</sup>, S.Y. Rha<sup>14</sup>, <sup>1</sup>Seoul National University Bundang Hospital, Seongnam, KR, <sup>2</sup>Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, <sup>3</sup>Taipei Veterans General Hospital, Taipei City, TW, <sup>4</sup>NCCH - National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, JP, <sup>5</sup>St.Marianna University School of Medicine, Kawasaki, JP, <sup>6</sup>SAMSUNG MEDICAL CENTER, SEOUL, KR, <sup>7</sup>NTUH - National Taiwan University Hospital, Taipei City, TW, <sup>8</sup>NUHS - National University Health System, Singapore, SG, <sup>9</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>10</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>11</sup>AMGEN (Headquarters) - USA, Thousand Oaks, US, <sup>12</sup>AMGEN Ltd, Uxbridge, GB, <sup>13</sup>Amgen Inc - SSF, South San Francisco, US, <sup>14</sup>Yonsei University, Seoul, KR

18:10 - 18:10

**147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)**

S. Chan<sup>1</sup>, B. Sangro<sup>2</sup>, R.K. Kelley<sup>3</sup>, G. Lau<sup>4</sup>, M. Kudo<sup>5</sup>, W. Sukeepaisarnjaroen<sup>6</sup>, E. De Toni<sup>7</sup>, J. Furuse<sup>8</sup>, Y.-K. Kang<sup>9</sup>, P. Galle<sup>10</sup>, L. Rimassa<sup>11</sup>, A. Heurgue<sup>12</sup>, V. Tam<sup>13</sup>, T. Dao<sup>14</sup>, S. Chiradoni Thungappa<sup>15</sup>, V. Breder<sup>16</sup>, Y. Ostapenko<sup>17</sup>, M.E. Reig Monzon<sup>18</sup>, C. Gupta<sup>19</sup>, G. Abou-Alfa<sup>20</sup>, <sup>1</sup>Sir Yue-Kong Pao Center for Cancer, The Chinese University of Hong Kong, Hong Kong SAR, CN, <sup>2</sup>Clínica Universidad de Navarra and CIBEREHD, Pamplona, ES, <sup>3</sup>University of California, San Francisco, US, <sup>4</sup>Humanity and Health Medical Group, Hong Kong SAR, CN, <sup>5</sup>Kindai University Faculty of Medicine, Osaka, JP, <sup>6</sup>Songklanagarind Hospital, Khon Kaen University, Khon Kaen, TH, <sup>7</sup>University Hospital, LMU Munich, Munich, DE, <sup>8</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>9</sup>University of Ulsan College of Medicine, Asan Medical Center, Seoul, KR, <sup>10</sup>University Medical Center, Mainz, DE, <sup>11</sup>Humanitas University, Pieve Emanuele and Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, IT, <sup>12</sup>Robert-Debré Hospital, Reims, FR, <sup>13</sup>University of Calgary, Calgary, CA, <sup>14</sup>National Cancer Hospital, Hanoi, VN, <sup>15</sup>Health Care Global Enterprises Ltd, Bangalore, IN, <sup>16</sup>Chemotherapy Unit, Moscow, RU, <sup>17</sup>National Cancer Institute, Kyiv, UA, <sup>18</sup>Hospital Clinic de Barcelona, IDIBAPS, CIBEREHD, University of Barcelona, Barcelona, ES, <sup>19</sup>AstraZeneca, Wilmington, US, <sup>20</sup>Memorial Sloan Kettering Cancer Center, Cornell University and Weill Medical College, Cornell University, New York, US

- 18:10 - 18:10 **148P - Safety and efficacy of atezolizumab (Atezo) &#x2b; bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)**  
 T. Kuzuya<sup>1</sup>, T. Yamashita<sup>2</sup>, T. Takehara<sup>3</sup>, H. Aikata<sup>4</sup>, N. Kato<sup>5</sup>, Y. Hiasa<sup>6</sup>, S. Nakamura<sup>7</sup>, N. Morimoto<sup>8</sup>, M. Moriguchi<sup>9</sup>, M. Ikeda<sup>10</sup>, J. Inoue<sup>11</sup>, J. Tani<sup>12</sup>, Y. Ueno<sup>13</sup>, K. Chayama<sup>14</sup>, R. Tateishi<sup>15</sup>, Y. Kawamura<sup>16</sup>, J. Furuse<sup>17</sup>, M. Kudo<sup>18</sup>, K. Yamamoto<sup>19</sup>, N. Kokudo<sup>20</sup>, <sup>1</sup>Fujita Health University, Toyoake, JP, <sup>2</sup>Kanazawa University, Kanazawa, JP, <sup>3</sup>Osaka University, Suita, JP, <sup>4</sup>Hiroshima Prefectural Hospital, Minami, JP, <sup>5</sup>Chiba University, School of Medicine, Chiba, JP, <sup>6</sup>Ehime University Graduate School of Medicine, Toon, JP, <sup>7</sup>Japanese Red Cross Society Himeji Hospital, Himeji, JP, <sup>8</sup>Jichi Medical University Hospital, Shimotsuke, JP, <sup>9</sup>Kyoto Prefectural University of Medicine, Kyoto, JP, <sup>10</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>11</sup>Tohoku University Hospital, Sendai, JP, <sup>12</sup>Kagawa University Faculty of Medicine/Graduate School of Medicine, Miki, JP, <sup>13</sup>Yamagata University Faculty of Medicine, Yamagata, JP, <sup>14</sup>Hiroshima University Hospital, Hiroshima, JP, <sup>15</sup>The University of Tokyo Hospital, Bunkyo-ku, JP, <sup>16</sup>Toranomon Hospital, Minato City, JP, <sup>17</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>18</sup>Kindai University - Faculty of Medicine, Osaka, JP, <sup>19</sup>Yokohama City University Hospital, Yokohama, JP, <sup>20</sup>NCGM - National Center for Global Health and Medicine, Shinjuku-ku, JP
- 18:10 - 18:10 **149P - A prospective observational study of MSI screening in unresectable chemotherapy-na&#xef;ve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS**  
 Y. Narita<sup>1</sup>, A. Komori<sup>2</sup>, S. Hironaka<sup>3</sup>, H. Kawakami<sup>4</sup>, M. Furuta<sup>5</sup>, T. Kawakami<sup>6</sup>, A. Makiyama<sup>7</sup>, K. Sugiyama<sup>8</sup>, N. Takegawa<sup>9</sup>, H. Hirano<sup>10</sup>, T. Ando<sup>11</sup>, T. Matsushima<sup>12</sup>, A. Chida<sup>13</sup>, T. Kashiwada<sup>14</sup>, M. Komoda<sup>15</sup>, T. Matsumoto<sup>16</sup>, H. Oda<sup>17</sup>, H. Yabusaki<sup>18</sup>, K. Yoshimura<sup>19</sup>, K. Muro<sup>1</sup>, <sup>1</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>2</sup>National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, <sup>3</sup>Kyorin University Faculty of Medicine, Mitaka, JP, <sup>4</sup>Kindai University Faculty of Medicine, Osakasayama, JP, <sup>5</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>6</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>7</sup>Gifu University Hospital, Gifu, JP, <sup>8</sup>National Hospital Organization, Nagoya Medical Center, Nagoya, JP, <sup>9</sup>Hyogo Cancer Center, Akashi, JP, <sup>10</sup>National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, JP, <sup>11</sup>University of Toyama, Toyama, JP, <sup>12</sup>Saitama Prefectural Cancer Center, Ina, JP, <sup>13</sup>Keio University School of Medicine, Tokyo, JP, <sup>14</sup>Saga-Ken Medical Centre Koseikan, Saga, JP, <sup>15</sup>National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, <sup>16</sup>Kobe City Medical Center General Hospital, Kobe, JP, <sup>17</sup>Saiseikai Kumamoto Hospital, Kumamoto, JP, <sup>18</sup>Niigata Cancer Center Hospital, Niigata, JP, <sup>19</sup>Hiroshima University Hospital, Hiroshima, JP
- 18:10 - 18:10 **150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C**  
 J. Wu<sup>1</sup>, C. Zhou<sup>1</sup>, J. Yan<sup>2</sup>, Z. Han<sup>3</sup>, C. Wang<sup>2</sup>, Z. Qin<sup>4</sup>, J. Jiang<sup>1</sup>, C. Wang<sup>5</sup>, X. Tang<sup>6</sup>, L. Zhu<sup>7</sup>, J. Chen<sup>8</sup>, Y. Mao<sup>9</sup>, X. Wei<sup>10</sup>, C. Shangguan<sup>1</sup>, J. Zhang<sup>1</sup>, <sup>1</sup>Ruijin Hospital - Shanghai Jiao Tong University School of Medicine, Shanghai, CN, <sup>2</sup>Jiading Central Hospital, Shanghai, CN, <sup>3</sup>THE AFFILIATED HOSPITAL OF XUZHOU MEDICAL UNIVERSITY, Xuzhou, CN, <sup>4</sup>Zhejiang Provincial People's Hospital, Hangzhou, CN, <sup>5</sup>3rd People's Hospital of Yancheng, Yancheng, CN, <sup>6</sup>Wuxi Branch of Ruijin Hospital, Wuxi, CN, <sup>7</sup>Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN, <sup>8</sup>The Affiliated People's Hospital of Ningbo University, Ningbo, CN, <sup>9</sup>Wuxi Fourth

People's Hospital , Jiangnan University, Wuxi, CN, <sup>10</sup>Nanjing First Hospital, Nanjing, CN

18:10 - 18:10

**151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer**

E. Kuroki<sup>1</sup>, K. Nio<sup>2</sup>, M. Shimokawa<sup>3</sup>, T. Otsuka<sup>4</sup>, J. Nakazawa<sup>1</sup>, T. Shibuki<sup>5</sup>, S. Arima<sup>6</sup>, K. Miwa<sup>7</sup>, F. Koga<sup>8</sup>, Y. Ueda<sup>9</sup>, Y. Kubotsu<sup>10</sup>, H. Shimokawa<sup>11</sup>, S. Takeshita<sup>12</sup>, K. Nishikawa<sup>13</sup>, A. Hosokawa<sup>14</sup>, H. Oda<sup>15</sup>, S. Arita<sup>16</sup>, T. Shirakawa<sup>17</sup>, T. Mizuta<sup>18</sup>, K. Mitsugi<sup>19</sup>, <sup>1</sup>Kagoshima City Hospital, Kagoshima, JP, <sup>2</sup>Hamanomachi Hospital, Fukuoka, JP, <sup>3</sup>Yamaguchi University Graduate School of Medicine, Yamaguchi, JP, <sup>4</sup>Minato Medical Clinic, Fukuoka, JP, <sup>5</sup>National Cancer Center Hospital East, Chiba, JP, <sup>6</sup>Kagoshima University Graduate school of Medical and Dental Sciences, Kagoshima, JP, <sup>7</sup>Kurume University Hospital, Kurume, JP, <sup>8</sup>Saga Medical Center Koseikan, Saga, JP, <sup>9</sup>Japanese Red Cross Kumamoto Hospital, Kumamoto, JP, <sup>10</sup>Karatsu Red Cross Hospital, Saga, JP, <sup>11</sup>Japan Community Healthcare Organization Kyushu Hospital, Fukuoka, JP, <sup>12</sup>Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, JP, <sup>13</sup>Oita University Faculty of Medicine, Oita, JP, <sup>14</sup>University of Miyazaki Hospital, Miyazaki, JP, <sup>15</sup>Saiseikai Kumamoto Hospital, Kumamoto, JP, <sup>16</sup>Miyazaki Prefectural Miyazaki Hospital, Miyazaki, JP, <sup>17</sup>Karatsu Higashi-matsuura Medical Association Center, Saga, JP, <sup>18</sup>Fujikawa Hospital, Saga, JP, <sup>19</sup>Sasebo Kyosai Hospital, Nagasaki, JP

18:10 - 18:10

**152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage**

F. Koga<sup>1</sup>, T. Shirakawa<sup>2</sup>, M. Shimokawa<sup>3</sup>, T. Otsuka<sup>4</sup>, H. Shimokawa<sup>5</sup>, J. Nakazawa<sup>6</sup>, H. Oda<sup>7</sup>, S. Takeshita<sup>8</sup>, Y. Kawaguchi<sup>9</sup>, S. Arita<sup>10</sup>, H. Taguchi<sup>11</sup>, T. Sakai<sup>12</sup>, K. Nishikawa<sup>13</sup>, S. Arima<sup>14</sup>, Y. Ueda<sup>15</sup>, M. Kawahira<sup>16</sup>, T. Sakae<sup>17</sup>, Y. Ide<sup>18</sup>, T. Mizuta<sup>19</sup>, K. Mitsugi<sup>20</sup>, <sup>1</sup>Saga-Ken Medical Centre Koseikan, Saga, JP, <sup>2</sup>Karatsu Higashimatsuura Medical Association Medical Centre, Saga, JP, <sup>3</sup>Yamaguchi University Graduate School of Medicine, Ube, JP, <sup>4</sup>Minato Medical Clinic, Fukuoka, JP, <sup>5</sup>JCHO - Japan Community Healthcare Organization Kyushu Hospital, Kitakyushu, JP, <sup>6</sup>Kagoshima City Hospital, Kagoshima, JP, <sup>7</sup>Saiseikai Kumamoto Hospital, Kumamoto, JP, <sup>8</sup>Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, JP, <sup>9</sup>Asakura Medical Association Hospital, Asakura, JP, <sup>10</sup>Miyazaki Prefectural Miyazaki Hospital, Miyazaki, JP, <sup>11</sup>Imamura General Hospital, Kagoshima, JP, <sup>12</sup>National Hospital Organization Kumamoto Medical Center, Kumamoto, JP, <sup>13</sup>Oita University Faculty of Medicine, Yufu, JP, <sup>14</sup>Kagoshima University, Kagoshima, JP, <sup>15</sup>Japanese Red Cross Kumamoto Hospital, Kumamoto, JP, <sup>16</sup>Kagoshima Kouseiren Hospital, Kagoshima, JP, <sup>17</sup>Saiseikai Sendai Hospital, Satsumasendai, JP, <sup>18</sup>National Hospital Organization Saga Hospital,, Saga city, JP, <sup>19</sup>Fujikawa Hospital, Saga, JP, <sup>20</sup>Sasebo Kyosai Hospital, Sasebo, JP

18:10 - 18:10

**153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)**

M. Kudo<sup>1</sup>, T. Yamashita<sup>2</sup>, R. Finn<sup>3</sup>, P. Galle<sup>4</sup>, M. Ducreux<sup>5</sup>, A.-L. Cheng<sup>6</sup>, K. Tsuchiya<sup>7</sup>, N. Sakamoto<sup>8</sup>, S. Hige<sup>9</sup>, R. Take<sup>10</sup>, K. Yamada<sup>10</sup>, T. Asakawa<sup>10</sup>, Y. Nakagawa<sup>10</sup>, M. Ikeda<sup>11</sup>, <sup>1</sup>Kindai University - Faculty of Medicine, Osaka, JP, <sup>2</sup>Kanazawa University, Kanazawa, JP, <sup>3</sup>UCLA - David Geffen School of Medicine, Los Angeles, US, <sup>4</sup>Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, DE, <sup>5</sup>Gustave Roussy - Cancer Campus,

Villejuif, FR, <sup>6</sup>NTUH - National Taiwan University Hospital, Taipei City, TW, <sup>7</sup>Japanese Red Cross Musashino Hospital, Musashino, JP, <sup>8</sup>Hokkaido University Hospital, Sapporo, JP, <sup>9</sup>Sapporo-Kosei General Hospital, Sapporo, JP, <sup>10</sup>Chugai Pharmaceutical Co., Ltd., Chuo-ku, JP, <sup>11</sup>National Cancer Center Hospital East, Kashiwa, JP

- 18:10 - 18:10 **154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)**
- M. Persano<sup>1</sup>, M. Rimini<sup>2</sup>, T. Tada<sup>3</sup>, G. Suda<sup>4</sup>, S. Shimose<sup>5</sup>, M. Kudo<sup>6</sup>, C. Yoo<sup>7</sup>, J. Cheon<sup>8</sup>, F. Finkelmeier<sup>9</sup>, H.Y. Lim<sup>10</sup>, J. Presa<sup>11</sup>, G. Masi<sup>12</sup>, F. Bergamo<sup>13</sup>, M. Iavarone<sup>14</sup>, G. Cabibbo<sup>15</sup>, F.G. Foschi<sup>16</sup>, F. Piscaglia<sup>17</sup>, S. Cascinu<sup>2</sup>, M. Scartozzi<sup>1</sup>, A. Casadei Gardini<sup>2</sup>, <sup>1</sup>AOU di Cagliari - Ospedale Civile, Cagliari, IT, <sup>2</sup>IRCCS Ospedale San Raffaele, Milan, IT, <sup>3</sup>Japanese Red Cross Society Himeji Hospital, Himeji, JP, <sup>4</sup>Hokkaido University, Sapporo, JP, <sup>5</sup>Kurume University Hospital, Kurume, JP, <sup>6</sup>Kindai University - Faculty of Medicine, Osaka, JP, <sup>7</sup>Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, <sup>8</sup>CHA Bundang Medical Center, Seongnam, KR, <sup>9</sup>Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), Frankfurt am Main, DE, <sup>10</sup>Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, <sup>11</sup>rás-os-Montes e Alto Douro Hospital Centre, Vila real, PT, <sup>12</sup>University Hospital of Pisa, Pisa, IT, <sup>13</sup>Veneto Institute of Oncology IOV - IRCCS, Padua, IT, <sup>14</sup>Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Milan, IT, <sup>15</sup>University of Palermo, Palermo, IT, <sup>16</sup>Ospedale di Faenza, Faenza, IT, <sup>17</sup>AOU Policlinico S. Orsola-Malpighi, Bologna, IT
- 18:10 - 18:10 **155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study**
- J. Du<sup>1</sup>, F. Tong<sup>1</sup>, H. Sha<sup>1</sup>, Y. Sun<sup>1</sup>, Y. Zhu<sup>1</sup>, L. Qi<sup>1</sup>, X. Li<sup>2</sup>, W. Li<sup>3</sup>, Y. Yang<sup>4</sup>, Z. Li<sup>2</sup>, C. Xu<sup>3</sup>, J. Ni<sup>1</sup>, X. Zhang<sup>5</sup>, C. Zhu<sup>5</sup>, X. Wang<sup>5</sup>, X. Qian<sup>1</sup>, B. Liu<sup>1</sup>, <sup>1</sup>The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, CN, <sup>2</sup>Affiliated Zhenjiang Hospital of Jiangsu University, Zhenjiang, CN, <sup>3</sup>The First Affiliated Hospital Of Soochow University, Suzhou, CN, <sup>4</sup>The Affiliated Jiangning Hospital of Nanjing Medical University - Gushan Road Campus, Nanjing, CN, <sup>5</sup>Jiangsu Simcere Pharmaceuticals Co., Ltd., Nanjing, CN
- 18:10 - 18:10 **156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial**
- J. Cheon<sup>1</sup>, B.-Y. Ryoo<sup>2</sup>, H.-D. Kim<sup>2</sup>, K.-P. Kim<sup>2</sup>, M.H. Ryu<sup>3</sup>, H. Chon<sup>1</sup>, B. Kang<sup>1</sup>, R. Finn<sup>4</sup>, C. Yoo<sup>3</sup>, <sup>1</sup>CHA Bundang Medical Center, Seongnam, KR, <sup>2</sup>Asan Medical Center - University of Ulsan, Seoul, KR, <sup>3</sup>Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, <sup>4</sup>UCLA - David Geffen School of Medicine, Los Angeles, US
- 18:10 - 18:10 **157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study**
- D.Y.Y. Peh<sup>1</sup>, K. Chen<sup>2</sup>, T.S.K. Ong<sup>3</sup>, E.X. Yeo<sup>3</sup>, F.N.N. Moe<sup>2</sup>, D.C.E. Ng<sup>2</sup>, K. Loke<sup>2</sup>, S.X. Yan<sup>2</sup>, S.P. Thang<sup>2</sup>, A. Tong<sup>2</sup>, H.L. Huang<sup>2</sup>, B.M. Magsombol<sup>2</sup>, R.H.G. Lo<sup>2</sup>, A. Gogna<sup>2</sup>, N.K.K. Venkatanarasimha<sup>2</sup>, C.W. Too<sup>2</sup>, S. Chandramohan<sup>2</sup>, K.D. Zhuang<sup>2</sup>, P. Chow<sup>2</sup>, <sup>1</sup>Lee Kong Chian School of Medicine - NTU Main Campus, Singapore, SG, <sup>2</sup>SGH - Singapore

General Hospital, Singapore, SG, <sup>3</sup>NUS-National University of Singapore-Yong Loo Lin School of Medicine (YLLSoM), Singapore, SG

- 18:10 - 18:10 **158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis**  
 Y.-Y. Su<sup>1</sup>, M.-Y. Lin<sup>2</sup>, S.M. Cheng<sup>1</sup>, W.-L. Chang<sup>2</sup>, C.-M. Yeh<sup>1</sup>, C.-C. Yu<sup>3</sup>, C.-W. Hsu<sup>2</sup>, Y.-S. Shan<sup>2</sup>, D.-Y. Huang<sup>4</sup>, L.-T. Chen<sup>1</sup>, <sup>1</sup>National Health Research Institutes - National Institute of Cancer Research, Tainan City, TW, <sup>2</sup>NCKUH - National Cheng Kung University Hospital, Tainan City, TW, <sup>3</sup>Kaohsiung Medical University Hospital, Kaohsiung, TW, <sup>4</sup>National Health Research Institutes, Tainan City, TW
- 18:10 - 18:10 **159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer**  
 A. Khellaf<sup>1</sup>, L. Lando<sup>2</sup>, Q.-H. Trinh<sup>3</sup>, <sup>1</sup>CHUM - Centre Hospitalier de l'Université de Montréal, Montreal, CA, <sup>2</sup>Barretos Cancer Hospital, Barretos, BR, <sup>3</sup>University of Montreal Health Center, Montreal, CA
- 18:10 - 18:10 **160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer**  
 W. Kusano<sup>1</sup>, S. Arita<sup>1</sup>, M. Shimokawa<sup>2</sup>, T. Otsuka<sup>3</sup>, H. Shimokawa<sup>4</sup>, J. Nakazawa<sup>5</sup>, F. Koga<sup>6</sup>, H. Oda<sup>7</sup>, S. Takeshita<sup>8</sup>, Y. Kawaguchi<sup>9</sup>, H. Taguchi<sup>10</sup>, T. Sakai<sup>11</sup>, K. Nishikawa<sup>12</sup>, S. Arima<sup>13</sup>, Y. Ueda<sup>14</sup>, M. Kawahira<sup>15</sup>, T. Sakae<sup>16</sup>, T. Shirakawa<sup>17</sup>, T. Mizuta<sup>18</sup>, K. Mitsugi<sup>19</sup>, <sup>1</sup>Miyazaki Prefectural Miyazaki Hospital, Miyazaki, JP, <sup>2</sup>Yamaguchi University Graduate School of Medicine, Ube, JP, <sup>3</sup>Minato Medical Clinic, Fukuoka, JP, <sup>4</sup>JCHO - Japan Community Healthcare Organization Kyushu Hospital, Kitakyushu, JP, <sup>5</sup>Kagoshima City Hospital, Kagoshima, JP, <sup>6</sup>Saga-Ken Medical Centre Koseikan, Saga, JP, <sup>7</sup>Saiseikai Kumamoto Hospital, Kumamoto, JP, <sup>8</sup>Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, JP, <sup>9</sup>Asakura Medical Association Hospital, Asakura, JP, <sup>10</sup>Imamura General Hospital, Kagoshima, JP, <sup>11</sup>National Hospital Organization Kumamoto Medical Center, Kumamoto, JP, <sup>12</sup>Oita University Faculty of Medicine, Yufu, JP, <sup>13</sup>Kagoshima University, Kagoshima, JP, <sup>14</sup>Japanese Red Cross Kumamoto Hospital, Kumamoto, JP, <sup>15</sup>Kagoshima Kouseiren Hospital, Kagoshima, JP, <sup>16</sup>Saiseikai Sendai Hospital, Satsumasendai, JP, <sup>17</sup>Karatsu Higashimatsuura Medical Association Medical Centre, Saga, JP, <sup>18</sup>Fujikawa Hospital, Saga, JP, <sup>19</sup>Sasebo Kyosai Hospital, Sasebo, JP
- 18:10 - 18:10 **161P - Screening and Consensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer**  
 T. Fujii<sup>1</sup>, G. Prager<sup>2</sup>, S. Boeck<sup>3</sup>, D. Santini<sup>4</sup>, D. Modest<sup>5</sup>, F. Rivera<sup>6</sup>, J.M. Phelip<sup>7</sup>, M. Dioca<sup>8</sup>, E. Smyth<sup>9</sup>, A. Zaanani<sup>10</sup>, H. Wasan<sup>11</sup>, J. Furuse<sup>12</sup>, <sup>1</sup>University of Toyama, Toyoma, JP, <sup>2</sup>Medical University of Vienna, Vienna, AT, <sup>3</sup>Ludwig-Maximilians-University, Munich, DE, <sup>4</sup>Policlinico Umberto 1, La Sapienza Università di Roma, Rome, IT, <sup>5</sup>Charité - Universitaetsmedizin Berlin, Berlin, DE, <sup>6</sup>Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, ES, <sup>7</sup>University Hospital of Saint-Étienne, Saint-Priest-en-Jarez, FR, <sup>8</sup>Angel H. Roffo Oncology Institute, Buenos Aires, AR, <sup>9</sup>Oxford University Hospitals NHS Foundation Trust, Oxford, GB, <sup>10</sup>Georges Pompidou European Hospital, APHP, Université Paris Cité, Paris, FR, <sup>11</sup>Hammersmith Hospital - Imperial College Healthcare NHS Trust,

London, GB, <sup>12</sup>Kanagawa Cancer Center, Yokohama, JP

- 18:10 - 18:10 **162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update**  
L. Chan<sup>1</sup>, A. Chan<sup>2</sup>, A. Ngai<sup>1</sup>, F. Mo<sup>1</sup>, K. Mok<sup>1</sup>, S. Chan<sup>1</sup>, <sup>1</sup>The Chinese University of Hong Kong, Department of Clinical Oncology, Hong Kong, HK, <sup>2</sup>The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK
- 18:10 - 18:10 **163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer**  
V. Sekar<sup>1</sup>, A. Badola<sup>1</sup>, S. Anand<sup>1</sup>, A. Zaidi<sup>1</sup>, J. Verma<sup>1</sup>, P. Singh<sup>1</sup>, D. Das<sup>2</sup>, C. Lalrindiki<sup>2</sup>, D. Nongrum<sup>3</sup>, J. L<sup>2</sup>, <sup>1</sup>Asian Institute of Medical Sciences, Faridabad, IN, <sup>2</sup>RIMS - Regional Institute of Medical Sciences, Imphal, IN, <sup>3</sup>Civil Hospital, Shillong, IN
- 18:10 - 18:10 **164P - Neoadjuvant immune checkpoints inhibitors plus chemoradiotherapy for patients with locally advanced esophageal squamous cell carcinoma**  
M.-W. Kao<sup>1</sup>, K.-C. Hsieh<sup>1</sup>, K.-M. Rau<sup>2</sup>, H.-J. Ho<sup>2</sup>, K.-K. Huang<sup>2</sup>, Y.-H. Kuo<sup>1</sup>, M.-C. Hsieh<sup>1</sup>, <sup>1</sup>E-DA Hospital, Kaohsiung City, TW, <sup>2</sup>E-DA Cancer Hospital - Yida Medical Foundation Corporation, Kaohsiung City, TW
- 18:10 - 18:10 **165P - BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab**  
E. Amadeo<sup>1</sup>, M. Persano<sup>2</sup>, T. Tada<sup>3</sup>, G. Suda<sup>4</sup>, S. Shimose<sup>5</sup>, M. Kudo<sup>6</sup>, C. Yoo<sup>7</sup>, F. Rossari<sup>8</sup>, F. Vitiello<sup>1</sup>, A. Casadei Gardini<sup>1</sup>, M. Rimini<sup>1</sup>, <sup>1</sup>IRCCS Ospedale San Raffaele, Milan, IT, <sup>2</sup>AOU di Cagliari - Ospedale Civile, Cagliari, IT, <sup>3</sup>Japanese Red Cross Society Himeji Hospital, Himeji, JP, <sup>4</sup>Hokkaido University, Sapporo, JP, <sup>5</sup>Kurume University Hospital, Kurume, JP, <sup>6</sup>Kindai University - Faculty of Medicine, Osaka, JP, <sup>7</sup>Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, <sup>8</sup>UniSR - Università Vita e Salute San Raffaele Milano, Milan, IT
- 18:10 - 18:10 **166P - Preoperative risk factors strongly related to early recurrence after R0 resection of gallbladder cancer**  
S. Lee, Y.M. Seol, D.W. Kim, Pusan National University Hospital, Pusan National University College of Medicine, Busan, KR
- 18:10 - 18:10 **167P - Peripheral blood neutrophil-to-lymphocyte ratio correlated with serum IL-8 level and predict the outcome of hepatocellular carcinoma patients treated with immune-targeted combination therapy**  
X. Peng, W. Zhang, C. Gong, T. Liu, A. Zhou, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN
- 18:10 - 18:10 **168P - Real-world clinicopathological characteristics and treatment patterns of esophageal cancer patients in China**  
Z. Lu<sup>1</sup>, M. Geng<sup>2</sup>, Y. Han<sup>3</sup>, J. Cao<sup>4</sup>, J. Wang<sup>5</sup>, T. Liu<sup>6</sup>, X. Yuan<sup>7</sup>, X. Meng<sup>8</sup>, Y. Zhang<sup>9</sup>, R. Zhao<sup>10</sup>, L. Wan<sup>11</sup>, E. Li<sup>12</sup>, W. Wang<sup>13</sup>, Z. Li<sup>14</sup>, D.F. Shi<sup>15</sup>, Q. Jing<sup>15</sup>, S. Shi<sup>15</sup>, F. Dong<sup>15</sup>, L. Shen<sup>1</sup>, <sup>1</sup>Peking University Cancer Hospital, Beijing, CN, <sup>2</sup>Anyang Cancer Hospital, Anyang, CN, <sup>3</sup>Sichuan Cancer Hospital, Chengdu, CN, <sup>4</sup>Shanxi Provincial Cancer

Hospital, Taiyuan, CN, <sup>5</sup>The Fourth Hospital of Hebei Medical University, Shijiazhuang, CN, <sup>6</sup>Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, <sup>7</sup>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, <sup>8</sup>Shandong Cancer Hospital, Jinan, CN, <sup>9</sup>Cancer Hospital Affiliated to Harbin Medical University, Harbin, CN, <sup>10</sup>Affiliated Hospital of Jiangnan University, Jiangsu, CN, <sup>11</sup>Nanyang Central Hospital, Nanyang, CN, <sup>12</sup>The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CN, <sup>13</sup>The First Affiliated Hospital of Xinjiang Medical University, Urumqi, CN, <sup>14</sup>Weifang Second People's Hospital, Weifang, CN, <sup>15</sup>MSD China, Shanghai, CN

18:10 - 18:10

**169P - Conversion response and prognostic factors in HCC patients with macrovascular invasion treated with atezolizumab plus bevacizumab**

K. Wang<sup>1</sup>, H. Sun<sup>2</sup>, X. Bai<sup>3</sup>, Z.-Y. Huang<sup>4</sup>, T. Song<sup>5</sup>, M. Chen<sup>6</sup>, M. Kuang<sup>7</sup>, B. Xiang<sup>8</sup>, Y. Zeng<sup>9</sup>, L.-X. Liu<sup>10</sup>, D. Li<sup>11</sup>, Y. Chen<sup>12</sup>, J. Cai<sup>13</sup>, B. Xing<sup>14</sup>, T. Peng<sup>15</sup>, X. Zhang<sup>1</sup>, X. Zhu<sup>2</sup>, J. Zhou<sup>2</sup>, J. Fan<sup>2</sup>, F. Shen<sup>1</sup>, <sup>1</sup>Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, CN, <sup>2</sup>Zhongshan Hospital, Fudan University, Shanghai, CN, <sup>3</sup>The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, CN, <sup>4</sup>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, <sup>5</sup>TMUCIH - Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, <sup>6</sup>Sun Yat-sen University Cancer Center, Guangzhou, CN, <sup>7</sup>The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, <sup>8</sup>Affiliated Tumor Hospital of Guangxi Medical University, Guangxi, CN, <sup>9</sup>Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, CN, <sup>10</sup>The First Affiliated Hospital of USTC/ Anhui Provincial Hospital, Hefei, CN, <sup>11</sup>People's Hospital of Zhengzhou, Zhengzhou, CN, <sup>12</sup>Ruijin Hospital - Shanghai Jiao Tong University School of Medicine, Shanghai, CN, <sup>13</sup>Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN, <sup>14</sup>Peking University Cancer Hospital and Institute, Beijing, CN, <sup>15</sup>The First Affiliated Hospital of Guangxi Medical University, Nanning, CN

18:10 - 18:10

**170P - Atezolizumab plus bevacizumab (A&#x2b;B) versus lenvatinib for BCLC-B stage of patients with hepatocellular carcinoma (HCC): A large real-life worldwide population**

F. Vitiello<sup>1</sup>, M. Rimini<sup>1</sup>, M. Persano<sup>2</sup>, G. Suda<sup>3</sup>, S. Shimose<sup>4</sup>, F. Finkelmeier<sup>5</sup>, G. Masi<sup>6</sup>, F. Rossari<sup>7</sup>, E. Amadeo<sup>1</sup>, A. Casadei Gardini<sup>1</sup>, T. Tada<sup>8</sup>, M. Kudo<sup>9</sup>, J. Cheon<sup>10</sup>, H.Y. Lim<sup>11</sup>, C. Yoo<sup>12</sup>, <sup>1</sup>IRCCS Ospedale San Raffaele, Milan, IT, <sup>2</sup>AOU di Cagliari - Ospedale Civile, Cagliari, IT, <sup>3</sup>Hokkaido University, Sapporo, JP, <sup>4</sup>Kurume University Hospital, Kurume, JP, <sup>5</sup>Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), Frankfurt am Main, DE, <sup>6</sup>University Hospital of Pisa, Pisa, IT, <sup>7</sup>UniSR - Università Vita e Salute San Raffaele Milano, Milan, IT, <sup>8</sup>Japanese Red Cross Society Himeji Hospital, Himeji, JP, <sup>9</sup>Kindai University Faculty of Medicine, Osaka, JP, <sup>10</sup>CHA Bundang Medical Center, Seongnam, KR, <sup>11</sup>Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, <sup>12</sup>Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR

18:10 - 18:10

**171P - Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo&#x2b;Bev): ARISE study**

K. Ueshima, N. Nishida, S. Hagihara, Y. Minami, H. Ida, M. Takita, H. Chishina, M. Morita, T. Aoki, M. Kudo, Kindai University - Faculty of Medicine, Osaka, JP

- 18:10 - 18:10 **172P - Trastuzumab deruxtecan (T-DXd) in Chinese patients (pts) with previously treated HER2-positive locally advanced/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary efficacy and safety from the phase II single-arm DESTINY-Gastric06 (DG06) trial**
- L. Shen<sup>1</sup>, P. Chen<sup>2</sup>, J. Lu<sup>3</sup>, Y. Wan<sup>4</sup>, Y. Zheng<sup>5</sup>, F. Ye<sup>6</sup>, J. Yang<sup>7</sup>, Y. Liu<sup>8</sup>, H. Pan<sup>9</sup>, H. Chen<sup>10</sup>, M. Sun<sup>11</sup>, Q. Fan<sup>12</sup>, Y. Yuan<sup>13</sup>, K. Chen<sup>14</sup>, Z. Sun<sup>15</sup>, H. Tian<sup>15</sup>, X. Ye<sup>15</sup>, Z. Peng<sup>1</sup>, <sup>1</sup>Peking University Cancer Hospital & Institute, Beijing, CN, <sup>2</sup>General Hospital of Ningxia Medical University, Yinchuan, CN, <sup>3</sup>Sichuan Cancer Hospital and Institute/The Affiliated Cancer Hospital School of Medicine, UESTC, Chengdu, CN, <sup>4</sup>Jiangxi Cancer Hospital, Nanchang, CN, <sup>5</sup>The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, CN, <sup>6</sup>The First Affiliated Hospital of Xiamen University, Xiamen, CN, <sup>7</sup>Fujian Cancer Hospital, Fuzhou, CN, <sup>8</sup>Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, <sup>9</sup>Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, CN, <sup>10</sup>Lanzhou University Second hospital, Lanzhou, CN, <sup>11</sup>Jinan Central Hospital, Shandong University; Central Hospital Affiliated to Shandong First Medical University, Jinan, CN, <sup>12</sup>The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, <sup>13</sup>The Second Affiliated Hospital of Zhejiang University School of Medicine - East Gate 1, Hangzhou, CN, <sup>14</sup>The First Affiliated Hospital Of Soochow University, Suzhou, CN, <sup>15</sup>AstraZeneca China - Headquarters, Shanghai, CN
- 18:10 - 18:10 **173P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients progressed to atezolizumab plus bevacizumab (AB)**
- M. Persano<sup>1</sup>, M. Rimini<sup>2</sup>, T. Tada<sup>3</sup>, G. Suda<sup>4</sup>, S. Shimose<sup>5</sup>, M. Kudo<sup>6</sup>, C. Yoo<sup>7</sup>, J. Cheon<sup>8</sup>, F. Finkelmeier<sup>9</sup>, H.Y. Lim<sup>10</sup>, J. Presa<sup>11</sup>, G. Masi<sup>12</sup>, F. Bergamo<sup>13</sup>, M. Iavarone<sup>14</sup>, G. Cabibbo<sup>15</sup>, F.G. Foschi<sup>16</sup>, F. Piscaglia<sup>17</sup>, S. Cascinu<sup>2</sup>, M. Scartozzi<sup>1</sup>, A. Casadei Gardini<sup>2</sup>, <sup>1</sup>AOU di Cagliari - Ospedale Civile, Cagliari, IT, <sup>2</sup>IRCCS Ospedale San Raffaele, Milan, IT, <sup>3</sup>Japanese Red Cross Society Himeji Hospital, Himeji, JP, <sup>4</sup>Hokkaido University, Sapporo, JP, <sup>5</sup>Kurume University Hospital, Kurume, JP, <sup>6</sup>Kindai University - Faculty of Medicine, Osaka, JP, <sup>7</sup>Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, <sup>8</sup>CHA Bundang Medical Center, Seongnam, KR, <sup>9</sup>Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), Frankfurt am Main, DE, <sup>10</sup>Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, <sup>11</sup>rás-os-Montes e Alto Douro Hospital Centre, Vila real, PT, <sup>12</sup>University Hospital of Pisa, Pisa, IT, <sup>13</sup>Veneto Institute of Oncology IOV - IRCCS, Padua, IT, <sup>14</sup>Ospedale Maggiore Policlinico - Fondazione IRCCS Ca' Granda, Milan, IT, <sup>15</sup>University of Palermo, Palermo, IT, <sup>16</sup>Ospedale di Faenza, Faenza, IT, <sup>17</sup>AOU Policlinico S. Orsola-Malpighi, Bologna, IT
- 18:10 - 18:10 **174P - Unlocking the potential of blood-based biomarkers in pancreatic cancer for early detection and therapeutic screening**
- B. Lee<sup>1</sup>, J. Yousef<sup>2</sup>, K.Y. Fung<sup>1</sup>, S. Emery-Corbin<sup>2</sup>, L. Dagley<sup>2</sup>, P. Baldoni<sup>2</sup>, G. Smyth<sup>2</sup>, P. Gibbs<sup>1</sup>, T. Putoczki<sup>1</sup>, <sup>1</sup>Walter & Eliza Hall Institute, Melbourne, Parkville, AU, <sup>2</sup>WEHI - Walter and Eliza Hall Institute of Medical Research, Parkville, AU
- 18:10 - 18:10 **175P - Genomic evolution of peritoneal metastasis in gastric adenocarcinoma**
- L. Tu<sup>1</sup>, N. Tran<sup>1</sup>, L. Vo<sup>2</sup>, N. Doan<sup>2</sup>, P. Nguyen<sup>1</sup>, T.-A. Nguyen<sup>1</sup>, <sup>1</sup>Medical Genetics Institute, Ho Chi Minh City, VN, <sup>2</sup>University Medical Center HCMC, Ho Chi Minh City, VN
- 18:10 - 18:10 **176P - Identification of novel diagnostic markers for pancreatic neuroendocrine tumors by proteomics with patient blood**



H.S. Kim<sup>1</sup>, J. Jeong<sup>2</sup>, E. Koh<sup>1</sup>, K. Kim<sup>1</sup>, E. Jun<sup>1</sup>, <sup>1</sup>Asan Medical Center - University of Ulsan, Seoul, KR, <sup>2</sup>Asan Medical Center - Asan Institute for Life Science, Seoul, KR

- 18:10 - 18:10 **177P - Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis**  
P. Vaghela<sup>1</sup>, H.A.R. Bashir<sup>2</sup>, S.K. Yadav<sup>3</sup>, S.J. Obulareddy<sup>4</sup>, M. Khealani<sup>3</sup>, R. Patel<sup>5</sup>, S. Gangireddy<sup>6</sup>, H. Thogata<sup>6</sup>, <sup>1</sup>The Maharaja Sayajirao University of Baroda, Vadodara, IN, <sup>2</sup>CMH Lahore Medical College, Punjab, PK, <sup>3</sup>Mayo Clinic Health System - Mankato Hospital, Mankato, US, <sup>4</sup>Winthrop P. Rockefeller Cancer Institute University of Arkansas for Medical Sciences, Little Rock, US, <sup>5</sup>Unc Health Blue Ridge, Morganton, USA 28655, Morganton,, US, <sup>6</sup>Narayana Medical College And Hospital, Nellore, IN
- 18:10 - 18:10 **178P - Survival benefit of splenic hilar lymph nodes (no.10) dissection in B4 type gastric carcinoma: An IPTW propensity score analysis of large multi-institutional data**  
O. Jeong<sup>1</sup>, A. Jang<sup>2</sup>, <sup>1</sup>Chonnam National University Medical School-Gwangju, Gwangju, KR, <sup>2</sup>University of Ulsan, Ulsan, KR
- 18:10 - 18:10 **179P - The impact of pre-operative nutritional/rehabilitative assessments and support on postoperative outcomes in very elderly gastric cancer patients**  
Y. Ushimaru, R. Kawabata, T. Takeoka, A. Kitagawa, N. Ohara, H. Tomihara, S. Maeda, M. Imazato, S. Noura, A. Miyamoto, Sakai City Medical Center, Sakai, JP
- 18:10 - 18:10 **180P - Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer**  
S. Zhixin, Z.-Y. Liu, Q. Zhong, C. Huang, Fujian Medical University Union Hospital, Fuzhou, CN
- 18:10 - 18:10 **181P - TQB2450 (PD-L1 blockade) in combination with anlotinib as a perioperative treatment for patients with hepatocellular carcinoma at high risk of recurrence: Primary results from a prospective, single-arm, phase Ib study**  
Z. Huang, J. Zhou, M. Yang, W. Zhang, Y. Sun, H. Lu, H. Wang, X. Bi, Y. Zhang, J. Zhao, Y. Yang, B. Zhang, F. Ye, H. Zhao, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN
- 18:10 - 18:10 **182P - Cytoreductive surgery and chemotherapy in metastatic gastric adenocarcinoma: A population-based study**  
D. Al Zamer<sup>1</sup>, L. Theeb<sup>2</sup>, Y. Al-Zamer<sup>1</sup>, A. Hammad<sup>1</sup>, B. Rawashdeh<sup>3</sup>, <sup>1</sup>JUST - Jordan University of Science and Technology, Irbid, JO, <sup>2</sup>IAU - The University of Jordan, Amman, JO, <sup>3</sup>Froedtert Hospital & Medical College of Wisconsin, Milwaukee, US
- 18:10 - 18:10 **183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 &#x2b; oxaliplatin combination therapy for older patients with locally advanced gastric cancer**  
E. Oki<sup>1</sup>, M. Ota<sup>2</sup>, H. Saeki<sup>3</sup>, M. Shimokawa<sup>4</sup>, T. Yoshizumi<sup>5</sup>, Y. Kakeji<sup>6</sup>, H. Baba<sup>7</sup>, <sup>1</sup>Kyushu University - Graduate School of Medical Sciences - Faculty of Medical Sciences, Fukuoka,

JP, <sup>2</sup>Kyushu University, Fukuoka, JP, <sup>3</sup>Gunma University, Maebashi, JP, <sup>4</sup>Yamaguchi University Graduate School of Medicine, Ube, JP, <sup>5</sup>Kyushu University Hospital, Fukuoka, JP, <sup>6</sup>Kobe University Graduate School of Medicine, Kobe, JP, <sup>7</sup>Kumamoto University, Kumamoto, JP

18:10 - 18:10 **184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)**

Y. Sonoda<sup>1</sup>, T. Araki<sup>1</sup>, M. Shimokawa<sup>2</sup>, T. Otsuka<sup>3</sup>, T. Shibuki<sup>4</sup>, J. Nakazawa<sup>5</sup>, S. Arima<sup>6</sup>, K. Miwa<sup>7</sup>, F. Koga<sup>8</sup>, Y. Ueda<sup>9</sup>, Y. Kubotsu<sup>10</sup>, H. Shimokawa<sup>11</sup>, S. Takeshita<sup>12</sup>, K. Nishikawa<sup>13</sup>, A. Hosokawa<sup>14</sup>, H. Oda<sup>15</sup>, S. Arita<sup>16</sup>, T. Shirakawa<sup>17</sup>, T. Mizuta<sup>18</sup>, K. Mitsugi<sup>19</sup>, <sup>1</sup>Nagasaki University Hospital, Nagasaki, JP, <sup>2</sup>Yamaguchi University Graduate School of Medicine, Ube, JP, <sup>3</sup>Minato Medical Clinic, Fukuoka, JP, <sup>4</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>5</sup>Kagoshima City Hospital, Kagoshima, JP, <sup>6</sup>Kagoshima University, Kagoshima, JP, <sup>7</sup>Kurume University Hospital, Kurume, JP, <sup>8</sup>Saga-Ken Medical Centre Koseikan, Saga, JP, <sup>9</sup>Japanese Red Cross Kumamoto Hospital, Kumamoto, JP, <sup>10</sup>Karatsu Red Cross Hospital, Karatsu, JP, <sup>11</sup>JCHO - Japan Community Healthcare Organization Kyushu Hospital, Kitakyushu, JP, <sup>12</sup>Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, JP, <sup>13</sup>Oita University Faculty of Medicine, Yufu, JP, <sup>14</sup>University of Miyazaki Hospital, Miyazaki city, JP, <sup>15</sup>Saiseikai Kumamoto Hospital, Kumamoto, JP, <sup>16</sup>Miyazaki Prefectural Miyazaki Hospital, Miyazaki, JP, <sup>17</sup>Karatsu Higashimatsuura Medical Association Medical Centre, Saga, JP, <sup>18</sup>Fujikawa Hospital, Saga, JP, <sup>19</sup>Sasebo Kyosai Hospital, Sasebo, JP

18:10 - 18:10 **185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study**

F. Rossari<sup>1</sup>, T. Tada<sup>2</sup>, S. Shimose<sup>3</sup>, M. Kudo<sup>4</sup>, C. Yoo<sup>5</sup>, J. Cheon<sup>6</sup>, F. Finkelmeier<sup>7</sup>, H.Y. Lim<sup>8</sup>, J. Presa<sup>9</sup>, G. Masi<sup>10</sup>, F. Bergamo<sup>11</sup>, E. Amadeo<sup>12</sup>, F. Vitiello<sup>12</sup>, S. Foti<sup>12</sup>, M. Persano<sup>13</sup>, F. Piscaglia<sup>14</sup>, M. Scartozzi<sup>15</sup>, S. Cascinu<sup>12</sup>, M. Rimini<sup>12</sup>, A. Casadei Gardini<sup>12</sup>, <sup>1</sup>UniSR - Università Vita e Salute San Raffaele Milano, Milan, IT, <sup>2</sup>Japanese Red Cross Society Himeji Hospital, Himeji, JP, <sup>3</sup>Kurume University Hospital, Kurume, JP, <sup>4</sup>Kindai University - Faculty of Medicine, Osaka, JP, <sup>5</sup>Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, <sup>6</sup>Ulsan University Hospital, Ulsan, KR, <sup>7</sup>Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), Frankfurt am Main, DE, <sup>8</sup>Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, <sup>9</sup>rás-os-Montes e Alto Douro Hospital Centre, Vila real, PT, <sup>10</sup>University Hospital of Pisa, Pisa, IT, <sup>11</sup>Veneto Institute of Oncology IOV - IRCCS, Padua, IT, <sup>12</sup>IRCCS Ospedale San Raffaele, Milan, IT, <sup>13</sup>AOU di Cagliari - Ospedale Civile, Cagliari, IT, <sup>14</sup>AOU Policlinico S. Orsola-Malpighi, Bologna, IT, <sup>15</sup>University of Cagliari, Cagliari, IT

18:10 - 18:10 **186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial**

X. Ma<sup>1</sup>, K. Ou<sup>1</sup>, X. Liu<sup>1</sup>, Q. Wang<sup>2</sup>, L. Gao<sup>3</sup>, Y. Sun<sup>1</sup>, L. Yang<sup>1</sup>, <sup>1</sup>Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, <sup>2</sup>Beijing Chaoyang District Third Ring Cancer Hospital/ National Mark Cancer Hospital, Beijing, CN, <sup>3</sup>Cancer Hospital of Huanxing Chaoyang District Beijing, Beijing, CN

- 18:10 - 18:10 **187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)**  
P. Tao, Y. Wei, G. Zhu, Z. Zeng, Z. Lv, J. Ma, X. Ye, H. Su, K. Xiao, J. Liao, M. Su, S. Yu, L. Long, J. Wang, N. Peng, K. Zhao, C. Han, X. Liao, W. Qin, C. Yang, The First Affiliated Hospital of Guangxi Medical University, Nanning, CN
- 18:10 - 18:10 **188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab**  
M. Rimini<sup>1</sup>, E. Amadeo<sup>1</sup>, F. Vitiello<sup>1</sup>, S. Foti<sup>1</sup>, M. Persano<sup>2</sup>, T. Tada<sup>3</sup>, G. Suda<sup>4</sup>, S. Shimose<sup>5</sup>, M. Kudo<sup>6</sup>, J. Cheon<sup>7</sup>, F. Finkelmeier<sup>8</sup>, H.Y. Lim<sup>9</sup>, F. Piscaglia<sup>10</sup>, G. Masi<sup>11</sup>, C. Yoo<sup>12</sup>, S. Lonardi<sup>13</sup>, F. Rossari<sup>14</sup>, S. Camera<sup>1</sup>, A. Casadei Gardini<sup>1</sup>, J. Presa<sup>15</sup>, <sup>1</sup>IRCCS Ospedale San Raffaele, Milan, IT, <sup>2</sup>AOU di Cagliari - Ospedale Civile, Cagliari, IT, <sup>3</sup>Japanese Red Cross Society Himeji Hospital, Himeji, JP, <sup>4</sup>Hokkaido University, Sapporo, JP, <sup>5</sup>Kurume University Hospital, Kurume, JP, <sup>6</sup>Kindai University - Faculty of Medicine, Osaka, JP, <sup>7</sup>Ulsan University Hospital, Ulsan, KR, <sup>8</sup>Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), Frankfurt am Main, DE, <sup>9</sup>Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, <sup>10</sup>AOU Policlinico S. Orsola-Malpighi, Bologna, IT, <sup>11</sup>OSPEDALE SANTA CHIARA, Pisa, IT, <sup>12</sup>Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, <sup>13</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>14</sup>UniSR - Università Vita e Salute San Raffaele Milano, Milan, IT, <sup>15</sup>rás-os-Montes e Alto Douro Hospital Centre, Vila real, PT
- 18:10 - 18:10 **189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)**  
S. Yamamoto<sup>1</sup>, C.-Y. Lin<sup>2</sup>, C. Rojas<sup>3</sup>, F. Rivera Herrero<sup>4</sup>, D. Kwong<sup>5</sup>, M.-H. Chen<sup>6</sup>, Y. Zhang<sup>7</sup>, L. Yu<sup>8</sup>, S. Shah<sup>8</sup>, P. Bhagia<sup>8</sup>, L. Shen<sup>9</sup>, J.-M. Sun<sup>10</sup>, <sup>1</sup>National Cancer Center Hospital, Tokyo, JP, <sup>2</sup>China Medical University Hospital, Taichung, TW, <sup>3</sup>Bradford Hill Centro de Investigaciones Clinicas, Recoleta, CL, <sup>4</sup>Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, ES, <sup>5</sup>Queen Mary Hospital, Hong Kong, CN, <sup>6</sup>Taipei Veterans General Hospital, Taipei, TW, <sup>7</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>8</sup>Merck & Co., Inc., Rahway, US, <sup>9</sup>Beijing Cancer Hospital, Beijing, CN, <sup>10</sup>Samsung Medical Center, Seoul, KR
- 18:10 - 18:10 **190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial**  
J. He, Y. Yang, S. Zhou, B. Zhang, Z. Han, T. Wu, Q. Qiao, H. Yang, X. He, N. Wang, The Second Affiliate Hospital of Air Force Medical University/Tangdu Hospital, Xi'an, CN
- 18:10 - 18:10 **191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation**  
S.-H. Han, Dong-A University College of Medicine, Busan, KR
- 18:10 - 18:10 **192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib &#x2b;**

**chemotherapy: Results from two prospective studies**

R. Lin, S. Zhao, L. Su, Fujian Cancer Hospital, Fuzhou, CN

- 18:10 - 18:10 **193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab**  
Y.B. Sang<sup>1</sup>, C.R. Lee<sup>1</sup>, S.-G. Kim<sup>1</sup>, B. Lee<sup>2</sup>, C. Kim<sup>1</sup>, H. Chon<sup>1</sup>, <sup>1</sup>CHA Bundang Medical Center, Seongnam, KR, <sup>2</sup>Soonchunhyang University Hospital Seoul, Seoul, KR
- 18:10 - 18:10 **194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≥5**  
Q. Xu, J. Ying, L. Zhang, J. Li, P. Zeng, X. Yuan, Y. Huang, Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, CN
- 18:10 - 18:10 **195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis**  
Q.-H. Trinh<sup>1</sup>, A. Khellaf<sup>1</sup>, M.F. Gonzalez<sup>1</sup>, A. Khellaf<sup>1</sup>, L. Lando<sup>2</sup>, <sup>1</sup>CHUM - Centre Hospitalier de l'Université de Montréal, Montreal, CA, <sup>2</sup>Barretos Cancer Hospital, Barretos, BR
- 18:10 - 18:10 **196P - Clinical significance of circulating CD8<sup>+</sup> and CD4<sup>+</sup> T cell proliferation in advanced gastric cancer receiving first-line chemotherapy**  
I.-H. Kim<sup>1</sup>, K. Shin<sup>2</sup>, S.J. Park<sup>2</sup>, H. Kim<sup>3</sup>, J. Kim<sup>2</sup>, <sup>1</sup>The Catholic University of Korea - College of Medicine - Songeui Medical Campus, Seoul, KR, <sup>2</sup>The Catholic University of Korea - Seoul St. Mary's Hospital - Catholic Medical Center, Seoul, KR, <sup>3</sup>The Catholic University of Korea - St. Vincent's Hospital, Suwon, KR
- 18:10 - 18:10 **197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study**  
Y. Zhang<sup>1</sup>, J. Zhang<sup>2</sup>, X. Xie<sup>3</sup>, W. Pan<sup>4</sup>, G. Wang<sup>1</sup>, Q. Dong<sup>2</sup>, N. Zhang<sup>3</sup>, J. Dong<sup>4</sup>, G. Segall<sup>5</sup>, L. Zhou<sup>6</sup>, C. Zhou<sup>6</sup>, M. Khanal<sup>5</sup>, Y. Yang<sup>7</sup>, L. Zeng<sup>7</sup>, <sup>1</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>2</sup>Liaoning Cancer Institute and Hospital, Shenyang, CN, <sup>3</sup>The First Affiliated Hospital of Fujian Medical University, Fuzhou, CN, <sup>4</sup>Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, CN, <sup>5</sup>Eli Lilly and Company, Indianapolis, US, <sup>6</sup>Eli Lilly and Company, Shanghai, CN, <sup>7</sup>Happy Life Technology Co. Ltd, Shanghai, CN
- 18:10 - 18:10 **198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan**  
N. Izumi<sup>1</sup>, M. Kudo<sup>2</sup>, K. Motomura<sup>3</sup>, Y. Inaba<sup>4</sup>, Y. Katamura<sup>5</sup>, Y. Kondo<sup>6</sup>, K. Yabushita<sup>7</sup>, K. Motoyoshi<sup>8</sup>, J. Furuse<sup>9</sup>, <sup>1</sup>Japanese Red Cross Musashino Hospital, Musashino, JP, <sup>2</sup>Kindai University - Faculty of Medicine, Osaka, JP, <sup>3</sup>Iizuka Hospital, Iizuka, JP, <sup>4</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>5</sup>Ja Onomichi General Hospital, Onomichi, JP, <sup>6</sup>Sendai Tokushukai Hospital, Sendai, JP, <sup>7</sup>Fukuyama City Hospital, Fukuyama, JP, <sup>8</sup>Eisai. Co., Ltd., Bunkyo-ku, JP, <sup>9</sup>Kanagawa Cancer Center, Yokohama, JP

- 18:10 - 18:10 **199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial**  
Y. Qi, L. Shao, Sun Yat-sen University Cancer Center Gansu Hospital, Lanzhou, CN
- 18:10 - 18:10 **200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score**  
B. Gong<sup>1</sup>, L. Lu<sup>2</sup>, H. Yang<sup>2</sup>, C. Xiong<sup>3</sup>, <sup>1</sup>Oriental Hospital Affiliated to Xiamen University, fuzhou, CN, <sup>2</sup>Fujian Medical University - Taijiang Campus, Fuzhou, CN, <sup>3</sup>Fuzhou General Hospital of Nanjing Military Command/The 9th Hospital of the People's Liberation Army/Oriental Hospital, Fuzhou, CN
- 18:10 - 18:10 **201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma**  
Z. Ren<sup>1</sup>, G. Shao<sup>2</sup>, J. Shen<sup>3</sup>, L. Zhang<sup>4</sup>, X. Zhu<sup>5</sup>, W. Fang<sup>6</sup>, G. Sun<sup>7</sup>, Y. Bai<sup>8</sup>, J. Wu<sup>9</sup>, L. Liu<sup>10</sup>, Y. Yuan<sup>11</sup>, J. Zhang<sup>12</sup>, Z. Li<sup>13</sup>, L. Zhang<sup>14</sup>, T. Yin<sup>15</sup>, J. Wu<sup>16</sup>, X. Hou<sup>17</sup>, Q. Wang<sup>17</sup>, J. Zhu<sup>17</sup>, J. Fan<sup>1</sup>, <sup>1</sup>Zhongshan Hospital, Fudan University, Shanghai, CN, <sup>2</sup>Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, CN, <sup>3</sup>Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, CN, <sup>4</sup>Chongqing University Three Gorges Hospital, Chongqing, CN, <sup>5</sup>Peking University Cancer Hospital & Institute, Beijing, CN, <sup>6</sup>The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN, <sup>7</sup>The First Affiliated Hospital of Anhui Medical University, Hefei, CN, <sup>8</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>9</sup>The Second Affiliated Hospital of Nanchang University, Nanchang, CN, <sup>10</sup>Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, CN, <sup>11</sup>Xuzhou Central Hospital, Xuzhou, CN, <sup>12</sup>Liaoning Cancer Hospital & Institute, Cancer Hospital of China Medical University, Shenyang, CN, <sup>13</sup>Linyi Cancer Hospital, Linyi, CN, <sup>14</sup>Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, <sup>15</sup>Hubei Cancer Hospital, Wuhan, CN, <sup>16</sup>Hainan General Hospital, Haikou, CN, <sup>17</sup>Shanghai Henlius Biotech, Inc., Shanghai, CN
- 18:10 - 18:10 **202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma**  
R. Li, W. Li, G. Yuan, Q. Li, X. Hu, P. Zhu, Y. Chen, K. Su, Y. Guo, M. Zang, J. Chen, Southern Medical University Nanfang Hospital, Guangzhou, CN
- 18:10 - 18:10 **203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)**  
J. He, L. Zhao, L. Li, PUMCH - Peking Union Medical College Hospital/Beijing Xiehe Hospital - Dongdan Campus, Beijing, CN
- 18:10 - 18:10 **204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer**  
Z. Li<sup>1</sup>, Y. Wang<sup>2</sup>, <sup>1</sup>West China School of Medicine/West China Hospital of Sichuan University, Chengdu, SG, <sup>2</sup>West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN

- 18:10 - 18:10 **205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)**
- T. Yamashita<sup>1</sup>, Y. Inaba<sup>2</sup>, M. Ikeda<sup>3</sup>, M. Sone<sup>4</sup>, K. Yamakado<sup>5</sup>, H. Nishiofuku<sup>6</sup>, K. Tsuchiya<sup>7</sup>, T. Tada<sup>8</sup>, Y. Sato<sup>2</sup>, T. Kodama<sup>9</sup>, T. Kuzuya<sup>10</sup>, S. Ogasawara<sup>11</sup>, M. Ueno<sup>12</sup>, H. Iwamoto<sup>13</sup>, M. Moriguchi<sup>14</sup>, K. Ueshima<sup>15</sup>, Y. Kodama<sup>16</sup>, T. Takehara<sup>9</sup>, T. Hamano<sup>17</sup>, M. Kudo<sup>15</sup>, <sup>1</sup>Kanazawa University, Kanazawa, JP, <sup>2</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>3</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>4</sup>National Cancer Center Hospital, Tokyo, JP, <sup>5</sup>Hyogo Medical University, Nishinomiya, JP, <sup>6</sup>Nara Medical University, Kashihara, JP, <sup>7</sup>Japanese Red Cross Musashino Hospital, Musashino, JP, <sup>8</sup>Japanese Red Cross Society Himeji Hospital, Himeji, JP, <sup>9</sup>Osaka University Graduate School of Medicine, Suita, JP, <sup>10</sup>Fujita Health University, Toyoake, JP, <sup>11</sup>Chiba University, Chiba, JP, <sup>12</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>13</sup>Kurume University School of Medicine, Kurume, JP, <sup>14</sup>Kyoto Prefectural University of Medicine, Kyoto, JP, <sup>15</sup>Kindai University - Faculty of Medicine, Osaka, JP, <sup>16</sup>Teine Keijinkai Hospital, Sapporo, JP, <sup>17</sup>P4 statistics co. ltd., Tokyo, JP
- 18:10 - 18:10 **206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma**
- S. Chan<sup>1</sup>, B. Sangro<sup>2</sup>, M. Kudo<sup>3</sup>, A. Dane<sup>4</sup>, C. Emery<sup>5</sup>, M. Paskow<sup>6</sup>, M. Makowsky<sup>6</sup>, B. Nguyen<sup>6</sup>, L. Rimassa<sup>7</sup>, <sup>1</sup>Sir Yue-Kong Pao Center for Cancer, The Chinese University of Hong Kong, Hong Kong SAR, CN, <sup>2</sup>Clínica Universidad de Navarra and CIBEREHD, Pamplona, ES, <sup>3</sup>Kindai University Faculty of Medicine, Osaka, JP, <sup>4</sup>Danestat Consulting Limited, Macclesfield, GB, <sup>5</sup>AstraZeneca, Cambridge, GB, <sup>6</sup>AstraZeneca, Gaithersburg, US, <sup>7</sup>Pieve Emanuele and Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, IT
- 18:10 - 18:10 **207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 - fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers**
- P. Bhargava<sup>1</sup>, A. Ramaswamy<sup>1</sup>, B. Dubashi<sup>2</sup>, A. Kapoor<sup>3</sup>, S. Srinivas<sup>1</sup>, O. Shetty<sup>4</sup>, R. Kaushal<sup>4</sup>, A. Shah<sup>4</sup>, V. Noronha<sup>1</sup>, A. Joshi<sup>1</sup>, N. Menon<sup>1</sup>, C. Nashikkar<sup>1</sup>, A. Gupta<sup>3</sup>, B.K. Mishra<sup>3</sup>, N. Sisodia<sup>3</sup>, V. Pal<sup>3</sup>, S. Kayal<sup>2</sup>, K. Prabhash<sup>1</sup>, V. Ostwal<sup>1</sup>, <sup>1</sup>Tata Memorial Hospital Centre, Mumbai, IN, <sup>2</sup>JIPMER - Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IN, <sup>3</sup>Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, IN, <sup>4</sup>Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN
- 18:10 - 18:10 **Genitourinary tumours, non-prostate**
- 18:10 - 18:10 **212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma**
- M. Li, J. Qin, X. Liang, S. Cao, Beijing Acornmed Biotechnology Co., Ltd., Beijing, CN
- 18:10 - 18:10 **213P - Prognostic significance of absolute lymphocyte count in patients with**

**metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)**

K. Takemura<sup>1</sup>, T. Yuasa<sup>1</sup>, A. Lemelin<sup>2</sup>, E. Ferrier<sup>2</sup>, J.C. Wells<sup>3</sup>, E. Saad<sup>4</sup>, R. Saliby<sup>4</sup>, N. Basappa<sup>5</sup>, L. Wood<sup>6</sup>, E. Jude<sup>7</sup>, S. Pal<sup>8</sup>, F. Donskov<sup>9</sup>, B. Beuselinck<sup>10</sup>, B. Szabados<sup>11</sup>, T. Powles<sup>11</sup>, R. Mckay<sup>12</sup>, G. Gebrael<sup>13</sup>, N. Agarwal<sup>13</sup>, T. Choueiri<sup>4</sup>, D. Heng<sup>2</sup>, <sup>1</sup>The Cancer Institute Hospital of JFCR, Tokyo, JP, <sup>2</sup>Tom Baker Cancer Centre, Calgary, CA, <sup>3</sup>BC Cancer Agency, Vancouver, CA, <sup>4</sup>Dana-Farber Cancer Institute, Boston, US, <sup>5</sup>Cross Cancer Institute, Edmonton, CA, <sup>6</sup>Queen Elizabeth II Health Sciences Centre, Halifax, CA, <sup>7</sup>Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, AU, <sup>8</sup>City of Hope Comprehensive Cancer Center, Duarte, US, <sup>9</sup>University Hospital of Southern Denmark, Esbjerg, DK, <sup>10</sup>Leuven Cancer Institute, Leuven, BE, <sup>11</sup>Barts Cancer Institute, London, GB, <sup>12</sup>Moore's Cancer Center, La Jolla, US, <sup>13</sup>Huntsman Cancer Institute, Salt Lake City, US

18:10 - 18:10 **214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma**

H. Xu<sup>1</sup>, S. Wang<sup>2</sup>, D. Xue<sup>3</sup>, Z. Xu<sup>2</sup>, Q. Zhang<sup>2</sup>, Q. Wo<sup>2</sup>, B. Huang<sup>2</sup>, Z. Mao<sup>2</sup>, F. Liu<sup>2</sup>, S. Lou<sup>2</sup>, J. Yuan<sup>3</sup>, S. Zhu<sup>3</sup>, Y. Wo<sup>4</sup>, Z. Luo<sup>4</sup>, J. Chen<sup>4</sup>, Q. Xu<sup>4</sup>, G. Li<sup>3</sup>, X. Qi<sup>2</sup>, D. Ye<sup>1</sup>, <sup>1</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>2</sup>Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, CN, <sup>3</sup>Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, CN, <sup>4</sup>Canhelp Genomics Co., Ltd., Hangzhou, CN

18:10 - 18:10 **215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mccRCC)**

T. Huang, L. Jiang, W. Wei, X. Zheng, Z. Zhang, S. Guo, H. Han, X. Cai, F. Zhou, P. Dong, Sun Yat-sen University Cancer Center, Guangzhou, CN

18:10 - 18:10 **216P - Preliminary efficacy and safety results from 'ReBirth': A phase II study of risk-based bladder-sparing therapy for MIBC**

Y. Shen<sup>1</sup>, X. Lu<sup>1</sup>, W. Liu<sup>2</sup>, X. Ma<sup>2</sup>, D. Ye<sup>1</sup>, <sup>1</sup>Fudan University Shanghai cancer center, Shanghai, CN, <sup>2</sup>Fudan University Shanghai Cancer Center, Shanghai, CN

18:10 - 18:10 **217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine**

Y. Dong<sup>1</sup>, S. Jiang<sup>1</sup>, Y. Dang<sup>2</sup>, W. Jiang<sup>3</sup>, J. Wang<sup>3</sup>, Z. Wang<sup>3</sup>, <sup>1</sup>Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, <sup>2</sup>Chongqing Medical University, Chongqing, CN, <sup>3</sup>Fudan University, Shanghai, CN

18:10 - 18:10 **218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study**

X. Tan, Z. Wu, Y. Wang, K. Yao, Sun Yat-sen University Cancer Center, Guangzhou, CN

18:10 - 18:10 **219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study**

P. Dong, T. Huang, L. Jiang, W. Wei, X. Zheng, Z. Zhang, S. Guo, H. Han, F. Zhou, Sun Yat-

sen University Cancer Center, Guangzhou, CN

- 18:10 - 18:10 **220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma**  
W. Xu, H. Zhang, D. Ye, Fudan University Shanghai Cancer Center, Shanghai, CN
- 18:10 - 18:10 **221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer**  
A. Kumar, V. Singh, M. Singh, KGMU - King George's Medical University, Lucknow, IN
- 18:10 - 18:10 **222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan**  
N. Hayakawa<sup>1</sup>, G. Kaneko<sup>2</sup>, R. Yamashita<sup>3</sup>, D. Ikarashi<sup>4</sup>, Y. Endo<sup>5</sup>, W. Obara<sup>4</sup>, M. Oyama<sup>2</sup>, Y. Kondo<sup>5</sup>, E. Kikuchi<sup>1</sup>, <sup>1</sup>St. Marianna University, Kawasaki, JP, <sup>2</sup>Saitama Medical University International Medical Center, Saitama, JP, <sup>3</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>4</sup>Iwate Medical University School of Medicine, Iwate, JP, <sup>5</sup>Nippon Medical School Main Hospital, Tokyo, JP
- 18:10 - 18:10 **223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma**  
N. Oliveira<sup>1</sup>, B. Li<sup>2</sup>, M. Kim<sup>3</sup>, I. Park<sup>4</sup>, A. Dsouza<sup>5</sup>, S. Chua<sup>6</sup>, E.M. Tan<sup>7</sup>, C. Spiteri<sup>8</sup>, Y.-L. Su<sup>9</sup>, C.K. Yang<sup>10</sup>, A. Zhang<sup>11</sup>, K. Wong<sup>12</sup>, <sup>1</sup>Mater Hospital Brisbane, Brisbane, AU, <sup>2</sup>Queen Mary Hospital, Hong Kong, HK, <sup>3</sup>SNUH - Seoul National University Hospital, Seoul, KR, <sup>4</sup>Asan Medical Center - University of Ulsan, Seoul, KR, <sup>5</sup>MSD International GmbH, Singapore Branch, Singapore, SG, <sup>6</sup>IQVIA Asia Pacific, Singapore, Singapore, SG, <sup>7</sup>IQVIA Asia Pacific, Singapore, SG, <sup>8</sup>Merck Sharp & Dohme (Australia) Pty Ltd, Macquarie Park, AU, <sup>9</sup>Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, TW, <sup>10</sup>Taichung Veterans General Hospital, Taichung City, TW, <sup>11</sup>Macquarie University Hospital, North Ryde, AU, <sup>12</sup>Prince of Wales Hospital, Kowloon, HK
- 18:10 - 18:10 **224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma**  
X. Liao, P. Zhang, J. Liu, S. Zhang, Q. Wei, Y. Bao, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN
- 18:10 - 18:10 **225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study**  
H. P S<sup>1</sup>, S. N<sup>1</sup>, R. Pappala<sup>1</sup>, D. Devi<sup>1</sup>, A. Narikot<sup>1</sup>, V. Veldore<sup>2</sup>, N. Tanwar<sup>2</sup>, P. Srikanthreddy<sup>2</sup>, H. Goswami<sup>2</sup>, S. Bs<sup>3</sup>, A. Korlimarla<sup>1</sup>, <sup>1</sup>Sri Shankara Cancer Hospital and Research Centre - SSCF, Bengaluru, IN, <sup>2</sup>basecare Onco Solutions Pvt Ltd, Bangalore, IN, <sup>3</sup>Sri Shankara Cancer Hospital and Research Centre - SSCF, Bangalore, IN
- 18:10 - 18:10 **226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma**  
X. Han<sup>1</sup>, H. Liu<sup>2</sup>, J. Qin<sup>3</sup>, S. Cao<sup>3</sup>, <sup>1</sup>Shanxi Province Cancer Hospital, Taiyuan, CN, <sup>2</sup>Acornmed Biotechnology Co., Ltd., Beijing, CN, <sup>3</sup>Beijing Acornmed Biotechnology Co.,



Ltd., Beijing, CN

- 18:10 - 18:10 **227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions**  
C. Hyun<sup>1</sup>, M. Song<sup>2</sup>, <sup>1</sup>Jeju National University Hospital, Jeju-si, KR, <sup>2</sup>Jeju National University School of Medicine, Jeju-si, KR
- 18:10 - 18:10 **228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma**  
A. Santhosh, H. Baskarane, A. Batra, R.K. Sahoo, A. Sharma, AIIMS - All India Institute of Medical Sciences, New Delhi, IN
- 18:10 - 18:10 **229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI**  
S. Jiang, Q. Li, B. Cao, J. Zhou, Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN
- 18:10 - 18:10 **230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage**  
M.W. Hsu, C.-R. Yang, China Medical University Hospital, Taichung City, TW
- 18:10 - 18:10 **231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients**  
M. Harada, University of Occupational and Environmental Health, Kitakyushu, JP
- 18:10 - 18:10 **232P - The immunosuppressive features of the 20S Proteasome  $\beta$ -subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study**  
S. Alzghoul, E. Al Masoud, L. Lataifeh, B. Abu Mousa, A. Al Sharie, JUST - Jordan University of Science and Technology, Irbid, JO
- 18:10 - 18:10 **233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response**  
A. Al Sharie, L. Lataifeh, S. Alzghoul, E. Al Masoud, S. Bashammakh, B. Abu Mousa, JUST - Jordan University of Science and Technology, Irbid, JO
- 18:10 - 18:10 **235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?**  
A. Al Hanafy<sup>1</sup>, S. Fathy<sup>2</sup>, M. Serag Eldin<sup>2</sup>, N. Holah<sup>2</sup>, <sup>1</sup>MFMM - Menoufia University - Faculty of Medicine, Shebeen El-Kom, EG, <sup>2</sup>Menoufeya University Faculty of Medicine, Cairo, EG
- 18:10 - 18:10 **236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma**  
K. Kitamura<sup>1</sup>, T. Kimura<sup>2</sup>, Y. Miyoshi<sup>1</sup>, S. Muto<sup>3</sup>, S. Horie<sup>4</sup>, <sup>1</sup>Juntendo Nerima Hospital,

Tokyo, JP, <sup>2</sup>Juntendo University Graduate School of Medicine, Bunkyo-ku, JP, <sup>3</sup>Juntendo Nerima Hospital, Nerima-ku, JP, <sup>4</sup>Juntendo University International Center (JUIC), Tokyo, JP

- 18:10 - 18:10 **237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients**  
M.-H. Chang, J.-I. Lai, C.-C. Yen, Taipei Veterans General Hospital, Taipei City, TW
- 18:10 - 18:10 **238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience**  
H. Mikami, Y. Endo, J. Akatsuka, G. Kimura, H. Takeda, S. Ikuma, M. Taniuchi, H. Hasegawa, Y. Toyama, M. Shibasaki, Y. Kondo, Nippon Medical School Main Hospital, Tokyo, JP
- 18:10 - 18:10 **239P - Elevated baseline C-reactive protein is a prognostic indicator for OS in patients with metastatic non clear cell renal cell carcinoma treated with systemic therapy**  
R. Mizuno, Y. Yasumizu, N. Tanaka, S. Morita, T. Takeda, K. Matsumoto, T. Kosaka, H. Asanuma, M. Oya, Keio University School of Medicine, Shinjuku-ku, JP
- 18:10 - 18:10 **240P - Efficacy and safety of first-line combination therapy with ipilimumab &#x2b; nivolumab for metastatic renal cell carcinoma in a single institution in Japan**  
M. Nagata<sup>1</sup>, S. Horie<sup>1</sup>, N. Nagaya<sup>2</sup>, <sup>1</sup>Juntendo University Graduate School of Medicine, Tokyo, JP, <sup>2</sup>Juntendo University, Shizuoka Hospital, Izunokuni, Shizuoka, JP
- 18:10 - 18:10 **241P - First-line cabozantinib in metastatic renal cell carcinoma (mRCC): A real-world exploratory study from eastern India**  
T. Chaudhuri, A. Upadhyay, J. Bankira, R. Panda, V. Pandey, S. Mitra, Meherbai Tata Memorial Hospital, Jamshedpur, IN
- 18:10 - 18:10 **244P - Clinicopathologic feature and treatment outcome of metastatic non clear cell kidney cancer: A single centre experience from India**  
S. Roy, B. Biswas, D. Dabkara, S. Ganguly, J. Ghosh, A. Bhattacharjee, S. Pal, J. Karmakar, K. Ray, S. Mandal, Y. Patel, TMC - Tata Medical Center, Kolkata, IN
- 18:10 - 18:10 **245P - The role of TGF- $\beta$ 2; in the formation of the protumor phenotype of circulating neutrophils at different stages of renal cancer**  
I. Myagdieva<sup>1</sup>, T. Abakumova<sup>1</sup>, D. Dolgova<sup>1</sup>, O. Gorshkov<sup>2</sup>, T. Gening<sup>1</sup>, <sup>1</sup>Ulyanovsk State University, Ulyanovsk, RU, <sup>2</sup>Regional Clinical Oncology Dispensary Ulyanovsk, Ulyanovsk, RU
- 18:10 - 18:10 **246P - Impact of renal impairment on first-line treatment in metastatic urothelial cancer**  
S. Wakeling<sup>1</sup>, A. Inderjeeth<sup>2</sup>, A. Weickhardt<sup>3</sup>, J. Lynam<sup>4</sup>, P. Gibbs<sup>5</sup>, S. O'Haire<sup>2</sup>, K. Zlatic<sup>5</sup>, S. Wong<sup>6</sup>, S. Sengupta<sup>7</sup>, P. Manohar<sup>8</sup>, A. Zhang<sup>9</sup>, L.-M. Wong<sup>10</sup>, B. Tran<sup>1</sup>, C. Conduit<sup>2</sup>, <sup>1</sup>Peter MacCallum Cancer Centre, Melbourne, AU, <sup>2</sup>Peter MacCallum Cancer Center,

Melbourne, AU, <sup>3</sup>Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg, AU, <sup>4</sup>Calvary Mater Hospital Newcastle, Newcastle, AU, <sup>5</sup>WEHI - Walter and Eliza Hall Institute of Medical Research, Parkville, AU, <sup>6</sup>Sunshine Hospital - Western Health, St Albans, AU, <sup>7</sup>Monash Health - Monash Cancer Centre, Bentleigh East, AU, <sup>8</sup>Monash Health - Monash Medical Centre, Clayton, AU, <sup>9</sup>Macquarie University Hospital, North Ryde, AU, <sup>10</sup>St Vincent's Hospital, Melbourne, AU

- 18:10 - 18:10 **247P - Adjuvant chemoradiotherapy in the management of bladder adenocarcinoma compared to multiple treatment modalities**  
O. Mohammed<sup>1</sup>, A. Ellaithy<sup>2</sup>, <sup>1</sup>National University of Sudan, Khartoum, SD, <sup>2</sup>Suez Canal University Hospital, Ismailia, EG
- 18:10 - 18:10 **248P - Screening zinc homeostasis-related genes identifies metallothionein 1H (MT1H) as a potential prognostic biomarker in clear cell renal cell carcinoma (ccRCC)**  
E. Al Masoud, S. Alzghoul, L. Lataifeh, B. Abu Mousa, A. Al Sharie, JUST - Jordan University of Science and Technology, Irbid, JO
- 18:10 - 18:10 **249P - The prognostic utility of Progesterone associated Endometrial protein (PAEP) gene expression in clear cell renal cell carcinoma (ccRCC)**  
L. Lataifeh, S. Alzghoul, E. Al Masoud, B. Abu Mousa, A. Al Sharie, JUST - Jordan University of Science and Technology, Irbid, JO
- 18:10 - 18:10 **250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma**  
M. Eleisawy<sup>1</sup>, A. Ellaithy<sup>2</sup>, <sup>1</sup>Benha University Hospital, Quesna, EG, <sup>2</sup>Suez Canal University Hospital, Ismailia, EG
- 18:10 - 18:10 **251P - LDH isozyme as a prognostic factor for patients with metastatic clear cell renal cell carcinoma (mCRCC)**  
H. Takeda, G. Kimura, M. Taniuchi, H. Hasegawa, H. Mikami, J. Akatsuka, Y. Endo, Y. Toyama, Y. Kondo, Nippon Medical School Main Hospital, Tokyo, JP
- 18:10 - 18:10 **252P - Risk factors for recurrence after curative nephrectomy in non-metastatic renal cell carcinoma: A retrospective cohort study**  
K. Tejada, National Kidney and Transplant Institute, Quezon City, PH
- 18:10 - 18:10 **253TiP - WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma: A phase II multi-center study**  
Y. Bao, X. Liao, P. Zhang, H. Zeng, J. Liu, Q. Wei, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN
- 18:10 - 18:10 **254TiP - Prospective observational trial of cabozantinib plus nivolumab in Japanese patients with advanced or metastatic renal cell carcinoma: JACUMET trial**  
Y. Miura<sup>1</sup>, K. Fujita<sup>2</sup>, T. Ichikawa<sup>3</sup>, S. Tamada<sup>4</sup>, N. Sassa<sup>5</sup>, K. Kobayashi<sup>6</sup>, H. Azuma<sup>7</sup>, H. Hasumi<sup>8</sup>, C. Ohe<sup>9</sup>, M. Eto<sup>10</sup>, M. Oya<sup>11</sup>, T. Kamba<sup>12</sup>, N. Shinohara<sup>13</sup>, T. Tsuzuki<sup>5</sup>, N.

Nonomura<sup>14</sup>, S. Hinotsu<sup>15</sup>, Y. Fujii<sup>16</sup>, G. Kimura<sup>17</sup>, H. Uemura<sup>2</sup>, <sup>1</sup>Toranomon Hospital, Tokyo, JP, <sup>2</sup>Kindai University Faculty of Medicine, Osaka-sayama, JP, <sup>3</sup>Graduate School of Medicine, Chiba University, Chiba, JP, <sup>4</sup>Bell-Land General Hospital, Sakai, JP, <sup>5</sup>Aichi Medical University, Nagakute, JP, <sup>6</sup>Yokosuka Kyosai Hospital, Yokosuka, JP, <sup>7</sup>Faculty of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, JP, <sup>8</sup>Yokohama City University, Yokohama, JP, <sup>9</sup>Osaka Metropolitan University, Osaka, JP, <sup>10</sup>Kyushu University Graduate School of Medical Sciences, Fukuoka, JP, <sup>11</sup>Keio University School of Medicine, Tokyo, JP, <sup>12</sup>Kumamoto University, Graduate School of Medical Sciences, Kumamoto, JP, <sup>13</sup>Hokkaido University Graduate School of Medicine, Sapporo, JP, <sup>14</sup>Osaka University Graduate School of Medicine, Suita, JP, <sup>15</sup>Sapporo Medical University School of Medicine, Sapporo, JP, <sup>16</sup>Tokyo Medical and Dental University, Tokyo, JP, <sup>17</sup>Nippon Medical School Hospital, Tokyo, JP

- 18:10 - 18:10 **264P - Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2#x2b;1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)**
- W. Kelly<sup>1</sup>, D. Danila<sup>2</sup>, C.-C. Lin<sup>3</sup>, J.-L. Lee<sup>4</sup>, N. Matsubara<sup>5</sup>, P. Ward<sup>6</sup>, A. Armstrong<sup>7</sup>, D. Pook<sup>8</sup>, M. Kim<sup>9</sup>, T. Dorff<sup>10</sup>, S. Fischer<sup>11</sup>, Y.-C. Lin<sup>12</sup>, L. Horvath<sup>13</sup>, C. Sumey<sup>14</sup>, Z. Yang<sup>15</sup>, G. Jurida<sup>15</sup>, J. Connarn<sup>15</sup>, H. Penny<sup>15</sup>, J. Stieglmaier<sup>16</sup>, L. Appleman<sup>17</sup>, <sup>1</sup>Thomas Jefferson University, Philadelphia, US, <sup>2</sup>MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, <sup>3</sup>NTUH - National Taiwan University Hospital, Taipei City, TW, <sup>4</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>5</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>6</sup>Oncology Hematology Care, Cincinnati, US, <sup>7</sup>Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, US, <sup>8</sup>Monash Medical Centre, Clayton, AU, <sup>9</sup>Seoul National University Hospital, Seoul, KR, <sup>10</sup>City of Hope Comprehensive Cancer Center, Duarte, US, <sup>11</sup>Kantonsspital St. Gallen, St. Gallen, CH, <sup>12</sup>Linkou Chang Gung Memorial Hospital, Taoyuan City, TW, <sup>13</sup>Chris O'Brien Lifehouse, University of Sydney, Camperdown, AU, <sup>14</sup>Sanford Cancer Center, Sioux Falls, US, <sup>15</sup>Amgen Inc., Thousand Oaks, US, <sup>16</sup>Amgen Research (Munich) GmbH, Munich, DE, <sup>17</sup>UPMC Hillman Cancer Center, Pittsburgh, US
- 18:10 - 18:10 **266P - Clinical application and potential impact of liquid biopsy on the management of Chinese patients with metastatic castration-resistant prostate cancer (mCRPC): A territory-wide prospective analysis**
- W.K.P. Kwong<sup>1</sup>, D. Poon<sup>2</sup>, T. Chan<sup>3</sup>, F.Y. Cheung<sup>1</sup>, H.S. Chung<sup>3</sup>, C.S. Ho<sup>3</sup>, H.C. Lam<sup>1</sup>, K. Law<sup>4</sup>, A. Leung<sup>5</sup>, L.H. Tse<sup>4</sup>, T. Yuen<sup>3</sup>, <sup>1</sup>HKIOC - Hong Kong Integrated Oncology Centre, Hong Kong, HK, <sup>2</sup>Hong Kong Sanatorium & Hospital, Hong Kong, HK, <sup>3</sup>Queen Elizabeth Hospital, Kowloon, HK, <sup>4</sup>Princess Margaret Hospital, Kowloon, HK, <sup>5</sup>Private Practice - Dr. Angus Leung, Hong Kong, HK
- 18:10 - 18:10 **267P - Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer**
- J. Wang<sup>1</sup>, D. Zhao<sup>1</sup>, Y. Zhao<sup>2</sup>, Y. Li<sup>1</sup>, F. Zhou<sup>1</sup>, <sup>1</sup>Sun Yat-sen University Cancer Center, Guangzhou, CN, <sup>2</sup>Precision Scientific (Beijing) Co., Ltd., Beijing, CN
- 18:10 - 18:10 **268P - Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study**
- H.I. Chou<sup>1</sup>, L. Lu<sup>2</sup>, C.T. Chung<sup>3</sup>, J.S.K. Chan<sup>3</sup>, R.N.C. Chan<sup>3</sup>, Y.H.A. Lee<sup>4</sup>, E. Dee<sup>5</sup>, K. Ng<sup>6</sup>,

H.H.H. Pui<sup>1</sup>, S. Lee<sup>3</sup>, B. Cheung<sup>7</sup>, G. Tse<sup>8</sup>, J. Zhou<sup>9</sup>, <sup>1</sup>HKU - The University of Hong Kong, Hong Kong, HK, <sup>2</sup>University of Oxford, Oxford, GB, <sup>3</sup>Cardiovascular Analytics Group, Hong Kong, HK, <sup>4</sup>The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK, <sup>5</sup>MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, <sup>6</sup>UCL - University College London, London, GB, <sup>7</sup>University of Hong Kong, Hong Kong, HK, <sup>8</sup>The Second Hospital of Tianjin Medical University, Tianjin, CN, <sup>9</sup>University of Warwick, Coventry, GB

- 18:10 - 18:10 **269P - Prostate cancer harboring low COMT expression correlates with a poor prognosis and response to enzalutamide**  
S. Maekawa<sup>1</sup>, R. Takata<sup>2</sup>, D. Ikarashi<sup>1</sup>, T. Matsuura<sup>1</sup>, R. Kato<sup>1</sup>, M. Kanehira<sup>1</sup>, J. Sugimura<sup>1</sup>, W. Obara<sup>1</sup>, <sup>1</sup>Iwate Medical University, Iwate, JP, <sup>2</sup>Iwate Medical University, Shiwa-gun, JP
- 18:10 - 18:10 **270P - Germline BRCA1/2 pathogenic variants in Japanese patients with prostate cancer are predictive factors for androgen receptor-axis-targeted therapy or chemotherapy for castration-resistant prostate cancer**  
S. Maekawa<sup>1</sup>, R. Takata<sup>2</sup>, T. Matsuura<sup>2</sup>, D. Ikarashi<sup>3</sup>, R. Kato<sup>2</sup>, M. Kanehira<sup>2</sup>, J. Sugimura<sup>2</sup>, W. Obara<sup>1</sup>, <sup>1</sup>Iwate Medical University, Iwate, JP, <sup>2</sup>Iwate Medical University, Shiwa-gun, JP, <sup>3</sup>Iwate Medical University School of Medicine, Morioka, JP
- 18:10 - 18:10 **271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib**  
N. Muramoto<sup>1</sup>, M. Iwasaki<sup>2</sup>, Y. Sera<sup>2</sup>, H. Ide<sup>1</sup>, S. Horie<sup>1</sup>, H. Honda<sup>2</sup>, <sup>1</sup>Juntendo University Graduate School of Medicine, Bunkyo-ku, JP, <sup>2</sup>Tokyo Women's Medical University, Tokyo, JP
- 18:10 - 18:10 **272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis**  
M. Sabran, C.E.O.L. Hutauruk, M.D. Sembiring, C.A. Sutedja, E. Budiarti, Y.A.P. Ontowirjo, N.B.S.A. Purushotama, A. Kurniawan, UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, ID
- 18:10 - 18:10 **273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?**  
Y. Toyama, G. Kimura, J. Akatsuka, Y. Kondo, Nippon Medical School Main Hospital, Tokyo, JP
- 18:10 - 18:10 **274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins**  
J. Akatsuka, Y. Ogata, Y. Endo, T. Tsuchiya, M. Taniuchi, S. Ikuma, M. Shibasaki, H. Hasegawa, H. Mikami, M. Yanagi, H. Takeda, Y. Toyama, G. Kimura, Y. Kondo, Nippon Medical School Main Hospital, Tokyo, JP
- 18:10 - 18:10 **275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells**  
N. Nagaya, M. Nagata, T. Ashizawa, Y. Lu, K. Fujita, S. Horie, Juntendo University Graduate School of Medicine, Bunkyo-ku, JP

- 18:10 - 18:10 **276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer**  
L. Kamala, A. Mathews, S. Kumar Soman, S. V N, RCC - Regional Cancer Centre, Thiruvananthapuram, Thiruvananthapuram, IN
- 18:10 - 18:10 **277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma**  
M. Salomov, Surkhandarya regional branch Republican medical research centre of oncology and radiology, Termez, UZ
- 18:10 - 18:10 **278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases**  
B. Xu, X. Zhao, H. Zhuang, Shanghai Changhai Hospital, Yangpu District, CN
- 18:10 - 18:10 **279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review**  
T. Nguyen, FV - Franco - Vietnamese Hospital, Ho Chi Minh City, VN
- 18:10 - 18:10 **280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience**  
K.M. Chiang, Y.-H. Chou, S.-W. Huang, L.-H. Yuan, Y.-W. Huang, Y.-J. Chen, H.-J. Yu, J.-P. Chen, National Taiwan University Hospital - Yunlin Branch, Douliu City, TW
- 18:10 - 18:10 **281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran**  
R. Bayani<sup>1</sup>, N. Mousavi Darzikolaee<sup>2</sup>, M. Garousi<sup>3</sup>, <sup>1</sup>Hamadan University of Medical Sciences, Hamedan, IR, <sup>2</sup>Imam Khomeini Hospital Complex - Cancer Institute, Tehran, IR, <sup>3</sup>Iran University of Medical Sciences, Tehran, IR
- 18:10 - 18:10 **282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy**  
J.-S. Kim<sup>1</sup>, T.H. Kim<sup>2</sup>, D.-Y. Kim<sup>3</sup>, <sup>1</sup>Seoul National University Bundang Hospital, Seongnam, KR, <sup>2</sup>Seoul National University Hospital, Seoul, KR, <sup>3</sup>Chung-Ang University Hospital, Seoul, KR
- 18:10 - 18:10 **283P - Radiotherapy utilization rate and treatment pattern of prostate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era**  
R. Apriantoni, RSUPN Dr. Cipto Mangunkusumo, Central Jakarta, ID
- 18:10 - 18:10 **284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer**  
N. Matsubara<sup>1</sup>, N. Agarwal<sup>2</sup>, M.R. Smith<sup>3</sup>, R. McKay<sup>4</sup>, T. Todenhöfer<sup>5</sup>, J.M. Piulats Rodriguez<sup>6</sup>, K.L. Chung<sup>7</sup>, D. Heirich<sup>8</sup>, S. Sherwood<sup>9</sup>, C. Schaverien<sup>10</sup>, N. Fasnacht<sup>11</sup>, A. Lithio<sup>10</sup>, K. Nacerddine<sup>12</sup>, T. Zhang<sup>13</sup>, <sup>1</sup>National Cancer Center Hospital East, Kashiwa,

JP, <sup>2</sup>University of Utah Health - Huntsman Cancer Institute, Salt Lake City, US, <sup>3</sup>Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US, <sup>4</sup>University of California San Diego - UCSD, La Jolla, US, <sup>5</sup>Studienpraxis Urologie, Nuertingen, DE, <sup>6</sup>ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, <sup>7</sup>Eli Lilly and Company, New York, US, <sup>8</sup>Loxo Oncology, Inc, South San Francisco, US, <sup>9</sup>Eli Lilly and Company, West Ryde, AU, <sup>10</sup>Eli Lilly and Company, Indianapolis, US, <sup>11</sup>Eli Lilly (Suisse) S.A., Vernier, CH, <sup>12</sup>Eli Lilly France, Neuilly-sur-Seine, FR, <sup>13</sup>Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, US

18:10 - 18:10 **Gynaecological cancers**

18:10 - 18:10 **292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women**

G. Goyibova<sup>1</sup>, U. Soatov<sup>2</sup>, <sup>1</sup>Tashkent Pediatric Medical Institute, Tashkent, UZ, <sup>2</sup>Republican Specialized Scientific Practical Medical Center of Oncology and Radiology, Tashkent, UZ

18:10 - 18:10 **293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin**

N.I. Valdiviezo Lama, I. Otoya Fernández, L. Chavez Jimenez, R. Ruiz, O. Coanqui Gonzales, M. Olivera, C. Velarde Navarrete, L.A. Mas Lopez, INEN - Instituto Nacional de Enfermedades Neoplasicas, Lima, PE

18:10 - 18:10 **294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial**

L. Nguyen<sup>1</sup>, M. Dang<sup>2</sup>, C.V. Nguyen<sup>1</sup>, N. Thanh<sup>2</sup>, V.A. Dang<sup>1</sup>, H. Khuc Chi<sup>1</sup>, A.D. To<sup>1</sup>, H. Phung Thi<sup>1</sup>, <sup>1</sup>K Hospital - Vietnam National Cancer Hospital - BASE 3, Hanoi, VN, <sup>2</sup>K Hospital - Vietnam National Cancer Hospital - BASE 1, Hanoi, VN

18:10 - 18:10 **295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer**

R. Mishra<sup>1</sup>, A. Pandey<sup>2</sup>, S. Singh<sup>1</sup>, A. Mandal<sup>1</sup>, H. Mishra<sup>1</sup>, <sup>1</sup>Institute of Medical Sciences, Banaras Hindu University, IMS-BHU, Varanasi, IN, <sup>2</sup>PGIMER - Post Graduate Institute of Medical Education and Research, Chandigarh, IN

18:10 - 18:10 **296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review**

C.A. Gonçalves<sup>1</sup>, L.C. Lopes-Júnior<sup>2</sup>, G.S. Bisson<sup>3</sup>, <sup>1</sup>Universidade Ceuma, Sao Luis, BR, <sup>2</sup>Universidade Federal do Espírito Santo, Campus de Maruípe, Vitoria, BR, <sup>3</sup>University of Sao Paulo, Ribeirao Preto, BR

18:10 - 18:10 **297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?**

C. Kotambunan, G.B. Prajogi, H. Handoko, T.B.M. Permata, S. Gondhowiardjo, Dr. Cipto Mangunkusumo National General Hospital, Central Jakarta, ID

- 18:10 - 18:10 **298P - Managing locally advanced cervical cancer: Insights from a tertiary care center and a 3-year follow-up on outcomes**  
A. Yadala<sup>1</sup>, B. Gundapuneedi<sup>2</sup>, L. Ramachandran<sup>2</sup>, J. Pandjatcharam<sup>2</sup>, <sup>1</sup>Regional Cancer Centre, JIPMER, Puducherry, IN, <sup>2</sup>JIPMER - Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IN
- 18:10 - 18:10 **299P - Sexual dysfunction assessment in longterm survivors of carcinoma cervix using LENT SOMA scale**  
N. Sethi<sup>1</sup>, A. Shankar<sup>2</sup>, <sup>1</sup>VMMC-SJH - Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi, IN, <sup>2</sup>AIIMS - All India Institute of Medical Sciences, New Delhi, IN
- 18:10 - 18:10 **300P - Assessing ovarian function in Vietnamese cervical cancer patients who underwent ovary transposition prior to pelvic radiation therapy**  
C. Nguyen<sup>1</sup>, N.L. Tran Dang<sup>2</sup>, <sup>1</sup>International Cancer Specialists, Ho Chi Minh City, VN, <sup>2</sup>HCMC Oncology Hospital, Ho Chi Minh City, VN
- 18:10 - 18:10 **301P - Correlation between cervical cancer recurrence after radiation therapy and vaginal microbiome**  
X. Xu, Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, CN
- 18:10 - 18:10 **302P - Expression of ERCC4 gene and its correlation with clinical and pathological parameters in cervical cancer**  
H. Mishra, R. Mishra, B. Parida, G. Narayan, Institute of Medical Sciences, Banaras Hindu University, IMS-BHU, Varanasi, IN
- 18:10 - 18:10 **303P - Prognostic value of body composition and systemic inflammatory markers in patients with locally advanced cervical cancer following chemoradiotherapy**  
H. Guo, S. Feng, Y. Yin, D. Li, Shandong Cancer Hospital and Institute, Jinan, CN
- 18:10 - 18:10 **305P - A real-world multicenter cohort study of lenvatinib (LEN) plus pembrolizumab (PEM) in Japanese patients with endometrial cancer: Interim analysis of GOGO-EM4 study**  
Y. Nagase<sup>1</sup>, S. Nakagawa<sup>2</sup>, Y. Ueda<sup>2</sup>, H. Ogimoto<sup>3</sup>, M. Kobayashi<sup>2</sup>, M. Shiomi<sup>4</sup>, R. Kakubari<sup>5</sup>, A. Otake<sup>6</sup>, E. Yoshioka<sup>7</sup>, M. Watanabe<sup>8</sup>, T. Egawa-Takata<sup>7</sup>, S. Matsuzaki<sup>5</sup>, S. Koyama<sup>4</sup>, T. Yokoi<sup>1</sup>, K. Amemiya<sup>3</sup>, K. Ito<sup>7</sup>, S. Kamiura<sup>5</sup>, T. Kimura<sup>2</sup>, <sup>1</sup>Kaizuka City Hospital, Kaizuka, JP, <sup>2</sup>Graduate School of Medicine / Faculty of Medicine, Osaka University, Suita, JP, <sup>3</sup>Itami City Hospital, Itami, JP, <sup>4</sup>Osaka Police Hospital, Osaka, JP, <sup>5</sup>OICI - Osaka International Cancer Institute, Osaka, JP, <sup>6</sup>Minoh City Hospital, Minoh, JP, <sup>7</sup>Kansai Rosai Hospital, Amagasaki, JP, <sup>8</sup>Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, JP
- 18:10 - 18:10 **306P - Adjuvant treatment and impact on relapse in stage IA uterine papillary serous and clear cell carcinomas: A single center retrospective study**  
S. Khurana<sup>1</sup>, K. Kalra<sup>2</sup>, P. Malik<sup>3</sup>, D. Sharma<sup>1</sup>, R. Pramanik<sup>3</sup>, N. Bhatla<sup>1</sup>, <sup>1</sup>AIIMS - All



India Institute of Medical Sciences, New Delhi, IN, <sup>2</sup>VMMC-SJH - Vardhman Mahavir Medical College & Safdarjung Hospital, New Delhi, IN, <sup>3</sup>Institute Rotary Cancer Hospital, New Delhi, IN

- 18:10 - 18:10 **307P - Hormonal therapy vs combination chemotherapy in metastatic leiomyosarcomas: A systematic review**  
P. Angel<sup>1</sup>, F. Wijovi<sup>2</sup>, A. Kurniawan<sup>2</sup>, <sup>1</sup>Siloam Hospital/Medical faculty of Pelita Harapan University, Tangerang - Kota, ID, <sup>2</sup>UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, ID
- 18:10 - 18:10 **309P - Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR**  
H. Fujii, T. Nishikawa, H. Yoshida, R. Ozawa, M. Hoshino, A. Saito, M. Ito, S. Kita, A. Maejima, Y. Kojima, K. Sudo, T. Shimoi, K. Yonemori, National Cancer Center Hospital, Tokyo, JP
- 18:10 - 18:10 **310P - A study on the prediction of recurrence site of endometrial cancer using various machine learning techniques**  
W. Shin<sup>1</sup>, S.J. Yang<sup>2</sup>, <sup>1</sup>Chungnam National University Sejong Hospital, Sejong-si, KR, <sup>2</sup>Jeonbuk National University, Jeonju, KR
- 18:10 - 18:10 **311P - Circulating cytokines in the differential diagnosis of endometrial cancer**  
T. Abakumova, I. Antoneeva, T. Gening, Ulyanovsk State University, Ulyanovsk, RU
- 18:10 - 18:10 **312P - Molecular and genetic features of squamous cell carcinoma of vulvar cancer depending on HPV status**  
V. Navruzova, Private Hospital "Yangi Hayot", Tashkent, UZ
- 18:10 - 18:10 **313P - Efficacy and safety of oral metronomic chemotherapy in recurrent refractory advanced gynaecological cancer: Experience from regional cancer center of eastern India**  
R. Ghosh<sup>1</sup>, P. Biswas<sup>1</sup>, K. Mukherjee<sup>1</sup>, R. Mandal<sup>1</sup>, M. Vernekar<sup>2</sup>, P. Chatterjee<sup>1</sup>, T. Maji<sup>1</sup>, D. Lahiri<sup>3</sup>, B. Dutta<sup>1</sup>, S. Mazumder<sup>1</sup>, J. Chakrabarti<sup>1</sup>, <sup>1</sup>CNCI - Chittaranja National Cancer Institute, Kolkata, IN, <sup>2</sup>CNCI - Chitaranjan National Cancer Institute, Kolkata, IN, <sup>3</sup>CHITTARANJAN National Cancer Institute, Kolkata, IN
- 18:10 - 18:10 **314P - Perioperative outcomes in advanced epithelial ovarian cancer treated with neoadjuvant bevacizumab and chemotherapy: Real-world experience from an Indian cancer centre**  
U. Palo<sup>1</sup>, D. Mondal<sup>2</sup>, A. Ghosh<sup>1</sup>, B. Chakraborti<sup>1</sup>, J. Mishra<sup>1</sup>, J. Ghosh<sup>1</sup>, S. Roy<sup>1</sup>, J. Bhaumik<sup>1</sup>, <sup>1</sup>Tata Medical Center, Kolkata, IN, <sup>2</sup>Saroj Gupta Cancer Centre & Research Institute, Kolkata, IN
- 18:10 - 18:10 **315P - Real-world experience of niraparib as maintenance therapy in newly diagnosed advanced ovarian cancer: A single-center retrospective study**  
W. Liu<sup>1</sup>, K. Wang<sup>2</sup>, L. Zhang<sup>3</sup>, Y. Ma<sup>1</sup>, H. Wu<sup>3</sup>, Y. Chen<sup>1</sup>, L. Bao<sup>3</sup>, X. Fu<sup>3</sup>, <sup>1</sup>Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, <sup>2</sup>TMUCIH - Tianjin Medical

University Cancer Institute and Hospital, Tianjin, CN, <sup>3</sup>Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN

- 18:10 - 18:10 **316P - First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study**  
J. Li<sup>1</sup>, C. Youguo<sup>2</sup>, H. Mian<sup>3</sup>, X. Chen<sup>4</sup>, H. Wen<sup>5</sup>, Y. Kang<sup>6</sup>, K.J. Liu<sup>7</sup>, G. Lou<sup>8</sup>, X. Wang<sup>9</sup>, Q.L. Wen<sup>10</sup>, L. Wang<sup>11</sup>, Z. Lin<sup>12</sup>, <sup>1</sup>Sun Yat-sen Memorial Hospital, Guangzhou, CN, <sup>2</sup>The First Affiliated Hospital of Soochow University, Suzhou, CN, <sup>3</sup>The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, <sup>4</sup>Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu, CN, <sup>5</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>6</sup>Obstetrics and Gynecology Hospital of Fudan University, Shanghai, CN, <sup>7</sup>Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CN, <sup>8</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>9</sup>Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, CN, <sup>10</sup>The Affiliated Hospital of Southwest Medical University, Luzhou, CN, <sup>11</sup>The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, CN, <sup>12</sup>Sun Yat-Sen University, Guangzhou, CN
- 18:10 - 18:10 **317P - Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy**  
W. Assaf, M. Andraous, O. Lavie, Y. Segev, Technion - Israel Institute of Technology, Haifa, IL
- 18:10 - 18:10 **319P - Survival prediction for ovarian cancer patients from Taiwan cancer registry data**  
T.-P. Lu<sup>1</sup>, A. Chattopadhyay<sup>1</sup>, Y.-T. Wu<sup>2</sup>, H.-C. Chan<sup>2</sup>, Y.-T. Kang<sup>2</sup>, Y.-C. Chiang<sup>3</sup>, R.R.C.-J. Chiang<sup>2</sup>, W.-C. Lee<sup>1</sup>, <sup>1</sup>National Taiwan University, Taipei, TW, <sup>2</sup>National Taiwan University, Taipei City, TW, <sup>3</sup>National Taiwan University Hospital, Taipei City, TW
- 18:10 - 18:10 **320P - Treatment patterns and outcomes in Indian patients with advanced ovarian cancer: A single center experience**  
P. Hirapara<sup>1</sup>, M. Shah<sup>2</sup>, K. Patel<sup>2</sup>, V. Patel<sup>2</sup>, N. Dethariya<sup>2</sup>, P. Leuva<sup>2</sup>, K. Kothari<sup>2</sup>, <sup>1</sup>HCG Cancer Hospital, Ahmedabad, IN, <sup>2</sup>HCG Cancer Centre Ahmedabad, Ahmedabad, IN
- 18:10 - 18:10 **321P - Epidemiology and survival analysis of epithelial ovarian cancer: Results from comprehensive care center in north India**  
A. Badola, P. Singh, S. Anand, V. Sekar, J. Verma, Asian Institute of Medical Sciences, Faridabad, IN
- 18:10 - 18:10 **322P - Evaluation of chemotherapy response score as a prognostic factor in advanced epithelial ovarian cancer: A prospective single centre study**  
U. Palo<sup>1</sup>, A. Ghosh<sup>1</sup>, B. Chakraborti<sup>1</sup>, D. Mondal<sup>2</sup>, J. Ghosh<sup>1</sup>, S. Roy<sup>1</sup>, J. Mishra<sup>1</sup>, J. Bhaumik<sup>1</sup>, <sup>1</sup>Tata Medical Center, Kolkata, IN, <sup>2</sup>Saroj Gupta Cancer Centre & Research Institute, Kolkata, IN
- 18:10 - 18:10 **323P - Platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio as prognostic biomarkers in ovarian cancer among**

**the Asian population: A meta-analysis**

W.W.W. I Gede, I.G.K.A. Sadeva, N.P.S.I. Remitha, I.G.A.S. Sadvika, I.N.B. Mahendra, D.M. Wihandani, I.G.P. Supadmanaba, Udayana University - Faculty of Medical and Health Sciences, Denpasar, ID

- 18:10 - 18:10 **324P - All-trans retinoic acid sensitizes ovarian cancer to niraparib by inhibiting ALDH1A1 activity**  
 B. Mei<sup>1</sup>, J. Li<sup>1</sup>, S. He<sup>2</sup>, X. Wang<sup>2</sup>, J. Huang<sup>3</sup>, G. Zhang<sup>3</sup>, <sup>1</sup>University of Electronic Science and Technology of China, Chengdu, CN, <sup>2</sup>Chengdu University of Traditional Chinese Medicine, Chengdu, CN, <sup>3</sup>Sichuan Cancer Hospital and Institute/The Affiliated Cancer Hospital School of Medicine, UESTC, Chengdu, CN
- 18:10 - 18:10 **325TiP - A phase III randomized controlled trial in primary stage three and four ovarian cancer after interval cytoreductive surgery (FOCUS/KOV-HIPEC-04)**  
 M.C. Lim<sup>1</sup>, J.H. Kim<sup>2</sup>, B. Park<sup>3</sup>, J.-Y. Park<sup>4</sup>, J.-Y. Lee<sup>5</sup>, S.-J. Chang<sup>6</sup>, Y.-Y. Lee<sup>7</sup>, D.G. Hong<sup>8</sup>, S.-Y. Park<sup>2</sup>, <sup>1</sup>NCC - National Cancer Center, Goyang-si, KR, <sup>2</sup>NCC - National Cancer Center, Goyang, KR, <sup>3</sup>Samsung medical Center, Seoul, KR, <sup>4</sup>Asan Medical Center - University of Ulsan, Seoul, KR, <sup>5</sup>Yonsei University, Seoul, KR, <sup>6</sup>Ajou University Hospital School of Medicine, Suwon, KR, <sup>7</sup>Samsung Medical Center (SMC), Seoul, KR, <sup>8</sup>Kyungpook National University Chilgok Hospital, Daegu, KR
- 18:10 - 18:10 **327TiP - A single arm phase II study of single agent pemetrexed in platinum resistant/refractory epithelial ovarian or primary peritoneal cancer**  
 S. Parampalli<sup>1</sup>, S. Khurana<sup>1</sup>, A. Kumar<sup>1</sup>, P. Malik<sup>1</sup>, R. Pramanik<sup>2</sup>, S. Mathur<sup>1</sup>, M. Kumar<sup>1</sup>, N. Bhatla<sup>1</sup>, M. Ray<sup>1</sup>, <sup>1</sup>AIIMS - All India Institute of Medical Sciences, New Delhi, IN, <sup>2</sup>Institute Rotary Cancer Hospital, New Delhi, IN
- 18:10 - 18:10 **Haematological malignancies**
- 18:10 - 18:10 **337P - Demographic patterns and survival outcomes of patients with T and NK-cell lymphoma at the National Cancer Centre Singapore**  
 X.Y. Lim, M.H. Bin Hasan Mohamed, F. Rafiee, J. Ha, L.P. Khoo, A. Sairi, S.T. Lim, J.C.Y. Sheng, NCCS - National Cancer Centre Singapore, Singapore, SG
- 18:10 - 18:10 **338P - Multicenter real-world study of advanced-stage non-nasal type NK/T cell lymphoma (NKTCL): Clinical features, treatment and prognosis**  
 Y. Wei<sup>1</sup>, W.-X. Liu<sup>2</sup>, F. Qi<sup>2</sup>, C.-G. Zhang<sup>1</sup>, B.-M. Zheng<sup>2</sup>, Y. Xie<sup>2</sup>, C. Bo<sup>1</sup>, D. Zhang<sup>1</sup>, W. Liu<sup>2</sup>, H. Fang<sup>1</sup>, Y. Chai<sup>1</sup>, S. Qi<sup>1</sup>, Y. Li<sup>1</sup>, W.-H. Wang<sup>2</sup>, Y. Song<sup>2</sup>, J. Zhu<sup>2</sup>, M. Dong<sup>1</sup>, <sup>1</sup>National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, <sup>2</sup>Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education / Beijing), Peking University Cancer Hospital & Institute, Beijing, CN
- 18:10 - 18:10 **339P - A comparison of survival of patients with relapsed or refractory diffuse large B cell lymphoma undergoing allogeneic stem cell transplantation or receiving CAR-T therapy**

K. Hayashino<sup>1</sup>, H. Nishimori<sup>2</sup>, K. Fujiwara<sup>2</sup>, K. Kondo<sup>2</sup>, C. Matsubara<sup>2</sup>, T. Terao<sup>2</sup>, W. Kitamura<sup>2</sup>, C. Kamoi<sup>2</sup>, K. Seike<sup>2</sup>, H. Fujiwara<sup>2</sup>, N. Asada<sup>2</sup>, D. Ennishi<sup>2</sup>, K. Fujii<sup>2</sup>, N. Fujii<sup>2</sup>, K.-I. Matsuoka<sup>2</sup>, Y. Maeda<sup>3</sup>, <sup>1</sup>Okayama University Hospital, Okayama, JP, <sup>2</sup>Okayama University Hospital, Okayama, JP, <sup>3</sup>Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, JP

- 18:10 - 18:10 **340P - The role of CT scans and laboratory tests for surveillance in patients with diffuse large B cell lymphoma who achieved complete remission after first-line chemotherapy**  
Y. Yagi, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, JP
- 18:10 - 18:10 **341P - NUP214 gene rearrangements in leukemia patients: Case series from a single institution**  
Y.J. Choi, S.-T. Lee, J.R. Choi, S. Shin, Severance Hospital - Yonsei University College of Medicine, Seoul, KR
- 18:10 - 18:10 **344P - Venetoclax and azacitidine compared with azacitidine monotherapy for acute myeloid leukemia patients: A systematic review and meta-analysis**  
A. Noersamsjah, Y. Lim, A. Chandra, A. Kurniawan, Pelita Harapan University - Faculty of Medicine, Tangerang, ID
- 18:10 - 18:10 **345P - Safety and efficacy of platinum substitution in induction chemotherapy for mantle cell lymphoma**  
O. Pitiyarachchi<sup>1</sup>, H. Range<sup>2</sup>, Z. Househ<sup>2</sup>, E. Hamad<sup>2</sup>, L. Dunlop<sup>2</sup>, N. Viiala<sup>2</sup>, <sup>1</sup>UNSW Sydney, Randwick, AU, <sup>2</sup>Liverpool Hospital - South Western Sydney Local Health District, Liverpool, AU
- 18:10 - 18:10 **346P - An assessment of marrow-infiltrating T cells in early relapsed hematologic cancer patients after allogeneic hematopoietic stem cell transplantation**  
I.-C. Song<sup>1</sup>, T.T.D. Pham<sup>2</sup>, S.Y. Choi<sup>3</sup>, B.Y. Heo<sup>3</sup>, M. Lee<sup>1</sup>, J.S. Koh<sup>1</sup>, D.-Y. Jo<sup>1</sup>, J. Kwon<sup>3</sup>, <sup>1</sup>Chungnam National University Hospital, Daejeon, KR, <sup>2</sup>Chungnam National University, Daejeon, KR, <sup>3</sup>Chungnam National University, Daejeon, KR
- 18:10 - 18:10 **347P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy**  
Z. Rezaei Borojerdi<sup>1</sup>, S.A. Rezaee<sup>2</sup>, <sup>1</sup>Shariati Hospital - Tehran University of Medical Sciences (TUMS), Tehran, IR, <sup>2</sup>Mashhad University of Medical Sciences, Mashhad, IR
- 18:10 - 18:10 **348P - In-depth molecular analysis in the diagnosis of lymphomas with lymphoplasmacytic differentiation may provide a more precise diagnosis and rational treatment allocation**  
E. Willenbacher<sup>1</sup>, W. Willenbacher<sup>2</sup>, A. Brunner<sup>1</sup>, <sup>1</sup>Medical University of Innsbruck, Innsbruck, AT, <sup>2</sup>Innsbruck University Hospital, Innsbruck, AT
- 18:10 - 18:10 **349P - Overall survival and progression-free survival comparison of lenalidomide &#x2b; standard therapy versus standard therapy only in indolent lymphoma: A**

**meta-analysis**

K. Winston<sup>1</sup>, R. Jonlean<sup>2</sup>, I. Damara<sup>3</sup>, O. Oktrian<sup>3</sup>, K. Tjoa<sup>3</sup>, <sup>1</sup>Bhakti Medicare Hospital, West Java, ID, <sup>2</sup>Tzu Chi Hospital, North Jakarta, ID, <sup>3</sup>Universitas Indonesia, Central Jakarta, ID

18:10 - 18:10 **350P - Intratumoural CD66b to predict treatment response in diffuse large B cell lymphoma (DLBCL)**

M. Adriani<sup>1</sup>, A. Wirdah<sup>1</sup>, I. Hermiyana<sup>2</sup>, Y. Andayani<sup>3</sup>, N. Djamaludin<sup>3</sup>, M. Syahrir<sup>3</sup>, <sup>1</sup>Sriwijaya University, Palembang, ID, <sup>2</sup>Bakti Timah Hospital, Pangkal Pinang, ID, <sup>3</sup>RSUP Dr. Mohammad Hoesin, Palembang, ID

18:10 - 18:10 **351P - Clinical features and treatment outcomes of Waldenstrom macroglobulinemia patients: A single center study**

D. Amelia<sup>1</sup>, A. Kurniawan<sup>2</sup>, C. Sari<sup>1</sup>, D. Djatnika<sup>1</sup>, M.A. Nasution<sup>1</sup>, W. Rajabto<sup>1</sup>, <sup>1</sup>Universitas Indonesia, Central Jakarta, ID, <sup>2</sup>UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, ID

18:10 - 18:10 **352TiP - Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study)**

T. Suzuki<sup>1</sup>, D. Maruyama<sup>2</sup>, R. Machida<sup>3</sup>, Y. Ito<sup>4</sup>, K. Kataoka<sup>5</sup>, H. Nagai<sup>6</sup>, <sup>1</sup>Nagoya City University Graduate School of Medical Sciences, Nagoya, JP, <sup>2</sup>Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JP, <sup>3</sup>National Cancer Center Hospital, Chuo-ku, JP, <sup>4</sup>National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, JP, <sup>5</sup>Keio University School of Medicine, Fujisawa, JP, <sup>6</sup>National Hospital Organization Nagoya Medical Center, Nagoya, JP

18:10 - 18:10 **362P - Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)**

P. Bossi<sup>1</sup>, G. Minuti<sup>2</sup>, I. Braña<sup>3</sup>, V. Moreno Garcia<sup>4</sup>, V. Boni<sup>5</sup>, P. Jamme<sup>6</sup>, J. Call<sup>7</sup>, C. Yan<sup>8</sup>, B. Barasa<sup>8</sup>, P. Doze<sup>8</sup>, A.K. Joe<sup>8</sup>, G. Laus<sup>8</sup>, A. Daste<sup>9</sup>, <sup>1</sup>IRCCS Humanitas Research Hospital, Milano, IT, <sup>2</sup>IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES, <sup>5</sup>Hospital Universitario Quirónsalud Madrid, Pozuelo de Alarcon, ES, <sup>6</sup>CHU Lille - Centre Hospitalier Régional Universitaire de Lille, Lille, FR, <sup>7</sup>South Texas Accelerated Research Therapeutics (START), San Antonio, US, <sup>8</sup>Merus N.V., Utrecht, NL, <sup>9</sup>CHU Bordeaux - Hopital St. André, Bordeaux, FR

18:10 - 18:10 **363P - Effect of financial distress and mental well-being of patients with early vs advanced oral cancer on informal caregiver's quality of life: A prospective real-world data from public health sector hospital**

A. Thaduri, K. Majumdar, A. Panuganti, S. Usmani, D. Dungala, V. Kailey, M. Malhotra, AIIMS - All India Institute of Medical Science - Rishikesh, Rishikesh, IN

18:10 - 18:10 **364P - Artificial intelligence provides more accurately neck lymph nodes auto-segmentation in radiotherapy**

C. Chen, Taichung Veterans General Hospital, Taichung City, TW

- 18:10 - 18:10 **366P - Pre-treatment oral fungal microbiome and nasopharyngeal carcinoma prognosis: A population-based cohort study in southern China**  
Y. Chen<sup>1</sup>, Y. Du<sup>1</sup>, W. Li<sup>2</sup>, R. Feng<sup>2</sup>, W. Ye<sup>1</sup>, <sup>1</sup>Karolinska Institutet, Stockholm, SE, <sup>2</sup>Fujian Medical University, Fuzhou, CN
- 18:10 - 18:10 **367P - Prevalence and association of sarcopenia with mortality in patients with head and neck cancer: A meta-analysis**  
 J.H. Koh<sup>1</sup>, C. Lim<sup>2</sup>, L. Tan<sup>2</sup>, A. Makmur<sup>3</sup>, E. Gao<sup>4</sup>, J.S.Y. Ho<sup>5</sup>, A.J. Tan<sup>5</sup>, A. See<sup>4</sup>, B.K.J. Tan<sup>1</sup>, L.F. Tan<sup>5</sup>, B.Y.Q. Tan<sup>3</sup>, <sup>1</sup>NUS-National University of Singapore-Yong Loo Lin School of Medicine (YLLSoM), Singapore, SG, <sup>2</sup>University of Auckland, Auckland, NZ, <sup>3</sup>NUH - National University Hospital (S) Pte. Ltd., Singapore, SG, <sup>4</sup>SGH - Singapore General Hospital, Singapore, SG, <sup>5</sup>Alexandra Hospital, Singapore, SG
- 18:10 - 18:10 **368P - Distinct gene expression profiling explored using nanostring tumor signalling 360 panel with validations in different clinical stages of oral submucous fibrosis patients: A first Indian study**  
Y. Madhavan<sup>1</sup>, A. Lochan G<sup>2</sup>, V. Shyamsundar<sup>2</sup>, M. Kuppuloganathan<sup>2</sup>, A. Krishnamurthy<sup>2</sup>, V. Ramshankar<sup>2</sup>, D. Catakapatri Venugopal<sup>1</sup>, <sup>1</sup>Sri Ramachandra Institute of Higher Education and Research (DU), Chennai, IN, <sup>2</sup>Cancer Institute (WIA), Chennai, IN
- 18:10 - 18:10 **370P - Low-dose nivolumab with induction chemotherapy for inoperable HNSCC in 111 patients: Response rates, survival, and implications for LMICs**  
J.T. Georgy<sup>1</sup>, Z. Thomas<sup>1</sup>, R.V. Georgy<sup>2</sup>, S. Regi<sup>2</sup>, A. Joel<sup>1</sup>, D.B. Thumaty<sup>1</sup>, A. John<sup>1</sup>, S. Devabhaktuni<sup>1</sup>, J.P. Wisely<sup>1</sup>, P.K. Marimuthu<sup>1</sup>, P. Jambunathan<sup>1</sup>, H. Kovilapu<sup>1</sup>, J.P. Rao<sup>1</sup>, A. Tirkey<sup>2</sup>, B.K. Sasidharan<sup>1</sup>, R. Isiah<sup>1</sup>, M. Thomas<sup>2</sup>, R.T. Chacko<sup>1</sup>, A. Singh<sup>1</sup>, <sup>1</sup>CMC - Christian Medical College Hospital, Vellore, IN, <sup>2</sup>CMC - Christian Medical College Hospital Vellore, Vellore, IN
- 18:10 - 18:10 **371P - The role of FDG-PET/CT in the assessment of response to radiation therapy in head and neck cancers: A systematic review and meta-analysis**  
F. Wijovi<sup>1</sup>, P. Angel<sup>1</sup>, M. Claudia<sup>1</sup>, N. Reina<sup>1</sup>, A. Kurniawan<sup>2</sup>, D.H. Kirana<sup>3</sup>, <sup>1</sup>Siloam Hospital/Medical faculty of Pelita Harapan University, Tangerang, ID, <sup>2</sup>UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, ID, <sup>3</sup>MRCCC - Mochtar Riady Comprehensive Cancer Center - Siloam Hospitals Semanggi, South Jakarta, ID
- 18:10 - 18:10 **372P - Effectiveness of HAN-MI-RADS (head and neck molecular imaging-reporting and data system) criterion in head and neck squamous cell carcinoma post concurrent chemoradiotherapy**  
M. Gupta<sup>1</sup>, A. Jajodia<sup>2</sup>, P. Alhawat<sup>1</sup>, M. Gairola<sup>1</sup>, M. Agarwal<sup>1</sup>, P.S. Choudhury<sup>1</sup>, <sup>1</sup>Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, <sup>2</sup>Hamilton Health Sciences, McMaster University, Hamilton, CA
- 18:10 - 18:10 **373P - Investigating the impact of treatment on geriatric patients with locally advanced head and neck squamous cell carcinoma**  
Y.T. Liu<sup>1</sup>, S.-Y. Chen<sup>2</sup>, H.-K.T. Liang<sup>1</sup>, J.P. Chen<sup>2</sup>, <sup>1</sup>National Taiwan University, Taipei City,

TW, <sup>2</sup>National Taiwan University Hospital Yunlin Branch, Yunlin, TW

- 18:10 - 18:10 **374P - Immunohistochemical evaluation of oral lichen planus: A prospective clinical study**  
S. Sampooram Pape<sup>1</sup>, D.L. Francis<sup>2</sup>, <sup>1</sup>Army Hospital Research And Referral, New Delhi, IN, <sup>2</sup>Saveetha Institute of Medical and Technical Sciences, Poonamallee, IN
- 18:10 - 18:10 **375P - Survival and prognostic factors of head and neck squamous cell carcinoma patients treated with either definitive CCRT or post operative CCRT with platinum-based chemotherapy in Rajavithi hospital, Thailand**  
W. Samadee<sup>1</sup>, K. Maneenil<sup>2</sup>, S. Payapwattanawong<sup>2</sup>, P. Tienchaiananda<sup>2</sup>, S. Sangausai<sup>2</sup>, <sup>1</sup>Rajvithi, Bangkok, TH, <sup>2</sup>Rajavithi Hospital, Bangkok, TH
- 18:10 - 18:10 **376P - Nutrition as an independent prognostic factor in locally advanced nasopharyngeal carcinoma: A retrospective cohort study and propensity score-matched analysis**  
H. Yi, Yulin First People's Hospital/The Sixth Affiliated Hospital of Guangxi Medical University, Yulin, CN
- 18:10 - 18:10 **377P - Oropharyngeal squamous cell carcinomas in Indian population: P16 positivity and treatment outcomes following chemoradiotherapy**  
P. Verma, A. R, P. Ku, R. M. P, N. Haridas, W. Jose, K. Thankappan, S. Iyer, K. Pavithran, D. Dutta, AIMS - Amrita Institute of Medical Sciences/Amrita Hospital, Kochi/Cochin, IN
- 18:10 - 18:10 **378P - A real-world retrospective analysis of the efficacy of pembrolizumab combined with chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (LA HNSCC)**  
Z. Liu, D. Li, J. Li, H.L. Dong, W. Zhang, J. Wang, D.N. Huang, H.M. Wei, Y. Xu, T. Lu, C. Cui, H.W. Liu, Y.G. Li, C.J. Xu, Liaoning Cancer Hospital & Institute, Shenyang, CN
- 18:10 - 18:10 **379P - Nimotuzumab in combination with chemoradiation for patients with intermediate stage and locally advanced nasopharyngeal carcinoma: A retrospective comparative analysis using 5-year real-world survival data**  
A. Rachman<sup>1</sup>, S.R. Sari<sup>2</sup>, M. Adham<sup>2</sup>, A. Munandar<sup>2</sup>, <sup>1</sup>RSUPN Dr. Cipto Mangunkusumo, Central Jakarta, ID, <sup>2</sup>University of Indonesia, Depok, ID
- 18:10 - 18:10 **380P - An epidemiological analysis on the prevalence of oral cancer and its awareness among Irula tribes of South India**  
D.L. Francis, Saveetha Institute of Medical and Technical Sciences, Chennai, IN
- 18:10 - 18:10 **381P - P16INK4 over-expression, early stages, keratinization, and surgical margin-free status are associated with better prognosis of oral squamous cell carcinoma (OSCC)**  
S.L. Anwar, G.D. Pradana, H.Y. Boediman, R. Cahyono, W. Sugandhi, E. Dwianingsih, Gadjah Mada University/Dr. Sardjito General Hospital, Yogyakarta, ID
- 18:10 - 18:10 **382P - Oral health disparities in privileged and underprivileged tribes of south India: A study of the prevalence of precancerous oral lesions**

S. Palliyal, DM Wayanad Institute of Medical Sciences, Kalpetta, IN

- 18:10 - 18:10 **383P - Pre-treatment body mass index and neutrophil lymphocyte ratio predict 3-years progression free survival in locally advanced stage nasopharyngeal carcinoma**  
N.P. Pusvita Dewi<sup>1</sup>, A. Rachman<sup>2</sup>, C. Irawan<sup>2</sup>, <sup>1</sup>Universitas Indonesia, Central Jakarta, ID, <sup>2</sup>RSUPN Dr. Cipto Mangunkusumo, Central Jakarta, ID
- 18:10 - 18:10 **384P - Sequential multi-modality strategies for locally advanced betel-nuts related hypopharyngeal cancer in Taiwan**  
W.-C. Lu<sup>1</sup>, R.-L. Hong<sup>2</sup>, <sup>1</sup>National Taiwan University Hospital - Yunlin Branch, Douliu City, TW, <sup>2</sup>NTUH - National Taiwan University Hospital, Taipei City, TW
- 18:10 - 18:10 **385P - The prognostic factors of induction chemotherapy followed by concurrent chemoradiotherapy in patients with HPV associated with oropharyngeal cancer**  
H.J. Bang<sup>1</sup>, S. Lee<sup>1</sup>, M.-G. Noh<sup>1</sup>, H.-J. Kim<sup>2</sup>, S.-H. Cho<sup>2</sup>, <sup>1</sup>Chonnam National University Hwasun Hospital, Hwasun, KR, <sup>2</sup>Chonnam National University Medical School & Chonnam National University Hwasun Hospital, Hwasun, KR
- 18:10 - 18:10 **386P - FOLR1 stabilized beta-catenin promotes laryngeal carcinoma progression through EGFR signal**  
H. Tuo<sup>1</sup>, Z. Yu<sup>1</sup>, H. Zhao<sup>2</sup>, <sup>1</sup>Taihe Hospital, Shiyan, CN, <sup>2</sup>Hubei University of Medicine, Shiyan, CN
- 18:10 - 18:10 **387P - A comprehensive analysis of the oral health status, tobacco use, and cancer prevalence among the tribal communities in India**  
D.L. Francis<sup>1</sup>, S. Sampooram Pape<sup>2</sup>, S.S. Chopra<sup>2</sup>, <sup>1</sup>Saveetha Institute of Medical and Technical Sciences, Poonamallee, IN, <sup>2</sup>Army Hospital Research And Referral, New Delhi, IN
- 18:10 - 18:10 **388P - Clinicopathological correlation of P53 expression in oral cancers**  
V.M. Bellala, GITAM Institute of Medical Sciences and Research, Visakhapatnam, IN
- 18:10 - 18:10 **389P - Lack of cross-resistance to erlotinib in human head and neck cancer cells with acquired resistance to cetuximab**  
J.A. Bonner<sup>1</sup>, C. Xing<sup>2</sup>, H. Trummell<sup>2</sup>, <sup>1</sup>University of Alabama at Birmingham Hospital, Birmingham, US, <sup>2</sup>The University of Alabama at Birmingham, Birmingham, US
- 18:10 - 18:10 **390P - Epidemiological aspects of the development of oral cancer in the Republic of Uzbekistan**  
A. Yusupbekov, Tashkent medical academy, Tashkent, UZ
- 18:10 - 18:10 **391P - Lip cancer: Racial disparities, treatment modalities and long-term survival outcome in young and adults versus older age patients**  
F. Ibrahim<sup>1</sup>, A. Ellaithy<sup>2</sup>, <sup>1</sup>Alraqi hospital, Khartoum, SD, <sup>2</sup>Suez Canal University Hospital, Ismailia, EG



- 18:10 - 18:10 **392TiP - A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy**  
J. Wen, J. Li, W. Zheng, J. Zhao, H. Sun, L. Chen, H. Fang, J. Zhao, J. Yang, J. Li, Y. Liu, The Sixth Medical Center of Chinese PLA General Hospital, Beijing, CN
- 18:10 - 18:10 **Palliative care**
- 18:10 - 18:10 **397P - Comparison between Y-site co-infusion versus standard dexamethasone for preventing hypersensitivity reactions from oxaliplatin administration: A randomized controlled trial**  
J. Phavirunsiri, N. Prasongsook, T. Thambamroong, S. Saichaemchan, Phramongkutklao Hospital, Bangkok, TH
- 18:10 - 18:10 **398P - Evaluation of the effectiveness of denosumab therapy giant cell tumor of the pelvis**  
A. Nurjabov<sup>1</sup>, D. Polatova<sup>2</sup>, D. Rasulbek Rakhimberdiyevich<sup>3</sup>, N. Asamedinov<sup>1</sup>, O. Abdusattorov<sup>1</sup>, <sup>1</sup>Tashkent State Dental Institute, Tashkent, UZ, <sup>2</sup>Republican Specialized Scientific Practical Medical Center of Oncology and Radiology, Tashkent, UZ, <sup>3</sup>Republican Specialized Scientific-Practical Medical Center of Oncology and Radiology, Urgench, UZ
- 18:10 - 18:10 **399P - Long-term outcomes of patients with gastric cancer who received the best supportive care without any anticancer treatment**  
Y. Arihara<sup>1</sup>, R. Shibuya<sup>1</sup>, M. Ono<sup>2</sup>, N. Suzuki<sup>1</sup>, G. Ohmori<sup>1</sup>, Y. Ikeda<sup>2</sup>, M. Yamada<sup>2</sup>, T. Abe<sup>2</sup>, K. Takada<sup>1</sup>, M. Maeda<sup>2</sup>, <sup>1</sup>Sapporo Medical University School of Medicine, Sapporo, JP, <sup>2</sup>Steel Memorial Muroran Hospital, Hokkaido, JP
- 18:10 - 18:10 **401TiP - Oral opioid vs intravenous patient-controlled analgesia (PCA) with hydromorphone bolus-only or continuous infusion to maintain analgesia for severe cancer pain: A randomized phase III trial**  
R. Lin<sup>1</sup>, L. He<sup>2</sup>, M. Lu<sup>3</sup>, Y. Wang<sup>4</sup>, J. Liu<sup>5</sup>, Q. Li<sup>6</sup>, X. Lu<sup>7</sup>, L. Zhuang<sup>8</sup>, Z. Zhang<sup>9</sup>, L. Gong<sup>10</sup>, Y. Luo<sup>11</sup>, L. Cao<sup>12</sup>, J. Zhong<sup>13</sup>, H. Zou<sup>14</sup>, T. Ren<sup>15</sup>, C. Shang<sup>16</sup>, S. Lin<sup>17</sup>, S. Zhao<sup>1</sup>, L. Su<sup>1</sup>, C. Huang<sup>7</sup>, <sup>1</sup>Fujian Cancer Hospital, Fuzhou, CN, <sup>2</sup>Chengdu Fifth People's Hospital ( The Second Clinical Medical College, Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Medicine ) , Chengdu, CN, <sup>3</sup>Chengdu Fifth People's Hospital ( The Second Clinical Medical College, Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Medicine ) , Chengdu, CN, <sup>4</sup>Guizhou Cancer Hospital/ The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, CN, <sup>5</sup>Xingtai People's Hospital, Xingtai, CN, <sup>6</sup>Zhumadian Central Hospital, Zhumadian, CN, <sup>7</sup>Xiamen Humanity Hospital, Xiamen, CN, <sup>8</sup>Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, CN, <sup>9</sup>Hainan Cancer Hospital, Haikou, CN, <sup>10</sup>Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, CN, <sup>11</sup>Qinghai University Affiliated Hospital, Xining, CN, <sup>12</sup>Chengdu Qingbaijiang District People's Hospital, Chengdu, CN, <sup>13</sup>The First Affiliated Hospital of Guangxi Medical University, Nanning, CN, <sup>14</sup>Cancer Hospital Affiliated to Harbin Medical University, Harbin, CN, <sup>15</sup>The First Affiliated Hospital of Chengdu Medical College, Chengdu, CN, <sup>16</sup>The Fifth

People's Hospital of Qinghai Province/ Qinghai Province Cancer Hospital, Xining, CN,  
 17Public Health School of Fujian Medical University, Fuzhou, CN

- 18:10 - 18:10 **407P - K-Track™: A streamlined personalized assay to detect molecular residual disease in solid tumors**  
 N. Vo<sup>1</sup>, V.-A. Nguyen<sup>2</sup>, A.-T. Nguyen<sup>2</sup>, H.-G. Vu<sup>2</sup>, L. Tu<sup>2</sup>, <sup>1</sup>University of Medicine and Pharmacy, Ho Chi Minh City, VN, <sup>2</sup>Medical Genetics Institute, Ho Chi Minh City, VN
- 18:10 - 18:10 **408P - Increased EGFR and MET expression and corresponding tumor microenvironment (TME) change in hepatocellular carcinoma (HCC) tissues after sorafenib (Sora) treatment**  
 C.J. Yen<sup>1</sup>, M. Qing<sup>2</sup>, X. Lyu<sup>2</sup>, M. Gormley<sup>3</sup>, J. Curtin<sup>3</sup>, M. Xia<sup>2</sup>, F. Yang<sup>2</sup>, L. Zhou<sup>2</sup>, <sup>1</sup>NCKUH - National Cheng Kung University Hospital, Tainan City, TW, <sup>2</sup>Janssen Research & Development, Shanghai, CN, <sup>3</sup>Janssen Research & Development, Spring House, US
- 18:10 - 18:10 **410P - Systematic evaluation of cell-free DNA fragmentation patterns for cancer diagnosis and enhanced cancer detection through integration of multiple fragmentations**  
 X.-Y. Meng<sup>1</sup>, Y.-Y. Hou<sup>2</sup>, X.-H. Zhou<sup>2</sup>, <sup>1</sup>Hubei Minzu University, Enshi, CN, <sup>2</sup>Huazhong Agricultural University, Wuhan, CN
- 18:10 - 18:10 **412P - Multiplex digital spatial profiling (DSP) of protein reveals distinct immune and molecular phenotypes in hepatocellular carcinoma**  
 C.J. Yen<sup>1</sup>, M. Qing<sup>2</sup>, Q. Wu<sup>2</sup>, X. Lyu<sup>2</sup>, M. Xia<sup>2</sup>, F. Yang<sup>2</sup>, H. Xu<sup>2</sup>, L. Zhou<sup>2</sup>, <sup>1</sup>NCKUH - National Cheng Kung University Hospital, Tainan City, TW, <sup>2</sup>Janssen Research & Development, Shanghai, CN
- 18:10 - 18:10 **413P - Clinical utility of advanced features provided by circulating tumor DNA-based comprehensive genomic profiling**  
 Y.-G. Kim<sup>1</sup>, C. Ha<sup>2</sup>, S.H. Lim<sup>1</sup>, J.Y. Hong<sup>1</sup>, S. Kim<sup>2</sup>, J.-M. Sun<sup>1</sup>, J. Lee<sup>1</sup>, J.-W. Kim<sup>2</sup>, <sup>1</sup>Samsung Medical Center, Seoul, KR, <sup>2</sup>Samsung Medical Center (SMC), Seoul, KR
- 18:10 - 18:10 **414P - Landscape of ERBB2 mutations in advanced cancers (AC) using circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and Middle East (AME)**  
 B.C. Cho<sup>1</sup>, S. Dawood<sup>2</sup>, T. Golan<sup>3</sup>, N. Sandhir<sup>4</sup>, S. Hsing<sup>4</sup>, <sup>1</sup>Yonsei University, Seoul, KR, <sup>2</sup>Mediclinic City Hospital, Dubai, AE, <sup>3</sup>Chaim Sheba Medical Center, Ramat Gan, IL, <sup>4</sup>Guardant Health Pte. Ltd., Singapore, SG
- 18:10 - 18:10 **415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay**  
 S. Tucker<sup>1</sup>, M. Pek<sup>2</sup>, C. Hao<sup>2</sup>, Z.Y. Wan<sup>2</sup>, K.C. Ngeow<sup>2</sup>, J. Poh<sup>2</sup>, M. Lim<sup>3</sup>, D. Poon<sup>4</sup>, M.-H. Tan<sup>2</sup>, <sup>1</sup>Tucker Medical Singapore Pte. Ltd., Singapore, SG, <sup>2</sup>Lucence Diagnostics Singapore Headquarters-Service Laboratory, Singapore, SG, <sup>3</sup>Royal Healthcare, Singapore, SG, <sup>4</sup>Dr D.Y.H Poon & Associates Medical Oncology Clinic, Singapore, SG
- 18:10 - 18:10 **416P - Three-dimensional bioprinting model of ovarian cancer for identification**

**of patient-specific therapy response**

J. Zhang, Y. Shan, H. Yang, M. Pang, R. Yan, H. Sun, H. Yang, L. Pan, Y. Mao, J. Ying, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, Beijing, CN

- 18:10 - 18:10 **417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East**
- S. Dawood<sup>1</sup>, S. Jain<sup>2</sup>, V. Lavingia<sup>3</sup>, D. Aderka<sup>4</sup>, E. Tahover<sup>5</sup>, M. Temper<sup>6</sup>, A. Goldman<sup>7</sup>, M. Al Akasheh<sup>8</sup>, S. Olsen<sup>2</sup>, S. Hsing<sup>2</sup>, N. Joshi<sup>9</sup>, <sup>1</sup>Mediclinic City Hospital, Dubai, AE, <sup>2</sup>Guardant Health Pte. Ltd., Singapore, SG, <sup>3</sup>HCG, Cancer Hospital Ahmedabad, Ahmedabad, IN, <sup>4</sup>Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL, <sup>5</sup>Assuta Hospital in Ramat HaHayal, Tel Aviv, IL, <sup>6</sup>Hadassah Ein Kerem, Jerusalem, IL, <sup>7</sup>Meir Medical Center, Kfar Saba, IL, <sup>8</sup>Maggi Medical Center, Amman, JO, <sup>9</sup>Guardant health, Singapore, IN
- 18:10 - 18:10 **418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis**
- D. Shek<sup>1</sup>, J. Lai<sup>2</sup>, B. Gloss<sup>2</sup>, H. Mahajan<sup>3</sup>, A. Nagrial<sup>3</sup>, T. Moujaber<sup>3</sup>, M. Carlino<sup>3</sup>, B. Gao<sup>4</sup>, S. Read<sup>1</sup>, G. Ahlenstiel<sup>1</sup>, <sup>1</sup>Western Sydney University, Blacktown, AU, <sup>2</sup>The Westmead Institute for Medical Research, Westmead, AU, <sup>3</sup>Westmead Hospital, Westmead, AU, <sup>4</sup>Blacktown Hospital, Blacktown, AU
- 18:10 - 18:10 **420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment**
- X. Zhang, Y. Chen, W. Zhou, L. Gao, Z. Xie, J. Chen, Y. Huang, W. Yan, X. Yang, B.-C. Wang, D. Lu, Z. Lv, W. Guo, S. Zhang, Y.-L. Wu, J.-J. Yang, Guangdong Provincial People's Hospital/Guangdong Academy of Medical Sciences, Guangzhou, CN
- 18:10 - 18:10 **421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum**
- R. Kodandapani<sup>1</sup>, S. Lingaraju<sup>1</sup>, K. Raghavendracher<sup>1</sup>, G. Balaram<sup>1</sup>, V. Erappareddy<sup>1</sup>, V. Keriyappa<sup>1</sup>, S. Ghorpade<sup>1</sup>, S. Patil<sup>2</sup>, S. Chiradoni Thungappa<sup>2</sup>, S. Papaiah Sheela<sup>1</sup>, S. Belagutti Jayappa<sup>2</sup>, S. Bhattacharjee<sup>1</sup>, R. Dasgupta<sup>2</sup>, M. Naseer R<sup>2</sup>, D. Hattangdi<sup>1</sup>, A. Ravichandran<sup>3</sup>, U. Bahadur<sup>3</sup>, B.S. Ajaikumar<sup>1</sup>, M. Ghosh<sup>1</sup>, <sup>1</sup>HCG HealthCare Global Enterprises Ltd, Bangalore, IN, <sup>2</sup>HCG Cancer Centre, Bangalore, IN, <sup>3</sup>Strand Life Sciences Pvt Ltd, Bangalore, IN
- 18:10 - 18:10 **422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy**
- L. Mao<sup>1</sup>, Y. Yu<sup>1</sup>, C. Jian<sup>2</sup>, W. Ouyang<sup>1</sup>, Z. Wang<sup>3</sup>, R. Lin<sup>4</sup>, Y. Tan<sup>1</sup>, W. Ren<sup>1</sup>, Z. He<sup>1</sup>, Z. Zhang<sup>1</sup>, T. Li<sup>1</sup>, H. Yao<sup>1</sup>, <sup>1</sup>Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN, <sup>2</sup>Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet, Stockholm, SE, <sup>3</sup>Beijing Normal University-Hong Kong Baptist University United International College, zhuhai, HK, <sup>4</sup>Guangzhou Huali College, China, Guangzhou, CN

- 18:10 - 18:10 **423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)**  
M. Ghosh<sup>1</sup>, G. Balaram<sup>1</sup>, S. Lingaraju<sup>1</sup>, K. Raghavendracher<sup>1</sup>, R. Kodandapani<sup>1</sup>, V. Erappareddy<sup>1</sup>, V. Keriyappa<sup>1</sup>, S. Ghorpade<sup>1</sup>, S. Patil<sup>2</sup>, S. Chiradoni Thungappa<sup>2</sup>, S. Bhattacharjee<sup>2</sup>, S. Papaiah Susheela<sup>2</sup>, M. Naseer R<sup>2</sup>, R. Dasgupta<sup>2</sup>, S. Belagutti Jayappa<sup>2</sup>, V. Ramaswamy<sup>1</sup>, D. Hattangdi<sup>1</sup>, A. Ravichandran<sup>3</sup>, U. Bahadur<sup>3</sup>, B.S. Ajaikumar<sup>2</sup>, <sup>1</sup>HCG HealthCare Global Enterprises Ltd, Bangalore, IN, <sup>2</sup>HCG Cancer Centre, Bangalore, IN, <sup>3</sup>Strand Life Sciences Pvt Ltd, Bangalore, IN
- 18:10 - 18:10 **424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)**  
B. Ma<sup>1</sup>, A. Johnson<sup>2</sup>, K.R. Mills Shaw<sup>2</sup>, H.H.F. Loong<sup>1</sup>, F. Mo<sup>1</sup>, R. Lui<sup>3</sup>, K.H. Wong<sup>4</sup>, Z. Zeng<sup>2</sup>, V. Holla<sup>2</sup>, M. Kahle<sup>2</sup>, T. Vu<sup>2</sup>, F. Su<sup>2</sup>, S.-H. Kim<sup>2</sup>, T. Conway<sup>2</sup>, Q. Wang<sup>2</sup>, W. Tao<sup>2</sup>, L. Zhou<sup>2</sup>, J. Rodon<sup>2</sup>, F. Meric-Bernstam<sup>5</sup>, T.A. Yap<sup>2</sup>, <sup>1</sup>CUHK - Chinese University of Hong Kong, Sha Tin, HK, <sup>2</sup>The M.D. Anderson Cancer Center, Houston, US, <sup>3</sup>The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK, <sup>4</sup>Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK, <sup>5</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US
- 18:10 - 18:10 **425P - Engineered Lactococcus lactis as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens**  
M. Zhu, B. Liu, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, CN
- 18:10 - 18:10 **426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions**  
R. Kakuta<sup>1</sup>, S. Ikeda<sup>2</sup>, R. Kudo<sup>3</sup>, Y. Kinugasa<sup>1</sup>, <sup>1</sup>TMDU - Tokyo Medical and Dental University, Bunkyo-ku, JP, <sup>2</sup>Tokyo Medical and Dental University, Tokyo, JP, <sup>3</sup>Kyoto Katsura Hospital, Kyoto city, JP
- 18:10 - 18:10 **427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)**  
N. Rohatgi<sup>1</sup>, A. Agarwal<sup>2</sup>, A. Bahl<sup>3</sup>, C.-M. Tsai<sup>4</sup>, N. Sandhir<sup>5</sup>, S. Olsen<sup>5</sup>, <sup>1</sup>Fortis Flt. Lt. Rajan Dhall Hospital, Vasant Kunj, New Delhi, IN, <sup>2</sup>Fortis Hospital, Bangalore, IN, <sup>3</sup>Max Super Speciality Hospital, Saket, New Delhi, IN, <sup>4</sup>Taipei Veterans General Hospital, Taipei City, TW, <sup>5</sup>Guardant Health Pte. Ltd., Singapore, SG
- 18:10 - 18:10 **428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries**  
F.A. Agatha<sup>1</sup>, F. Ng<sup>2</sup>, F. Aldila<sup>2</sup>, J. Audrienna<sup>2</sup>, L. Lim<sup>2</sup>, S. Tang<sup>2</sup>, S.G. Tanu<sup>2</sup>, E. Fernandez<sup>2</sup>, M. Wijaya<sup>1</sup>, S. Sormin<sup>1</sup>, L. Sani<sup>2</sup>, A. Irwanto<sup>2</sup>, S. Haryono<sup>3</sup>, A. Chan<sup>4</sup>, J. Li<sup>5</sup>, M. Hartman<sup>6</sup>, <sup>1</sup>SJH Initiatives, Jakarta, ID, <sup>2</sup>NalaGenetics, Singapore, SG, <sup>3</sup>Mochtar Riady Comprehensive Cancer Center, Siloam Hospitals Semanggi, South Jakarta, ID, <sup>4</sup>UCI - University of California, Irvine - School of Medicine, Irvine, US, <sup>5</sup>A\*STAR - Genome Institute of Singapore (GIS), Singapore, SG, <sup>6</sup>NUH - National University Hospital (S) Pte. Ltd., Singapore, SG

- 18:10 - 18:10 **429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines**  
O. Maaño, C. Dy, St. Luke's Medical Center, Quezon City, PH
- 18:10 - 18:10 **Supportive care**
- 18:10 - 18:10 **436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis**  
A. Srinivasan<sup>1</sup>, M. Ramasubbu<sup>1</sup>, R. Maiti<sup>1</sup>, D. Hota<sup>1</sup>, S.K. Das Majumdar<sup>2</sup>, <sup>1</sup>AIIMS - All India Institute of Medical Sciences - Bhubaneswar, Bhubaneswar, IN, <sup>2</sup>AIIMS-All India Institute of Medical Sciences - Bhubaneswar, Bhubaneswar, IN
- 18:10 - 18:10 **437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine**  
L. Wanichtanom<sup>1</sup>, M. Boonsiri<sup>2</sup>, G. Vrakornvoravuti<sup>1</sup>, A. Sutepvarnon<sup>2</sup>, <sup>1</sup>Faculty of Medicine vajira Hospital. Navamindradhiraj University, Bangkok, TH, <sup>2</sup>Vajira Hospital - Faculty of Medicine - Navamindradhiraj University, Bangkok, TH
- 18:10 - 18:10 **438P - A novel treatment for immune checkpoint inhibitor-related myocarditis**  
T. Niimura<sup>1</sup>, K. Uchida<sup>2</sup>, H. Unten<sup>1</sup>, M. Uno<sup>2</sup>, M. Kanamori<sup>2</sup>, H. Hamano<sup>3</sup>, M. Goda<sup>2</sup>, K. Yagi<sup>1</sup>, F. Aizawa<sup>1</sup>, Y. Izawa-Ishizawa<sup>4</sup>, Y. Zamami<sup>3</sup>, K. Ishizawa<sup>2</sup>, <sup>1</sup>Tokushima University Hospital, Tokushima, JP, <sup>2</sup>Tokushima University Graduate School, Tokushima, JP, <sup>3</sup>Okayama University Hospital, Okayama, JP, <sup>4</sup>Tokushima University Graduate School of Biomedical Sciences, Tokushima, JP
- 18:10 - 18:10 **439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention**  
C. Wongkraisri<sup>1</sup>, K. Chusuwanrak<sup>2</sup>, A. Laocharoenkeat<sup>2</sup>, L. Chularojmontri<sup>2</sup>, A. Nimmannit<sup>2</sup>, S. Ithimakin<sup>1</sup>, <sup>1</sup>Siriraj Hospital, Bangkok, TH, <sup>2</sup>Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, TH
- 18:10 - 18:10 **440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic**  
T. Pornwisetsirikul<sup>1</sup>, J. Khanthawong<sup>1</sup>, J. Yoodee<sup>2</sup>, <sup>1</sup>Maharaj Nakorn Chiang Mai Hospital, Chiang Mai university, Mueang Chiang Mai District, TH, <sup>2</sup>Chiang Mai University - Faculty of Pharmacy, Chiang Mai, TH
- 18:10 - 18:10 **441P - The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study**  
Y.-K. Shi<sup>1</sup>, Q. Zhang<sup>2</sup>, X. Wang<sup>3</sup>, Z. Pei<sup>4</sup>, J. Wang<sup>5</sup>, T. Yi<sup>6</sup>, Z. Ouyang<sup>7</sup>, J. Mei<sup>8</sup>, H. Shi<sup>9</sup>, T. Sun<sup>10</sup>, Y. Zhang<sup>11</sup>, J. Bai<sup>12</sup>, T. Ma<sup>13</sup>, S. Cang<sup>14</sup>, Y. Guo<sup>3</sup>, Y. Li<sup>15</sup>, G. Fu<sup>16</sup>, Y. Dong<sup>17</sup>, S.

Zhou<sup>1</sup>, L. Sun<sup>18</sup>, <sup>1</sup>National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, <sup>2</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>3</sup>Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, CN, <sup>4</sup>Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, CN, <sup>5</sup>Anyang Tumor Hospital, Anyang, CN, <sup>6</sup>Xiangyang Central Hospital, Hubei University of Art and Science, Xiangyang, CN, <sup>7</sup>The First Affiliated Hospital of Xiamen University, Xiamen, CN, <sup>8</sup>Zhengzhou People's Hospital, Zhengzhou, CN, <sup>9</sup>the First Affiliated Hospital of Gannan Medical university, Ganzhou, CN, <sup>10</sup>Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital, Shenyang, CN, <sup>11</sup>Shaanxi Provincial Cancer Hospital Affiliated to Medical College, Xi'an Jiao Tong University, xi'an, CN, <sup>12</sup>Heping Hospital Affiliated to Changzhi Medical College, Changzhi, CN, <sup>13</sup>Luohe Central Hospital, Luohe, CN, <sup>14</sup>Henan Provincial People's Hospital, Zhengzhou, CN, <sup>15</sup>The Second Hospital of Jilin University, Changchun, CN, <sup>16</sup>Sanya Central Hospital ( Hainan Third People's Hospital ) Affiliated to Hainan Medical college, sanya, CN, <sup>17</sup>Xiangyang No. 1 People's Hospital, Hubei University of Medicine, xiangyang, CN, <sup>18</sup>Xiamen Amoytop Biotech Co., LTD, xiamen, CN

- 18:10 - 18:10 **442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy**  
Y. Nisha<sup>1</sup>, B. Dubashi<sup>2</sup>, Z. Bobby<sup>2</sup>, J.P. Sahoo<sup>2</sup>, S. Kayal<sup>2</sup>, R. Ananthakrishnan<sup>2</sup>, V.B. Reddy<sup>3</sup>, C. L<sup>2</sup>, P. Ganesan<sup>2</sup>, <sup>1</sup>Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IN, <sup>2</sup>JIPMER - Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, IN, <sup>3</sup>Vijay Diabetes, Thyroid & Endocrine Clinic, Puducherry, IN
- 18:10 - 18:10 **443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis**  
V. Irawan<sup>1</sup>, H. Haroen<sup>1</sup>, K. Pandelaki<sup>1</sup>, L. Rotty<sup>1</sup>, P. Lasut<sup>1</sup>, C. Hendratta<sup>1</sup>, W. Wariki<sup>2</sup>, <sup>1</sup>Sam Ratulangi University / Prof. dr. R. D. Kandou General Hospital, Manado, ID, <sup>2</sup>Sam Ratulangi University, Manado, ID
- 18:10 - 18:10 **444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre**  
S. Bartlett, Ballarat Regional Integrated Cancer Centre (BRICC) - BHS, Ballarat, AU
- 18:10 - 18:10 **445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey**  
V. Tam<sup>1</sup>, J. Ching<sup>1</sup>, S. Yip<sup>1</sup>, V. Kwong<sup>2</sup>, C. Chan<sup>3</sup>, K. Wong<sup>2</sup>, S. Lee<sup>1</sup>, <sup>1</sup>The Hong Kong Polytechnic University, Hong Kong, HK, <sup>2</sup>Prince of Wales Hospital, Hong Kong, HK, <sup>3</sup>Chinese University of Hong Kong, Hong Kong, HK
- 18:10 - 18:10 **446P - A single center experience of anamorelin in patients with non-small cell lung cancer**  
T. Ito<sup>1</sup>, K. Fujita<sup>2</sup>, T. Imakita<sup>3</sup>, O. Kanai<sup>1</sup>, <sup>1</sup>Kyoto Medical Center, Kyoto, JP, <sup>2</sup>National Hospital Organization Kyoto Medical Center, Kyoto, JP, <sup>3</sup>Hyogo Prefectural Amagasaki Hospital, Amagasaki, JP

- 18:10 - 18:10 **447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy**  
N. Menon<sup>1</sup>, V. Noronha<sup>1</sup>, O. Row Chowdhury<sup>1</sup>, A. Pawar<sup>1</sup>, V. Patil<sup>2</sup>, A. Singh<sup>3</sup>, S. More<sup>1</sup>, S. Goud<sup>1</sup>, A. Yadav<sup>1</sup>, M. Shah<sup>4</sup>, K. Jobanputra<sup>1</sup>, D. Shah<sup>1</sup>, K. Prabhash<sup>1</sup>, <sup>1</sup>Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN, <sup>2</sup>Tata Memorial Hospital Centre, Mumbai, IN, <sup>3</sup>Tata Memorial Hospital - Parel, Mumbai, IN, <sup>4</sup>Tata Memorial Centre, Mumbai, IN
- 18:10 - 18:10 **448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy**  
S. Hutajulu<sup>1</sup>, Y. Astari<sup>2</sup>, M. Ucche<sup>3</sup>, D. Paramita<sup>4</sup>, R.H. Asdie<sup>3</sup>, R.B. Pramono<sup>3</sup>, M. Hardianti<sup>1</sup>, K.W. Taroeno-Hariadi<sup>1</sup>, I. Purwanto<sup>1</sup>, J. Kurnianda<sup>1</sup>, <sup>1</sup>Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, ID, <sup>2</sup>Dr. Sardjito General Hospital, Yogyakarta, ID, <sup>3</sup>Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada/Dr. Sardjito General Hospital, Yogyakarta, ID, <sup>4</sup>Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Yogyakarta, ID
- 18:10 - 18:10 **449P - Psychometric validation of the MD Anderson symptom inventory head&#x26;neck module: Chinese version in nasopharyngeal cancer survivors**  
S. Lee<sup>1</sup>, V. Tam<sup>1</sup>, J. Ching<sup>1</sup>, S. Yip<sup>1</sup>, V. Kwong<sup>2</sup>, C. Chan<sup>3</sup>, K. Wong<sup>2</sup>, <sup>1</sup>The Hong Kong Polytechnic University, Hong Kong, HK, <sup>2</sup>Prince of Wales Hospital, Hong Kong, HK, <sup>3</sup>Chinese University of Hong Kong, Hong Kong, HK
- 18:10 - 18:10 **450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia**  
M. Okada<sup>1</sup>, A. Ohba<sup>1</sup>, S. Mitsunaga<sup>2</sup>, T. Shibuki<sup>2</sup>, T. Satake<sup>2</sup>, K. Watanabe<sup>2</sup>, M. Sasaki<sup>2</sup>, H. Imaoka<sup>2</sup>, Y. Maruki<sup>1</sup>, Y. Nagashio<sup>1</sup>, S. Kondo<sup>1</sup>, H. Susumu<sup>1</sup>, C. Morizane<sup>1</sup>, H. Ueno<sup>1</sup>, M. Ikeda<sup>2</sup>, T. Okusaka<sup>1</sup>, <sup>1</sup>NCCCH - National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, JP, <sup>2</sup>National Cancer Center Hospital East, Kashiwa, JP
- 18:10 - 18:10 **451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia**  
D. Arai, R. Kido, J. Yamaguchi, S. Kamimoto, S. Furuya, A. Kanzawa, M. Miyazaki, R. Baba, S. Okamori, H. Takahashi, I. Nakachi, Saiseikai Utsunomiya Hospital, Utsunomiya, JP
- 18:10 - 18:10 **452P - The relationship between BCG immunotherapy and oxidative stress parameters in patients with non-muscle invasive bladder cancer**  
M. Singh, V. Singh, A. Kumar, KGMU - King George's Medical University, Lucknow, IN
- 18:10 - 18:10 **453P - Palonosetron plus megestrol acetate verses palonosetron plus dexamethasone in preventing moderately emetogenic chemotherapy-induced nausea and vomiting: A randomized, multicenter, crossover, phase II trial**  
Q. Li<sup>1</sup>, B. Yang<sup>2</sup>, C. Yi<sup>3</sup>, <sup>1</sup>SCU - Sichuan University - Huaxi Campus, Chengdu, CN, <sup>2</sup>West China Hospital, Huaxi, Sichuan University, Chengdu, CN, <sup>3</sup>West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN
- 18:10 - 18:10 **454P - A multicenter randomized open-label phase II study investigating optimal**

**antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study**

A. Ooki<sup>1</sup>, T. Aoyama<sup>2</sup>, K. Oba<sup>3</sup>, K. Nishikawa<sup>4</sup>, R. Kawabata<sup>5</sup>, M. Honda<sup>6</sup>, H. Maeda<sup>7</sup>, M. Kanda<sup>8</sup>, K. Sugiyama<sup>9</sup>, A. Makiyama<sup>10</sup>, K. Segami<sup>11</sup>, M. Takahashi<sup>12</sup>, Y. Shindo<sup>13</sup>, T. Namikawa<sup>7</sup>, T. Oshima<sup>14</sup>, A. Katayama<sup>15</sup>, K. Shiosakai<sup>16</sup>, J. Sakamoto<sup>17</sup>, <sup>1</sup>The Cancer Institute Hospital of JFCR, Koto-ku, JP, <sup>2</sup>Yokohama City University Hospital, Yokohama, JP, <sup>3</sup>The University of Tokyo Graduate School of Medicine, Tokyo, JP, <sup>4</sup>Osaka Police Hospital, Osaka, JP, <sup>5</sup>Sakai City Medical Center, Sakai, JP, <sup>6</sup>Fukushima Medical University, Fukushima, JP, <sup>7</sup>Kochi Medical School Hospital, Nankoku, JP, <sup>8</sup>Nagoya University Graduate School of Medicine, Nagoya, JP, <sup>9</sup>National Hospital Organization, Nagoya Medical Center, Nagoya, JP, <sup>10</sup>Gifu University Hospital, Gifu, JP, <sup>11</sup>Saiseikai Yokohama-shi Nanbu Hospital, Yokohama, JP, <sup>12</sup>Yokohama Municipal Citizen's Hospital, Yokohama, JP, <sup>13</sup>Nakadori General Hospital, Akita, JP, <sup>14</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>15</sup>Daiichi Sankyo Co., Ltd., Chuo-ku, JP, <sup>16</sup>Daiichi Sankyo Co., LTD, Tokyo, JP, <sup>17</sup>Tokai Central Hospital, Kakamigahara, JP

18:10 - 18:10 **455P - Assessing model-predicted neurokinin-1 (NK1) receptor occupancy (RO) of netupitant to support efficacy over an extended time period**

F. Scotté<sup>1</sup>, L. Zelek<sup>2</sup>, C. Giuliano<sup>3</sup>, S. Olivari Tilola<sup>3</sup>, W.L. Bailey<sup>4</sup>, C. Ruhlmann<sup>5</sup>, H. Iihara<sup>6</sup>, M. Aapro<sup>7</sup>, <sup>1</sup>Gustave Roussy Cancer Center, Villejuif, FR, <sup>2</sup>Hopital Avicenne, Bobigny, FR, <sup>3</sup>Helsinn Healthcare SA, Pazzallo-Lugano, CH, <sup>4</sup>Helsinn Therapeutics (US), Inc., Iselin, US, <sup>5</sup>OUH - Odense University Hospital, Odense, DK, <sup>6</sup>Gifu University Hospital, Gifu, JP, <sup>7</sup>Clinique de Genolier, Genolier, CH

18:10 - 18:10 **456P - Oxycodone/naloxone in moderate-to-severe cancer pain: A phase III study in China**

S. Yu<sup>1</sup>, G. Xie<sup>2</sup>, Q. Zhang<sup>3</sup>, H. Zhang<sup>4</sup>, P. Li<sup>5</sup>, P. Lu<sup>6</sup>, J. Zhang<sup>1</sup>, J. Feng<sup>7</sup>, H. Pan<sup>8</sup>, <sup>1</sup>Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan City, CN, <sup>2</sup>Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, <sup>3</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>4</sup>Tangdu Hospital, Air Force Medical University, Xi'an, CN, <sup>5</sup>Peking University Cancer Hospital and Institute, Beijing, CN, <sup>6</sup>The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, CN, <sup>7</sup>Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, CN, <sup>8</sup>Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, CN

18:10 - 18:10 **457P - Anticoagulation for terminal cancer patients with cancer associated venous thromboembolism**

S.B. Oh, Pusan National University Yangsan Hospital, Yangsan, KR

18:10 - 18:10 **458P - Association between TSPAN15 and SLC44A2 genetic polymorphisms and venous thromboembolism in cancer patients**

A. Al Hanafy<sup>1</sup>, S. Genena<sup>2</sup>, S. Omar<sup>2</sup>, M. Mansour<sup>2</sup>, M. Kora<sup>3</sup>, M. Abdelhafez<sup>2</sup>, M. Khalil<sup>2</sup>, <sup>1</sup>MFM - Menoufia University - Faculty of Medicine, Shebeen El-Kom, EG, <sup>2</sup>Menoufeya University Faculty of Medicine, Cairo, EG, <sup>3</sup>Menoufia University - Faculty of Medicine, Shebeen El-Kom, EG

18:10 - 18:10 **459P - Association between national health screening program and**



**undertreatment of dyslipidemia in cancer survivors: A cross-sectional study**

S. Shin, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, KR

18:10 - 18:10 **460P - Group to grow: A systematic review of group-based interventions for post-traumatic growth on cancer patients**

D. William<sup>1</sup>, N. Reina<sup>1</sup>, D. Alfa Cipta<sup>2</sup>, A. Saputra<sup>2</sup>, <sup>1</sup>UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, ID, <sup>2</sup>Siloam Hospital/Medical faculty of Pelita Harapan University, Tangerang, ID

18:10 - 18:10 **461P - A randomized controlled trial of yoga in locally advanced non-small cell lung cancer patients receiving chemoradiotherapy**

I. Khan, Hope Kolkata Foundation (General Hospital), Kolkata, IN

18:10 - 18:10 **462P - Cognitive function of survivors with non-central nervous system cancer and its correlates: A community rehabilitation perspective**

A. Kuo, Singapore Cancer Society, Singapore, SG

18:10 - 18:10 **463P - The use of antipsychotic for managing delirium in patients with cancer**

N. Reina<sup>1</sup>, D. Alfa Cipta<sup>2</sup>, D. William<sup>1</sup>, A. Saputra<sup>2</sup>, <sup>1</sup>UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, ID, <sup>2</sup>Siloam Hospital/Medical faculty of Pelita Harapan University, Tangerang, ID

18:10 - 18:10 **464P - The prevalence and correlates of frailty and pre-frailty in elderly patients with breast cancer: A cross-sectional study from China**

M. Xiao, X. Chen, X. Qian, L. Ji, M. Xiu, Z. Li, H. Cao, S. Chen, Q. Li, Q. Li, X. Wang, J. Wang, Y. Li, B. Xu, P. Zhang, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN

18:10 - 18:10 **465P - Oncological care needs of people with mental illness: A single institution experience in Australia**

H.L. Yeoh, C. Holmes, M. Leong, K. Courts, N. Potasz, J. Lundy, Z.W. Wong, R. Newton, Y. Antill, Peninsula Health, Frankston, AU

18:10 - 18:10 **466P - Identification of patient satisfaction predictors among women attending oncology daycare unit using validated survey questionnaire (PSS Tool): An institutional experience in central India**

P. Patel<sup>1</sup>, S. Bansal<sup>1</sup>, V. Asati<sup>1</sup>, R. Patidar<sup>2</sup>, M. Kharbanda<sup>1</sup>, H. Mishra<sup>1</sup>, P. Chitalkar<sup>1</sup>, <sup>1</sup>SAIMS - Sri Aurobindo Institute of Medical Sciences, Indore, IN, <sup>2</sup>SAIMS-Sri Aurobindo Institute of Medical Sciences, Indore, IN

18:10 - 18:10 **467P - Evaluation of the effectiveness of a cluster management model based on evidence-based concepts in oncology nutrition case management**

L. He<sup>1</sup>, T. Huo<sup>2</sup>, <sup>1</sup>Shaanxi Provincial People's Hospitalxi provincial people's hospital, Xi'an, CN, <sup>2</sup>Shaanxi Provincial People's Hospital, Xi'an, CN

18:10 - 18:10 **468P - The patterns of use of Traditional Chinese Medicine (TCM) in cancer patients in Hong Kong**

O.L.T. Chan<sup>1</sup>, K.M. Cheung<sup>2</sup>, C.H.L. Wong<sup>3</sup>, Y.H. Ng<sup>1</sup>, H.H.Y. Yiu<sup>2</sup>, <sup>1</sup>Pok Oi Hospital - HKBU Chinese Medicine Clinic cum Training and Research Center, Hong Kong, HK, <sup>2</sup>Queen Elizabeth Hospital, Kowloon, HK, <sup>3</sup>The University of Hong Kong, Hong Kong, HK

- 18:10 - 18:10 **469P - The need of special care for adolescent and young adult (AYA) cancer survivors: Perspective from oncologists in India**  
N. Menon, D. Kalra, M. Trikha, V. Kapu, V. Noronha, K. Prabhash, A. Joshi, Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN
- 18:10 - 18:10 **470TiP - Randomised controlled trial to evaluate the efficacy and safety of moisturising creams with or without palm-oil-derived vitamin E concentrate in addition to urea-based cream or urea-based cream alone in Capecitabine-associated Palmar-Plantar Erythrodysesthesia (ECaPPE)**  
P.J. Voon<sup>1</sup>, T.L. King<sup>2</sup>, X.Y. Lim<sup>1</sup>, E. Lau<sup>1</sup>, N. Ishak<sup>1</sup>, D. Lee<sup>1</sup>, S.P. Beh<sup>1</sup>, S.H. Tan<sup>1</sup>, S. Tan<sup>1</sup>, L.L. Tiong<sup>1</sup>, D.A. Mohamed Noor<sup>3</sup>, K.H. Yuen<sup>3</sup>, <sup>1</sup>Sarawak General Hospital, Kuching, MY, <sup>2</sup>Hospital UMUM Sarawak, Kuching, MY, <sup>3</sup>Universiti Sains Malaysia, George Town, MY
- 18:10 - 18:10 **471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV) in patients belonging to low socio-economic status**  
M. Ramasubbu<sup>1</sup>, D. Hota<sup>1</sup>, S.K. Das Majumdar<sup>2</sup>, P. Mukherjee<sup>2</sup>, A. Srinivasan<sup>1</sup>, <sup>1</sup>AIIMS - All India Institute of Medical Sciences - Bhubaneswar, Bhubaneswar, IN, <sup>2</sup>AIIMS-All India Institute of Medical Sciences - Bhubaneswar, Bhubaneswar, IN
- 18:10 - 18:10 **Thoracic tumours, early stage**
- 18:10 - 18:10 **472P - Risk of recurrence and optimal adjuvant treatment in invasive lung adenocarcinomas manifesting as radiological part-solid nodules**  
Y. Wo, Y. Sun, Fudan University, Shanghai, CN
- 18:10 - 18:10 **473P - Treatment (tx) patterns in resectable stage IA&#x2013;IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study**  
H. Wang<sup>1</sup>, S. Lu<sup>2</sup>, Y. Zhao<sup>3</sup>, Y. Li<sup>3</sup>, G. Hu<sup>4</sup>, Y.-C. Lee<sup>5</sup>, C.-C. Yang<sup>6</sup>, A. Yin<sup>7</sup>, Q. Wang<sup>8</sup>, S. Tan<sup>8</sup>, M. Sandelin<sup>9</sup>, D. Kahangire<sup>10</sup>, <sup>1</sup>The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, CN, <sup>2</sup>Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CN, <sup>3</sup>First Affiliated Hospital of Dalian Medical University, Dalian Medical University, Dalian, CN, <sup>4</sup>Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, CN, <sup>5</sup>IQVIA, Taipei, TW, <sup>6</sup>IQVIA, Shanghai, CN, <sup>7</sup>IQVIA, Beijing, CN, <sup>8</sup>Medical Affairs, AstraZeneca, Shanghai, CN, <sup>9</sup>Oncology Business Unit, Södertälje, Stockholm, SE, <sup>10</sup>Medical Affairs, AstraZeneca, Cambridge, GB
- 18:10 - 18:10 **474P - The efficacy of image guided coil localisation for surgical resection of undiagnosed solitary lung nodule**  
Y. Li<sup>1</sup>, J.R. Leong<sup>2</sup>, J. Chen<sup>3</sup>, J.K.C. Tam<sup>1</sup>, <sup>1</sup>NUHS - National University Health System,

Singapore, SG, <sup>2</sup>NUS - National University of Singapore, Singapore, SG, <sup>3</sup>NUH - National University Hospital (S) Pte. Ltd., Singapore, SG

- 18:10 - 18:10 **475P - 5-year overall survival and disease free survival outcome between lobectomy and segmentectomy for early stage lung cancer in a mixed Asian population**  
J. Chen<sup>1</sup>, Z. Ong<sup>1</sup>, J.K.C. Tam<sup>2</sup>, <sup>1</sup>NUH - National University Hospital (S) Pte. Ltd., Singapore, SG, <sup>2</sup>NUHS - National University Health System, Singapore, SG
- 18:10 - 18:10 **478P - Peri-operative risks in curative lung resection of early stage primary lung cancer patients above 70 years old in a mixed Asian population**  
I. Goh<sup>1</sup>, L.C.K. Leow<sup>2</sup>, J. Chen<sup>2</sup>, J.K.C. Tam<sup>2</sup>, <sup>1</sup>Yong Loo Lin School of Medicine, National University Singapore, Singapore, Singapore, SG, <sup>2</sup>NUHS - National University Health System, Singapore, SG
- 18:10 - 18:10 **480P - Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation**  
L. Wu, H.R. Jia, Shengjing Hospital of China Medical University - Nanhu Campus, Shenyang, CN
- 18:10 - 18:10 **481P - Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer**  
J.B. Lee<sup>1</sup>, S.J. Choi<sup>2</sup>, J.H. Kim<sup>2</sup>, M.H. Hong<sup>1</sup>, B.C. Cho<sup>1</sup>, S.M. Lim<sup>1</sup>, <sup>1</sup>Yonsei Cancer Center Yonsei University, Seoul, KR, <sup>2</sup>Yonsei University College of Medicine, Seoul, KR
- 18:10 - 18:10 **482P - Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort**  
P.L. Chia<sup>1</sup>, J.T. Kit Chung<sup>2</sup>, A. Asmat<sup>1</sup>, R. Huggenberger<sup>3</sup>, A. Verma<sup>4</sup>, R. Soo<sup>5</sup>, <sup>1</sup>National Healthcare Group - Tan Tock Seng Hospital, Singapore, SG, <sup>2</sup>NUH - National University Hospital (S) Pte. Ltd., Singapore, SG, <sup>3</sup>AstraZeneca AG, Zug, CH, <sup>4</sup>AstraZeneca Singapore Pte. Ltd., Singapore, SG, <sup>5</sup>NCIS - National University Cancer Institute Singapore, Singapore, SG
- 18:10 - 18:10 **483P - Genetic profiles and evolutionary trajectory of early stage lung adenocarcinoma (AAH, AIS, MIA and IAC) revealed by multiplex sequencing**  
L. Lin<sup>1</sup>, C.C. Li<sup>2</sup>, X. Liu<sup>3</sup>, Q. Cai<sup>2</sup>, L. Huang<sup>4</sup>, W. Liang<sup>3</sup>, <sup>1</sup>Affiliated Cancer Hospital and Insitutue of Guangzhou Medical University, Guangzhou, CN, <sup>2</sup>Guangzhou Medical University, Guangzhou, CN, <sup>3</sup>The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, <sup>4</sup>State Key Laboratory of Respiratory Diseases - The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou, CN
- 18:10 - 18:10 **484P - Treatment (tx) patterns and outcomes in resectable early-stage EGFR-mutated (EGFRm) NSCLC in South Korea: Subgroup analysis of a global real-world (rw) study**  
M.-J. Ahn<sup>1</sup>, J.H. Kang<sup>2</sup>, S.-W. Kim<sup>3</sup>, D. Kahangire<sup>4</sup>, S. Nagar<sup>5</sup>, K. Davis<sup>5</sup>, M. Jimenez<sup>5</sup>, M. Seo<sup>6</sup>, M. Jung<sup>7</sup>, M. Sandelin<sup>8</sup>, B.C. Cho<sup>9</sup>, <sup>1</sup>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, <sup>2</sup>Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, KR, <sup>3</sup>Asan Medical Center, University of Ulsan College of

Medicine, Seoul, KR, <sup>4</sup>Medical Affairs, AstraZeneca, Cambridge, GB, <sup>5</sup>Research Triangle Park, Durham, US, <sup>6</sup>AstraZeneca, Seoul, KR, <sup>7</sup>Oncology, AstraZeneca, Seoul, KR, <sup>8</sup>AstraZeneca, Södertälje, Stockholm, SE, <sup>9</sup>Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR

- 18:10 - 18:10 **485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers**  
 N. Triphuridet<sup>1</sup>, M. Nagasaka<sup>2</sup>, E. Shum<sup>3</sup>, S.-H. Ou<sup>2</sup>, <sup>1</sup>CRI - Chulabhorn Research Institute, Bangkok, TH, <sup>2</sup>UCI Health Chao Family Comprehensive Cancer Center, Orange, US, <sup>3</sup>New York University Medical Center, New York, US
- 18:10 - 18:10 **486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong's healthcare system**  
H.H.F. Loong<sup>1</sup>, X. Pan<sup>2</sup>, C.H. Chiu<sup>3</sup>, S.-C. Yang<sup>4</sup>, M.S.-H. Chung<sup>5</sup>, L. De Jong<sup>2</sup>, H. Groen<sup>6</sup>, M. Oudkerk<sup>2</sup>, M.J. Postma<sup>2</sup>, C. Wong<sup>5</sup>, P.-C. Yang<sup>7</sup>, <sup>1</sup>The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK, <sup>2</sup>University of Groningen, Groningen, NL, <sup>3</sup>Taipei Cancer Center and Taipei Medical University Hospital, Taipei City, TW, <sup>4</sup>NCKUH - National Cheng Kung University Hospital, Tainan City, TW, <sup>5</sup>HKU - The University of Hong Kong, Hong Kong, HK, <sup>6</sup>UMCG - University Medical Center Groningen, Groningen, NL, <sup>7</sup>National Taiwan University College of Medicine, Taipei City, TW
- 18:10 - 18:10 **487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients**  
 J.W. Tan<sup>1</sup>, S.T. Chong<sup>2</sup>, J. Chen<sup>1</sup>, J.K.C. Tam<sup>3</sup>, <sup>1</sup>NUH - National University Hospital (S) Pte. Ltd., Singapore, SG, <sup>2</sup>NUS-National University of Singapore-Yong Loo Lin School of Medicine (YLLSoM), Singapore, SG, <sup>3</sup>NUHS - National University Health System, Singapore, SG
- 18:10 - 18:10 **488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma**  
S. Shen, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN
- 18:10 - 18:10 **489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations &#x2b;/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)**  
 J. He<sup>1</sup>, P. Zhang<sup>2</sup>, H. Liu<sup>3</sup>, W. Liang<sup>1</sup>, W. Yu<sup>4</sup>, J. Shi<sup>4</sup>, B. Wei<sup>5</sup>, W. Zheng<sup>4</sup>, Z. Shen<sup>4</sup>, N. Wu<sup>6</sup>, <sup>1</sup>The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, <sup>2</sup>Shanghai Pulmonary Hospital, Shanghai, CN, <sup>3</sup>Liaoning Cancer Hospital and Institute, Shenyang, CN, <sup>4</sup>BeiGene (Beijing) Co., Ltd., Beijing, CN, <sup>5</sup>BeiGene USA, Inc., Cambridge, US, <sup>6</sup>Beijing Cancer Hospital, Beijing, CN
- 18:10 - 18:10 **491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience**  
Z. Wu<sup>1</sup>, Q. Zhang<sup>1</sup>, Z. He<sup>2</sup>, L. Ke<sup>1</sup>, T. He<sup>1</sup>, W. Lv<sup>1</sup>, J. Hu<sup>1</sup>, <sup>1</sup>The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang, CN, <sup>2</sup>Sir Run Run Shaw

Hospital - Zhejiang University School of Medicine - Xiasha Campus, Hangzhou, CN

- 18:10 - 18:10 **492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)**  
C. Wang<sup>1</sup>, M. Wang<sup>1</sup>, H. Long<sup>2</sup>, H. Guo<sup>3</sup>, B. Yu<sup>4</sup>, G. Zhao<sup>5</sup>, J. Wu<sup>6</sup>, <sup>1</sup>Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, <sup>2</sup>Sun Yat-Sen University Cancer Center, Guangzhou, CN, <sup>3</sup>Shandong Cancer Hospital and Institute, Jinan, CN, <sup>4</sup>The First Affiliated Hospital of Nanchang University, Nanchang, CN, <sup>5</sup>Hwa Mei Hospital, University of Chinese Academy of Sciences/NingboNo.2 Hospital, Ningbo, CN, <sup>6</sup>Hainan Cancer Hospital, Haikou, CN
- 18:10 - 18:10 **493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis**  
L. Peng<sup>1</sup>, W. Li<sup>2</sup>, K.-L. Huang<sup>3</sup>, <sup>1</sup>West China School of Medicine/West China Hospital of Sichuan University, China, CN, <sup>2</sup>West China Hospital of Sichuan University, Chengdu, CN, <sup>3</sup>West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN
- 18:10 - 18:10 **(Withdrawn)**
- 18:10 - 18:10 **495P - Intrinsic STING of CD8<sup>+</sup>T cells regulates self-metabolic reprogramming and exerts anti-tumor effects**  
Q. Xu<sup>1</sup>, H. Xin<sup>1</sup>, R. Wu<sup>1</sup>, B. Li<sup>2</sup>, B. Jiang<sup>2</sup>, R. Xu<sup>3</sup>, T. Lv<sup>4</sup>, Y. Song<sup>1</sup>, <sup>1</sup>Southeast University, School of medicine, Jinling Hospital/Eastern Theater General Hospital of PLA, Nanjing, CN, <sup>2</sup>Nanjing University of Traditional Chinese Medicine, Nanjing, CN, <sup>3</sup>University of Nottingham, Nottingham, GB, <sup>4</sup>Jinling Hospital Affiliated to Nanjing University/Eastern Theater General Hospital of PLA, Nanjing, CN
- 18:10 - 18:10 **496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study**  
S. Lu<sup>1</sup>, J. Fang<sup>2</sup>, A. Liu<sup>3</sup>, X. Dong<sup>4</sup>, Y. Yu<sup>1</sup>, S. Han<sup>2</sup>, Z. Zeng<sup>3</sup>, R. Zhang<sup>4</sup>, P. Lu<sup>5</sup>, H. Shi<sup>5</sup>, P. Tan<sup>5</sup>, S. Fan<sup>5</sup>, M. Shi<sup>5</sup>, W. Su<sup>5</sup>, <sup>1</sup>Shanghai Chest Hospital, Shanghai, CN, <sup>2</sup>Beijing Cancer Hospital, Beijing, CN, <sup>3</sup>2nd Affiliated Hospital of Nanchang University, Nanchang, CN, <sup>4</sup>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology/ Cancer Center Union Hospital, Wuhan, CN, <sup>5</sup>HUTCHMED (China) Limited - Research Center, Shanghai, CN
- 18:10 - 18:10 **497P - Sintilimab in combination with anlotinib in advanced NSCLC treated with first-line PD-1 antibodies: An open, single-arm, phase II trial**  
Y. Jin, X. Yu, Y. Fan, X. Shi, Q. He, C. Lin, W. Hong, C. Gu, Zhejiang Cancer Hospital, Hangzhou, CN
- 18:10 - 18:10 **498P - Frailty-adjusted life expectancy and survival in older lung cancer patients: A large-scale electronic health-record based study**  
T. Tu, T.-N. Tran, H. Kwon, H. Cho, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, KR

- 18:10 - 18:10 **499P - Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study**  
D. Fujimoto<sup>1</sup>, Y. Takiguchi<sup>2</sup>, S. Matsumoto<sup>3</sup>, N. Yamamoto<sup>1</sup>, G. Saito<sup>2</sup>, Y. Nishimura<sup>4</sup>, S. Sugiyama<sup>4</sup>, A. Oku<sup>5</sup>, P. Karia<sup>6</sup>, L. Antunes<sup>7</sup>, J. Chapaneri<sup>8</sup>, R. Salomonsen<sup>6</sup>, E. Martin<sup>8</sup>, P. Okhuoya<sup>8</sup>, M. Muto<sup>3</sup>, <sup>1</sup>Wakayama Medical University, Wakayama, JP, <sup>2</sup>Chiba University, Chiba, JP, <sup>3</sup>Kyoto University, Kyoto, JP, <sup>4</sup>AstraZeneca, Tokyo, JP, <sup>5</sup>AstraZeneca, Osaka, JP, <sup>6</sup>AstraZeneca, Gaithersburg, US, <sup>7</sup>IQVIA, Porto Salvo, PT, <sup>8</sup>AstraZeneca, Cambridge, GB
- 18:10 - 18:10 **500P - The effectiveness and safety of durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small cell lung cancer: Real-world, multicenter, observational study (NEJ056)**  
H. Horinouchi<sup>1</sup>, M. Furuta<sup>2</sup>, I. Yokota<sup>3</sup>, T. Yamaguchi<sup>4</sup>, S. Itoh<sup>5</sup>, T. Fukui<sup>6</sup>, A. Iwashima<sup>7</sup>, Y. Kawashima<sup>8</sup>, Y. Miura<sup>9</sup>, H. Tanaka<sup>10</sup>, T. Miyawaki<sup>11</sup>, H. Yokouchi<sup>12</sup>, K. Miura<sup>13</sup>, R. Saito<sup>14</sup>, H. Suzuki<sup>15</sup>, T. Kamoshida<sup>16</sup>, U. Uchinami<sup>2</sup>, T. Kato<sup>17</sup>, K. Kobayashi<sup>18</sup>, H. Asahina<sup>12</sup>, <sup>1</sup>National Cancer Center Hospital, Tokyo, JP, <sup>2</sup>Hokkaido University, Sapporo, JP, <sup>3</sup>Hokkaido University Graduate School of Medicine, Sapporo, JP, <sup>4</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>5</sup>Hyogo Cancer Center, Hyogo, JP, <sup>6</sup>Kobe University Graduate School of Medicine, Kobe, JP, <sup>7</sup>Nagaoka Chuo General Hospital, Niigata, JP, <sup>8</sup>Sendai Kousei Hospital, Sendai, JP, <sup>9</sup>Saitama Medical University, Hidaka, JP, <sup>10</sup>Hirosaki University Graduate School of Medicine, Hirosaki, JP, <sup>11</sup>Juntendo University Graduate School of Medicine, Tokyo, JP, <sup>12</sup>National Hospital Organization Hokkaido Cancer Center, Sapporo, JP, <sup>13</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>14</sup>Tohoku University Graduate School of Medicine, Sendai, JP, <sup>15</sup>Chiba University Graduate School of Medicine, Chiba, JP, <sup>16</sup>Yokosuka Kyosai Hospital, Yokosuka, JP, <sup>17</sup>Hokkaido University Hospital, Sapporo, JP, <sup>18</sup>Saitama Medical University International Medical Center, Hidaka, JP
- 18:10 - 18:10 **501P - One-year survival outcomes of unresectable stage III non-small cell lung cancer patients who underwent PD-1 inhibitor plus chemo as induction therapy**  
X. Wang, J. He, X. Zhuang, Sichuan Cancer Hospital and Institute/The Affiliated Cancer Hospital School of Medicine, UESTC, Chengdu, CN
- 18:10 - 18:10 **502P - Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab**  
K. Tamura<sup>1</sup>, H. Horinouchi<sup>1</sup>, M. Miyake<sup>1</sup>, K. Masuda<sup>1</sup>, Y. Shinno<sup>1</sup>, Y. Okuma<sup>1</sup>, T. Yoshida<sup>2</sup>, Y. Goto<sup>1</sup>, N. Yamamoto<sup>1</sup>, Y. Ohe<sup>1</sup>, <sup>1</sup>National Cancer Center Hospital, Chuo-ku, JP, <sup>2</sup>National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, JP
- 18:10 - 18:10 **503P - Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with locally advanced NSCLC**  
T. Hirata<sup>1</sup>, Y. Uehara<sup>1</sup>, T. Hakozaiki<sup>1</sup>, Y. Terashima<sup>2</sup>, K. Watanabe<sup>1</sup>, M. Yomota<sup>1</sup>, Y. Hosomi<sup>1</sup>, <sup>1</sup>Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, JP, <sup>2</sup>Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, JP

- 18:10 - 18:10 **504P - Real-world outcomes with induction systemic therapy for stage III in eligible for upfront local therapy: Pre vs post immunotherapy era in a tertiary referral centre**  
P.K. Marimuthu<sup>1</sup>, A. Singh<sup>1</sup>, A. Joel<sup>1</sup>, D.B. Thumaty<sup>1</sup>, J.T. Georgy<sup>1</sup>, A. John<sup>1</sup>, Z. Thomas<sup>1</sup>, J.P. Wisely<sup>1</sup>, S. Devabhaktuni<sup>1</sup>, P. Jambunathan<sup>1</sup>, H. Kovilapu<sup>1</sup>, R. Isiah<sup>1</sup>, S. Pavamani<sup>1</sup>, B.K. Sasidharan<sup>1</sup>, A. Irodi<sup>2</sup>, T. Alex<sup>2</sup>, R.T. Chacko<sup>1</sup>, <sup>1</sup>CMC - Christian Medical College Hospital, Vellore, IN, <sup>2</sup>CMC - Christian Medical College Hospital Vellore, Vellore, IN
- 18:10 - 18:10 **505P - Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum&#x2013;etoposide in patients with limited-stage small cell lung cancer: A phase II trial**  
J. Hu, F. Sun, D. Bian, J. Yang, J. Luo, G. Jiang, Y. Zhu, P. Zhang, Shanghai Pulmonary Hospital, Shanghai, CN
- 18:10 - 18:10 **506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy**  
B.H. Kim<sup>1</sup>, D. Kim<sup>2</sup>, H.J. Kim<sup>3</sup>, <sup>1</sup>SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, KR, <sup>2</sup>Chungnam National University Hospital, Daejeon, KR, <sup>3</sup>Seoul National University - College of Medicine - Yeongeon Medical Campus, Seoul, KR
- 18:10 - 18:10 **519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)**  
Y. Cheng<sup>1</sup>, J. Wang<sup>2</sup>, W. Yao<sup>3</sup>, Y. Yu<sup>4</sup>, A. Zang<sup>5</sup>, L. Cao<sup>6</sup>, D. Lv<sup>7</sup>, S. Li<sup>8</sup>, Z. Meng<sup>9</sup>, J. Zhang<sup>10</sup>, Q. Guo<sup>11</sup>, D. Huang<sup>12</sup>, A. Liu<sup>13</sup>, J. Liu<sup>14</sup>, W. Mao<sup>15</sup>, K. Tang<sup>16</sup>, Y. Zhang<sup>17</sup>, E. Chen<sup>18</sup>, Z. Wang<sup>19</sup>, J. Zheng<sup>20</sup>, <sup>1</sup>Jilin Cancer Hospital, Changchun, CN, <sup>2</sup>Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN, <sup>3</sup>Sichuan Cancer Hospital, Chengdu, CN, <sup>4</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>5</sup>Affiliated Hospital of Hebei University, Baoding, CN, <sup>6</sup>Anhui Provincial Hospital, Hefei, CN, <sup>7</sup>Taizhou Hospital of Zhejiang Province, Taizhou, CN, <sup>8</sup>Huashan Hospital Affiliated to Fudan University, Shanghai, CN, <sup>9</sup>The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an, CN, <sup>10</sup>Zhujiang Hospital of Southern Medical University, Guangzhou, CN, <sup>11</sup>Shandong Cancer Hospital & Institute, Jinan, CN, <sup>12</sup>Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, <sup>13</sup>The Second Affiliated Hospital of Nanchang University, Nanchang, CN, <sup>14</sup>The First Affiliated Hospital of Dalian Medical University, Dalian, CN, <sup>15</sup>The Affiliated Jiangyin Hospital of Southeast University School of Medicine, Jiangyin, CN, <sup>16</sup>The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, <sup>17</sup>The Affiliated Nanjing Chest Hospital of Medical School of Southeast University, Nanjing, CN, <sup>18</sup>Sir Run Run Shaw Hospital - Zhejiang University School of Medicine, Hangzhou, CN, <sup>19</sup>The Affiliated Hospital of Yangzhou University, Yangzhou, CN, <sup>20</sup>Wenzhou Central Hospital, Wenzhou, CN
- 18:10 - 18:10 **520P - Role of atezolizumab in controlling CNS progression in ES-SCLC**  
Y. Namgung, K. Lee, J. Choi, S.Y. Lee, E.J. Kang, Korea University Guro Hospital, Seoul, KR
- 18:10 - 18:10 **521P - Camrelizumab combined with chemotherapy and apatinib as first-line**

**therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research**

Y. Zhao, J. Liu, X. Li, Y. Li, H. Pu, X. Wang, M. Yang, S. Bai, L. Guo, L. Zhao, M. Zhang, H. Zhao, S. Xu, Y. Wang, Harbin Medical University Cancer Hospital, Harbin, CN

18:10 - 18:10

**522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia**

I. Nakachi<sup>1</sup>, D. Fujimoto<sup>2</sup>, R. Shibaki<sup>3</sup>, E. Miyauchi<sup>4</sup>, Y. Tsukita<sup>5</sup>, Y. Sakata<sup>6</sup>, N. Shingu<sup>6</sup>, D. Arai<sup>1</sup>, T. Kijima<sup>7</sup>, M. Tamiya<sup>8</sup>, S. Kawana<sup>9</sup>, S. Hara<sup>10</sup>, G. Saito<sup>11</sup>, Y. Sato<sup>12</sup>, S. Sakata<sup>13</sup>, H. Matsumoto<sup>14</sup>, T. Yamaguchi<sup>15</sup>, N. Yamamoto<sup>2</sup>, <sup>1</sup>Saiseikai Utsunomiya Hospital, Utsunomiya, JP, <sup>2</sup>Wakayama medical university, Wakayama-city, JP, <sup>3</sup>Wakayama Medical University, Wakayama, JP, <sup>4</sup>Tohoku University Hospital, Sendai, JP, <sup>5</sup>Miyagi Cancer Center, Natori, JP, <sup>6</sup>Saiseikai Kumamoto Hospital, Kumamoto, JP, <sup>7</sup>Hyogo College of Medicine, Nishinomiya, JP, <sup>8</sup>Osaka International Cancer Institute, Osaka, JP, <sup>9</sup>Sendai Kousei Hospital, Sendai, JP, <sup>10</sup>Itami City Hospital, Itami, JP, <sup>11</sup>Chiba University, School of Medicine, Chiba, JP, <sup>12</sup>Kobe City Medical Center General Hospital, Kobe, JP, <sup>13</sup>Kumamoto University, Kumamoto, JP, <sup>14</sup>Hyogo Prefectural Amagasaki Hospital, Amagasaki, JP, <sup>15</sup>Aichi Cancer Center Hospital, Nagoya, JP

18:10 - 18:10

**523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial**

Q. Wang<sup>1</sup>, Y. Wu<sup>2</sup>, Q. Wang<sup>3</sup>, S. Ma<sup>1</sup>, H. Lu<sup>2</sup>, Y. Liu<sup>3</sup>, <sup>1</sup>Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, <sup>2</sup>Luoyang Central Hospital, Luoyang, CN, <sup>3</sup>Nanyang Second General Hospital, Nanyang, CN

18:10 - 18:10

**524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan**

K. Huang<sup>1</sup>, C.-C. Wang<sup>1</sup>, Y. Yang<sup>2</sup>, W.-J. Chen<sup>2</sup>, C.-H. Chang<sup>3</sup>, P.-L. Su<sup>4</sup>, <sup>1</sup>National Taiwan University, Taipei City, TW, <sup>2</sup>AMGEN Taiwan Limited, Taipei City, TW, <sup>3</sup>AMGEN - Japan, Chiyoda-ku, JP, <sup>4</sup>NCKUH - National Cheng Kung University Hospital, Tainan City, TW

18:10 - 18:10

**525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score**

C. Chantharakhit, N. Sujaritvanichpong, Buddhasothorn Hospital, Chachoengsao, TH

18:10 - 18:10

**526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis**

M. Chhayani<sup>1</sup>, S.J. Obulareddy<sup>2</sup>, S.K. Yadav<sup>3</sup>, M. Khealani<sup>3</sup>, M. Gaddam<sup>4</sup>, S.M. Jain<sup>5</sup>, H. Chhayani<sup>1</sup>, H.D. Desai<sup>6</sup>, <sup>1</sup>G.M.E.R.S. Medical College, Gandhinagar, IN, <sup>2</sup>Winthrop P. Rockefeller Cancer Institute University of Arkansas for Medical Sciences, Little Rock, US, <sup>3</sup>Mayo Clinic Health System - Mankato Hospital, Mankato, US, <sup>4</sup>Hazard ARH Regional Medical Center, Hazard, US, <sup>5</sup>MVJ medical college and research hospital, Bengaluru, IN, <sup>6</sup>Gujarat Adani Institute of Medical Sciences, Affiliated to K.S.K.V University, Bhuj, IN



- 18:10 - 18:10 **527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study**  
F. Cun<sup>1</sup>, T. Xu<sup>2</sup>, X. Wang<sup>2</sup>, <sup>1</sup>Nanjing Chest Hospital, NAN JING, CN, <sup>2</sup>Nanjing Chest Hospital - Medical School of Southeast University, Nanjing, CN
- 18:10 - 18:10 **528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study**  
K.M. Cheung<sup>1</sup>, C.H.L. Wong<sup>2</sup>, J. Chow<sup>1</sup>, K.K.H. Bao<sup>1</sup>, K.S.J. Fong<sup>2</sup>, V. Lee<sup>2</sup>, M.Y. Lim<sup>3</sup>, T.Y. Kam<sup>4</sup>, S.F. Nyaw<sup>5</sup>, C.K. Kwan<sup>6</sup>, F. Mok<sup>7</sup>, A.W.M. Lee<sup>2</sup>, J.C.S. Ho<sup>1</sup>, <sup>1</sup>Queen Elizabeth Hospital, Kowloon, HK, <sup>2</sup>The University of Hong Kong, Hong Kong, HK, <sup>3</sup>Princess Margaret Hospital, Kowloon, HK, <sup>4</sup>Pamela Youde Nethersole Eastern Hospital, Hong Kong, HK, <sup>5</sup>Tuen Mun Hospital, New Territories, HK, <sup>6</sup>United Christian Hospital, Kowloon, HK, <sup>7</sup>Prince of Wales Hospital, New Territories, HK
- 18:10 - 18:10 **529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study**  
T. Yamada<sup>1</sup>, Y. Katayama<sup>1</sup>, S. Watanabe<sup>2</sup>, K. Watanabe<sup>3</sup>, T. Takeda<sup>4</sup>, Y. Chihara<sup>5</sup>, S. Shiotsu<sup>6</sup>, M. Hibino<sup>7</sup>, T. Harada<sup>8</sup>, K. Takayama<sup>1</sup>, <sup>1</sup>Kyoto Prefectural University of Medicine, Kyoto, JP, <sup>2</sup>Niigata University Medical and Dental Hospital, Niigata, JP, <sup>3</sup>Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, JP, <sup>4</sup>Japanese Red Cross Kyoto Daini Hospital, Kyoto, JP, <sup>5</sup>Uji-Tokushukai Medical Center, Uji-shi, JP, <sup>6</sup>Kyoto First Red Cross Hospital (Kyoto Daiichi Sekijyuji Byoin), Kyoto, JP, <sup>7</sup>Shonan Fujisawa Tokushukai Hospital, Fujisawa, JP, <sup>8</sup>Fukuchiyama City Hospital, Fukuchiyama, JP
- 18:10 - 18:10 **530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming**  
X. Song, L. Xu, G. Dong, F. Jiang, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, CN
- 18:10 - 18:10 **531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells**  
S. Hirai<sup>1</sup>, T. Yamada<sup>1</sup>, Y. Katayama<sup>1</sup>, Y. Sekido<sup>2</sup>, K. Takayama<sup>1</sup>, <sup>1</sup>Kyoto Prefectural University of Medicine, Kyoto, JP, <sup>2</sup>Aichi Cancer Center Research Institute, Nagoya, JP
- 18:10 - 18:10 **532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma**  
T. Otsuki, N. Kawamura, M. Murakami, T. Kondo, T. Fujioka, M. Morishita, M. Tokuda, T. Higashiyama, A. Tada, Y. Negi, D. Horio, K. Mikami, R. Takahashi, T. Minami, K. Kuribayashi, T. Kijima, Hyogo Medical University, Nishinomiya, JP
- 18:10 - 18:10 **533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs**  
T. Yamaguchi<sup>1</sup>, R. Matsuzawa<sup>1</sup>, M. Morise<sup>2</sup>, K. Ito<sup>3</sup>, O. Hataji<sup>3</sup>, K. Takahashi<sup>4</sup>, J. Koyama<sup>2</sup>, Y. Kuwatsuka<sup>5</sup>, Y. Goto<sup>6</sup>, K. Imaizumi<sup>6</sup>, H. Itani<sup>7</sup>, Y. Zenke<sup>8</sup>, M. Oki<sup>9</sup>, M. Ishii<sup>2</sup>, <sup>1</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>2</sup>Nagoya University Graduate School of Medicine, Nagoya, JP, <sup>3</sup>Matsusaka City Hospital, Matsusaka, JP, <sup>4</sup>Anjo Kosei Hospital, Anjo, JP

<sup>5</sup>Nagoya University Hospital, Nagoya, JP, <sup>6</sup>Fujita Health University, Toyoake, JP, <sup>7</sup>Ise Red Cross Hospital, Ise, JP, <sup>8</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>9</sup>NHO Nagoya Medical Center, Nagoya, JP

- 18:10 - 18:10 **534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway**  
Q. Li<sup>1</sup>, N. Lin<sup>2</sup>, <sup>1</sup>Affiliated Hangzhou First People's Hospital, Hangzhou, CN, <sup>2</sup>Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, CN
- 18:10 - 18:10 **535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC**  
H.G. Luna<sup>1</sup>, M. Imasa<sup>1</sup>, N. Juat<sup>2</sup>, K. Hernandez<sup>3</sup>, T.M. Sayo<sup>1</sup>, G. Cristal Luna<sup>2</sup>, S.M. Asur-Galang<sup>4</sup>, M. Bellengan<sup>4</sup>, K.J. Duga<sup>5</sup>, B.B. Buenaobra<sup>6</sup>, M. De Los Santos<sup>4</sup>, D. Medina<sup>6</sup>, V.M. Literal<sup>6</sup>, N.A. Bascos<sup>7</sup>, <sup>1</sup>Lung Center of the Philippines, Quezon City, PH, <sup>2</sup>National Kidney and Transplant Institute, Quezon City, PH, <sup>3</sup>East Avenue Medical Center, Quezon City, PH, <sup>4</sup>Philippine Council for Health Research and Development - Lung Center of the Philippines, Quezon City, PH, <sup>5</sup>Philippine Council for Health Research and Development-Lung Center of the Philippines, Quezon City, PH, <sup>6</sup>Philippine Council for Health Research and Development -Lung Center of the Philippines, Quezon City, PH, <sup>7</sup>University of the Philippines, Quezon City, PH
- 18:10 - 18:10 **536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Ruijin Hospital**  
Z. Zhang, Q. Bao, T. Liang, J. Wen, Y. Shen, W. Zhang, Ruijin Hospital - Shanghai Jiao Tong University School of Medicine, Shanghai, CN
- 18:10 - 18:10 **537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma**  
P.-K. Hsu, Taipei Veterans General Hospital, Taipei City, TW
- 18:10 - 18:10 **538P - First-line chemoimmunotherapy for metastatic thymic carcinoma**  
V. Andreas<sup>1</sup>, M. Alexander<sup>2</sup>, J. Rogers<sup>1</sup>, M. Faltys<sup>3</sup>, S. Bowyer<sup>4</sup>, L. Warburton<sup>5</sup>, A. Fantoni<sup>5</sup>, T. Clay<sup>6</sup>, P. Antippa<sup>7</sup>, B. Solomon<sup>1</sup>, T. John<sup>1</sup>, <sup>1</sup>Peter MacCallum Cancer Centre, Melbourne, AU, <sup>2</sup>The University of Melbourne, Parkville, AU, <sup>3</sup>Austin Health - Austin Hospital, Heidelberg, AU, <sup>4</sup>Sir Charles Gairdner Hospital, Nedlands, AU, <sup>5</sup>Fiona Stanley Hospital, Murdoch, AU, <sup>6</sup>Saint John of God Subiaco Hospital, Subiaco, AU, <sup>7</sup>Royal Melbourne Hospital, Melbourne, AU
- 18:10 - 18:10 **540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup**  
C. Zhou<sup>1</sup>, Y. Hu<sup>2</sup>, K. Ying<sup>3</sup>, F. Xu<sup>4</sup>, L. Wu<sup>5</sup>, X. Wang<sup>6</sup>, H. Sun<sup>7</sup>, F. Luo<sup>8</sup>, J. Shi<sup>9</sup>, A. Zang<sup>10</sup>, Y. Pan<sup>11</sup>, Z. Chen<sup>12</sup>, Z. Jia<sup>13</sup>, P. Lu<sup>14</sup>, L. Zhang<sup>4</sup>, Y. Cheng<sup>15</sup>, W. Kang<sup>16</sup>, Q. Wang<sup>16</sup>, J. Li<sup>16</sup>, J. Zhu<sup>16</sup>, <sup>1</sup>Shanghai Pulmonary Hospital, Shanghai, CN, <sup>2</sup>Hubei Cancer Hospital, Wuhan, CN, <sup>3</sup>Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, CN, <sup>4</sup>The First Affiliated Hospital of Nanchang University, Nanchang, CN, <sup>5</sup>Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CN, <sup>6</sup>Xuzhou Central Hospital, Xuzhou, CN, <sup>7</sup>Jiamusi Cancer

Hospital, Jiamusi, CN, <sup>8</sup>West China Hospital of Sichuan University, Chengdu, CN, <sup>9</sup>Linyi Cancer Hospital, Linyi, CN, <sup>10</sup>Affiliated Hospital of Hebei University, Baoding, CN, <sup>11</sup>Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei, CN, <sup>12</sup>The Second Affiliated Hospital of Anhui Medical University, Hefei, CN, <sup>13</sup>Linyi People's Hospital, Linyi, CN, <sup>14</sup>The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, CN, <sup>15</sup>Jilin Cancer Hospital, Changchun, CN, <sup>16</sup>Shanghai Henlius Biotech, Inc., Shanghai, CN

18:10 - 18:10

**541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)**

M. Nishio<sup>1</sup>, S. Watanabe<sup>2</sup>, H. Udagawa<sup>3</sup>, N. Aragane<sup>4</sup>, Y. Nakagawa<sup>5</sup>, Y. Kobayashi<sup>5</sup>, H. Saito<sup>6</sup>, <sup>1</sup>The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Tokyo, JP, <sup>2</sup>Niigata University Graduate School of Medical and Dental Sciences, Chuo-ku, Niigata, Niigata, JP, <sup>3</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>4</sup>Saga University, Saga, JP, <sup>5</sup>Chugai Pharmaceutical Co., Ltd., Chuo-ku, Tokyo, JP, <sup>6</sup>Kanagawa Cancer Center, Yokohama, JP

18:10 - 18:10

**542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study**

Y.-L. Wu<sup>1</sup>, Z. Wang<sup>1</sup>, X. Dong<sup>2</sup>, J. Li<sup>3</sup>, L. Wu<sup>4</sup>, L. Han<sup>5</sup>, X. Li<sup>6</sup>, A. Zang<sup>7</sup>, W. Li<sup>8</sup>, G. Wen<sup>9</sup>, W. Lin<sup>10</sup>, J. Feng<sup>11</sup>, L. Wang<sup>11</sup>, J. Li<sup>11</sup>, Q. Wang<sup>11</sup>, J. Zhu<sup>11</sup>, <sup>1</sup>Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, CN, <sup>2</sup>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, <sup>3</sup>Liuzhou People's Hospital, Liuzhou, CN, <sup>4</sup>Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CN, <sup>5</sup>Xuzhou Central Hospital, Xuzhou, CN, <sup>6</sup>The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, <sup>7</sup>Affiliated Hospital of Hebei University, Baoding, CN, <sup>8</sup>The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN, <sup>9</sup>The First Affiliated Hospital of Nanchang University, Nanchang, CN, <sup>10</sup>Cancer Hospital of Shantou University Medical College, Shantou, CN, <sup>11</sup>Shanghai Henlius Biotech, Inc., Shanghai, CN

18:10 - 18:10

**543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia**

Y. Ishida<sup>1</sup>, S. Ikeda<sup>2</sup>, T. Harada<sup>3</sup>, J. Sakakibara-Konishi<sup>1</sup>, K. Yokoo<sup>4</sup>, H. Kikuchi<sup>5</sup>, T. Iwasawa<sup>2</sup>, T. Misumi<sup>6</sup>, S. Konno<sup>1</sup>, T. Ogura<sup>2</sup>, <sup>1</sup>Hokkaido University Hospital, Sapporo, JP, <sup>2</sup>Kanagawa Cardiovascular and Respiratory Center, Yokohama, JP, <sup>3</sup>JCHO Hokkaido Hospital, Sapporo, JP, <sup>4</sup>Teine Keijinkai Hospital, Sapporo, JP, <sup>5</sup>JA Hokkaido Kouseiren - Obihiro Kosei General Hospital, Obihiro, JP, <sup>6</sup>National Cancer Center Hospital East, Kashiwa, JP

18:10 - 18:10

**544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients**

J. Seong<sup>1</sup>, H. Sim<sup>2</sup>, S.-H. Lee<sup>3</sup>, W.-Y. Park<sup>4</sup>, M. Choi<sup>2</sup>, <sup>1</sup>Seoul National University Hospital, Seoul, KR, <sup>2</sup>Seoul National University College of Medicine, Seoul, Korea, KR, <sup>3</sup>Samsung Medical Center (SMC), Seoul, KR, <sup>4</sup>Samsung Medical Center (SMC) - Samsung Genome

Institute, Seoul, KR

- 18:10 - 18:10 **545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)**  
A. Fantoni<sup>1</sup>, L. Warburton<sup>1</sup>, B. Solomon<sup>2</sup>, M. Alexander<sup>2</sup>, M. Maddula<sup>3</sup>, I. Pires Da Silva<sup>3</sup>, L. Brown<sup>4</sup>, A. Nagrial<sup>4</sup>, F. Abu Al-Hial<sup>5</sup>, M. Itchins<sup>5</sup>, N. Pavlakis<sup>5</sup>, S. Bowyer<sup>6</sup>, <sup>1</sup>Fiona Stanley Hospital, Perth, AU, <sup>2</sup>Peter MacCallum Cancer Center, Melbourne, AU, <sup>3</sup>Blacktown Hospital, Blacktown, AU, <sup>4</sup>Westmead Hospital, Westmead, AU, <sup>5</sup>Royal North Shore Hospital, St Leonards, AU, <sup>6</sup>Sir Charles Gairdner Hospital, Nedlands, AU
- 18:10 - 18:10 **546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation**  
T. Minami<sup>1</sup>, A. Tada<sup>2</sup>, H. Kitai<sup>2</sup>, T. Fujioka<sup>2</sup>, N. Kawamura<sup>2</sup>, T. Kondo<sup>2</sup>, M. Murakami<sup>2</sup>, M. Morishita<sup>2</sup>, M. Tokuda<sup>2</sup>, T. Higashiyama<sup>2</sup>, Y. Negi<sup>1</sup>, D. Horio<sup>2</sup>, T. Otsuki<sup>2</sup>, K. Mikami<sup>1</sup>, R. Takahashi<sup>1</sup>, K. Kuribayashi<sup>1</sup>, T. Kijima<sup>1</sup>, <sup>1</sup>Hyogo College of Medicine, Nishinomiya, JP, <sup>2</sup>Hyogo Medical University, Nishinomiya, JP
- 18:10 - 18:10 **547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data**  
N. K., A. Singh, V. Noronha, A. Joshi, V. Patil, N. Menon, K. Prabhash, Tata Memorial Hospital - Parel, Mumbai, IN
- 18:10 - 18:10 **548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis**  
P. Xu, M. Hu, Y. Liang, S. Guo, J. Xue, W. Cai, University-Town Hospital of Chongqing Medical University, Chongqing, CN
- 18:10 - 18:10 **549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung**  
S. Fujimoto, T. Tanaka, N. Katsurada, D. Hazama, T. Nagano, M. Yamamoto, M. Tachihara, Kobe University Graduate School of Medicine, Kobe, JP
- 18:10 - 18:10 **551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients**  
A. Knox<sup>1</sup>, T. Cloney<sup>1</sup>, H. Janssen<sup>1</sup>, B. Solomon<sup>1</sup>, M. Alexander<sup>2</sup>, T. John<sup>3</sup>, <sup>1</sup>Peter MacCallum Cancer Center, Melbourne, AU, <sup>2</sup>The University of Melbourne, Parkville, AU, <sup>3</sup>Peter MacCallum Cancer Centre, Melbourne, AU
- 18:10 - 18:10 **552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)**  
M.-J. Ahn<sup>1</sup>, B.C. Cho<sup>2</sup>, Y. Goto<sup>3</sup>, K. Yoh<sup>4</sup>, W.-C. Su<sup>5</sup>, J. Shimizu<sup>6</sup>, J.-S. Lee<sup>7</sup>, S. Oizumi<sup>8</sup>, J.C.-H. Yang<sup>9</sup>, H. Hayashi<sup>10</sup>, H. Zebger-Gong<sup>11</sup>, K. Sugiura<sup>12</sup>, L. Lan<sup>13</sup>, C. Liu<sup>13</sup>, S. Kitazono<sup>14</sup>, <sup>1</sup>Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, <sup>2</sup>Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, <sup>3</sup>National Cancer Center - Tsukiji Campus, Chuo-ku, JP, <sup>4</sup>National Cancer

Center Hospital East, Kashiwa, JP, <sup>5</sup>NCKU - National Cheng Kung University, Tainan City, TW, <sup>6</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>7</sup>Seoul National University Bundang Hospital, Seongnam, KR, <sup>8</sup>National Hospital Organization, Hokkaido Cancer Center, Sapporo, JP, <sup>9</sup>NTUCC - National Taiwan University Cancer Center, Taipei City, TW, <sup>10</sup>Kindai University Faculty of Medicine, Osaka-Sayama, Ōsakasayama, JP, <sup>11</sup>Daiichi Sankyo Europe GmbH, Munich, DE, <sup>12</sup>Daiichi Sankyo Co., Ltd., Tokyo, JP, <sup>13</sup>Daiichi Sankyo, Inc., Basking Ridge, US, <sup>14</sup>The Cancer Institute Hospital of JFCR, Koto-ku, JP

18:10 - 18:10 **553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong**

J. Du, T.Y. Kam, F. Hioe, Y.H. Lui, W.L. Tang, C.Y. Wong, K.S. Wong, K.W. Ng, M.W. Yeung, Pamela Youde Nethersole Eastern Hospital, Hong Kong, HK

18:10 - 18:10 **554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study**

K. Miyazaki, K. Ito, A. Hayashi, A. Shiba, Y. Higashi, M. Aga, Y. Hamakawa, Y. Taniguchi, Y. Misumi, Y. Agemi, Y. Nakamura, T. Shimokawa, H. Okamoto, Yokohama Municipal Citizen's Hospital, Yokohama, JP

18:10 - 18:10 **555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong**

J.C.S. Ho<sup>1</sup>, C.H.L. Wong<sup>2</sup>, K.S.J. Fong<sup>2</sup>, V. Lee<sup>2</sup>, M.Y. Lim<sup>3</sup>, T.Y. Kam<sup>4</sup>, S.F. Nyaw<sup>5</sup>, C.K. Kwan<sup>6</sup>, F. Mok<sup>7</sup>, A.W.M. Lee<sup>2</sup>, K.M. Cheung<sup>1</sup>, <sup>1</sup>Queen Elizabeth Hospital, Kowloon, HK, <sup>2</sup>The University of Hong Kong, Hong Kong, HK, <sup>3</sup>Princess Margaret Hospital, Kowloon, HK, <sup>4</sup>Pamela Youde Nethersole Eastern Hospital, Hong Kong, HK, <sup>5</sup>Tuen Mun Hospital, New Territories, HK, <sup>6</sup>United Christian Hospital, Kowloon, HK, <sup>7</sup>Prince of Wales Hospital, New Territories, HK

18:10 - 18:10 **556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)**

X. Hao<sup>1</sup>, S. Zhang<sup>2</sup>, Y. Hu<sup>3</sup>, W. Zhuang<sup>4</sup>, J. Fang<sup>5</sup>, Y. Liu<sup>6</sup>, M. Wang<sup>7</sup>, M. Si<sup>7</sup>, Y. Sang<sup>7</sup>, X. Kang<sup>7</sup>, Y.-K. Shi<sup>8</sup>, <sup>1</sup>National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, <sup>2</sup>Beijing Chest Hospital, Capital Medical University, Beijing, CN, <sup>3</sup>Chinese PLA General Hospital, Beijing, CN, <sup>4</sup>Fujian Cancer Hospital, Fuzhou, CN, <sup>5</sup>Peking University Cancer Hospital and Institute, Beijing, CN, <sup>6</sup>The First Hospital of China Medical University, Shenyang, CN, <sup>7</sup>Qilu Pharmaceutical Co., Ltd., Jinan, CN, <sup>8</sup>National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN

18:10 - 18:10 **557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy**

S. Wang<sup>1</sup>, Y.-K. Shi<sup>1</sup>, X. Han<sup>2</sup>, <sup>1</sup>National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, <sup>2</sup>Peking Union Medical College Hospital, State Key

Laboratory of Complex Severe and Rare Diseases, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Acade, Beijing, CN

- 18:10 - 18:10 **558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK<sup>+</sup> NSCLC in South Korea**  
J.E. Lee<sup>1</sup>, J.H. Nam<sup>2</sup>, S.H. Kwon<sup>3</sup>, B.-K. Kim<sup>4</sup>, S.-M. Ha<sup>4</sup>, <sup>1</sup>Chungnam National University, Daejeon, KR, <sup>2</sup>Korea University, Sejong, KR, <sup>3</sup>Sungkyunkwan University, Suwon, KR, <sup>4</sup>Takeda Pharmaceuticals Korea Co.,Ltd., Seoul, KR
- 18:10 - 18:10 **559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC**  
Z. Arter, M. Nagasaka, S.-H. Ou, UCI Health Chao Family Comprehensive Cancer Center, Orange, US
- 18:10 - 18:10 **560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC**  
C. Weng<sup>1</sup>, K. Tang<sup>2</sup>, S. Jin<sup>3</sup>, C. Zhou<sup>4</sup>, Y. Yao<sup>5</sup>, J.-W. Su<sup>1</sup>, H. Chen<sup>1</sup>, K. Liu<sup>6</sup>, Y. Li<sup>7</sup>, J. Yang<sup>1</sup>, <sup>1</sup>Guangdong Province People's Hospital, Guangzhou, CN, <sup>2</sup>The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, <sup>3</sup>Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, CN, <sup>4</sup>State Key Laboratory of Respiratory Diseases - The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou, CN, <sup>5</sup>Shenzhen People's Hospital, Jinan University, Shenzhen, CN, <sup>6</sup>Dongguan People's Hospital, Dongguan, CN, <sup>7</sup>West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN
- 18:10 - 18:10 **561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study**  
D. Harada<sup>1</sup>, A. Tamiya<sup>2</sup>, M. Osuga<sup>3</sup>, Y. Mizumori<sup>4</sup>, S.-I. Isa<sup>5</sup>, Y. Taniguchi<sup>2</sup>, K. Nakamura<sup>6</sup>, T. Shinohara<sup>7</sup>, H. Yanai<sup>8</sup>, K. Nakatomi<sup>9</sup>, M. Oki<sup>10</sup>, M. Mori<sup>11</sup>, T. Kuwako<sup>12</sup>, K. Yamazaki<sup>13</sup>, A. Tamura<sup>14</sup>, M. Ando<sup>15</sup>, Y. Koh<sup>3</sup>, <sup>1</sup>Shikoku Cancer Center, Matsuyama, JP, <sup>2</sup>NHO Kinki-Chuo Chest Medical Center, Sakai, JP, <sup>3</sup>Wakayama Medical University, Wakayama, JP, <sup>4</sup>NHO Himeji Medical Center, Himeji, JP, <sup>5</sup>NHO Kinki-Chuo Chest Medical Center, Sakai, JP, <sup>6</sup>National Hospital Organization Asahikawa Medical Center, Asahikawa, JP, <sup>7</sup>NHO Kochi Hospital, Kochi, JP, <sup>8</sup>NHO Mito Medical Center, Ibaraki, JP, <sup>9</sup>National Hospital Organization Ureshino Medical Center, Ureshino, JP, <sup>10</sup>NHO Nagoya Medical Center, Nagoya, JP, <sup>11</sup>National Hospital Organization Toneyama Hospital, Toyonaka, JP, <sup>12</sup>NHO Shibukawa Medical Center, Shibukawa, JP, <sup>13</sup>NHO Kyushu Medical Center, Fukuoka, JP, <sup>14</sup>NHO Tokyo National Hospital, Kiyose, JP, <sup>15</sup>Nagoya University Hospital, Nagoya, JP
- 18:10 - 18:10 **562P - First-line (1L) osimertinib (osi) vs platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort**  
Y. Cheng<sup>1</sup>, Y. Yu<sup>2</sup>, Y. Fan<sup>3</sup>, L. Jiang<sup>4</sup>, L. Wu<sup>5</sup>, J. Hu<sup>6</sup>, J. Wang<sup>7</sup>, W. Yao<sup>8</sup>, Z. Han<sup>9</sup>, Y. Yao<sup>10</sup>, J. Fang<sup>11</sup>, M. Sun<sup>12</sup>, Q. Wang<sup>13</sup>, Y. Pan<sup>14</sup>, R. Wu<sup>15</sup>, J. Liu<sup>16</sup>, Y. Liu<sup>17</sup>, D. Kulkarni<sup>18</sup>, X. Huang<sup>18</sup>, P. Jänne<sup>19</sup>, <sup>1</sup>Jilin Cancer Hospital, Changchun, CN, <sup>2</sup>3rd Affiliated Hospital of Harbin Medical University, Harbin, CN, <sup>3</sup>Zhejiang Cancer Hospital, Hangzhou, CN,

<sup>4</sup>Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, <sup>5</sup>Hunan Province Tumor Hospital, Changsha, CN, <sup>6</sup>Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, <sup>7</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>8</sup>Sichuan Cancer Hospital, Chengdu, CN, <sup>9</sup>The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, CN, <sup>10</sup>The First Affiliated Hospital of Xian Jiaotong University, Xian, CN, <sup>11</sup>Beijing Cancer Hospital, Beijing, CN, <sup>12</sup>Jinan Central Hospital, Shandong University; Central Hospital Affiliated to Shandong First Medical University, Jinan, CN, <sup>13</sup>Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, CN, <sup>14</sup>Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology, Hefei, CN, <sup>15</sup>Sheng Jing Hospital, Shenyang, CN, <sup>16</sup>AstraZeneca, Beijing, CN, <sup>17</sup>R&D China, AstraZeneca, Shanghai, CN, <sup>18</sup>AstraZeneca, Cambridge, GB, <sup>19</sup>Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, US

- 18:10 - 18:10 **563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)**
- J. Zhou<sup>1</sup>, L. Shen<sup>1</sup>, D. Lv<sup>2</sup>, K. Tang<sup>3</sup>, D. Zhu<sup>4</sup>, Y. Zhao<sup>5</sup>, K. Wang<sup>6</sup>, Y. Wang<sup>7</sup>, L. Xing<sup>8</sup>, J. Cui<sup>9</sup>, L. Ding<sup>10</sup>, X. Shi<sup>11</sup>, J. Zheng<sup>1</sup>, J. Zhou<sup>1</sup>, <sup>1</sup>The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN, <sup>2</sup>Affiliated Taizhou Hospital of Zhejiang Province of Wenzhou Medical University, Taizhou, CN, <sup>3</sup>The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, <sup>4</sup>Jinhua Municipal Central Hospital, Jinhua, CN, <sup>5</sup>The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, CN, <sup>6</sup>West China Hospital of Sichuan University, Chengdu, CN, <sup>7</sup>Tumor Hospital affiliated to Harbin Medical University, Harbin, CN, <sup>8</sup>Shandong Cancer Hospital and Institute, Shandong First Medical University, Jinan, CN, <sup>9</sup>The First Hospital of Jilin University, Changchun, CN, <sup>10</sup>The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN, <sup>11</sup>Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, CN
- 18:10 - 18:10 **564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC**
- W.F. Fang<sup>1</sup>, L. Pang<sup>1</sup>, Y.-H. Huang<sup>2</sup>, L. Zhang<sup>1</sup>, <sup>1</sup>Sun Yat-sen University Cancer Center, Guangzhou, CN, <sup>2</sup>State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, CN
- 18:10 - 18:10 **565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib**
- M. Li<sup>1</sup>, K. Mok<sup>2</sup>, G. Tsui<sup>2</sup>, W.C.K. Lee<sup>3</sup>, K.C. Lam<sup>4</sup>, H.H.F. Loong<sup>5</sup>, F. Mok<sup>6</sup>, L. Chan<sup>3</sup>, K. Yan<sup>3</sup>, T.Y.J. Ng<sup>6</sup>, D. Johnson<sup>5</sup>, B. Lam<sup>6</sup>, W. Wong<sup>6</sup>, A. Chen<sup>6</sup>, M.P. Lee<sup>5</sup>, O. Chen<sup>3</sup>, T.S.K. Mok<sup>6</sup>, <sup>1</sup>The Chinese University of Hong Kong, Hong Kong, HK, <sup>2</sup>Prince of Wales Hospital, Sha Tin, HK, <sup>3</sup>The Chinese University of Hong Kong, Department of Clinical Oncology, Hong Kong, HK, <sup>4</sup>Prince of Wales Hospital, HK, HK, <sup>5</sup>The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK, <sup>6</sup>Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK
- 18:10 - 18:10 **566P - Safety of tepotinib &#x2b; osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib**

C.K. Liam<sup>1</sup>, T.M. Kim<sup>2</sup>, J.-J. Yang<sup>3</sup>, C. Huang<sup>4</sup>, P.J. Voon<sup>5</sup>, L. Tho<sup>6</sup>, Q. Zhou<sup>7</sup>, J. Wang<sup>8</sup>, H. Hayashi<sup>9</sup>, D.S.W. Tan<sup>10</sup>, P. Danchaivijitr<sup>11</sup>, V.N. Nguyen<sup>12</sup>, K.H. Wong<sup>13</sup>, J.C.-H. Yang<sup>14</sup>, X. Le<sup>15</sup>, B. Eilers-Lenz<sup>16</sup>, N. Karachaliou<sup>16</sup>, V. Ghori<sup>16</sup>, K. Berghoff<sup>16</sup>, Y.-L. Wu<sup>17</sup>, <sup>1</sup>Faculty of Medicine, University of Malaya, Kuala Lumpur, MY, <sup>2</sup>Seoul National University Hospital, Seoul, KR, <sup>3</sup>Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN, <sup>4</sup>Fujian Cancer Hospital, Fuzhou, CN, <sup>5</sup>Kuching, Sarawak, MY, <sup>6</sup>Pantai Hospital Kuala Lumpur, Kuala Lumpur, MY, <sup>7</sup>West China Hospital, Sichuan University, Chengdu, Sichuan, CN, <sup>8</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>9</sup>Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, JP, <sup>10</sup>National Cancer Centre Singapore, Singapore, SG, <sup>11</sup>Department of Internal Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, TH, <sup>12</sup>-, Hanoi, VN, <sup>13</sup>Queen Elizabeth Hospital, Hong Kong, HK, <sup>14</sup>National Taiwan University Cancer Center, Taipei City, TW, <sup>15</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>16</sup>Merck Healthcare KGaA, Darmstadt, DE, <sup>17</sup>Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN

18:10 - 18:10

**567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR &#x2013;mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure**

F. Cun<sup>1</sup>, M. Zhao<sup>2</sup>, X. Wang<sup>3</sup>, T. Xu<sup>3</sup>, <sup>1</sup>Nanjing Chest Hospital, NAN JING, CN, <sup>2</sup>Nanjing Gaochun people's Hospital, Nanjing, CN, <sup>3</sup>Nanjing Chest Hospital - Medical School of Southeast University, Nanjing, CN

18:10 - 18:10

**568P - First-line (1L) osimertinib &#x2b; platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results**

D. Planchard<sup>1</sup>, A. Poltoratskiy<sup>2</sup>, S.-W. Kim<sup>3</sup>, T.M. Kim<sup>4</sup>, N. Yanagitani<sup>5</sup>, H. Kagamu<sup>6</sup>, P.-H. Feng<sup>7</sup>, B. Hughes<sup>8</sup>, T.-Y. Yang<sup>9</sup>, J.C.-H. Yang<sup>10</sup>, C.K. Lee<sup>11</sup>, N. Karaseva<sup>12</sup>, P. Mitchell<sup>13</sup>, Y. Tambo<sup>14</sup>, E. Armenteros Monterroso<sup>15</sup>, A. Todd<sup>15</sup>, A. Sahasrabudhe<sup>15</sup>, P. Jänne<sup>16</sup>, K. Kobayashi<sup>17</sup>, <sup>1</sup>Institut Gustave Roussy, Thoracic Unit, Villejuif, FR, <sup>2</sup>Petrov Research Institute of Oncology, St. Petersburg, RU, <sup>3</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>4</sup>Seoul National University Hospital, Seoul, KR, <sup>5</sup>The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JP, <sup>6</sup>Saitama Medical University, Saitama, JP, <sup>7</sup>Shuang Ho Hospital, Taipei Medical University, Taipei, TW, <sup>8</sup>The Prince Charles Hospital, Herston, AU, <sup>9</sup>Taichung Veterans General Hospital, Taichung, TW, <sup>10</sup>National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, TW, <sup>11</sup>Cancer Care Centre, St. George Hospital, Kogarah, AU, <sup>12</sup>City Clinical Oncology Hospital, Saint Petersburg, RU, <sup>13</sup>Olivia Newton-John Cancer Center, Austin Health, Melbourne, AU, <sup>14</sup>Kanazawa University Hospital, Kanazawa, JP, <sup>15</sup>AstraZeneca, Cambridge, GB, <sup>16</sup>Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, US, <sup>17</sup>Saitama Medical University International Medical Center, Hidaka, JP

18:10 - 18:10

**569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD&#x2013;like and SCLC&#x2013;like subsets**

C.-Y. Zhang<sup>1</sup>, H. Sun<sup>2</sup>, J.-W. Su<sup>1</sup>, X.-H. Zhang<sup>2</sup>, W.-N. Feng<sup>3</sup>, Y.-L. Wu<sup>1</sup>, J.-J. Yang<sup>1</sup>, <sup>1</sup>Guangdong Province People's Hospital, Guangzhou, CN, <sup>2</sup>Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University,,



Guangzhou, CN, <sup>3</sup>The First People's Hospital of Foshan,, Foshan, Guangdong, China, CN

- 18:10 - 18:10 **570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study**  
W. Ji<sup>1</sup>, D. Jiang<sup>2</sup>, J. Zhang<sup>3</sup>, H. Zhang<sup>4</sup>, Q. Wang<sup>5</sup>, S. Cang<sup>6</sup>, X. Li<sup>7</sup>, J. Tan<sup>8</sup>, Y. Xiang<sup>9</sup>, X. Li<sup>10</sup>, A. Liu<sup>11</sup>, S. Lu<sup>12</sup>, <sup>1</sup>Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, <sup>2</sup>The Fourth Hospital of Hebei Medical University - North Gate, Shijiazhuang, CN, <sup>3</sup>Shanxi Da Hospital, Taiyuan, CN, <sup>4</sup>Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, CN, <sup>5</sup>Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, <sup>6</sup>Henan Provincial People's Hospital, Zhengzhou, CN, <sup>7</sup>The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, <sup>8</sup>Suzhou Fourth People's Hospital/ Suzhou Municipal Hospital, Suzhou, CN, <sup>9</sup>Shanghai Ruijin - Ammed Cancer Centre, Shanghai, CN, <sup>10</sup>Liaoning Cancer Hospital & Institute, Shenyang, CN, <sup>11</sup>2nd Affiliated Hospital of Nanchang University, Nanchang, CN, <sup>12</sup>Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CN
- 18:10 - 18:10 **571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study**  
Y. Yu<sup>1</sup>, Y. Pan<sup>2</sup>, J. Zhou<sup>3</sup>, S. Lu<sup>4</sup>, <sup>1</sup>Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, <sup>2</sup>Anhui Provincial Hospital, Hefei, CN, <sup>3</sup>The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, CN, <sup>4</sup>Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CN
- 18:10 - 18:10 **572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs**  
Q.-A. Wang<sup>1</sup>, C.T. Yang<sup>2</sup>, C.-H. Kuo<sup>2</sup>, P.-C. Hsu<sup>3</sup>, J.W.-C. Chang<sup>2</sup>, C.-E. Wu<sup>3</sup>, <sup>1</sup>Chang Gung University, Taoyuan City, TW, <sup>2</sup>Chang Gung Medical Foundation- Taipei Chang Gung Memorial Hospital, Taipei City, TW, <sup>3</sup>Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW
- 18:10 - 18:10 **573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets**  
B.C. Cho<sup>1</sup>, Q. Xu<sup>2</sup>, S. Ng<sup>2</sup>, J. Goldman<sup>3</sup>, N. Girard<sup>4</sup>, D. Planchard<sup>5</sup>, S. Bajjal<sup>6</sup>, R. Kamalakar<sup>2</sup>, V. Blot<sup>2</sup>, H. Alhasani<sup>2</sup>, S. Karve<sup>2</sup>, S. Lu<sup>7</sup>, <sup>1</sup>Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, <sup>2</sup>AbbVie Inc, North Chicago, US, <sup>3</sup>David Geffen School of Medicine at UCLA, Los Angeles, US, <sup>4</sup>Institut Curie, Paris, FR, <sup>5</sup>Institut Gustave Roussy, Thoracic Unit, Villejuif, FR, <sup>6</sup>University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB, <sup>7</sup>Shanghai Chest Hospital, Shanghai, CN
- 18:10 - 18:10 **574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations**  
L. Wu, X. Pu, Y. Zhou, Y. Kong, B. Chen, A. Yang, J. Li, K. Li, Y. Xu, Hunan Cancer Hospital, Changsha, CN

- 18:10 - 18:10 **575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study**  
P. Xing<sup>1</sup>, Y. Zhou<sup>2</sup>, Z. Liu<sup>3</sup>, Y. Yao<sup>4</sup>, J. Liu<sup>1</sup>, S. Wang<sup>5</sup>, Y. Hu<sup>5</sup>, J. Li<sup>1</sup>, L. Wu<sup>2</sup>, <sup>1</sup>Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, <sup>2</sup>Hunan Cancer Hospital, Changsha, CN, <sup>3</sup>The First Hospital of Jilin University, Changchun, CN, <sup>4</sup>The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CN, <sup>5</sup>Beijing Chest Hospital, Beijing, CN
- 18:10 - 18:10 **576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer**  
L. Pang<sup>1</sup>, W.-T. Zhuang<sup>1</sup>, L. Zhang<sup>2</sup>, W.F. Fang<sup>2</sup>, <sup>1</sup>State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, CN, <sup>2</sup>Sun Yat-sen University Cancer Center, Guangzhou, CN
- 18:10 - 18:10 **577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC**  
D. Choi, H.A. Jung, S. Park, J.-M. Sun, J.S. Ahn, M.-J. Ahn, S.-H. Lee, Samsung Medical Center (SMC), Seoul, KR
- 18:10 - 18:10 **578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study**  
L.-J. Hung<sup>1</sup>, J.W.-C. Chang<sup>1</sup>, C.-Y. Huang<sup>2</sup>, Y.-F. Fang<sup>1</sup>, C.-F. Chang<sup>1</sup>, C.-H.S. Kuo<sup>1</sup>, P.-C. Hsu<sup>1</sup>, C.-T. Yang<sup>1</sup>, C.-E. Wu<sup>1</sup>, <sup>1</sup>Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW, <sup>2</sup>Duke-NUS Graduate Medical School, Singapore, SG
- 18:10 - 18:10 **579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer**  
J.E. Shin, Samsung Medical Center, Seoul, KR
- 18:10 - 18:10 **580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) 21L858R mutation: A multicenter, ambispective, consecutive case-series study**  
S. Wang<sup>1</sup>, Y. Wang<sup>2</sup>, L. Wang<sup>2</sup>, Y. Liu<sup>2</sup>, Y. Hu<sup>1</sup>, Z. Liu<sup>3</sup>, Y. Yao<sup>4</sup>, L. Liang<sup>5</sup>, J. Liu<sup>2</sup>, J. Li<sup>2</sup>, P. Xing<sup>2</sup>, <sup>1</sup>Beijing Chest Hospital, Beijing, CN, <sup>2</sup>Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, <sup>3</sup>The First Hospital of Jilin University, Changchun, CN, <sup>4</sup>The First Affiliated Hospital of Xian Jiaotong University, Xian, CN, <sup>5</sup>3rd Hospital Beijing University, Beijing, CN
- 18:10 - 18:10 **581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer**  
W.-C. Tang, Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW
- 18:10 - 18:10 **582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell**

**lung cancer and leptomeningeal metastases: A real-world study**

H. Chen, L. Wang, Y. Wu, Y. Wu, S. Ma, Y. Sen, H. Zhen, Y. Mo, C. Zhang, Q. Wang, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, CN

18:10 - 18:10

**583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR**

J. Deng<sup>1</sup>, J. Qin<sup>2</sup>, N. Lin<sup>1</sup>, <sup>1</sup>Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, CN, <sup>2</sup>The Second Affiliated Hospital of Guangxi Medical University, Nanning, CN

18:10 - 18:10

**584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis**

T. Lv, Y. Song, P. Zhan, Y. Yao, Jinling Hospital Affiliated to Nanjing University School of Medicine/Eastern Theater General Hospital of PLA, Nanjing, CN

18:10 - 18:10

**585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib**

T.S.K. Mok<sup>1</sup>, G. Liu<sup>2</sup>, S.F. Nyaw<sup>3</sup>, H. Curcio<sup>4</sup>, A. Cortot<sup>5</sup>, T.Y. Kam<sup>6</sup>, R. Descourt<sup>7</sup>, Y.K. Chik<sup>8</sup>, P. Cheema<sup>9</sup>, J. Gwinnutt<sup>10</sup>, E. Churchill<sup>11</sup>, J. Nyborn<sup>12</sup>, E. Curran<sup>13</sup>, Y. Yin<sup>13</sup>, K. Chong<sup>14</sup>, Y. Tanaka-Chambers<sup>15</sup>, J. Kretz<sup>16</sup>, J. Cadranel<sup>17</sup>, <sup>1</sup>The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, HK, <sup>2</sup>Ontario Cancer Institute, Princess Margaret Cancer Centre, Toronto, CA, <sup>3</sup>Tuen Mun Hospital, Hong Kong, CN, <sup>4</sup>Centre Francois Baclesse, Caen, FR, <sup>5</sup>CHRU de Lille, Lille, FR, <sup>6</sup>Pamela Youde Nethersole Eastern Hospital Main Block, Hong Kong, CN, <sup>7</sup>CHU Brest, Hopital Morvan, Brest, FR, <sup>8</sup>Queen Elizabeth Hospital (QEH), Hong Kong, CN, <sup>9</sup>William Osler Health System, University of Toronto, Brampton, CA, <sup>10</sup>IQVIA, Reading, GB, <sup>11</sup>Takeda Pharmaceuticals U.S.A., Inc., Lexington, US, <sup>12</sup>Takeda Development Center Americas, Inc., Cambridge, US, <sup>13</sup>Takeda Development Center Americas, Inc., Lexington, US, <sup>14</sup>Takeda Development Center America, Inc., Cambridge, US, <sup>15</sup>Takeda Pharmaceuticals, Cambridge, US, <sup>16</sup>Takeda Pharmaceuticals International AG, Glattpark-Opfikon (Zurich), CH, <sup>17</sup>APHP Hôpital Tenon and Sorbonne Université Paris, Paris, FR

18:10 - 18:10

**586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment**

C. Zhou<sup>1</sup>, B. Li<sup>2</sup>, J. Fang<sup>3</sup>, J. Zhou<sup>4</sup>, Y. Hu<sup>5</sup>, C. Zhu<sup>6</sup>, V. Bunn<sup>7</sup>, M. Lin<sup>7</sup>, J.-L. Hong<sup>7</sup>, J. Huang<sup>7</sup>, J. Wang<sup>8</sup>, R. Fram<sup>7</sup>, S. Vincent<sup>7</sup>, Y. Li<sup>7</sup>, <sup>1</sup>Shanghai Pulmonary Hospital, Shanghai, CN, <sup>2</sup>Beijing Chest Hospital, Capital Medical University, Beijing, CN, <sup>3</sup>Beijing Chest Hospital, Peking University, Beijing, CN, <sup>4</sup>The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, CN, <sup>5</sup>Hubei Cancer Hospital, Wuhan, CN, <sup>6</sup>Amoy Diagnostics Co., Ltd., Shanghai, CN, <sup>7</sup>Takeda Development Center Americas, Inc., Lexington, US, <sup>8</sup>Takeda APAC Biopharmaceutical R&D Ltd., Shanghai, CN

18:10 - 18:10

**587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort**

N.Y. Yap<sup>1</sup>, K. Perumal<sup>1</sup>, P. Rajadurai<sup>2</sup>, <sup>1</sup>SJMC - Sime Darby Medical Centre Subang Jaya, Subang Jaya, MY, <sup>2</sup>Subang Jaya Medical Centre, Subang Jaya, MY

- 18:10 - 18:10 **588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer**
- M. Zhang<sup>1</sup>, L. Wang<sup>2</sup>, Q. Wang<sup>1</sup>, J. Yang<sup>1</sup>, W. Peng<sup>2</sup>, M. Shi<sup>2</sup>, K. Lu<sup>1</sup>, <sup>1</sup>Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN, <sup>2</sup>Jiangsu Institute of Cancer Research, the Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, CN
- 18:10 - 18:10 **590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)**
- B. Markman<sup>1</sup>, B. Solomon<sup>2</sup>, L. Nott<sup>3</sup>, R. Roberts-Thomson<sup>4</sup>, B. Hughes<sup>5</sup>, N. Pavlakis<sup>6</sup>, A. Davis<sup>7</sup>, L. Brown<sup>8</sup>, S. Parakh<sup>9</sup>, D. Brungs<sup>10</sup>, S. Bowyer<sup>11</sup>, I. Nordman<sup>12</sup>, R. Jennens<sup>13</sup>, L. Warburton<sup>14</sup>, S. Harris<sup>15</sup>, E. Samuel<sup>16</sup>, S. Ramanujam<sup>17</sup>, A. Wang<sup>18</sup>, M. Dumas<sup>19</sup>, G. Gard<sup>19</sup>, <sup>1</sup>Alfred Hospital, Melbourne, AU, <sup>2</sup>Peter MacCallum Cancer Center, Melbourne, AU, <sup>3</sup>Royal Hobart Hospital, Hobart, AU, <sup>4</sup>The Queen Elizabeth Hospital, Woodville, AU, <sup>5</sup>The Prince Charles Hospital, Chermside, AU, <sup>6</sup>Royal North Shore Hospital, St Leonards, AU, <sup>7</sup>Chris O'Brien Lifehouse, Camperdown, AU, <sup>8</sup>Westmead Hospital, Sydney, AU, <sup>9</sup>Olivia Newton-John Cancer Research Institute, Heidelberg, AU, <sup>10</sup>Illawarra Cancer Centre, Wollongong Hospital, Wollongong, AU, <sup>11</sup>Sir Charles Gairdner Hospital, Nedlands, AU, <sup>12</sup>Calvary Mater Hospital Newcastle, Newcastle, AU, <sup>13</sup>Peter MacCallum Cancer Centre, East Melbourne, AU, <sup>14</sup>Fiona Stanley Hospital, Perth, AU, <sup>15</sup>Bendigo Health, Bendigo, AU, <sup>16</sup>Latrobe Regional Hospital, Traralgon, AU, <sup>17</sup>Griffith Base Hospital, Griffith, AU, <sup>18</sup>Amgen Inc, Sydney, AU, <sup>19</sup>Walter and Eliza Hall Institute of Medical Research, Parkville, AU
- 18:10 - 18:10 **591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study**
- A. Pluzanski, A. Tysarowski, K. Seliga, A. Gos, R. Zub, M. Krzakowski, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL
- 18:10 - 18:10 **592P - Treatment patterns and outcomes in patients with advanced non-small cell lung cancer with MET exon 14 skipping alterations in China**
- J. Zhao<sup>1</sup>, C. Chen<sup>2</sup>, Y. Zhang<sup>2</sup>, H. Vioix<sup>3</sup>, H. Chen<sup>1</sup>, <sup>1</sup>-, Beijing, CN, <sup>2</sup>Beijing, China, an affiliate of Merck KGaA, Beijing, CN, <sup>3</sup>-, Darmstadt, DE
- 18:10 - 18:10 **593P - MET TKIs in Asian patients (pts) with MET exon 14 skipping NSCLC: A matching-adjusted indirect comparison (MAIC)**
- E.-E. Ke<sup>1</sup>, Y.-L. Wu<sup>2</sup>, T. Douglas<sup>3</sup>, A. Hatswell<sup>3</sup>, Y. Yao<sup>4</sup>, H. Vioix<sup>5</sup>, <sup>1</sup>Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, CN, <sup>2</sup>Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, CN, <sup>3</sup>-, Nottingham, GB, <sup>4</sup>Merck Serono Co., Ltd., Beijing, China, an affiliate of Merck KGaA, Beijing, CN, <sup>5</sup>Merck Healthcare KGaA, Darmstadt, DE
- 18:10 - 18:10 **594P - The treatment pattern and clinical outcome in NSCLC patients with MET alteration: A retrospective real-world analysis in China**

Y. Yu<sup>1</sup>, L. Shen<sup>1</sup>, W. Li<sup>2</sup>, B. Jin<sup>3</sup>, Y. Xia<sup>2</sup>, S. Zhang<sup>3</sup>, S. Lu<sup>4</sup>, <sup>1</sup>Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, <sup>2</sup>The Second Affiliated Hospital of Zhejiang University School of Medicine - East Gate 1, Hangzhou, CN, <sup>3</sup>The First Affiliated Hospital of China Medical University, Shenyang, CN, <sup>4</sup>Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CN

18:10 - 18:10 **595P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1&#x2b;) non-small cell lung cancer (NSCLC)**

D.-W. Kim<sup>1</sup>, K. Goto<sup>2</sup>, A. Schram<sup>3</sup>, A. Hollebecque<sup>4</sup>, S.Y. Rha<sup>5</sup>, K. Nishino<sup>6</sup>, M. Duruisseaux<sup>7</sup>, K. Umemoto<sup>8</sup>, J.O. Park<sup>9</sup>, N. Leigh<sup>10</sup>, T. Macarulla Mercade<sup>11</sup>, S. Liu<sup>12</sup>, M.N. Al-Hallak<sup>13</sup>, J. Cleary<sup>14</sup>, C. Neuzillet<sup>15</sup>, Y. Goto<sup>16</sup>, A.K. Joe<sup>17</sup>, S. Adeyemi<sup>17</sup>, S. Jauhari<sup>17</sup>, A. Drilon<sup>18</sup>, <sup>1</sup>Seoul National University Hospital and Seoul National University College of Medicine, Seoul, KR, <sup>2</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>3</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>4</sup>Gustave Roussy Cancer Campus, Villejuif, Cedex, FR, <sup>5</sup>Yonsei Cancer Center, Yonsei University Health System, Seoul, KR, <sup>6</sup>Osaka International Cancer Institute, Osaka, JP, <sup>7</sup>Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute; Cancer Research Centre of Lyon, UMR INSERM 1052 CNRS 5286; Claude Bernard University Lyon 1, University of Lyon, Lyon, FR, <sup>8</sup>St. Marianna University School of Medicine, Kawasaki, JP, <sup>9</sup>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, <sup>10</sup>Princess Margaret Cancer Centre Toronto, Toronto, CA, <sup>11</sup>Vall d'Hebrón University Hospital, Vall d'Hebrón Institute of Oncology (VHIO), Barcelona, ES, <sup>12</sup>Lombardi Comprehensive Cancer Center Georgetown University, Washington, US, <sup>13</sup>Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, US, <sup>14</sup>Dana-Farber Cancer Institute, Harvard Medical School, Boston, US, <sup>15</sup>Curie Institute, Paris, FR, <sup>16</sup>National Cancer Center Hospital, Tokyo, JP, <sup>17</sup>Merus N.V., Utrecht, NL, <sup>18</sup>Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US

18:10 - 18:10 **596P - Repotrectinib in patients (pts) from Asia and China with ROS1 fusion-positive (ROS1&#x2b;) non-small cell lung cancer (NSCLC): Results from the phase I/II TRIDENT-1 trial**

S. Lu<sup>1</sup>, X. Hu<sup>2</sup>, S.-W. Kim<sup>3</sup>, K. Goto<sup>4</sup>, N. Yang<sup>5</sup>, R. Soo<sup>6</sup>, J. Fang<sup>7</sup>, W. Yao<sup>8</sup>, K.H. Lee<sup>9</sup>, D.W.-T. Lim<sup>10</sup>, T. Kato<sup>11</sup>, M. Tamiya<sup>12</sup>, J. Wu<sup>13</sup>, Y. Zhang<sup>14</sup>, J. Zhou<sup>15</sup>, F. Ades<sup>16</sup>, J. Hua<sup>17</sup>, P. Wang<sup>16</sup>, B.C. Cho<sup>18</sup>, <sup>1</sup>Shanghai Chest Hospital, Shanghai, CN, <sup>2</sup>Henan Cancer Hospital, Zhengzhou, CN, <sup>3</sup>Asan Medical Center, Seoul, KR, <sup>4</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>5</sup>Hunan Cancer Hospital, Changsha, CN, <sup>6</sup>National University Cancer Institute and National University Hospital, Singapore, SG, <sup>7</sup>Beijing Cancer Hospital, Beijing, CN, <sup>8</sup>Sichuan Cancer Hospital, Chengdu, CN, <sup>9</sup>Chungbuk National University Hospital, Cheongju, KR, <sup>10</sup>National Cancer Centre Singapore, Singapore, SG, <sup>11</sup>Kanagawa Cancer Center, Yokohama, JP, <sup>12</sup>Osaka International Cancer Institute, Osaka, JP, <sup>13</sup>The First Affiliated Hospital of Xiamen University, Xiamen, CN, <sup>14</sup>Zhejiang Cancer Hospital, Hangzhou, CN, <sup>15</sup>The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, CN, <sup>16</sup>Bristol Myers Squibb, Princeton, US, <sup>17</sup>Zai Laboratory, Shanghai, CN, <sup>18</sup>Yonsei Cancer Center, Seoul, KR

18:10 - 18:10 **597TiP - A phase I/II study to evaluate the safety and anti-tumor activity of JIN-A02 in patients with EGFR TKI-refractory, EGFR-mutant advanced NSCLC**

S.M. Lim<sup>1</sup>, B.C. Cho<sup>2</sup>, J.-Y. Han<sup>3</sup>, S.-W. Kim<sup>4</sup>, K. Lee<sup>5</sup>, M. Nagasaka<sup>6</sup>, T. Baisamut<sup>7</sup>, A. Jo<sup>8</sup>, E. Seah<sup>8</sup>, C. Kim<sup>8</sup>, S.-H. Ou<sup>6</sup>, <sup>1</sup>Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, <sup>2</sup>Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, <sup>3</sup>National Cancer Center - Graduate School of Cancer Science and Policy, Goyang, KR, <sup>4</sup>Asan Medical Center, University of Ulsan, Seoul, KR, <sup>5</sup>Chungbuk National University Hospital, Cheongju, KR, <sup>6</sup>Chao Family Comprehensive Cancer Center, University of California Irvine Healthcare, Orange, US, <sup>7</sup>Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, TH, <sup>8</sup>J INTS BIO, Seoul, KR

18:10 - 18:10

**598TiP - Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)**

C. Zhou, X. Xie, J. Wu, H. Deng, X. Lin, State Key Laboratory of Respiratory Diseases - The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou, CN

18:10 - 18:10

**599TiP - A prospective study of savolitinib plus docetaxel in pretreated EGFR/ALK/ROS1/METex14m-wildtype advanced NSCLC patients with MET overexpression (FirstMET)**

S. Zhan, J. Li, B. Cheng, J. He, W. Liang, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN

18:10 - 18:10

**600TiP - Phase III study of telisotuzumab vedotin (Teliso-V) vs docetaxel in pretreated c-Met overexpressing EGFR wildtype (WT) non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC)**

J. Tanizaki<sup>1</sup>, H. Akamatsu<sup>2</sup>, J. Su<sup>3</sup>, G.-W. Lee<sup>4</sup>, M.S. Xia<sup>5</sup>, B. Ainsworth<sup>6</sup>, M. Li<sup>6</sup>, E. Bolotin<sup>6</sup>, J. Seraj<sup>6</sup>, S. Lu<sup>7</sup>, <sup>1</sup>Kindai University - Faculty of Medicine, Osaka, JP, <sup>2</sup>Wakayama Medical University, Wakayama, JP, <sup>3</sup>Mackay Memorial Hospital - Taipei Branch, Taipei City, TW, <sup>4</sup>Gyeongsang National University Hospital and Gyeongsang National University School of Medicine, Jinju, KR, <sup>5</sup>Abbvie, Mettawa, US, <sup>6</sup>Abbvie Inc. - Headquarters, North Chicago, US, <sup>7</sup>Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CN

18:10 - 18:10

**601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158**

X. Wu<sup>1</sup>, Y. Mao<sup>2</sup>, N. Xu<sup>3</sup>, Y. Bai<sup>4</sup>, D. Wang<sup>5</sup>, X. Chen<sup>6</sup>, X. Yin<sup>7</sup>, Y. Deng<sup>8</sup>, J. Yang<sup>9</sup>, J. Zhang<sup>10</sup>, J. Tang<sup>11</sup>, Y. Huang<sup>12</sup>, J. Li<sup>13</sup>, M. Xu<sup>14</sup>, N. Li<sup>14</sup>, Y. Mao<sup>14</sup>, A. Gozman<sup>15</sup>, J. Xu<sup>16</sup>, <sup>1</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>2</sup>Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, CN, <sup>3</sup>The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, CN, <sup>4</sup>Harbin Medical University Hospital, Harbin, CN, <sup>5</sup>Chongqing University Cancer Hospital, Chongqing, CN, <sup>6</sup>Obstetrics & Gynecology Hospital of Fudan University, Shanghai, CN, <sup>7</sup>Hunan Cancer Hospital, Changsha, CN, <sup>8</sup>The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN, <sup>9</sup>Fujian Provincial Hospital, Fuzhou, CN, <sup>10</sup>The First Affiliated Hospital of Guangxi Medical University, Nanning, CN, <sup>11</sup>Hunan Cancer Hospital, Wuhan, CN, <sup>12</sup>Hubei Cancer Hospital, Wuhan, CN, <sup>13</sup>The First Affiliated Hospital of Xiamen University, Xiamen, CN, <sup>14</sup>MSD, Beijing, CN, <sup>15</sup>Merck & Co., Inc., Rahway, US, <sup>16</sup>The Fifth Medical Center of Chinese PLA General Hospital/Beijing 302 Hospital, Beijing, CN

- 18:10 - 18:10 **602P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) &#x2b; binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma**
- A. Haydon<sup>1</sup>, D. Schadendorf<sup>2</sup>, R. Dummer<sup>3</sup>, K. Flaherty<sup>4</sup>, C. Robert<sup>5</sup>, A.M. Arance Fernandez<sup>6</sup>, J.W. De Groot<sup>7</sup>, C. Garbe<sup>8</sup>, H. Gogas<sup>9</sup>, R. Gutzmer<sup>10</sup>, I. Krajsova<sup>11</sup>, G. Liskay<sup>12</sup>, C. Loquai<sup>13</sup>, M. Mandalà<sup>14</sup>, N. Yamazaki<sup>15</sup>, C. Guenzel<sup>16</sup>, A. Polli<sup>17</sup>, M. Thakur<sup>18</sup>, A. Di Pietro<sup>19</sup>, P. Ascierto<sup>20</sup>, <sup>1</sup>Alfred Hospital, Brighton East, AU, <sup>2</sup>WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, <sup>3</sup>USZ - University Hospital Zürich, Zurich, CH, <sup>4</sup>MGH - Massachusetts General Hospital, Boston, US, <sup>5</sup>Institut Gustave Roussy, Villejuif, Cedex, FR, <sup>6</sup>H. Clinic Barcelona, Barcelona, ES, <sup>7</sup>Isala Hospital, Zwolle, NL, <sup>8</sup>Universitaets-Hautklinik Tuebingen, Tuebingen, DE, <sup>9</sup>National and Kapodistrian University of Athens - School of Medicine, Athens, GR, <sup>10</sup>Ruhr University Bochum Medizinische Universitätsklinik, Bochum, DE, <sup>11</sup>Charles University - First Faculty of Medicine, Prague, CZ, <sup>12</sup>National Institute of Oncology, Budapest, HU, <sup>13</sup>Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, DE, <sup>14</sup>Università degli Studi di Perugia, Perugia, IT, <sup>15</sup>National Cancer Center - Tsukiji Campus, Chuo-ku, JP, <sup>16</sup>Pfizer - France, Paris, FR, <sup>17</sup>Pfizer Italy, Milan, IT, <sup>18</sup>Pfizer Inc, San Diego, US, <sup>19</sup>Pfizer Italia S.r.l., Milan, IT, <sup>20</sup>Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT
- 18:10 - 18:10 **603P - An individualised postoperative radiological surveillance schedule for IDH-wildtype glioblastoma patients (HK-GBM Registry)**
- A.C.K. Lau<sup>1</sup>, P.Y.M. Woo<sup>2</sup>, J.C.Y. Li<sup>3</sup>, T.Y.H. Chan<sup>1</sup>, D.K.K. Wong<sup>4</sup>, <sup>1</sup>HKU - The University of Hong Kong, Hong Kong, HK, <sup>2</sup>The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK, <sup>3</sup>CUHK - Chinese University of Hong Kong, Sha Tin, HK, <sup>4</sup>Queen Elizabeth Hospital, Kowloon, HK
- 18:10 - 18:10 **604P - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status**
- M. Brose<sup>1</sup>, B. Keam<sup>2</sup>, B. Robinson<sup>3</sup>, S. Sherman<sup>4</sup>, J. Krajewska<sup>5</sup>, C.-C. Lin<sup>6</sup>, F. Vaisman<sup>7</sup>, A. Hoff<sup>8</sup>, E. Hitre<sup>9</sup>, D. Bowles<sup>10</sup>, N. Ngamphaiboon<sup>11</sup>, X. Guo<sup>12</sup>, F. Zhang<sup>12</sup>, M. Schwickart<sup>12</sup>, D. Williamson<sup>12</sup>, D. Curran<sup>12</sup>, N. Berry<sup>12</sup>, J. Capdevila Castillon<sup>13</sup>, <sup>1</sup>Sidney Kimmel Cancer Center, Jefferson University, Philadelphia, US, <sup>2</sup>Seoul National University Hospital, Seoul, KR, <sup>3</sup>Royal North Shore Hospital, University of Sydney, Sydney, AU, <sup>4</sup>University of Texas MD Anderson Cancer Center, Houston, US, <sup>5</sup>Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, PL, <sup>6</sup>National Taiwan University Hospital Hospital, Taipei City, TW, <sup>7</sup>Instituto Nacional de Câncer, Rio de Janeiro, BR, <sup>8</sup>Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, Sao Paulo, BR, <sup>9</sup>The Multidisciplinary Head and Neck Cancer Center, Országos Onkológiai Intézet, Budapest, HU, <sup>10</sup>University of Colorado Anschutz Medical Campus, Aurora, US, <sup>11</sup>Ramathibodi Hospital, Mahidol University, Bangkok, TH, <sup>12</sup>Exelixis, Inc., Alameda, US, <sup>13</sup>Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), IOB Quiron-Teknon, Barcelona, ES
- 18:10 - 18:10 **606P - BRAF and NRAS mutations are associated with poor prognosis in Asians with acral-lentiginous and nodular cutaneous melanoma**
- R. Cahyono, S.L. Anwar, G.D. Pradana, H.Y. Boediman, Gadjah Mada University/Dr. Sardjito General Hospital, Yogyakarta, ID

- 18:10 - 18:10 **607P - Single institutional outcomes of radiotherapy and systemic therapy for melanoma brain metastases in Japan**  
N. Yamazaki<sup>1</sup>, S. Wada<sup>2</sup>, D. Ogata<sup>2</sup>, E. Nakano<sup>2</sup>, T. Kashihara<sup>2</sup>, K. Okuma<sup>2</sup>, H. Eto<sup>1</sup>, A. Takahashi<sup>3</sup>, H. Igaki<sup>4</sup>, K. Namikawa<sup>1</sup>, <sup>1</sup>National Cancer Center - Tsukiji Campus, Chuo-ku, JP, <sup>2</sup>NCCH - National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, JP, <sup>3</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>4</sup>NCCH - National Cancer Center Hospital, Chuo-ku, JP
- 18:10 - 18:10 **608P - The efficacy of immune checkpoint inhibitors and targeted therapy in mucosal melanomas: A systematic review and meta-analysis**  
A. Teo<sup>1</sup>, C.E. Yau<sup>1</sup>, C.E. Low<sup>1</sup>, J. Pereira<sup>2</sup>, J. Ng<sup>3</sup>, T.K. Soong<sup>4</sup>, J. Lo<sup>5</sup>, V. Yang<sup>6</sup>, <sup>1</sup>NUS-National University of Singapore-Yong Loo Lin School of Medicine (YLLSoM), Singapore, SG, <sup>2</sup>Singapore Health Services, Singapore, SG, <sup>3</sup>Changi General Hospital, Singapore, SG, <sup>4</sup>MOHH - Ministry of Health Holdings, Singapore, SG, <sup>5</sup>National Neuroscience Institute, Singapore, SG, <sup>6</sup>NCCS - National Cancer Centre Singapore, Singapore, SG
- 18:10 - 18:10 **609P - The association between thyroid function abnormalities and vitiligo induced by pembrolizumab regarding prognosis in patients with advanced melanoma**  
M. Mobarek<sup>1</sup>, A. Alsammarraie<sup>1</sup>, R. Mohammed Hussein<sup>2</sup>, S. Hadi<sup>3</sup>, <sup>1</sup>Baghdad Medical City - Oncology Teaching Hospital, Baghdad, IQ, <sup>2</sup>Medical City Complex, Baghdad, Baghdad, IQ, <sup>3</sup>Icahn School of Medicine at Mount Sinai, New York, US
- 18:10 - 18:10 **610P - Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding of the studies showcased, allowing for more objective evaluation and interpretation**  
S. Seghers<sup>1</sup>, P. Mando<sup>2</sup>, C.J. Tan<sup>3</sup>, M. Eid<sup>4</sup>, A. Jayraj<sup>5</sup>, L.-A. Teuwen<sup>1</sup>, J. Young<sup>6</sup>, E. Segelov<sup>7</sup>, H. Prenen<sup>1</sup>, <sup>1</sup>UZA - University Hospital Antwerp, Edegem, BE, <sup>2</sup>CEMIC - Centro de Educacion Medica e Investigacones Clinicas Dr Norberto Quirno, Buenos Aires, AR, <sup>3</sup>St. Luke's Medical Center - Quezon City, Quezon City, PH, <sup>4</sup>Saint Joseph University - Faculty of Medicine, Beirut, LB, <sup>5</sup>James Cook University Hospital, Middlesbrough, GB, <sup>6</sup>Blue Ridge Cancer Care, Wytheville, US, <sup>7</sup>University of Bern, Bern, CH
- 18:10 - 18:10 **611P - ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22)**  
P. Mando<sup>1</sup>, M.S. Faisal<sup>2</sup>, K. Jatwani<sup>3</sup>, S. Seghers<sup>4</sup>, J. Young<sup>5</sup>, L.-A. Teuwen<sup>4</sup>, H. Prenen<sup>4</sup>, T.T.V. Luong<sup>6</sup>, E. Segelov<sup>7</sup>, <sup>1</sup>CEMIC - Centro de Educacion Medica e Investigacones Clinicas Dr Norberto Quirno, Buenos Aires, AR, <sup>2</sup>University at Buffalo - Jacobs School Of Medicine and Biomedical Sciences, Buffalo, US, <sup>3</sup>Roswell Park Comprehensive Cancer Center, Buffalo, US, <sup>4</sup>UZA - University Hospital Antwerp, Edegem, BE, <sup>5</sup>Blue Ridge Cancer Care, Wytheville, US, <sup>6</sup>Austin Health, Melbourne, AU, <sup>7</sup>University of Bern, Bern, CH
- 18:10 - 18:10 **612P - Is the juice worth the squeeze? Overall survival gain per unit treatment**



**time as a metric of clinical benefit of systemic treatment in incurable cancers**

V. Bamunuarachchi<sup>1</sup>, A. Joseph<sup>2</sup>, V. Peiris<sup>3</sup>, S. Wijesekera<sup>1</sup>, D. Rajapaksha<sup>4</sup>, D. Gunasekera<sup>1</sup>, <sup>1</sup>Apeksha Hospital Maharagama, Maharagama, LK, <sup>2</sup>District General Hospital, Hambantota, Hambantota, LK, <sup>3</sup>District General Hospital, Vavuniya, Vavuniya, LK, <sup>4</sup>Teaching Hospital, Ratnapura, Ratnapura, LK

- 18:10 - 18:10 **613P - Differences in the interactions with pharmaceutical companies between medical oncologists and infectious diseases physicians**  
H.L. Yeoh<sup>1</sup>, P.L. Chia<sup>2</sup>, B. Cowie<sup>3</sup>, T. John<sup>4</sup>, <sup>1</sup>Alfred Hospital, Melbourne, AU, <sup>2</sup>National Healthcare Group - Tan Tock Seng Hospital, Singapore, SG, <sup>3</sup>Royal Melbourne Hospital, Melbourne, AU, <sup>4</sup>Peter MacCallum Cancer Centre, Melbourne, AU
- 18:10 - 18:10 **614P - The role of PD-L1 expression in prognosis of osteosarcoma patients: A systematic review and meta-analysis**  
A. Purnomo, M. Gerald Lokanata, G.H. Tumiwa, B.L. Frandi, J.H. Wijaya, E.F. Lokanata, R.S. Heriyanto, A. Kurniawan, UPH - Pelita Harapan University - Faculty of Medicine, Tangerang, ID
- 18:10 - 18:10 **615P - Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial**  
Q. Bao, Z. Zhang, J. Wen, R. Wan, X. Yang, X. Chen, Y. Shen, W. Zhang, Ruijin Hospital - Shanghai Jiao Tong University School of Medicine, Shanghai, CN
- 18:10 - 18:10 **616P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis**  
P. Franco<sup>1</sup>, G.R. Alcala<sup>2</sup>, R.D. Maravilla<sup>2</sup>, A.M. Pascual-Panganiban<sup>3</sup>, J.C. Pilapil<sup>4</sup>, A. Gorospe<sup>2</sup>, <sup>1</sup>St. Luke's Medical Center - Quezon City, PARANAQUE, PH, <sup>2</sup>St. Luke's Medical Center - Quezon City, Quezon City, PH, <sup>3</sup>St. Luke's Medical Center - Global City, Taguig, PH, <sup>4</sup>University of the Philippines - Philippine General Hospital, Manila, PH
- 18:10 - 18:10 **617P - The risk of acute myeloid leukaemia in patients with Ewing's sarcoma and trend analysis: A SEER-based study 2000-2020**  
M. Abdalla<sup>1</sup>, A. Ellaithy<sup>2</sup>, <sup>1</sup>Royal Cornwall Hospital Trust NHS Trust, Truro, GB, <sup>2</sup>Suez Canal University Hospital, Ismailia, EG
- 18:10 - 18:10 **618P - Adult renal Ewing's sarcoma/primitive neuroectodermal tumor: A 20-year retrospective review of molecular histopathological profiles, and clinical outcomes**  
J.T. Georgy<sup>1</sup>, Z. Thomas<sup>1</sup>, D.B. Thumaty<sup>1</sup>, A. Joel<sup>1</sup>, V.R. Gopinathan<sup>2</sup>, R. Pai<sup>1</sup>, A. John<sup>1</sup>, S. Devabhaktuni<sup>1</sup>, J.P. Wisely<sup>1</sup>, N. John<sup>2</sup>, R. Balakrishnan<sup>2</sup>, A. Augustine<sup>2</sup>, A. Chandramohan<sup>2</sup>, J. Rani<sup>2</sup>, R.T. Chacko<sup>1</sup>, A. Singh<sup>1</sup>, <sup>1</sup>CMC - Christian Medical College Hospital, Vellore, IN, <sup>2</sup>CMC - Christian Medical College Hospital Vellore, Vellore, IN
- 18:10 - 18:10 **619P - Single-cell and bulk RNA-seq analyses decode the renal microenvironment induced by polystyrene microplastics in mice receiving high-fat diet**

H. Zhang<sup>1</sup>, W. Xu<sup>1</sup>, W. Liu<sup>2</sup>, D. Ye<sup>1</sup>, <sup>1</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>2</sup>Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, CN

- 18:10 - 18:10 **620P - A unique circulating microRNA pairs signature serves as a superior tool for early diagnosis of pan-cancer**  
D. Li<sup>1</sup>, P. Wu<sup>1</sup>, C. Zhang<sup>2</sup>, S. Nan<sup>3</sup>, J. He<sup>2</sup>, <sup>1</sup>Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, <sup>2</sup>Chinese Academy of Medical Sciences - National Cancer Center, Cancer Hospital, Beijing, CN, <sup>3</sup>Chinese Academy of Medical Sciences and Peking Union Medical College, Peking, CN
- 18:10 - 18:10 **621P - Effective identification of primary liver cancer from cirrhosis or chronic hepatitis virus infection using eight methylated plasma DNA markers: Marker discovery, phase I pilot, and phase II clinical validation**  
T. Yang<sup>1</sup>, N. Wang<sup>2</sup>, X. Zhu<sup>3</sup>, M. Wang<sup>1</sup>, L. Yao<sup>1</sup>, Z. Fan<sup>2</sup>, X. Sun<sup>2</sup>, M. Pan<sup>4</sup>, L. Zhang<sup>3</sup>, Q. You<sup>3</sup>, J. Xu<sup>3</sup>, Y. Xu<sup>3</sup>, H. Lu<sup>3</sup>, B. Li<sup>3</sup>, G. Wang<sup>3</sup>, S. Cai<sup>3</sup>, F. Shen<sup>1</sup>, G. Lv<sup>2</sup>, <sup>1</sup>Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, CN, <sup>2</sup>First Hospital of Jilin University, Changchun, CN, <sup>3</sup>Burning Rock Biotech, Guangzhou, CN, <sup>4</sup>Zhujiang Hospital of Southern Medical University, Guangzhou, CN
- 18:10 - 18:10 **622P - A prognostic and immune infiltration analysis of CCL26 in pan-cancer**  
M. Li, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, CN
- 18:10 - 18:10 **623P - Advances in methylation analysis of liquid biopsy in early cancer detection of colorectal and lung cancer**  
S. Martin<sup>1</sup>, H.-J. Kwon<sup>1</sup>, S.H. Shin<sup>2</sup>, H.H. Kim<sup>3</sup>, N.Y. Min<sup>1</sup>, Y. Lim<sup>1</sup>, K.J. Lee<sup>1</sup>, D. Park<sup>1</sup>, S. Lee<sup>1</sup>, M.S. Lee<sup>4</sup>, <sup>1</sup>Eone-Diagnomics Genome Center, Inc., Incheon, KR, <sup>2</sup>Samsung Medical Center (SMC), Seoul, KR, <sup>3</sup>The Catholic University of Korea - Bucheon St. Mary's Hospital, Bucheon, KR, <sup>4</sup>Diagnomics, Inc., San Diego, US
- 18:10 - 18:10 **624P - Pan-cancer single-cell isoform atlas: Unraveling isoform dynamics in cancer immunotherapy**  
L. Pan, Karolinska Institutet, Solna, SE
- 18:10 - 18:10 **625P - The association of tumor marker concentration and air pollution in cancer survivors and the general population**  
K.H. Kim, Seoul National University Hospital, Seoul, KR
- 18:10 - 18:10 **626P - Percentage of cancer patients undergoing adjusted targeted therapy after ctDNA testing: Insights from a tertiary hospital experience**  
J. Yim, M.-H. Nam, Korea University College of Medicine, Seoul, KR
- 18:10 - 18:10 **627P - Racial disparities in synchronous and metachronous colorectal and prostate cancer: SEER based study 2000-2020**  
T. Nagib<sup>1</sup>, A. Ellaithy<sup>2</sup>, <sup>1</sup>University of Tripoli, Tripoli, LY, <sup>2</sup>Suez Canal University Hospital, Ismailia, EG



03-12-2023

<b>09:00 - 10:30</b>	<b>Type: Educational session</b> <b>Title: Improving outcomes in high-risk genitourinary cancers: Updates on perioperative therapy</b> Chair: Ravindran Kanesvaran, SG; Deborah Mukherji, AE	<b>Hall 404</b>
09:00 - 09:15	<b>Updates on adjuvant therapy for testicular cancer</b> <u>J. Oldenburg</u> , University of Oslo, Oslo, NO	
09:15 - 09:30	<b>Adjuvant and salvage radiation in prostate cancer</b> <u>D. Tilki</u> , UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE	
09:30 - 09:45	<b>How to manage the conflicting adjuvant data in renal cell carcinoma (RCC)</b> <u>V. Talwar</u> , Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN	
09:45 - 10:00	<b>Updates on penile cancer management</b> <u>Y. Miura</u> , Toranomon Hospital, Minato-ku, JP	
10:00 - 10:15	<b>Perioperative management of high-risk urothelial cancer</b> <u>E. Grande</u> , MD Anderson Cancer Center Madrid, Madrid, ES	
10:15 - 10:30	<b>Q&amp;A and discussion</b> <u>A. Speakers</u> , Lugano, CH	

**09:00 - 10:30** **Type: Multidisciplinary Tumour Board** **Hall 401**  
**Title: Advances in systemic and loco regional treatment for metastatic colorectal cancer (mCRC)**  
 Chair: Iain Tan, SG; Julien Taieb, FR

09:00 - 09:15 **Local and locoregional treatments: An update on current options**  
U. Pua, National Healthcare Group - Tan Tock Seng Hospital, Singapore, SG

09:15 - 09:30 **Cytoreductive surgery and HIPEC (locoregional oligometastatic)**  
J. Ong, NUHS - National University Health System, Singapore, SG

09:30 - 09:45 **Stereotactic radiotherapy for oligometastatic colorectal cancer: Are we there yet?**  
J. Chu, Peter MacCallum Cancer Centre, Melbourne, AU

09:45 - 10:00 **Hepatic arterial infusion: Enhancing response in neoadjuvant or salvage?**  
M. Ducreux, Gustave Roussy - Cancer Campus, Villejuif, FR

10:00 - 10:15 **Q&A and discussion**  
A. Speakers, Lugano, CH

**09:00 - 10:30** **Type: Collaborative session** **Hall 402**  
**Title: In collaboration with AACR: Targeting the kinome**  
 Chair: Ruth Plummer, GB; Channing Der, US

09:00 - 09:20 **Progress in preclinical development of targets and inhibitors**  
I. Braña, Vall d'Hebron University Hospital, Barcelona, ES

09:20 - 09:40 **Optimising dose selection in phase I trials**  
R. Plummer, Newcastle University, Newcastle-upon-Tyne, GB

09:40 - 10:00 **Selecting driver kinases in cell biology**  
C. Der, University of North Carolina - Chapel Hill, Chapel Hill, US

10:00 - 10:20 **Optimising combos of kinase inhibitors with other targeted agents**  
K. Ouali, Gustave Roussy - Cancer Campus, Villejuif, FR

10:20 - 10:30 **Q&A and discussion**  
A. Speakers, Lugano, CH

**09:00 - 10:30** **Type: Mini oral session** **Hall 406**  
**Title: Mini oral session 2: Thoracic cancer**  
 Chair: Junko Tanizaki, JP; Herbert Ho Fung Loong, HK

- 09:00 - 09:05 **512MO - FLAURA2: Safety and CNS outcomes of first-line (1L) osimertinib (osi) &#xb1; chemotherapy (CTx) in EGFRm advanced NSCLC**
- D. Planchard<sup>1</sup>, P. Jänne<sup>2</sup>, Y. Cheng<sup>3</sup>, C.K. Lee<sup>4</sup>, K. Laktionov<sup>5</sup>, T.-Y. Yang<sup>6</sup>, Y. Yu<sup>7</sup>, T. Kato<sup>8</sup>, L. Jiang<sup>9</sup>, B. Chewaskulyong<sup>10</sup>, S. Lucien Geater<sup>11</sup>, J.-M. Maurel<sup>12</sup>, C. Rojas<sup>13</sup>, L. Havel<sup>14</sup>, F.A. Shepherd<sup>15</sup>, K. Tanaka<sup>16</sup>, D. Ghiorghiu<sup>17</sup>, E. Armenteros Monterroso<sup>17</sup>, X. Huang<sup>17</sup>, J.C.-H. Yang<sup>18</sup>, <sup>1</sup>Institut Gustave Roussy, Thoracic Unit, Villejuif, Paris, FR, <sup>2</sup>Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, US, <sup>3</sup>Jilin Cancer Hospital, Changchun, CN, <sup>4</sup>Cancer Care Centre, St. George Hospital, Kogarah, AU, <sup>5</sup>"N.N.Blokhin National Medical Research Center of Oncology", Ministry of Health of the Russian Federation, Moscow, RU, <sup>6</sup>Taichung Veterans General Hospital, Taichung, TW, <sup>7</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>8</sup>Kanagawa Cancer Center, Asahi Ward, Yokohama, JP, <sup>9</sup>Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, <sup>10</sup>Faculty of Medicine, Chiang Mai University, Chiang Mai, TH, <sup>11</sup>Prince of Songkla University, Hat Yai District, Songkhla, TH, <sup>12</sup>Cancercare, Rondebosch Oncology Centre, Rondebosch, Cape Town, ZA, <sup>13</sup>Bradford Hill Clinical Research Center, Santiago, CL, <sup>14</sup>First Faculty of Medicine, Charles University, Thomayer Hospital, Prague, CZ, <sup>15</sup>University Health Network, Princess Margaret Cancer Centre, Toronto, CA, <sup>16</sup>Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, <sup>17</sup>AstraZeneca, Cambridge, GB, <sup>18</sup>National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, TW
- 09:05 - 09:10 **513MO - Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): PAPPILLON subgroup analysis**
- C. Zhou<sup>1</sup>, K. Tang<sup>2</sup>, B. Liu<sup>3</sup>, S.-W. Kim<sup>4</sup>, S. Kitazono<sup>5</sup>, A. Ono<sup>6</sup>, M. Thiagarajan<sup>7</sup>, J.-Y. Hung<sup>8</sup>, M. Boyer<sup>9</sup>, J. Xie<sup>10</sup>, A. Bhattacharya<sup>11</sup>, M. Baig<sup>10</sup>, T. Agrawal<sup>12</sup>, R. Knoblauch<sup>12</sup>, B.C. Cho<sup>13</sup>, <sup>1</sup>Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, CN, <sup>2</sup>The First Affiliated Hospital of Sun Yat-sen University, Shanghai, CN, <sup>3</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>4</sup>Asan Medical Center, Seoul, KR, <sup>5</sup>Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JP, <sup>6</sup>Shizuoka Cancer Center, Shizuoka, JP, <sup>7</sup>General Hospital Kuala Lumpur, Kuala Lumpur, MY, <sup>8</sup>Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, TW, <sup>9</sup>Chris O'Brien Lifecare, Camperdown, AU, <sup>10</sup>Janssen R&D, Raritan, US, <sup>11</sup>Janssen R&D, High Wycombe, GB, <sup>12</sup>Janssen R&D, Spring House, US, <sup>13</sup>Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR
- 09:10 - 09:15 **514MO - Acquired mechanisms of resistance to first-line (1L) osimertinib with or without platinum-based chemotherapy (CT) in EGFR-mutated (EGFRm) advanced NSCLC: Preliminary data from FLAURA2**
- C.K. Lee<sup>1</sup>, J.P. Robichaux<sup>2</sup>, P. Jänne<sup>3</sup>, S.-W. Kim<sup>4</sup>, T.M. Kim<sup>5</sup>, K. Kobayashi<sup>6</sup>, D. Planchard<sup>7</sup>, S. Sugawara<sup>8</sup>, N. Yanagitani<sup>9</sup>, T.-Y. Yang<sup>10</sup>, A. Markovets<sup>2</sup>, P. Bhetaryia<sup>2</sup>, L. Poole<sup>11</sup>, Y. Rukazenzov<sup>11</sup>, R. Hartmaier<sup>2</sup>, J.C.-H. Yang<sup>12</sup>, <sup>1</sup>Cancer Care Centre, St. George Hospital, Kogarah, AU, <sup>2</sup>AstraZeneca, Boston, US, <sup>3</sup>Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, US, <sup>4</sup>Asan Medical Center, Seoul, KR, <sup>5</sup>Seoul National University Hospital, Seoul, KR, <sup>6</sup>Saitama Medical University International Medical Center, Hidaka, Saitama, JP, <sup>7</sup>Institut Gustave Roussy, Thoracic Unit, Villejuif, FR, <sup>8</sup>Sendai Kousei Hospital, Hirosemachi, Aoba-ku, Sendai City, Miyagi Prefecture, JP, <sup>9</sup>The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JP, <sup>10</sup>Taichung Veterans General Hospital, Taichung, TW, <sup>11</sup>AstraZeneca, Cambridge, GB, <sup>12</sup>National Taiwan University Hospital and National Taiwan University Cancer Center,

Taipei, TW

- 09:15 - 09:25 **Invited Discussant 512MO, 513MO and 514MO**  
H.H.F. Loong, The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK
- 09:25 - 09:30 **Q&A and discussion**  
A. Speakers, Lugano, CH
- 09:30 - 09:35 **LBA9 - Final overall survival (OS) results of befotertinib in patients with pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)**  
 S. Lu<sup>1</sup>, Y. Zhang<sup>2</sup>, G. Zhang<sup>3</sup>, J. Zhou<sup>4</sup>, S. Cang<sup>5</sup>, Y. Cheng<sup>6</sup>, G. Wu<sup>7</sup>, P. Cao<sup>8</sup>, D. Lv<sup>9</sup>, H. Jian<sup>10</sup>, C. Chen<sup>11</sup>, X. Jin<sup>12</sup>, P. Tian<sup>13</sup>, K. Wang<sup>14</sup>, G. Jiang<sup>15</sup>, G. Chen<sup>16</sup>, Q. Chen<sup>17</sup>, H. Zhao<sup>18</sup>, C. Ding<sup>19</sup>, L. Ding<sup>20</sup>, <sup>1</sup>Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, CN, <sup>2</sup>Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, CN, <sup>3</sup>The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, <sup>4</sup>The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, CN, <sup>5</sup>Henan Provincial People's Hospital, Zhengzhou, CN, <sup>6</sup>Jilin Cancer Hospital, Changchun, CN, <sup>7</sup>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology/ Cancer Center Union Hospital, Wuhan, CN, <sup>8</sup>The Third Xiangya Hospital of Central South University, Changsha, CN, <sup>9</sup>Taizhou Hospital of Zhejiang Province, Taizhou, CN, <sup>10</sup>Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, <sup>11</sup>The First Affiliated Hospital of Wenzhou Medical University - Nanbaixiang Site, Wenzhou, CN, <sup>12</sup>General Hospital of Ningxia Medical University, Yinchuan, CN, <sup>13</sup>West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN, <sup>14</sup>The Second Affiliated Hospital of Zhejiang University School of Medicine - East Gate 1, Hangzhou, CN, <sup>15</sup>Dongguan People's Hospital, dongguan, CN, <sup>16</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>17</sup>Fuzhou Pulmonary Hospital of Fujian, Fuzhou, CN, <sup>18</sup>The Second Affiliated Hospital of Anhui Medical University, Hefei, CN, <sup>19</sup>The Fourth Hospital of Hebei Medical University - North Gate, Shijiazhuang, CN, <sup>20</sup>Betta Pharmaceuticals Co., Ltd., Hangzhou, CN
- 09:35 - 09:40 **515MO - Phase Ib study of telisotuzumab vedotin (Teliso-V) and osimertinib in patients (Pts) with advanced EGFR-mutated (Mut), c-Met overexpressing (OE) non-small cell lung cancer (NSCLC): Final efficacy and safety updates**  
H. Horinouchi<sup>1</sup>, B.C. Cho<sup>2</sup>, D. Camidge<sup>3</sup>, K. Goto<sup>4</sup>, P. Tomasini<sup>5</sup>, Y. Li<sup>6</sup>, A. Vasilopoulos<sup>6</sup>, P. Brunson<sup>6</sup>, D. Hoffman<sup>6</sup>, W. Shi<sup>6</sup>, V. Blot<sup>6</sup>, J. Goldman<sup>7</sup>, <sup>1</sup>National Cancer Center Hospital, Tokyo, JP, <sup>2</sup>Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, <sup>3</sup>University of Colorado Cancer Center, Aurora, US, <sup>4</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>5</sup>Aix Marseille University, APHM, INSERM, CNRS, CRCM, Hôpital Nord, Marseille, FR, <sup>6</sup>AbbVie Inc., North Chicago, US, <sup>7</sup>David Geffen School of Medicine at UCLA, Los Angeles, US
- 09:40 - 09:45 **516MO - Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)**

F. Cappuzzo<sup>1</sup>, V. Moreno Garcia<sup>2</sup>, S.-H. Ou<sup>3</sup>, M. Brandão<sup>4</sup>, M.F. Sanmamed<sup>5</sup>, C. Helissey<sup>6</sup>, M. Wislez<sup>7</sup>, J. Call<sup>8</sup>, S. Grisanti<sup>9</sup>, M. Johnson<sup>10</sup>, V. Boni<sup>11</sup>, P. Jamme<sup>12</sup>, I. Monnet<sup>13</sup>, S. Siena<sup>14</sup>, C. Yan<sup>15</sup>, B. Barasa<sup>15</sup>, B. Richard<sup>15</sup>, A.K. Joe<sup>15</sup>, G. Laus<sup>15</sup>, E. Felip<sup>16</sup>, <sup>1</sup>IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT, <sup>2</sup>Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES, <sup>3</sup>UCI Health Chao Family Comprehensive Cancer Center, Orange, US, <sup>4</sup>Institute Jules Bordet, Anderlecht, BE, <sup>5</sup>Clinica Universidad de Navarra, Pamplona, ES, <sup>6</sup>Bégin Military Teaching Hospital, Saint-Mandé, FR, <sup>7</sup>Hopital Cochin AP-HP, Paris, FR, <sup>8</sup>South Texas Accelerated Research Therapeutics (START), San Antonio, US, <sup>9</sup>University of Brescia, Brescia, IT, <sup>10</sup>Sarah Cannon Research Institute-Cancer Centre, Nashville, US, <sup>11</sup>Hospital Universitario Quirónsalud Madrid, Pozuelo de Alarcon, ES, <sup>12</sup>CHU Lille - Centre Hospitalier Régional Universitaire de Lille, Lille, FR, <sup>13</sup>Chi De Creteil, Creteil, FR, <sup>14</sup>UNIMI - Università degli Studi di Milano Statale, Milan, IT, <sup>15</sup>Merus N.V., Utrecht, NL, <sup>16</sup>Vall d'Hebron University Hospital, Barcelona, ES

09:45 - 09:55

**Invited Discussant LBA9, 515MO and 516MO**J. Tanizaki, Kindai University - Faculty of Medicine, Osaka, JP

09:55 - 10:00

**Q&A and discussion**A. Speakers, Lugano, CH

10:00 - 10:05

**490MO - Patient-reported outcomes of first-line selpercatinib versus chemotherapy with or without pembrolizumab in RET fusion-positive advanced non-small cell lung cancer: Interim analysis of LIBRETTO-431**

K. Goto<sup>1</sup>, S. Novello<sup>2</sup>, P. Garrido Lopez<sup>3</sup>, C. Doms<sup>4</sup>, J. Alatorre Alexander<sup>5</sup>, N. Reinmuth<sup>6</sup>, A. Gilligan<sup>7</sup>, N. Payakachat<sup>7</sup>, A. Lin<sup>8</sup>, K. Cocks<sup>9</sup>, G. Worthy<sup>10</sup>, C. Zhou<sup>11</sup>, <sup>1</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>2</sup>Università Degli Studi Di Torino - Orbassano, Orbassano, IT, <sup>3</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>4</sup>UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, <sup>5</sup>INER - Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Ciudad de Mexico, MX, <sup>6</sup>Asklepios-Fachklinikum, Gauting, DE, <sup>7</sup>Eli Lilly and Company, Indianapolis, US, <sup>8</sup>Eli Lilly and Company - Global Headquarters, Indianapolis, US, <sup>9</sup>Adelphi Communications - Adelphi Group, Bollington, GB, <sup>10</sup>Adelphi Values, Bollington, GB, <sup>11</sup>Shanghai Pulmonary Hospital, Shanghai, CN

10:05 - 10:10

**518MO - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)**

S. Kitazono<sup>1</sup>, L. Paz-Ares<sup>2</sup>, M.-J. Ahn<sup>3</sup>, A. Lisberg<sup>4</sup>, B.C. Cho<sup>5</sup>, G. Blumenschein<sup>6</sup>, E. Shum<sup>7</sup>, E. Pons-Tostivint<sup>8</sup>, Y. Goto<sup>9</sup>, K. Yoh<sup>10</sup>, R. Heist<sup>11</sup>, P. Baas<sup>12</sup>, D. Planchard<sup>13</sup>, M. Pérol<sup>14</sup>, E. Felip<sup>15</sup>, W.-C. Su<sup>16</sup>, H. Zebger-Gong<sup>17</sup>, L. Lan<sup>18</sup>, C. Liu<sup>18</sup>, J. Sands<sup>19</sup>, <sup>1</sup>The Cancer Institute Hospital of JFCR, Tokyo, JP, <sup>2</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>3</sup>Samsung Medical Center, Seoul, KR, <sup>4</sup>David Geffen School of Medicine at UCLA, Los Angeles, US, <sup>5</sup>Severance Hospital, Seoul, KR, <sup>6</sup>University of Texas MD Anderson Cancer Center, Houston, US, <sup>7</sup>NYU Perlmutter Cancer Center, New York, US, <sup>8</sup>University Hospital of Nantes, Nantes, Cedex, FR, <sup>9</sup>National Cancer Center Hospital, Tokyo, JP, <sup>10</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>11</sup>Massachusetts General Hospital Cancer Center, Boston, US, <sup>12</sup>The Netherlands Cancer Institute, Amsterdam, NL, <sup>13</sup>Institut Gustave Roussy, Villejuif, Cedex, FR, <sup>14</sup>Centre Léon Bérard, Lyon, FR,



15Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, ES, 16National Cheng Kung University Hospital, Tainan City, TW, 17Daiichi Sankyo Europe GmbH, Munich, DE, 18Daiichi Sankyo, Inc., Basking Ridge, US, 19Dana-Farber Cancer Institute, Boston, US

10:10 - 10:20 **Invited Discussant 490MO and 518MO**

S.M. Lim, , Seoul, KR

10:20 - 10:25 **Q&A and discussion**

A. Speakers, Lugano, CH

**09:00 - 10:40 Type: Mini oral session**

**Hall 407**

**Title: Mini oral session: Haematological malignancies**

Chair: Koji Izutsu, JP; Michelle Poon, SG; Jason Chan Yong Sheng, SG; Dok Hyun Yoon, KR

09:00 - 09:05 **328MO - The pivotal clinical study of IM19 CAR-T cells in the treatment of relapsed or refractory aggressive B cell non-Hodgkin lymphomas**

Y. Xie<sup>1</sup>, T. He<sup>2</sup>, F. Wu<sup>2</sup>, G. Liu<sup>2</sup>, Y. Ding<sup>2</sup>, X. Lu<sup>2</sup>, Y. Song<sup>1</sup>, <sup>1</sup>Peking University Cancer Hospital and Institute, Beijing, CN, <sup>2</sup>Beijing Immunopharm Technology Co., Ltd., Beijing, CN

09:05 - 09:10 **329MO - HLX208, a novel BRAF V600E inhibitor, in adult patients with Langerhans cell histiocytosis and/or Erdheim-Chester disease harbouring BRAF V600E mutation**

X.-X. Cao<sup>1</sup>, Y. Wu<sup>2</sup>, P. Liu<sup>3</sup>, T. Ding<sup>4</sup>, H. Ye<sup>4</sup>, Z. Cai<sup>5</sup>, Y. Zhang<sup>6</sup>, J. Ma<sup>7</sup>, Y. Xu<sup>8</sup>, G. Fu<sup>8</sup>, C. Hu<sup>9</sup>, X. Hou<sup>9</sup>, Q. Wang<sup>9</sup>, J. Zhu<sup>9</sup>, J. Li<sup>1</sup>, <sup>1</sup>Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, <sup>2</sup>West China Hospital of Sichuan University, Chengdu, CN, <sup>3</sup>Zhongshan Hospital, Fudan University, Shanghai, CN, <sup>4</sup>Huashan Hospital, Fudan University, Shanghai, CN, <sup>5</sup>The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN, <sup>6</sup>Guangdong Provincial People's Hospital, Guangzhou, CN, <sup>7</sup>The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, <sup>8</sup>Xiangya Hospital Central South University, Changsha, CN, <sup>9</sup>Shanghai Henlius Biotech, Inc., Shanghai, CN

09:10 - 09:15 **330MO - Pooled safety analysis of zanubrutinib monotherapy in Asian patients with B cell malignancies**

J. Zhu<sup>1</sup>, J. Li<sup>2</sup>, C. Tam<sup>3</sup>, H. Guo<sup>4</sup>, L. Wang<sup>5</sup>, H. Zhou<sup>4</sup>, M. Zhang<sup>5</sup>, J. Zhang<sup>5</sup>, A. Cohen<sup>5</sup>, N. Bahadur<sup>6</sup>, P. Khanna<sup>6</sup>, W.S. Kim<sup>7</sup>, L. Qiu<sup>8</sup>, <sup>1</sup>Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, CN, <sup>2</sup>Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN, <sup>3</sup>Alfred Hospital and University of Melbourne, Melbourne, AU, <sup>4</sup>BeiGene (Shanghai) Co., Ltd., Shanghai, CN, <sup>5</sup>BeiGene USA, Inc., San Mateo, US, <sup>6</sup>BeiGene Singapore Pte Ltd, South Beach Tower, SG, <sup>7</sup>Samsung Medical Center (SMC), Seoul, KR, <sup>8</sup>Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, CN

09:15 - 09:25 **Invited Discussant 328MO, 329MO and 330MO**

K. Izutsu, National Cancer Center - Tsukiji Campus, Chuo-ku, JP

09:25 - 09:30

**Q&A and discussion**

A. Speakers, Lugano, CH

09:30 - 09:35

**331MO - Comparing data distribution and prognosis of acute myeloid leukemia according to 5th WHO classification and international consensus**

S.J. Lee, D. Kwag, J.-M. Lee, H.S. Kim, B.-S. Cho, M. Kim, Y. Kim, J. Jung, The Catholic University of Korea - Seoul St. Mary's Hospital, Seoul, KR

09:35 - 09:40

**332MO - Long-term toxicities after allogeneic HSCT with or without total body irradiation: A population-based study in Korea**

B.H. Kim<sup>1</sup>, J. Kwon<sup>2</sup>, <sup>1</sup>SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, KR, <sup>2</sup>Chungnam National University Hospital, Daejeon, KR

09:40 - 09:47

**Invited Discussant 331MO and 332MO**

M. Poon, National Healthcare Group - Tan Tock Seng Hospital, Singapore, SG

09:47 - 09:52

**Q&A and discussion**

A. Speakers, Lugano, CH

09:52 - 09:57

**333MO - Treatment patterns in patients with mantle cell lymphoma: Updated report of the Asia-Pacific multinational retrospective registry study**

D.H. Yoon<sup>1</sup>, H. Cho<sup>2</sup>, J.C.Y. Sheng<sup>3</sup>, D.J. Kim<sup>4</sup>, K.-W. Kang<sup>5</sup>, J.-Y. Kwak<sup>6</sup>, S.-M. Tan<sup>7</sup>, J.-O. Lee<sup>8</sup>, S.Y. Oh<sup>9</sup>, H.-S. Eom<sup>10</sup>, Y.R. Do<sup>11</sup>, S.H. Jeong<sup>12</sup>, H.J. Kang<sup>13</sup>, Y. Koh<sup>14</sup>, U. Bunworasate<sup>15</sup>, H.J. Kim<sup>16</sup>, J.-C. Jo<sup>17</sup>, S.-H. Kim<sup>18</sup>, K. Kato<sup>19</sup>, W.S. Kim<sup>20</sup>, <sup>1</sup>University of Ulsan College of Medicine, Seoul, KR, <sup>2</sup>Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, <sup>3</sup>NCCS - National Cancer Centre Singapore, Singapore, SG, <sup>4</sup>Kosin Univeristy Gospel Hospital, Busan, KR, <sup>5</sup>Korea University Anam Hospital, Seoul, KR, <sup>6</sup>Chonbuk National University Hospital, Jeonju, KR, <sup>7</sup>Hospital Ampang, Ampang Jaya, MY, <sup>8</sup>Seoul National University Bundang Hospital, Seongnam, KR, <sup>9</sup>Dong-A University College of Medicine, Busan, KR, <sup>10</sup>National Cancer Center Hospital, Goyang, KR, <sup>11</sup>Dongsan Medical center (DSMC) - Keimyung University School of Medicine, Daegu, KR, <sup>12</sup>Ajou University School of Medicine, Suwon, KR, <sup>13</sup>Korea Cancer Center Hospital, Seoul, KR, <sup>14</sup>SNUH - Seoul National University Hospital, Seoul, KR, <sup>15</sup>Chulalongkorn University - Faculty of Medicine, Bangkok, TH, <sup>16</sup>HUMC - Hallym University Sacred Heart Hospital (HUSHH), Anyang, KR, <sup>17</sup>Asan Medical Center - Asan Institute for Life Science, Seoul, KR, <sup>18</sup>Soonchunhyang University Bucheon Hospital, Bucheon, KR, <sup>19</sup>Kyushu University Hospital, Fukuoka, JP, <sup>20</sup>Samsung Medical Center (SMC), Seoul, KR

09:57 - 10:02

**334MO - A multicenter retrospective study to understand the clinical characteristics, treatment patterns, and outcomes of CLL patients in the Middle East: A subgroup analysis of the CREEK study**

R.M. Abdelfattah Soliman<sup>1</sup>, A. Alhuraiji<sup>2</sup>, Y. Buyukasik<sup>3</sup>, M. Siddiqui<sup>4</sup>, S. Alamoudi<sup>5</sup>, H. Alshehri<sup>6</sup>, A. Aboutaleb<sup>7</sup>, F. Gonzalez Hernandez<sup>8</sup>, V. Rajadhyaksha<sup>9</sup>, A. Absi<sup>5</sup>, <sup>1</sup>National Cancer Institute - Cairo University, Cairo, EG, <sup>2</sup>KCCC - Kuwait Cancer Control Center, Shuwaikh, KW, <sup>3</sup>Hacettepe University Oncology Hospital, Ankara, TR, <sup>4</sup>Sheikh Shakboot

Medical City, Abu Dhabi, AE, <sup>5</sup>King Khalid National Guard Hospital - King Abdul Aziz Medical City, Jeddah, SA, <sup>6</sup>KFMC - King Fahad Medical City, Riyadh, SA, <sup>7</sup>AstraZeneca Pharma Egypt, New Cairo, EG, <sup>8</sup>AstraZeneca Plc, Baar, CH, <sup>9</sup>AstraZeneca Malaysia Sdn Bhd, Petaling Jaya, MY

10:02 - 10:09 **Invited Discussant 333MO and 334MO**

J.C.Y. Sheng, NCCS - National Cancer Centre Singapore, Singapore, SG

10:09 - 10:14 **335MO - Real-world outcomes of diffuse large B cell lymphoma treated with R-CHOP(-like) therapy in an Asian multi-ethnic population**

J.C.Y. Sheng<sup>1</sup>, Z.E.Q. Heng<sup>1</sup>, J.Y. Tan<sup>1</sup>, Y.H. Tan<sup>1</sup>, E. Chang<sup>1</sup>, J. Hoe<sup>1</sup>, V. Yang<sup>1</sup>, J. Chiang<sup>1</sup>, E. Poon<sup>1</sup>, N. Somasundaram<sup>1</sup>, M.F. Harunal Rashid<sup>1</sup>, J.Q. Lim<sup>1</sup>, C.K. Ong<sup>1</sup>, L.C.K. Ng<sup>2</sup>, F. Lim<sup>2</sup>, M. Tao<sup>1</sup>, Y.T. Goh<sup>2</sup>, S.T. Lim<sup>1</sup>, <sup>1</sup>NCCS - National Cancer Centre Singapore, Singapore, SG, <sup>2</sup>SGH - Singapore General Hospital, Singapore, SG

10:14 - 10:19 **336MO - Genetic landscape and prognostic value of IRF4 alterations in diffuse large B cell lymphoma patients**

X. Chen<sup>1</sup>, Y. Qin<sup>2</sup>, Z. Xie<sup>1</sup>, J. Yang<sup>1</sup>, S. Yang<sup>1</sup>, L. Gui<sup>1</sup>, Y.-K. Shi<sup>1</sup>, <sup>1</sup>Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, <sup>2</sup>Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen Cancer Hospital, Guangdong, CN

10:19 - 10:26 **Invited Discussant 335MO and 336MO**

D.H. Yoon, University of Ulsan College of Medicine, Seoul, KR

10:26 - 10:36 **Q&A and discussion**

A. Speakers, Lugano, CH

**10:45 - 12:10 Type: Mini oral session**

**Hall 405**

**Title: Mini oral session 2: Gastrointestinal tumours**

Chair: Hanneke van Laarhoven, NL; Raghav Sundar, SG

10:45 - 10:50 **134MO - Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab &#x2b; CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2&#x2b;), HER2&#x2212;, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma**

F. Lordick<sup>1</sup>, M. Shah<sup>2</sup>, K. Shitara<sup>3</sup>, J. Ajani<sup>4</sup>, Y.-J. Bang<sup>5</sup>, P. Enzinger<sup>6</sup>, D. Ilson<sup>7</sup>, E. Van Cutsem<sup>8</sup>, J. Gallego Plazas<sup>9</sup>, J. Huang<sup>10</sup>, L. Shen<sup>11</sup>, S.C. Oh<sup>12</sup>, P. Sunpaweravong<sup>13</sup>, S.H. Hwoei Fen<sup>14</sup>, H. Türk<sup>15</sup>, J.W. Park<sup>16</sup>, D. Moran<sup>16</sup>, P. Bhattacharya<sup>16</sup>, Y. Cao<sup>16</sup>, R.-H. Xu<sup>17</sup>, <sup>1</sup>University of Leipzig Medical Center, Leipzig, DE, <sup>2</sup>Weill Cornell Medical College - Upper East Side, New York, US, <sup>3</sup>National Cancer Center Hospital East, Kashiwa, JP, <sup>4</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>5</sup>Seoul National University College of Medicine, Seoul, KR, <sup>6</sup>Dana-Farber Cancer Institute, Boston, US, <sup>7</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>8</sup>University Hospitals Gasthuisberg, Leuven, and KULeuven, Leuven, BE, <sup>9</sup>Hospital General Universitario de Elche, Elche, ES, <sup>10</sup>National Cancer Center / National Clinical Research Center for

Cancer / Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, <sup>11</sup>Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, CN, <sup>12</sup>Korea University Guro Hospital, Seoul, KR, <sup>13</sup>Prince of Songkla University, Songkhla, TH, <sup>14</sup>Penang Hospital, Penang, MY, <sup>15</sup>Bezmialem Vakif University, Istanbul, TR, <sup>16</sup>Astellas Pharma Global Development, Inc., Northbrook, US, <sup>17</sup>Sun Yat-Sen University Cancer Center State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, CN

10:50 - 10:55

**135MO - Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab &#x2b; mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2&#x2b;), HER2&#x2212;, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma**

J. Ajani<sup>1</sup>, F. Lordick<sup>2</sup>, Y.-J. Bang<sup>3</sup>, P. Enzinger<sup>4</sup>, D. Ilson<sup>5</sup>, M. Shah<sup>6</sup>, E. Van Cutsem<sup>7</sup>, R.-H. Xu<sup>8</sup>, G. Aprile<sup>9</sup>, J. Xu<sup>10</sup>, R. Pazo Cid<sup>11</sup>, Y.-K. Kang<sup>12</sup>, J. Yang<sup>13</sup>, D. Moran<sup>13</sup>, P. Bhattacharya<sup>13</sup>, M. Matsangou<sup>14</sup>, A. Arozullah<sup>13</sup>, J.W. Park<sup>13</sup>, K. Shitara<sup>15</sup>, <sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>2</sup>University of Leipzig Medical Center, Leipzig, DE, <sup>3</sup>Seoul National University College of Medicine, Seoul, KR, <sup>4</sup>Dana-Farber Cancer Institute, Boston, US, <sup>5</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>6</sup>Weill Cornell Medical College, New York, US, <sup>7</sup>University Hospitals Gasthuisberg and KU Leuven, Leuven, BE, <sup>8</sup>Sun Yat-Sen University Cancer Center, Guangzhou, CN, <sup>9</sup>Azienda ULSS 8 Berica, Vicenza, IT, <sup>10</sup>The Fifth Medical Center of the PLA General Hospital, Beijing, CN, <sup>11</sup>Hospital Universitario Miguel Servet, Zaragoza, ES, <sup>12</sup>University of Ulsan College of Medicine, Asan Medical Center, Seoul, KR, <sup>13</sup>Astellas Pharma Global Development, Inc., Northbrook, US, <sup>14</sup>Astellas Pharma Inc., Northbrook, US, <sup>15</sup>National Cancer Center Hospital East, Kashiwa, JP

10:55 - 11:00

**136MO - Bemarituzumab (bema)&#x2b;FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/GEJC): East Asia subgroup of FIGHT final analysis**

Y.-K. Kang<sup>1</sup>, S. Qin<sup>2</sup>, K.-W. Lee<sup>3</sup>, S.C. Oh<sup>4</sup>, I.-H. Kim<sup>5</sup>, J.G. Kim<sup>6</sup>, Y. Li<sup>7</sup>, Z. Yan<sup>8</sup>, J. Li<sup>9</sup>, L.-Y. Bai<sup>10</sup>, C.P.K. Chan<sup>11</sup>, A. Yusuf<sup>12</sup>, A. Zahlten-Kuemeli<sup>13</sup>, K. Taylor<sup>14</sup>, K. Yamaguchi<sup>15</sup>, <sup>1</sup>Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, <sup>2</sup>Nanjing Jingdu Hospital, Nanjing, CN, <sup>3</sup>Seoul National University Bundang Hospital, Seongnam, KR, <sup>4</sup>Korea University, Seoul, KR, <sup>5</sup>The Catholic University of Korea - College of Medicine - Songeui Medical Campus, Seoul, KR, <sup>6</sup>Kyungpook National University Chilgok Hospital, Daegu, KR, <sup>7</sup>The Fourth Hospital of Hebei Medical University - North Gate, Shijiazhuang, CN, <sup>8</sup>Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, <sup>9</sup>Shanghai East/Oriental Hospital Affiliated to Tongji University - Southern Division, Shanghai, CN, <sup>10</sup>China Medical University Hospital, New Taipei City, TW, <sup>11</sup>Amgen Hong Kong, Hong Kong, HK, <sup>12</sup>AMGEN (Headquarters) - USA, Thousand Oaks, US, <sup>13</sup>Amgen Inc - SSF, South San Francisco, US, <sup>14</sup>AMGEN Ltd, Uxbridge, GB, <sup>15</sup>The Cancer Institute Hospital of JFCR, Koto-ku, JP

11:00 - 11:10

**Invited Discussant 134MO, 135MO and 136MO**

H. Van Laarhoven, Academic Medical Center, University of Amsterdam, Amsterdam, NL

11:10 - 11:15

**Q&A and discussion**

A. Speakers, Lugano, CH

11:15 - 11:20

**138MO - Pembrolizumab (Pembro) or placebo (Pbo) plus chemotherapy (Chemo) for advanced HER2-negative gastric/gastroesophageal junction (G/GEJ) adenocarcinoma (KEYNOTE-859): Asia subgroup analysis**

D.-Y. Oh<sup>1</sup>, Y. Bai<sup>2</sup>, M.H. Ryu<sup>3</sup>, J. Lee<sup>4</sup>, J. Li<sup>5</sup>, S. Luo<sup>6</sup>, H. Pan<sup>7</sup>, Y. Qu<sup>8</sup>, J. Lu<sup>9</sup>, L. Yang<sup>10</sup>, H. Yasui<sup>11</sup>, H. Yabusaki<sup>12</sup>, C.J. Yen<sup>13</sup>, W. Chan<sup>14</sup>, K. Yamaguchi<sup>15</sup>, K.-H. Yeh<sup>16</sup>, L. Yin<sup>17</sup>, S. Bordia<sup>17</sup>, P. Bhagia<sup>17</sup>, S.Y. Rha<sup>18</sup>, <sup>1</sup>Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, <sup>2</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>3</sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, <sup>4</sup>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, <sup>5</sup>Shanghai East Hospital, Tongji University School of Medicine, Shanghai, CN, <sup>6</sup>The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, CN, <sup>7</sup>Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, CN, <sup>8</sup>The Affiliated Cancer Hospital of Xinjiang Medical University, Xinjiang, CN, <sup>9</sup>Jiangsu Cancer Hospital, Nanjing, CN, <sup>10</sup>National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, <sup>11</sup>Kobe City Medical Center General Hospital, Kobe, JP, <sup>12</sup>Niigata Cancer Center Hospital, Niigata, JP, <sup>13</sup>National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, TW, <sup>14</sup>The University of Hong Kong, Hong Kong, CN, <sup>15</sup>The Cancer Institute Hospital of Japanese Foundation for Cancer, Tokyo, JP, <sup>16</sup>National Taiwan University Hospital and Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, TW, <sup>17</sup>Merck & Co., Inc., Rahway, US, <sup>18</sup>Yonsei University College of Medicine, Yonsei Cancer Center, Yonsei University Health System, Seoul, KR

11:20 - 11:25

**139MO - Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study**

R.-H. Xu<sup>1</sup>, D.-Y. Oh<sup>2</sup>, K. Kato<sup>3</sup>, H.-T. Arkenau<sup>4</sup>, J. Tabernero<sup>5</sup>, M. Cruz-Correa<sup>6</sup>, A. Zimina<sup>7</sup>, Y. Bai<sup>8</sup>, J. Shi<sup>9</sup>, K.-W. Lee<sup>10</sup>, H. Hirano<sup>3</sup>, D. Spigel<sup>11</sup>, L. Wyrwicz<sup>12</sup>, R. Pazo Cid<sup>13</sup>, L. Li<sup>14</sup>, Y. Xu<sup>15</sup>, M.B. Mchenry<sup>16</sup>, S. Yang<sup>17</sup>, M. Moehler<sup>18</sup>, <sup>1</sup>Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, CN, <sup>2</sup>Seoul National University Hospital Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, <sup>3</sup>National Cancer Center Hospital, Tokyo, JP, <sup>4</sup>Sarah Cannon Research Institute, London, GB, <sup>5</sup>Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, ES, <sup>6</sup>University of Puerto Rico, San Juan, PR, <sup>7</sup>BIH of Omsk Region, Omsk Oblast, RU, <sup>8</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>9</sup>Linyi Cancer Hospital, Linyi, CN, <sup>10</sup>Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, KR, <sup>11</sup>Tennessee Oncology, Nashville, US, <sup>12</sup>Maria Sklodowska-Curie National Cancer Center and Institute of Oncology, Warsaw, PL, <sup>13</sup>Hospital Universitario Miguel Servet, Zaragoza, ES, <sup>14</sup>BeiGene (Beijing) Co., Ltd., Beijing, CN, <sup>15</sup>BeiGene (Shanghai) Co., Ltd., Shanghai, CN, <sup>16</sup>BeiGene USA, Inc., Cambridge, US, <sup>17</sup>BeiGene (Beijing) Co., Ltd, Beijing, CN, <sup>18</sup>Johannes Gutenberg-University Clinic, Mainz, DE

11:25 - 11:35

**Invited Discussant 138MO and 139MO**

R. Sundar, NUHS - National University Health System, Singapore, SG

11:35 - 11:40 **Q&A and discussion**  
A. Speakers, Lugano, CH

**10:45 - 12:15** **Type: Educational session** **Hall 404**  
**Title: Novel approaches and challenges for treatment of head and neck cancer**  
 Chair: Naomi Kiyota, JP; Lisa Licitra, IT

10:45 - 11:05 **Challenges to overcoming radio-resistance in head and neck cancer**  
M.L.K. Chua, NCCS - National Cancer Centre Singapore, Singapore, SG

11:05 - 11:25 **Boron neutron capture therapy (BNCT) as an emerging tool to treat head and neck cancer**  
L. Kankaanranta, Helsinki University Central Hospital (HUCH), Helsinki, FI

11:25 - 11:45 **Tumour biology and clinical outcomes in head and neck cancer: Does gender matter?**  
C. Even, Institut Gustave Roussy, Villejuif, Cedex, FR

11:45 - 12:05 **Novel immunotherapy approaches for head and neck cancer**  
N. Kiyota, Kobe University Hospital, Kobe, JP

12:05 - 12:15 **Q&A and discussion**  
A. Speakers, Lugano, CH

**10:45 - 12:15** **Type: Mini oral session** **Hall 401**  
**Title: Mini oral session: Breast cancer**  
 Chair: Sung-Bae Kim, KR; Mastura Md Yusof, MY; Jason Pitt, SG

10:45 - 10:50 **LBA2 - Analytical and clinical validation of a ctDNA-based assay for multi-cancer detection**  
L.S. Tran, L.H.D. Nguyen, T.H.H. Nguyen, Medical Genetics Institute, Ho Chi Minh City, VN

10:50 - 10:55 **1MO - Image biomarker discovery from DCE-MRI for identifying responders of MK-2206 on early-stage breast cancer patients: A secondary radio-genomics analysis of I-SPY2 trial**  
J. Zhang, X. Teng, Q. Lai, X. Zhang, X. Fan, T. Zhou, Y.-H. Huang, C. Jing, The Hong Kong Polytechnic University, Kowloon, HK

10:55 - 11:00 **56MO - Landscape of ESR1 mutations in advanced breast cancer using circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and Middle East (AME)**  
S. Dawood<sup>1</sup>, M. Al Akasheh<sup>2</sup>, T. Peretz-Yablonski<sup>3</sup>, N. Ben-Baruch<sup>4</sup>, N. Sandhir<sup>5</sup>, S. Jain<sup>5</sup>,  
<sup>1</sup>Mediclinic City Hospital, Dubai, AE, <sup>2</sup>Maggi Medical Center, Amman, JO, <sup>3</sup>Hadassah

University Hospital - Ein Kerem, Jerusalem, IL, <sup>4</sup>Kaplan Medical Center Oncology Institute, Rehovot, IL, <sup>5</sup>Guardant Health Pte. Ltd., Singapore, SG

- 11:00 - 11:10 **Invited Discussant one LBA2, 1MO and 56MO**  
S.-B. Kim, Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR
- 11:10 - 11:15 **Q&A and discussion**  
A. Speakers, Lugano, CH
- 11:15 - 11:20 **2MO - Multimodal data fusion enhanced precision neoadjuvant chemotherapy in breast cancer with a multi-task transformer-CNN-mixed learning**  
Y. Yu<sup>1</sup>, Z. He<sup>1</sup>, Z. Wang<sup>2</sup>, R. Lin<sup>3</sup>, T. Li<sup>1</sup>, Z. Zhang<sup>1</sup>, W. Ren<sup>1</sup>, L. Mao<sup>1</sup>, H. Yao<sup>1</sup>, <sup>1</sup>The Second Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, <sup>2</sup>Beijing Normal University-Hong Kong Baptist University United International College, Zhuhai, CN, <sup>3</sup>Macau University of Science and Technology, Macau, CN
- 11:20 - 11:25 **3MO - Multimodal data fusion for improved risk stratification of breast cancer with multi-task 3D deep learning model: A multicenter study**  
W. Ren<sup>1</sup>, Y. Yu<sup>2</sup>, W. Ouyang<sup>1</sup>, L. Mao<sup>3</sup>, Q. Yao<sup>4</sup>, Y. Tan<sup>5</sup>, Z. He<sup>1</sup>, T. Li<sup>3</sup>, Z. Zhang<sup>3</sup>, J. Wang<sup>4</sup>, H. Yao<sup>5</sup>, <sup>1</sup>2nd Affiliated Hospital/Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, CN, <sup>2</sup>The Second Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, <sup>3</sup>Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN, <sup>4</sup>Cells Vision, Guang Zhou, CN, <sup>5</sup>2nd Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN
- 11:25 - 11:30 **4MO - A prediction model for developing lymphedema in breast cancer patients receiving sentinel node biopsy**  
J.Y. Byeon<sup>1</sup>, I. Shin<sup>1</sup>, H. Lee<sup>1</sup>, J.-J. Jung<sup>1</sup>, E. Kang<sup>1</sup>, H.-K. Kim<sup>1</sup>, H.-B. Lee<sup>1</sup>, W. Han<sup>2</sup>, H.-G. Moon<sup>1</sup>, <sup>1</sup>Seoul National University Hospital, Seoul, KR, <sup>2</sup>Seoul National University - College of Medicine - Yeongeon Medical Campus, Seoul, KR
- 11:30 - 11:40 **Invited Discussant 2MO, 3MO and 4MO**  
J. Pitt, Cancer Science Institute (CSI) - National University of Singapore (NUS), Singapore, SG
- 11:40 - 11:45 **Q&A and discussion**  
A. Speakers, Lugano, CH
- 11:45 - 11:50 **LBA3 - Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC): KEYNOTE-522 Korean subgroup analysis**  
Y.H. Park<sup>1</sup>, S.-A. Im<sup>2</sup>, J.-H. Ahn<sup>3</sup>, M.H. Kim<sup>4</sup>, J. Cortés<sup>5</sup>, R. Dent<sup>6</sup>, L. Pusztai<sup>7</sup>, H. McArthur<sup>8</sup>, S. Kummel<sup>9</sup>, C. Denkert<sup>10</sup>, J. O'Shaughnessy<sup>11</sup>, M.-A. Mouret-Reynier<sup>12</sup>, M. Ferreira<sup>13</sup>, M. Gion Cortes<sup>14</sup>, J.-F. Boileau<sup>15</sup>, R. Hui<sup>16</sup>, Y. Zhu<sup>17</sup>, W. Pan<sup>17</sup>, V. Karantza<sup>17</sup>, P. Schmid<sup>18</sup>, <sup>1</sup>Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, <sup>2</sup>Seoul National University, Seoul, KR, <sup>3</sup>Asan Medical Center, University of

Ulsan College of Medicine, Seoul, KR, <sup>4</sup>Yonsei University College of Medicine, Seoul, KR, <sup>5</sup>International Breast Cancer Center, Quironsalud Group; Vall d'Hebron Institute of Oncology (VHIO), Madrid & Barcelona, and Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Madrid, ES, <sup>6</sup>National Cancer Centre Singapore, Duke-NUS Medical School, Singapore, SG, <sup>7</sup>Yale Cancer Center, New Haven, US, <sup>8</sup>University of Texas Southwestern Medical Center, Dallas, US, <sup>9</sup>Kliniken Essen-Mitte, Essen, Germany and Charité – Universitätsmedizin Berlin, Berlin, DE, <sup>10</sup>Philipps-University Marburg and University Hospital Marburg (UKGM), Marburg, DE, <sup>11</sup>Baylor University Medical Center, Texas Oncology, The US Oncology Network, Dallas, US, <sup>12</sup>Centre Jean-Perrin, Clermont-Ferrand, FR, <sup>13</sup>Instituto Português de Oncologia do Porto Francisco Gentil (IPO-Porto), Porto, PT, <sup>14</sup>Ramon y Cajal University Hospital, Madrid, ES, <sup>15</sup>McGill University, Jewish General Hospital Segal Cancer Centre, Montreal, CA, <sup>16</sup>Centre of Cancer Medicine, University of Hong Kong, Hong Kong; Westmead Breast Cancer Institute, Westmead Hospital and the University of Sydney, Westmead, AU, <sup>17</sup>Merck & Co., Inc., Rahway, US, <sup>18</sup>Barts Cancer Institute, Queen Mary University London, London, GB

- 11:50 - 11:55 **LBA6 - A phase II, single arm, open label, Simon two-stage study of pembrolizumab in metastatic HER2-negative breast cancer patients: Evaluation of impact of germline variants in APOBEC3B (AUROR)**  
 G.F. Ho<sup>1</sup>, S.C. Lee<sup>2</sup>, J.W. Pan<sup>3</sup>, A. Bustam<sup>4</sup>, A. Alip<sup>4</sup>, N.F. Bt Abdul Satar<sup>4</sup>, M. Saad<sup>4</sup>, R. Abdul Malik<sup>5</sup>, S.E. Lim<sup>6</sup>, S. Ow<sup>6</sup>, N. Ngoi<sup>7</sup>, K.B. Law<sup>8</sup>, Y.Y. Toh<sup>4</sup>, B. Selvam<sup>3</sup>, J. Lim<sup>3</sup>, S.-H. Teo<sup>3</sup>, <sup>1</sup>Pusat Perubatan Universiti Malaya (PPUM), Kuala Lumpur, MY, <sup>2</sup>Cancer Science Institute (CSI) - National University of Singapore (NUS), Singapore, SG, <sup>3</sup>Cancer Research Malaysia, Subang Jaya, MY, <sup>4</sup>UMMC - University Malaya Medical Centre, Kuala Lumpur, MY, <sup>5</sup>University of Malaya Faculty of Medicine, Kuala Lumpur, MY, <sup>6</sup>NCIS - National University Cancer Institute Singapore, Singapore, SG, <sup>7</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US, <sup>8</sup>Institute of Clinical Research, Shah Alam, MY
- 11:55 - 12:00 **57MO - First-line (1L) ribociclib (RIB) &#x2b; endocrine therapy (ET) vs combination chemotherapy (combo CT) in HR&#x2b;/HER2&#x2212; advanced breast cancer (ABC): A post hoc analysis of Asian and non-Asian patients (pts) from the phase II RIGHT choice trial**  
 Y.-S. Yap<sup>1</sup>, S.-A. Im<sup>2</sup>, Y.-S. Lu<sup>3</sup>, H. Azim<sup>4</sup>, Y. Eralp<sup>5</sup>, G.B. Kanakasetty<sup>6</sup>, H. Abdel-Razeq<sup>7</sup>, L. Zhukova<sup>8</sup>, A. Thuerigen<sup>9</sup>, T. Delgar Alfaro<sup>10</sup>, J. Wu<sup>11</sup>, M. Gao<sup>9</sup>, N. El Saghir<sup>12</sup>, <sup>1</sup>National Cancer Centre Singapore, Singapore, SG, <sup>2</sup>Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, <sup>3</sup>National Taiwan University Hospital, Taipei, TW, <sup>4</sup>School of Medicine, Cairo University, Cairo, EG, <sup>5</sup>Acibadem Research Institute of Senology, Acibadem University, Istanbul, TR, <sup>6</sup>HCG Curie Centre of Oncology and Kidwai Memorial Institute of Oncology, Bangalore, IN, <sup>7</sup>King Hussein Cancer Center, Amman, JO, <sup>8</sup>Loginov Moscow Clinical Scientific Center, Moscow, RU, <sup>9</sup>Novartis Pharma AG, Basel, CH, <sup>10</sup>Novartis Pharma AG - Novartis Institutes for Biomedical Research NIBR, Basel, CH, <sup>11</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>12</sup>American University of Beirut Medical Center, Beirut, LB
- 12:00 - 12:10 **Invited Discussant LBA3, LBA6 and 57MO**  
 M. Md Yusof, Pantai Hospital Kuala Lumpur, Kuala Lumpur, MY



12:10 - 12:15 **Q&A and discussion**  
A. Speakers, Lugano, CH

**10:45 - 12:15** **Type: Educational session** **Hall 402**  
**Title: Brain metastasis**  
 Chair: Giuseppe Minniti, IT; Evangelia Razis, GR

10:45 - 11:10 **Systemic treatments of brain metastases: Latest from trials**  
M. Preusser, Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT

11:10 - 11:35 **Radiation for brain metastases: Upfront, at progression or nothing at all?**  
G. Minniti, Sapienza Università di Roma, Rome, IT

11:35 - 12:00 **Standards and advances in the diagnosis and treatment of leptomeningeal disease**  
K. Wong, The Chinese University of Hong Kong, Hong Kong, HK

12:00 - 12:15 **Q&A and discussion**  
A. Speakers, Lugano, CH

**10:45 - 12:15** **Type: Educational session** **Hall 406**  
**Title: Oncogene-driven non-small cell lung cancer (NSCLC): Update on the new kids on the block**  
 Chair: Jordi Remon Masip, FR; Myung-Ju Ahn, KR

10:45 - 11:00 **METex14**  
J. Remon Masip, Institut Gustave Roussy, Villejuif, Cedex, FR

11:00 - 11:15 **HER2 mutation**  
P.L.S. Saw, NCCS - National Cancer Centre Singapore, Singapore, SG

11:15 - 11:30 **Exon 20 insertion**  
M.-J. Ahn, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR

11:30 - 11:45 **KRAS**  
B. Solomon, Peter MacCallum Cancer Center, Melbourne, AU

11:45 - 12:00 **New fusions RET, NTRK, ROS1**  
J. Tanizaki, Kindai University - Faculty of Medicine, Osaka, JP

12:00 - 12:15 **Q&A and discussion**  
A. Speakers, Lugano, CH

<b>12:30 - 14:00</b>	<b>Type: Industry satellite symposium</b> <b>Title: Astellas Pharma Ltd. - Rapidly changing frontline management of locally advanced or metastatic urothelial carcinoma (la/mUC)</b>	<b>Hall 405</b>
	Chair: Ravindran Kanesvaran, SG	
12:30 - 12:35	<b>Introduction and background</b> <u>R. Kanesvaran</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
12:35 - 12:45	<b>Unmet needs in frontline management of locally advanced and/or metastatic urothelial cancer (la/ m UC) along with Asian perspectives</b> <u>R. Kanesvaran</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
12:45 - 13:05	<b>Evolving clinical data in the front-line management of la/ m UC</b> <u>E. Grande</u> , MD Anderson Cancer Center Madrid, Madrid, ES	
13:05 - 13:25	<b>Enfortumab vedotin in the frontline management of la/ m UC with management of adverse events</b> <u>S. Gupta</u> , Taussig Cancer Center-Cleveland Clinic, Cleveland, US	
13:25 - 13:55	<b>Panel Discussion: In the rapidly changing treatment landscape, where do we stand today in the frontline management of la/ m UC?</b>	
13:55 - 14:00	<b>Summary and conclusion</b> <u>R. Kanesvaran</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	

**12:30 - 14:00** **Type: Industry satellite symposium** **Hall 404**  
**Title: AstraZeneca - Transforming outcomes for patients across all stages of NSCLC**  
 Chair: Pasi Jänne, US

12:30 - 12:35 **Welcome and introduction**  
P. Jänne, Dana Farber Cancer Institute, Boston, US

12:35 - 12:55 **Navigating treatment decisions in resectable NSCLC**  
P.L.S. Saw, NCCS - National Cancer Centre Singapore, Singapore, SG

12:55 - 13:10 **Optimising outcomes for unresectable stage III NSCLC**  
S. Siva, Peter MacCallum Cancer Centre, Melbourne, AU

13:10 - 13:30 **Navigating treatment decisions in metastatic NSCLC**  
P. Jänne, Dana Farber Cancer Institute, Boston, US

13:30 - 13:55 **Panel discussion and audience Q&A**

13:55 - 14:00 **Summary and close**  
P. Jänne, Dana Farber Cancer Institute, Boston, US

**12:30 - 14:00** **Type: Industry satellite symposium** **Hall 401**  
**Title: Amgen - Collaborating to improve oncology care in Asia Pacific**  
 Chair: Victoria Elegant, HK

12:30 - 12:45 **Overview of the current state of access to cancer care in Asia Pacific**  
J. Zalcberg, Alfred Hospital, Melbourne, AU

12:45 - 13:00 **Recommendations and accessibilities of next-generation sequencing in the Asia-Pacific region**  
H.H.F. Loong, The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK

13:00 - 13:15 **Impact of collaborations to improve access: Practical case examples**  
R. Vines, Rare cancers Australia, Bowral, AU

13:15 - 13:30 **What comes next: Recommendations for optimization**  
D.S.W. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG

13:30 - 14:00 **Panel discussion**  
A. Speakers, Lugano, CH

**12:30 - 14:00**    **Type: Industry satellite symposium**    **Hall 402**  
**Title: Novartis - How is PSMA-targeted theranostics shaping the prostate cancer precision revolution?**  
 Chair: Oliver Sartor, US

12:30 - 12:35    **Welcome, introduction and educational objectives**  
O. Sartor, Mayo Clinic - Rochester, Rochester, US

12:35 - 13:05    **Mapping the route to success: Optimal treatment sequencing in advanced PC**  
O. Sartor, Mayo Clinic - Rochester, Rochester, US

13:05 - 13:20    **Quality of life matters: Unmet needs in patients with mCRPC**  
A. Azad, Peter MacCallum Cancer Centre, Melbourne, AU

13:20 - 13:35    **Prostate cancer imaging: Are you on board with the new generation?**  
K. Herrmann, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE

13:35 - 13:50    **Panel discussion: The role of MDT throughout the treatment journey and implementation of radioligand therapy (RLT) into clinical practice**

13:50 - 14:00    **Live Q&A**  
O. Sartor, Mayo Clinic - Rochester, Rochester, US

**12:30 - 14:00**    **Type: Industry satellite symposium**    **Hall 407**  
**Title: MSD - Recent advances in immuno-oncology: A focus on lung and head & neck tumors**  
 Chair: Jerry Tan Chun Bing, PH

12:30 - 12:35    **Welcome and introduction**  
J. Tan Chun Bing, Cebu Doctors University Hospital, Cebu City, PH

12:35 - 13:05    **Evolving immuno-oncology landscape in early-stage and metastatic NSCLC**  
B. Solomon, Peter MacCallum Cancer Center, Melbourne, AU

13:05 - 13:35    **Current advance in immuno-oncology for head and neck cancers**  
H.-F. Kao, NTUH - National Taiwan University Hospital, Taipei City, TW

13:35 - 13:55    **Panel discussion and Q&A**

13:55 - 14:00    **Closing summary**  
J. Tan Chun Bing, Cebu Doctors University Hospital, Cebu City, PH

**12:30 - 13:15**    **Type: Young oncologists (YO) session**    **Discussion hub (exhibition area)**  
**Title: Vesalius talk: How to develop new trials and oncology services in Asia-pacific region**

Chair: Elizabeth Connolly, AU; Hongcheng Zhu, CN

12:30 - 13:15    **Panellists**

Y. Miura<sup>1</sup>, C. Scott<sup>2</sup>, C. Karapetis<sup>3</sup>, <sup>1</sup>Toranomon Hospital, Minato-ku, JP, <sup>2</sup>Walter and Eliza Hall Institute WEHI, Parkville, AU, <sup>3</sup>Flinders Centre for Innovation in Cancer, Bedford Park, AU

**14:15 - 15:45**    **Type: Educational session**    **Hall 405**  
**Title: Non-small cell lung cancer (NSCLC) treatment options after chemo-immuno failure**

Chair: Sanjay Popat, GB; Solange Peters, CH

14:15 - 14:35    **Mechanisms of resistance to immunotherapy**

S. Popat, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

14:35 - 14:55    **Antibody drug conjugates (ADCs)**

N. Reguart Aransay, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

14:55 - 15:15    **Novel immunotherapies to overcome resistance**

S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

15:15 - 15:30    **Role of local treatment**

S. Siva, Peter MacCallum Cancer Centre, Melbourne, AU

15:30 - 15:45    **Q&A and discussion**

A. Speakers, Lugano, CH

<b>14:15 - 15:45</b>	<b>Type: Multidisciplinary Tumour Board</b> <b>Title: Transition from hormone-sensitive to castration-resistant prostate cancer</b> Chair: Ravindran Kanesvaran, SG; Derya Tilki, DE	<b>Hall 404</b>
14:15 - 14:25	<b>Introduction to the session and presentation of case/condition</b> <u>M. Saad</u> , UMMC - University Malaya Medical Centre, Kuala Lumpur, MY	
14:25 - 14:40	<b>First-line treatment selection in metastatic hormone-sensitive prostate cancer (mHSPC)</b> <u>D. Mukherji</u> , Clemenceau Medical Center, Dubai, AE	
14:40 - 14:45	<b>Progression of the case</b> <u>M. Saad</u> , UMMC - University Malaya Medical Centre, Kuala Lumpur, MY	
14:45 - 15:00	<b>Pragmatic approach to treatment selection in metastatic castration-resistant prostate cancer (mCRPC)</b> <u>R. Kanesvaran</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
15:00 - 15:15	<b>Use of PARP inhibitors in prostate cancer: Current data and future directions</b> <u>A. Azad</u> , Peter MacCallum Cancer Centre, Melbourne, AU	
15:15 - 15:30	<b>PSMA imaging and theranostics</b> <u>S.P. Thang</u> , SGH - Singapore General Hospital, Singapore, SG	
15:30 - 15:40	<b>Q&amp;A and discussion</b> <u>A. Speakers</u> , Lugano, CH	

<b>14:15 - 15:45</b>	<b>Type: Multidisciplinary Tumour Board</b> <b>Title: Management of central nervous system (CNS) disease in HER2+ in metastatic breast cancer</b> Chair: Soo Chin Lee, SG; Mastura Md Yusof, MY	<b>Hall 401</b>
14:15 - 14:20	<b>Presentation of case/condition</b> <u>S. Ow</u> , NCIS - National University Cancer Institute Singapore, Singapore, SG	
14:20 - 14:35	<b>Imaging modalities to diagnose and assess CNS disease in metastatic breast cancer: Which to choose and when</b> <u>G. Garcia</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
14:35 - 14:55	<b>State of the art locoregional therapy for CNS metastases in metastatic HER2+ breast cancer</b> <u>S. Chilukuri</u> , Apollo Speciality Hospital - Teynampet, Chennai, IN	
14:55 - 15:15	<b>Emerging systemic therapy options for CNS disease in HER2+ metastatic breast cancer</b>  <u>S.C. Lee</u> , Cancer Science Institute (CSI) - National University of Singapore (NUS), Singapore, SG	
15:15 - 15:40	<b>Q&amp;A and discussion</b> <u>A. Speakers</u> , Lugano, CH	
<b>14:15 - 15:45</b>	<b>Type: Educational session</b> <b>Title: Leveraging the molecular biology of gastrointestinal cancers for optimal benefit from immunotherapeutic approaches</b> Chair: Hanneke van Laarhoven, NL; Stephen Chan, HK	<b>Hall 406</b>
14:15 - 14:40	<b>Leveraging the molecular biology of hepatocellular carcinoma (HCC) in optimising response to immunotherapy</b> <u>S. Chan</u> , The Chinese University of Hong Kong - Sino Building, Sha Tin, HK	
14:40 - 15:05	<b>Enhancing immunotherapy responsiveness in squamous versus adenocarcinoma based on molecular biology (focus on primarily esophageal cancer)</b> <u>B. Henick</u> , Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US	
15:05 - 15:30	<b>Immunotherapy in microsatellite stable (MSS) luminal gastrointestinal cancers</b> <u>H. Van Laarhoven</u> , Academic Medical Center, University of Amsterdam, Amsterdam, NL	
15:30 - 15:45	<b>Q&amp;A and discussion</b> <u>A. Speakers</u> , Lugano, CH	

<b>14:15 - 16:00</b>	<b>Type: Special session</b> <b>Title: Radiation oncology session 2 - Radiotherapy 2023: Optimal management and future</b> Chair: Francoise Mornex, FR; Melvin Lee Kiang Chua, SG	<b>Hall 407</b>
14:15 - 14:40	<b>Current status of SBRT in lung cancer</b> <u>Y. Nagata</u> , Nagasaki University Hospital, Nagasaki, JP	
14:40 - 15:05	<b>State of the art of radiotherapy in advanced prostate cancer</b> <u>V. Murthy</u> , ACTREC Tata Memorial Centre, Mumbai, IN	
15:05 - 15:30	<b>Carbon and proton therapy in rare tumours of the head and neck: The CNAO experience</b> <u>B. Vischioni</u> , Centro Nazionale di Adroterapia Oncologica - CNAO, Pavia, IT	
15:30 - 15:55	<b>FLASH radiotherapy: From basic concept to clinical perspectives</b> <u>C. Fouillade</u> , Institut Curie, Paris, FR	
15:55 - 16:00	<b>General discussion and conclusions</b> <u>A. Speakers</u> , Lugano, CH	